











This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
• This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
• A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
• This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
• The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
• When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given. 
 
 
Ph.D. – The University of Edinburgh – 2010 
 
Loop-mediated isothermal amplification (LAMP) for 
the diagnosis of human sleeping sickness: towards a 
point-of-care diagnostic test. 
 
Sally Louise Wastling 
 








I declare that the research described within this thesis is my own work 







List of Figures          i 
List of Tables          iii 
Acknowledgements         ix 
Abstract          xi 
1. Chapter 1. Introduction        1 
1.1. Diagnostics for Global Health      1 
  1.1.1. The roles of diagnostic tests for infectious diseases  2 
  1.1.2. Diagnostics in the developing world    2 
1.1.2.1. Barriers to the development and uptake of appropriate 
diagnostics in the developing world    3 
   1.1.2.2. The Foundation for Innovative New Diagnostics 4 
   1.1.2.3. Global Health Diagnostics Forum   5 
1.1.2.4. African Network for Drugs and Diagnostics 
Innovations (ANDI)      6 
   1.1.2.5. The future      6 
 1.2. Sleeping sickness        8 
  1.2.1. Parasites, hosts and vectors     8 
  1.2.2. Lifecycle       11 
  1.2.3. Clinical features      12 
  1.2.4. Epidemiology       13 
 1.2.5. Control        14 
 
 
1.2.5.1. Differences in control strategies for Gambian and 
Rhodesian sleeping sickness     15 
   1.2.5.2. Control in the human host    16 
   1.2.5.3. Control in the animal host    19 
   1.2.5.4. Control of the tsetse vector    20 
 1.3. Diagnosis of sleeping sickness      21 
  1.3.1. Clinical suspicion      21 
  1.3.2. Serological screening      22 
  1.3.3. Parasitological diagnosis     24 
  1.3.4. Molecular diagnosis      26 
  1.3.5. Staging tools       27 
  1.3.6. FIND and the search for new sleeping sickness diagnostics 28 
   1.3.6.1. Microscopy      28 
   1.3.6.2. Serodiagnosis      29 
   1.3.6.3. Molecular diagnostics    31 
   1.3.6.4. Disease staging tools     31 
1.4. Loop-mediated isothermal amplification (LAMP): A novel diagnostic for 
use in developing countries?       32 
  1.4.1. The LAMP reaction      32 
   1.4.1.1. Primers      32 
   1.4.1.2. Reaction conditions, reagents and templates  33 
   1.4.1.3. Mechanism      34 
 
 
   1.4.1.4. Detection      36 
  1.4.2. Applications and uptake of LAMP technology  38 
1.4.2.1. Applications of LAMP for identification of African 
trypanosomes       40 
 1.5. Other isothermal amplification techniques    40 
  1.5.1. Isothermal, transcription based amplification   41 
   1.5.1.1. Transcription mediated amplification  42 
   1.5.1.2. Nucleic acid based amplification   42 
  1.5.2. Strand displacement amplification    42 
  1.5.3. Rolling circle amplification     43 
  1.5.4. NEAR        43 
  1.5.5. Helicase dependent amplification    44 
  1.5.6. Recombinase polymerase amplification   44 
 1.6. Evaluating diagnostics       45 
  1.6.1. The evaluation process      45 
   1.6.1.1. Sensitivity and specificity    46 
   1.6.1.2. Predictive values     46 
   1.6.1.3. Kappa: a chance adjusted measure of agreement 47 
   1.6.1.4. Reliability      47 
1.7. Identification and discrimination of the T. brucei s.l. sub-species: a 
historical overview        47 
  1.7.1. Discovery of the T. brucei s.l. sub-species   48 
 
 
1.7.2. The discovery and characterisation of the SRA gene for the 
identification of T. b. rhodesiense     48 
1.7.3. The discovery and characterisation of the TgsGP gene for the 
identification of T. b. gambiense     50 
1.8. Prospects for point-of-care molecular methods of sleeping sickness 
diagnosis         52 
 1.9 Thesis aims        53 
2. Chapter 2. Materials and Methods       54 
 2.1. Samples         54 
  2.1.1. Commerically available human and cattle genomic DNA 54 
  2.1.2. Cryopreserved trypanosome samples    55 
   2.1.2.1. DNA extraction from cryopreserved samples 56 
   2.1.2.2. Molecular characterisation of DNA extractions 57 
  2.1.3. FTA card samples      57 
   2.1.3.1 FTA card samples used in Chapter 3   58 
   2.1.3.2 FTA card samples used in Chapter 7   59 
 2.2. PCR reactions        60 
  2.2.1. Trypanosoma congolense PCR reaction   60 
  2.2.2. Trypanozoon specific PCR reaction    61 
  2.2.3. T. b. gambiense specific PCR reaction    61 
  2.2.4. T. b. rhodesiense specific PCR reaction   62 
  2.2.5. ITS PCR       63 
  2.2.6. Identifying PCR positive reactions    63 
 
 
 2.3. LAMP reactions        64 
  2.3.1. Trypanozoon specific LAMP      65 
  2.3.2. T. b. rhodesiense specific LAMP    66 
  2.3.3. T. b. gambiense specific LAMP    66 
  2.3.4. Detecting LAMP products     68 
 2.4. Novel LAMP primer design      70 
  2.4.1. LAMP primer design for novel T. b. rhodesiense specific assays
           72 
  2.4.2. LAMP primer design for novel T. b. gambiense specific assays
           74 
 2.5 Development of novel LAMP assays     76 
  2.5.1. Initial trial of primers for T. b. rhodesiense   76 
2.5.2 Adaptation of the novel assay for T. b. rhodesiense for use with 
the real time turbidimeter                      77 
2.5.3. Application of the novel assay for T. b. rhodesiense to the 
complete sample set using a heating block    78 
2.5.4 Application of the novel assay for T. b. rhodesiense to the 
complete sample set using the real time turbidimeter  78 
2.5.5. Optimisation of reaction conditions including loop primer 
concentration and temperature     78 
2.5.6. Initial trial of primers for T. b. gambiense   79 
2.5.7 Adaptation of the novel assay for T. b. gambiense for use with 
the real time turbidimeter                      80 
2.5.8 Application of the novel assay for T. b. gambiense to the 
complete sample set using the real time turbidimeter  80 
 
 
2.5.9. Application of the novel assay for T. b. ganmbiense to the 
complete sample set using a heating block    80 
2.5.10. Absolute sensitivity of LAMP versus PCR   81 
 2.6. Statistical analyses       81 
  2.6.1. Sensitivity and specificity     82 
  2.6.2. Positive and negative predictive values   82 
  2.6.3. Cohen’s kappa       82 
 2.7. Multiobserver study       86 
3. Chapter 3. Detection of human infective trypanosomes in the zoonotic reservoir 
using LAMP          87 
 3.1 Introduction        87 
 3.2. Aims         89 
 3.3. Study outline        90 
 3.4. Results         92 
  3.4.1. Comparative detection study     92 
   3.4.1.1. Comparison to current reference standard  93 
   3.4.1.2. Comparison to the extended reference standard 95 
   3.4.1.3. Cost comparison     97 
  3.4.2. Non-specific LAMP RIME reactions    98 
   3.4.2.1. With T. congolense and T. vivax DNA  98 
   3.4.2.2. With Zambian cattle blood samples                        100 
3.4.2.3. With commercially available human and cattle 
genomic DNA                 103 
 
 
  3.4.3. Sequence analysis               104 
3.4.4. Designing novel Trypanozoon specific LAMP primers for the 
177 bp TBR PCR target sequence               106 
 3.5. Discussion                  106 
4. Chapter 4. LAMP assays for the specific detection of Trypanosoma brucei 
rhodesiense                   114 
 4.1. Introduction                  114 
4.2. Aims                  116 
 4.3.Study outline                 116 
 4.4. Results                  118 
  4.4.1. Molecular assays               118 
   4.4.1.1. Trypanozoon specific PCR reaction             118 
   4.4.1.2. Trypanozoon specific LAMP reaction            119 
   4.4.1.3. T. b. rhodesiense specific PCR reaction            119 
  4.4.2. Validation of the exisiting assay             121 
  4.4.3. Development of the novel assay             122 
   4.4.3.1. Initial trial of primers               122 
4.4.3.2. Adaptation of SRALAMP_a for use with the real time 
turbidimeter                 125 
4.4.3.3. Optimisation of the reaction conditions for the novel 
assay                  126 
   4.4.3.4. Endpoint detection               131 
  4.4.4. Evaluation of the novel assays              132 
 
 
  4.4.5. Multiple sequence alignment of databased SRA sequences   136 
4.4.6. Comparison of LAMP primer binding sites with northern and 
southern variant SRA sequences              136 
   4.4.6.1. Published LAMP primers             136 
   4.4.6.2. Novel LAMP primers             137 
 4.5. Discussion                 137 
  4.5.1. Conclusion                142 
5. Chapter 5. Evaluation of a LAMP protocol designed for the specific detection of 
Trypanosoma brucei gambiense                144 
 5.1. Introduction                 144 
 5.2. Aims                  145 
 5.3. Study outline                 146 
 5.4. Results                  147 
  5.4.1. T. b. gambiense specific PCR reaction             147 
  5.4.2. T. b. gambiense specific LAMP reaction            149 
5.4.3. Agreement between real time turbidimetry and gel 
electrophoresis for LAMP TBG1              150 
  5.4.4. Detection of T. b. gambiense by LAMP TBG1           150 
  5.4.5. Comparing LAMP TBG1 and TgsGP PCR            152 
  5.4.6. Sequence alignment of primers to the target region           155 
   5.4.6.1. The FIP primer              156 
   5.4.6.2. The BIP primer              156 
   5.4.6.3. The F3 primer              156 
 
 
   5.4.6.3. The B3 primer              156 
 5.5. Discussion                 159 
  5.5.1. T. b. gambiense specific PCR              159 
  5.5.2. Real time turbidimetry for LAMP TBG1            160 
  5.5.3. Validation of LAMP TBG1              161 
  5.5.4. Conclusions                162 
6. Chapter 6. Design and evaluation of a novel LAMP protocol for the specific 
detection of Group 1 Trypanosoma brucei gambiense              164 
 6.1. Introduction                  164 
6.2. Aims                   165 
 6.3. Study outline                  165 
 6.4. Results                   166 
  6.4.1. Molecular assays                166 
  6.4.2. Initial trial and adaptation for use with a real time tubidimeter
                     167 
6.4.3. Application of the TgsGP LAMP assay to 86 trypanosome 
DNA samples                  167 
   6.4.3.1. Accuracy of the TgsGP LAMP assay            168 
6.4.4. Agreement between real time turbidimetry and gel 
elctrophoresis for LAMP TgsGP                176 
  6.4.5. Absolute sensitivity of LAMP versus PCR             177 
 6.5. Discussion                  178 
7. Chapter 7. The reliability of LAMP                184 
 
 
 7.1. Introduction                  184 
7.2. Aims                   185 
 7.3. Study outline                  186 
 7.4. Results                   188 
  7.4.1. Control DNA samples                188 
7.4.1.1 Agreement between LAMP and the equivalent PCR 
assays                   188 
   7.4.1.2. LAMP test-retest agreement               189 
   7.4.1.3. Pentaplicate repeats for a subset of samples            191 
7.4.2. LAMP and PCR assay reproducibility when applied to field 
samples                  194 
7.5. Discussion                  200 
7.5.1. Reliability of the LAMP assays upon three repeated 
applications to the 86 control DNA samples              201 
7.5.2. Reliability of the LAMP assays upon five repeated applications 
to a subset of 15 DNA samples               203 
  7.5.3. Reliability of the assays when applied to FTA card samples 203 
  7.5.4. Reliability requirements for clinical diagnostic tests            206 
  7.5.5. Conclusion                 206 
8. Chapter 8. Comparing simple methods for reading the results of LAMP reactions
                     208 
 8.1. Introduction                  208 
8.2. Aims                   209 
 8.3. Study outline                  210 
 
 
 8.4. Results                   212 
  8.4.1. Ease of use and sensitivity of four simple endpoint methods 212 
   8.4.1.1. Turbidity                212 
   8.4.1.2. Quant-iT PicoGreen               213 
   8.3.1.3. Hydroxynaphthol blue              213 
   8.4.1.4. Calcein with MnCl2               214 
  8.4.2. Turbidity for LAMP PfrA, SRALAMP_a and LAMP TgsGP 
                     216 
  8.4.3. Multi-observer study                221 
   8.4.3.1. Participants                221 
   8.4.3.2. Questionnaire                221 
8.4.3.3. Individual observer agreement with reference standard 
method                 221 
   8.4.3.4. Inter-observer agreement              224 
  8.4.4. Reagent costs                  225 
8.5. Discussion                  226 
9. Chapter 9. Discussion                  231 
 9.1. Background                  231 
9.1.1. The development of LAMP diagnostics for sleeping sickness: a 
potted history                  231 
9.2. Aims                   233 
 9.3. Major findings and conclusions                234 
 9.4. Further work                  244 
 
 
  9.4.1. Arising from Chapter 3                244 
  9.4.2. Arising from Chapter 4                246 
  9.4.3. Arising from Chapters 5 and 6               248 
  9.4.4. Arising from Chapter 7                250 
  9.4.5. Arising from Chapter 8                251 
 9.5. LAMP as a future clinical diagnostic for sleeping sickness?            251 
  9.5.1. Politics and economics                252 
  9.5.2. Operational feasibility                255 
  9.5.3. A second isothermal nucleic acid amplification test for HAT 
                     258 
  9.5.4. Other diagnositics for sleeping sickness             259 
  9.5.5. Clinical significance of the detection of trypanosome DNA? 
                     261 
 9.6. Evaluating diagnostics in the absence of a gold standard            263 
  9.6.1. Frequentist approaches                264 
  9.6.1.1. A user friendly latent class analysis tool             264 
  9.6.2. Bayesian models                265 
  9.6.2. Limitations of latent class analysis              266 
 9.7. Final words                  266 
 References                   269 








List of Figures 
Figure 1.1. LAMP primers and their binding sites on the target DNA  33 
Figure 1.2. The mechanism of the LAMP reaction     35 
Figure 1.3. Citations per year following the original publication of the LAMP 
method          38 
Figure 1.4. Timeline illustrating the development of isothermal amplification, 
and its application to T. brucei s.l.       41 
Figure 2.1. LAMP primers and their binding sites on the target DNA  72 
Figure 2.2. Relative target regions of the TgsGP PCR and LAMP primers 
within the TgsGP gene AJ277951       75 
Figure 3.1. Kappa, sensitivity and specificity estimates for LAMP PfrA and 
LAMP RIME compared to TBR PCR, with 95 % confidence intervals 95 
Figure 4.1.  SRALAMP_a primers at 2 mM MgSO4            124 
Figure 4.2. Assessing the endpoint of the SRALAMP_a assay at 0.8 μM loop 
primers with Thermopol reaction buffer              132 
Figure 4.3. Kappa, sensitivity and specificity estimates, with 95 % CI for 
LAMP SRA1 and SRALAMP_a compared to the reference SRA PCR       136 
Figure 5.1. Kappa, sensitivity and specificity estimates, with 95 % CI for all 
comparisons made between LAMP TBG1 and the reference methods       155 
Figure 6.1. Kappa, sensitivity and specificity estimates, with 95 % confidence 
intervals for all comparisons made between LAMP TgsGP and the reference 
methods                  176 
Figure 7.1. LAMP assay agreement with reference PCR results          189 
Figure 7.2. LAMP assay test-retest agreement             191 
Figure 7.3. LAMP and PCR test-retest agreement using DNA prepared from 
cattle blood samples                196 
 
 ii 
Figure 7.4. LAMP and PCR test-retest agreement using DNA prepared from 
human blood samples                198 
Figure 7.5. LAMP and PCR test-retest agreement pooling all data from cattle 
and human samples                 200 
Figure 8.1. Colour change reactions with hydroxynaphthol blue, calcein with 
MnCl2 and Quant-iT Picogreen               216 
Figure 8.2. Kappa, sensitivity and specificity, with 95 % confidence intervals 
for the agreement between turbidity and endpoint detection by gel 
electrophoresis for three LAMP assays              220 
Figure 8.3. Agreement between the endpoint assessed by colour change 
(hydroxynapthol blue or calcein-MnCl2) and gel electrophoresis for thirty 
three observers                 224 
Figure 9.1. Development timeline for LAMP diagnostics for human sleeping 




List of Tables 
Table 1.1. Similarities and differences between the T. brucei s.l. subspecies
           10 
Table 1.2. Chemotherapy of human African trypanosomiasis   17 
Table 1.3. Comparative detection sensitivities of various parasitological 
diagnostic techniques        26 
Table 1.4. Loopamp Detection Kits (developed and marketed by Eiken 
Chemical Company, Japan)       39 
Table 1.5. LAMP assays developed for the detection of African trypanosomes
           40 
Table 2.1. PCR primer sequences used for identification of Trypanosoma 
congolense savannah, Trypanozoon DNA and species specific identification 
of T. b. gambiense and T. b. rhodesiense     64 
Table 2.2. LAMP primer sequences used for identification of Trypanozoon 
DNA           67 
Table 2.3. LAMP primer sequences used for identification of T. b. 
rhodesiense          68 
Table 2.4. LAMP primer sequences used for identification of T. b. gambiense
           68 
Table 2.5. Design process for SRA specific LAMP primers   73 
Table 2.6. Loop primer design for SRA specific primers    73 
Table 2.7. Characteristics of the LAMP TgsGP primers   76 
Table 2.8. Summary of primer sets trialled for SRA specific LAMP   77 
Table 2.9. Possible outcomes of a diagnostic test and associated formulae 
           85 
Table 2.10. The interpretation of Cohen’s kappa statistic    86 
 
 iv 
Table 3.1. Contingency tables for the comparison of the LAMP reactions with 
the current standard TBR PCR       93 
Table 3.2. Comparative summary statistics when the two LAMP assays were 
compared to the TBR PCR assay       94 
Table 3.3. Prevalence and bias indices, and the maximum attributable kappa 
for LAMP PfrA and LAMP RIME versus TBR PCR    95 
Table 3.4. Sensitivity of each method relative to the total number of positive 
samples identified in the study       97 
Table 3.5. LAMP and PCR performed on dilution series of T. congolense and 
T. vivax DNA          99 
Table 3.6. LAMP and PCR performed on T. congolense and T. vivax DNA  
                   100 
Table 3.7. LAMP RIME positive samples among the Zambian cattle blood 
samples                  101 
Table 3.8. Contingency table for the agreement between LAMP RIME and 
TBR PCR                  102 
Table 3.9. Kappa statistic for the agreement between LAMP RIME and TBR 
PCR                   102 
Table 3.10. Contingency table for the agreement between LAMP RIME and 
TCS PCR                  103 
Table 3.11. Kappa statistic and sensitivity for the agreement between LAMP 
RIME and TCS PCR                103 
Table 3.12. LAMP PfrA and RIME results performed on dilution series of 
human and cattle DNA                104 
Table 3.13. BLAST hits against the sequence used for LAMP PfrA primer 
design                  106 
Table 4.1.  Anomalous SRA PCR and TgsGP PCR results           120 
 
 v 
Table 4.2. The multiplex SRA PCR compared to previous identification as T. 
b. rhodesiense (see Appendix 2 for the identity and corresponding reference 
for all samples)                 120 
Table 4.3. Two by two table summarising the agreement between LAMP 
SRA1 and SRA PCR                121 
Table 4.4. Summary statistics for the agreement between LAMP SRA1 and 
SRA PCR                  122 
Table 4.5. Effect of loop primers on the sensitivity and efficiency of the 
SRALAMP_a reaction                127 
Table 4.6. Two by two table comparing SRALAMP_a with the reference PCR 
at two different concentrations of loop primers              128 
Table 4.7. Summary statistics for SRALAMP_a using different concentrations 
of loop primers compared to the reference SRA PCR               129 
Table 4.8. Prevalence and bias indices, as well as the maximum attributable 
kappa for the data in Tables 4.6 and 4.7.                       130 
Table 4.9. Effect of temperature on the efficiency and sensitivity of the 
SRALAMP_a assay                 131 
Table 4.10.  SRALAMP_a versus SRA PCR (real time turbidimeter)          133 
Table 4.11. SRALAMP_a, incubated in a thermocycler and assessed by gel 
electrophoresis, applied three times to the sample set, versus SRA PCR  133 
Table 4.12. Summary statistics for the comparison of the index test, 
SRALAMP_a, and the reference test SRA PCR             134 
Table 4.13. Prevalence and bias indices, as well as the maximum attributable 
kappa for the data in Tables 4.11 and 4.12.             135 
Table 4.14. Comparing the diagnostic sensitivity and specificity of the two T. 
b. rhodesiense LAMP assays               143 
Table 5.1. TgsGP PCR agreement and earlier speciation of the isolates   148 
 
 vi 
Table 5.2. Discrepancies between the TgsGP PCR and published sample 
identities                  149 
Table 5.3. Two by two table summarising the agreement between real time 
turbidimetry and gel electrophoresis for LAMP TBG1            150 
Table 5.4. Two by two table summarising the agreement between LAMP 
TBG1 and published identity as T. b. gambiense (Group 1 and Group 2)  151 
Table 5.5. LAMP_TBG1 compared to published T. b. gambiense identity 
(Group 1 and Group 2)                151 
Table 5.6. Prevalence and bias indices, as well as the maximum attributable 
kappa for the data in Tables 5.4 and 5.5.             152 
Table 5.7.  Agreement between the LAMP TBG1 and TgsGP PCR assays 
                   153 
Table 5.8. Summary statistics comparing LAMP TBG1 with TgsGP PCR  153 
Table 5.9. Prevalance and bias indices, as well as the maximum attributable 
kappa for the data in Tables 5.7 and 5.8.             154 
Table 5.10. A summary of the differences between the binding sites for the 
TBG1 LAMP primers for T. b. brucei isolates (see also Appendix 13)        157 
Table 5.11. A summary of the differences between the binding sites for the 
TBG1 LAMP primers for T. b. gambiense isolates (see also Appendix 13)158 
Table 6.1. Effect of dNTP concentration on the efficiency of the LAMP TgsGP 
reaction                  167 
Table 6.2. Agreement of TgsGP LAMP (by real time turbidimeter) with (i) 
published identity as Group 1 T. b. gambiense and (ii) TgsGP PCR          169 
Table 6.3. Summary statistics comparing LAMP TgsGP (by real time 
turbidimeter) with (i) published identity as Group 1 T. b. gambiense and (ii) 
TgsGP PCR                  169 
Table 6.4. Prevalence and bias indices, as well as the maximum attributable 
kappa for the data in Tables 6.2 and 6.3.             170 
 
 vii 
Table 6.5. TgsGP LAMP, incubated in a thermocycler and assessed by gel 
electrophoresis, applied three times to the sample set, versus published 
identity as Group 1 T. b. gambiense              171 
Table 6.6. Summary statistics comparing the three LAMP TgsGP replicates 
(incubated in a thermocycler and assessed by gel electrophoresis) versus 
published identity as Group 1 T. b. gambiense             172 
Table 6.7. Prevalence and bias indices, as well as the maximum attributable 
kappa for the data in Tables 6.5 and 6.6.             173 
Table 6.8. TgsGP LAMP, incubated in a thermocycler and assessed by gel 
electrophoresis, applied three times to the sample set, versus TgsGP PCR 
                   173 
Table 6.9. Summary statistics comparing the three LAMP TgsGP replicates 
(incubated in a thermocycler and assessed by gel electrophoresis) with 
TgsGP PCR                  174 
Table 6.10. Prevalence and bias indices, as well as the maximum attributable 
kappa for the data in Tables 6.8 and 6.9.                       175 
Table 6.11. Two by two table summarising the agreement between real time 
turbidimetry and gel electrophoresis for LAMP TgsGP             177 
Table 6.12. Detection limits of the TgsGP PCR and LAMP assays          178 
Table 6.13. Discrepant results for samples 12, 20 and 33           181 
Table 7.1. Overall percentage agreement for each LAMP assay applied in 
triplicate to 86 DNA samples               190 
Table 7.2. Number of positive LAMP reactions out of five repeats          193 
Table 7.3. Overall percentage agreement for each LAMP assay in 
pentaplicate (15 DNA samples)               194 
Table 7.4. Fleiss’ kappa statistic for agreement across five repeats          194 
Table 7.5. Repeatability of PCR and LAMP assays applied to cattle blood 
samples                   195 
 
 viii 
Table 8.1. Sensitivity with different assays and detection methods with a 10 
fold dilution series of 13.6 nM T. b. rhodesiense DNA            215 
Table 8.2. Turbidity by eye compared to UV visualisation of LAMP products 
after gel electrophoresis for LAMP PfrA, SRALAMP_a and LAMP TgsGP 217 
Table 8.3. Turbidity by eye compared to UV visualisation of LAMP products 
after gel electrophoresis for SRALAMP_a             218 
Table 8.4. Turbidity by eye compared to UV visualisation of LAMP products 
after gel electrophoresis for LAMP TgsGP             219 
Table 8.5. Prevalence and bias indices, and the maximum attributable kappa 
for turbidity versus gel electrophoresis with LAMP PfrA, SRALAMP_a and 
LAMP TgsGP                 220 
Table 8.6 Reagent costs and suppliers at the time of the study (2009)       225 
Table 8.7. Reagent costs per 100 reactions (based on the costs described in 
Table 8.6 above)                  225 
Table 9.1. The effect of sample size on the confidence interval of a specificity 
measure                  245 
Table 9.2. The effect of sample size on sensitivity and specificity estimates 





I would like to thank my supervisors, Sue Welburn and Kim Picozzi, for their 
guidance, support and encouragement. I am especially grateful for the many 
opportunities I have had to travel to the field, to attend conferences and courses, and 
to carry out laboratory work in Japan. More, I am grateful for their kindness shown 
on many occasions.  
 
In Japan, I would like to thank Professor Sugimoto for supporting my JSPS Short 
Term Fellowship and Chie Nakajima for sharing her knowledge of LAMP with me, 
as well as Ryo Nakao and the other postgraduate students at the Center for Zoonosis 
Control, Hokkaido University for being so welcoming.  
 
In Uganda, I would like to thank Abbas Kakembo for allowing me to travel with and 
observe the T. b. gambiense active screening team. Special thanks also go to Joseph 
Ssempija. 
 
I would like to thank Tanoé Miézan for his introduction to mAECT and many 
enlightening discussions about screening for T. b. gambiense. 
 
Here in Edinburgh, there are several people without whom completing this work 
would have been considerably more difficult. I would like to thank Ewan MacLeod, 
Ian Maudlin, Jenna Fyfe and Thorsten Forster for their invaluable assistance during 
the writing process. Ewan also deserves a special mention for the many hours spent 
searching through liquid nitrogen tanks for trypanosome isolates. I’d also like to 




I appreciate and acknowledge Louise Hamill and Christine Acup for their role in the 
laboratory work which significantly contributed to the data generated for Chapter 3. 
Further thanks go to all who participated in the multi-observer study in Chapter 8. 
 
I am grateful to the Medical Research Council, UK, for funding the main body of the 
work, as well as the Japanese Society for the Promotion of Sciences, for their Short 
Term Fellowship Award and the Birrell Gray Trust for contributing to the cost of 
attending conferences.   
 
I’d like to thank my parents for always supporting, encouraging and loving me, as 
well as my brother Stephen for being a listening ear and making me laugh. Finally, 





Acute and chronic sleeping sickness are fatal neglected tropical diseases caused by 
Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense respectively 
(members of the sub-genus Trypanozoon).  Accurate diagnostics are needed to guide 
treatment since the symptoms of disease are non-specific and the drugs that are used 
for treatment are too toxic to be administered to unconfirmed cases.  Tests need to be 
simple enough to confirm clinical diagnosis of sleeping sickness in poorly-resourced, 
peripheral health centres and for use as epidemiological tools to detect T. b. 
rhodesiense in the zoonotic reservoirs of infection.  
 
This study focuses upon LAMP (loop-mediated isothermal amplification) as a novel 
diagnostic for sleeping sickness that may serve to bridge the gap between the need 
for sensitive, specific molecular diagnostics on the one hand and ‘field-friendly’ 
diagnostics on the other.  
 
Here, two previously published LAMP assays for Trypanozoons were compared to 
classic PCR based methods for the diagnosis of Trypanozoon infection status in 428 
cattle blood samples.  The results did not support the use of LAMP as an improved 
system for surveillance of T. b. rhodesiense in the zoonotic cattle reservoir.   
 
T. b. rhodesiense and T. b. gambiense subspecies specific LAMP assays were 
evaluated against traditional reference subspecies specific PCR tests, using DNA 
purified from 86 cryopreserved trypanosome isolates. Novel LAMP assays for these 
subspecies were also designed and evaluated.   Both the published and novel assays 
for T. b. rhodesiense (targeting different regions of the SRA gene) were sensitive, 
specific and reliable when applied to purified DNAs, but were less consistent on field 
samples.  The novel T. b. gambiense LAMP (targeting TgsGP) was sensitive and 
specific but this was not the case for the published LAMP assay (targeting the 5.8S 




Finally, simple endpoint readout methods for LAMP were evaluated. The colour 
change reagent hydroxynaphthol blue was identified as the best currently available 
method taking cost, ease of use and reliability into consideration.  
 
In 2009 the number of reported sleeping sickness cases fell below 10,000 for the first 
time in 50 years. Improved LAMP diagnostics could facilitate the diagnosis of 
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1 Chapter 1. Introduction 
1.1 Diagnostics for Global Health 
‘Access to appropriate diagnostic tools is an essential component in the evaluation 
and improvement of global health’ [1]. 
 
This statement, made in the Nature supplement ‘Determining the Global Health 
Impact of Improved Diagnostic Technologies for the Developing World’ in 2006, 
highlights several of the key issues that remain pertinent to Global Health today. 
 
Firstly, effective diagnosis and the availability of diagnostic tools are an essential 
component of global healthcare (despite their often low-key status next to drugs and 
vaccines [1, 2]). They are crucial because they enable the current health status (of 
individuals and populations) to be evaluated in order that rational strategies for 
improvement can be made.  
 
Secondly, diagnostics must be appropriate for purpose and setting. They must meet 
specific user requirements as well as performance standards. It is not often possible 
or appropriate to develop a single tool with multiple diagnostic objectives. Therefore 
the aims and application of any proposed diagnostic tool should be clearly defined 
[1].  
 
Thirdly, diagnostics must be accessible. To a large extent accessibility is determined 
by the setting for which diagnostic tools are designed. Where end user requirements 
are misunderstood diagnostic tools will never be accessible to those who need them 
[1].  
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1.1.1 The roles of diagnostic tests for infectious diseases 
Diagnostic tests and techniques are designed and applied for different purposes. A 
single diagnostic might serve one or more diagnostic objectives which may include: 
(i) patient management, including treatment follow up; (ii) screening for 
asymptomatic diseases; (iii) surveillance (including verification of elimination); (iv) 
monitoring the effects of public health interventions; (iv) outbreak investigations and 
epidemiological studies; (v) detection of infections with drug resistance markers [1, 
3].   
 
Throughout this thesis the term ‘diagnostic’ is used in its broadest sense as any tool 
that reduces uncertainty about the state of infection or disease. In addition to 
diagnostic tests used for case confirmation among symptomatic individuals, it is also 
used to describe screening tests used for case detection in asymptomatic cases [4, 5].  
 
1.1.2 Diagnostics in the developing world 
Recently ‘modified molecular diagnostics for affordable, simple diagnosis of 
infectious diseases’ was ranked as the most promising biotechnology for improving 
health in developing countries. In a study which sought consensus opinion among 28 
scientific experts (with expertise in public health problems of developing countries), 
molecular diagnostic tools were collectively ranked above biotechnologies for both 
vaccine development and drug discovery [6].  
 
However, there are many challenges in providing appropriate diagnostics in the 
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1.1.2.1 Barriers to the development and uptake of appropriate 
diagnostics in the developing world 
Diagnostic tools have been typically developed by industrialised countries for use 
and application in those industrialised country settings.  As a consequence, they may 
often be ill suited for use in the developing world. They may be too expensive or 
technologically demanding for resource-poor settings.  They may need to be 
executed in centralised facilities and require considerable training of the end users, 
most of which are not available in developing countries with limited health care 
budgets and facilities [6, 7]. Even where centralised reference laboratories are not a 
necessity, a good quality laboratory service is still needed, which includes technical 
competence, access to the proper reagents, an understanding of quality control and 
proper interpretation of diagnostic test results by healthcare providers as well as a 
timely system for the communication of test results between technicians and the 
healthcare providers [8]. At present there often exists a cycle of neglect, whereby 
poor laboratory services generate untrustworthy results, leading to the devaluation of 
the laboratory services by clinicians, undermining opportunities for improvement [8]. 
In sub-Saharan Africa the variable and often poor quality of laboratory services 
remains a barrier to effective healthcare [9, 10]. There is a lack of investment in 
diagnostic services development; for example, in a Malawian district hospital only 6 
% of health expenditure was on diagnosis [11] . Further, diagnostics might not have 
been properly and rigorously validated in developing world settings [12, 13]. The 
ethical and strategic importance of developing country involvement in the diagnostic 
evaluation process has been noted elsewhere [2]. Apart from tests used for blood 
banking, regulatory standards are often lacking for diagnostic tests, especially those 
uncommon in industrialised countries [3, 14]. Even where appropriate and effective 
tests exist,  advocacy might be insufficient to generate the necessary levels of uptake 
[15] and there may be inadequate quality control of tests once they are implemented 
[16, 17].  
 
Historically there have been few incentives and little impetus to address this 
imbalance. This could be attributed to a private sector perception that diagnostics 
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generate poor investment returns, lack of information about the requirements for high 
impact diagnostics in the developing world, and lack of information about the 
potential health benefits appropriate diagnostics could bring [7].  
 
Interest in diagnostics for the developing world has begun to grow. Over the past 
decade funding has improved [8] and several large-scale initiatives have been 
launched to develop novel diagnostic technologies and improve access to novel and 
existing diagnostics. These new initiatives include the Foundation for Innovative 
New Diagnostics (FIND), the Global Health Diagnostics Forum and the African 
Network for Drugs and Diagnostics Innovations (ANDI).  
 
1.1.2.2 The Foundation for Innovative New Diagnostics (FIND) 
FIND was established as a product development and implementation partnership 
seeking novel and improved solutions for the diagnosis of sleeping sickness, malaria 
and tuberculosis. FIND is a non–profit Swiss based foundation which was launched 
on 22nd May 2003 at the World Health Assembly (see www.finddiagnostics.org) as a 
spin-out from the World Health Organisation (WHO) and TDR (Special Programme 
for Research and Training in Tropical Diseases, executed by the WHO and co-
sponsored by the United Nations Children’s Fund (UNICEF), the United Nations 
Development Programme (UNDP), the World Bank and the WHO). Their work on 
diagnostics for sleeping sickness is included in Section 1.3.  
 
FIND is not the first public private, product development partnership with a remit 
which includes diagnostic technologies. The Program for Appropriate Technology in 
Health (PATH) was established in 1980, from the Program for the Introduction and 
Adaptation of Contraceptive Technology (PIACT). More recently, the Center for 
Point-of-Care Diagnostics for Global Health was established as a collaboration of 
PATH and the University of Washington. The center focuses on (i) clinical needs 
assessment for technology developers; (ii) supporting exploratory projects; (iii) 
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clinical testing of prototype point-of-care diagnostics; and (iv) training on the clinical 
realities of designing point-of-care products for low-resource settings. It is funded by 
the National Institutes of Health (NIH), National Institute of Biomedical Imaging and 
BioEngineering (NIBIB). See www.path.org.  
 
Another, notable example is the Infectious Diseases Research Institute (IDRI). Since 
it was founded in 1993, IDRI has developed diagnostic tests for Chagas disease, 
tuberculosis and leishmaniasis. See www.idri.org. 
 
1.1.2.3 Global Health Diagnostics Forum 
The Global Health Diagnostics Forum was convened in 2004, by the Bill and 
Melinda Gates Foundation (www.gatesfoundation.org) and the RAND Corporation 
(www.rand.org). The forum includes expertise in specific diseases, disease 
modelling, the introduction and adoption of diagnostic technologies, and includes 
representatives from the diagnostics industry and technology development sector.  
The forum has developed a mathematical modelling approach to quantify the 
potential health impact of novel diagnostics in developing countries, and to define 
the performance characteristics and user requirements necessary for high impact 
diagnostics [18].  A summary of their findings is given in Appendix 1. For example, 
they have estimated that a malaria diagnostic with no infrastructural requirements, 90 
% sensitivity and 90 % specificity would avert 300,000 child deaths and 450 million 
unnecessary treatments annually. 
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1.1.2.4 African Network for Drugs and Diagnostics Innovations 
(ANDI) 
Potential benefits from the development of novel diagnostics are not solely restricted 
to health per se. The African Network for Drugs and Diagnostics Innovations 
(ANDI), launched in October 2008, includes representation from 21 countries 
committed to coordinating their efforts to encourage research and innovation for 
Africa-centric health problems. Like FIND, ANDI was initiated by WHO/TDR. It is 
supported by WHO/TDR, the African Development Bank and the European Union, 
as well as governments and pharmaceutical companies. ANDI suggest that Africa 
does have the capacity to develop new drugs and diagnostics but have identified a 
widespread lack of translational mechanisms to take findings from the laboratory to 
commercialisation on the continent [19]. They also suggest that ‘a creative public-
health-centered environment for intellectual property management and licensing 
structures could advance health and support innovation in Africa’ [19] such that 
intellectual property rights could be used to as a driver of local innovation for local 
health problems. Such a strategy could bring economic development benefits, in 
addition to the direct health benefits from a particular innovation. In addition the 
WHO convened an Inter-governmental Working Group on Innovation, Intellectual 
Property and Public Health, which has developed a Global Strategy and Plan of 
Action to lower the barriers for public health innovation by creative intellectual 
property management strategies.  
 
1.1.2.5 The future 
In order to overcome the challenges outlined above there is a need for: advocacy; 
continued technological advancement towards ideal point-of-care tests; the 
development of harmonized regulatory standards; improved evaluation and uptake of 
diagnostic tests; capacity building, quality assurance and education of healthcare 
providers [8].   
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Although funding has improved, advocacy for diagnostic leadership in developing 
countries is needed.  
 
In 2003 WHO/TDR coined the acronym ‘ASSURED’ to summarise the 
characteristics of an ideal point-of-care test. These are: Affordable; Sensitive; 
Specific; User-friendly (simple to perform in a few steps with little training); Robust 
and rapid (can be stored at room temperature and results available in less than 30 
minutes); Equipment free (or minimal) and Deliverable to the point of need. 
Technological advances are being made which are likely to generate more tests that 
fulfil all these criteria over the nest few years. In this thesis the focus is on LAMP 
(loop-mediated isothermal amplification) as a new technology that might provide an 
ASSURED test for sleeping sickness.  
 
Regulatory standards would prevent the market being flooded with cheap, low 
quality tests. However, financing a product through the regulatory process is costly, 
therefore, harmonized international or regional regulatory standards would encourage 
the diagnostic industry to register their products in many countries. In addition an 
international federation of diagnostics manufacturers (similar to the International 
Federation of Pharmaceutical Manufacturers and Associations) which could set 
quality control standards, as well as working with governments to combat 
counterfeiting, would represent a leap forward.  
 
Technological advancement and regulation alone will not be enough. In addition 
significant capacity building and education are required to achieve laboratory 
services for diagnostic testing. In particular rigorous quality control systems will 
need to be implemented and facilitated. If this is achieved, clinicians may start to put 
their trust in test results, breaking the cycle of neglect described above. 
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1.2 Sleeping Sickness 
Sleeping sickness or human African trypanosomiasis (HAT) comprises two forms of 
a neglected tropical disease whose reported incidence (9,877 new cases in 2009 [20]) 
disguises a high disease burden, not least due to severe under reporting. Indeed, a 
recent study has highlighted the need for localised estimates of disease burden which 
account for under reporting [21]. Chronic sleeping sickness, caused by infection with 
T. b. gambiense parasites and acute form sleeping sickness caused by T. b. 
rhodesiense are both fatal if un-treated and yet diagnosis and treatment remain highly 
problematic. Although there are many different diagnostic approaches (Section 1.3) 
the much sought after sensitive, specific and low-resource tool remains elusive. 
Drugs for sleeping sickness are either highly toxic, complex to administer or both. 
Drug resistance is of increasing concern and treatment costs are extremely high. For 
example, individual treatment costs for T. b. rhodesiense have been estimated to be 
almost eight times higher than the per capita government health expenditure in 
Uganda, where the total costs of treating a Rhodesian sleeping sickness case has been 
estimated at US $147 in comparison to US $19 of government funding available for 
per capita healthcare in 2008 [22]. In the Democratic Republic of Congo Gambiense 
sleeping sickness costs have been estimated to average an equivalent to five months 
income for an affected household. Similar proportions of income are required to 
cover the direct and indirect costs of Rhodesian sleeping sickness for families living 
on less than US $1 day-1 in Tanzania [21].  
 
1.2.1 Parasites, host and vectors 
The causative agents of human sleeping sickness are parasites of the genus 
Trypanosoma, subgenus Trypanozoon. The Trypanozoons include Trypanosoma 
brucei sensu lato (s.l.), Trypanosoma equiperdum and Trypanosoma evansi, of which 
only T. brucei s.l. subspecies cause human sleeping sickness (although there has been 
a reported case of T. evansi infection in an immunocompromised individual [23]). 
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T. brucei s.l includes three (at least) subspecies of which two cause human sleeping 
sickness: Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense. 
These parasites are morphologically indistinguishable from each other and also from 
the third, non-human-infective member of the Trypanosoma brucei s.l. species 
complex, Trypanosoma brucei brucei.  At the molecular level, T. b. rhodesiense can 
be discriminated by the SRA gene [24]. Similarly, T. b. gambiense can be 
distinguished by the presence of the T. b. gambiense specific TgsGP gene [25].  The 
discovery of these subspecies specific diagnostic marker genes is described in more 
detail in Section 1.5.  T. equiperdum and T. evansi are now consided to be strains of 
T. brucei rather than separate species [26], while previously this was uncertain [27].  
 
Despite their morphological homogeneity T. b. brucei, T. b gambiense and T. b. 
rhodesiense differ in both host range and disease profile. T. b. brucei infects a range 
of domestic and wild mammalian hosts, with varying degrees of pathogenicity. For 
example, while indigenous African cattle are generally unaffected, the parasite is 
pathogenic in exotic cattle breeds, as well as horses and dogs [22].  T. b. brucei is not 
infective to humans; who have innate resistance conferred by apolipoprotein L-1 
(apoL1) and haptoglobin related protein (Hpr), present in normal human serum [28, 
29].  The human infective parasite T. b. rhodesiense has long been known to exist as 
a zoonotic disease, infecting both wildlife and domestic livestock [30, 31].  Recently 
the critical role of these reservoirs has become increasingly apparent; rapid spread of 
acute sleeping sickness in Uganda has been attributed to the movement of livestock 
(up to 18 % of which were shown to be infected with T. b. rhodesiense [32, 33]).  In 
contrast, the role of an animal reservoir for T. b. gambiense is less certain; Gambian 
sleeping sickness is thus considered to be principally anthroponotic [34], although 
domestic pigs are known reservoirs of infection and may play a role in disease 
transmission [35]. Table 1.1 summarises the key characteristics of T. b. brucei, T. b. 
gambiense and T. b. rhodesiense. 
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Table 1.1. Similarities and differences between the T. brucei s.l. 
subspecies 
Parasite Principal hosts Clinical profile Geographical 
profile 






T. b. gambiense Humans Chronic disease West and Central 
Africa 
 
T. b. rhodesiense Wildlife, domestic 
livestock and 
humans 
Acute disease in 
humans, clinically 




All T. brucei s.l. are vector borne parasites that are cyclically transmitted between 
mammalian hosts by both male and female tsetse flies of the genus Glossina [36]. 
 
Trypanosoma evansi is transmitted mechanically by haematophagous insects such as 
tabanid flies and causes Surra, a disease that affects wild and domestic animals [23, 
37]. Trypanosoma equiperdum is traditionally considered to be the causative agent of 
the equine disease Dourine, transmitted by direct, e.g. sexual, contact between 
animals. However, the classification of T. equiperdum as a distinct species remains 
controversial; it may be a mis-classified T. evansi or another member of the T. brucei 
subspecies [38]. Some authors have gone further to suggest that both T. evansi and T. 
equiperdum are both subspecies of T. brucei s.l. lacking part or all of their 
kinetoplast DNA [26].  
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In addition there are several animal infective trypanosomes, which cause ‘sleeping 
sickness’ or Nagana in animals and which fall into two other subgenera. The sub-
genus Duttonella includes Trypanosoma vivax, while the subgenus Nannomonas 
includes Trypanosoma congolense, Trypanosoma simiae and Trypanosoma godfreyi.  
 
Conventionally, it is believed that only T. b. rhodesiense and T. b. gambiense are 
human infective. However, exceptional atypical infections with T. b. brucei [39], T. 
evansi [23] and T. congolense [40] have been reported.  
 
1.2.2 Lifecycle 
A susceptible tsetse fly becomes infected with bloodstream form trypanosomes when 
it feeds upon an infected host. This establishes a dividing population of procyclic 
form trypanosomes within the tsetse midgut. In the case of T. brucei s.l. these then 
migrate to the tsetse salivary glands and mature to the metacyclic, mammalian 
infective, stage. The transmission cycle is completed when a second mammalian host 
is infected during a subsequent blood meal. The tsetse is not very hospitable to the 
trypanosome and has evolved several defence mechanisms against the invading 
parasite, indeed most flies are refractory to infection [41]. Furthermore, human-
infective trypanosomes are less able to mature within the fly than their human serum 
sensitive counterparts [42].  
 
Metacyclic stage trypanosomes are injected into the mammalian host via the tsetse 
proboscis and rapidly transform to bloodstream stages. Infection becomes systemic 
and the trypanosomes multiply by binary fission in lymph and blood, but the 
mammalian host mounts a lytic antibody response against the variable surface 
glycoprotein (VSG) outer parasite layer, leading to a reduction in the number of 
parasites in the blood. However, by stochastic antigen switching of the VSGs the 
parasite changes its coat [43], so that a subpopulation of parasites avoids destruction. 
This occurs repeatedly, generating waves of parasitaemia, each of a different variable 
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antigenic type (VAT). Therefore the infection is maintained, ready for transmission 
during the next tsetse blood meal. During the later stages of the disease the parasites 
cross the blood brain barrier and also multiply in the cerebrospinal fluid.  
 
1.2.3 Clinical features 
The clinical course of human sleeping sickness may be divided into two distinct 
stages, which may or may not be preceded by chancre development at the site of 
parasite inoculation. The early stage of the disease corresponds to the infection of the 
host haemolymphatic system, and is characterised by non-specific clinical signs, 
particularly fever and lymphadenopathy. The late stage of the disease develops upon 
trypanosome invasion of the central nervous system via the blood brain barrier, 
leading to meningitis and encephalitis. Clinical manifestations include headaches, 
backache and neck stiffness, behavioural and psychological changes, profound 
disturbance of the sleep-wake cycle, coma and death.  
 
These stages are common to both Rhodesian and Gambian sleeping sickness; though 
the rate of disease progression differs markedly between the two. Gambian sleeping 
sickness is a chronic disease with early stage symptoms appearing weeks or months 
after infection and if untreated death may not occur for many years [44]. However, 
recently this traditional view has been challenged, and evidence for spontaneous cure 
as well as chronic carriage has been reviewed by Checchi et al. [45]).  By contrast 
Rhodesian sleeping sickness follows a more acute clinical progression in which the 
two stages of the disease are less distinct, and where if untreated, 80% of deaths 
normally occur within six months of infection [44, 46]. However, across the 
geographic range of T. b. rhodesiense there is a spectrum of disease severity. In the 
northern part of the range, the disease is classically acute, such as in Uganda where 
death occurs within six months of the onset of illness in more than 80 % of reported 
cases [46].  In the southern part of the range, the disease has long been considered to 
be more chronic and human ‘carriers’ have been reported [47].  The observed clinical 
differences correlate with genetic differences reported between parasite strains 
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isolated from the northern and southern parts of the distribution range; observed by 
isoenzyme [48, 49], restriction fragment length polymorphism [50] and minisatellite 
[51] analyses. The north south divide is also characterised by small differences in the 
SRA gene [52, 53] (discussed in more detail below) as well as differences in host 
inflammatory cytokine response profiles [54].  
 
1.2.4 Epidemiology 
Sleeping sickness is a disease affecting poor rural communities who are exposed to 
tsetse as part of their daily activities such as agriculture, fishing, animal husbandry 
and hunting. However, epidemiologically Gambian and Rhodesian sleeping sickness 
are dissimilar and, at present, spatially allopatric. Chronic sleeping sickness, caused 
by T. b. gambiense, is an anthroponotic disease restricted to West and Central Africa, 
whereas T. b. rhodesiense in East Africa is zoonotic, with an acute clinical 
progression in humans.   
 
Both forms are characterized by discreet foci of disease which persist over time, 
expanding and contracting during epidemic and inter-epidemic periods and which are   
strictly restricted to tsetse inhabited regions of sub-Saharan Africa [22].  Yet even 
within these areas sleeping sickness does not present with a uniform distribution and 
the abundance of tsetse flies is not the only limiting factor for disease.  Animal 
reservoirs of disease are an important determinant of disease distribution, and 
population displacement, war and poverty all seem to contribute to exacerbate 
transmission. Recently Batchelor et al. [55] observed an important correlation 
between the proximity to livestock markets and the prevalence of Rhodesiense 
sleeping sickness in newly affected areas of Uganda, as well as noting correlations 
with measures of green vegetation, land surface temperature and the proximity to 
health facilities. Thus social, environmental and climatic factors all play a role: the 
epidemiology of sleeping sickness is complex and many features remain 
unexplained.   
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Given the focal nature of these diseases focal estimates of disease burden are 
required to truly represent the impact of the disease, and inform control [56]. This 
was achieved for a highly endemic region of Tanzania in a recent study by Matemba 
et al. [21].  
 
More than 250 endemic foci of disease have been recorded in 36 countries across 
sub-Saharan Africa [57]. Despite the current geographic separation of the two human 
infective parasites, concerns have recently been raised about the potential merging of 
foci in Uganda where the two forms are separated by a buffer of only 150 km [32]. 
This would have serious implications for disease control in terms of surveillance, 
diagnosis and treatment [32, 55]. 
 
1.2.5 Control 
Past experience indicates that control is feasible: towards the end of the colonial era, 
by the late 1960s, sleeping sickness was considered all but conquered.  Mobile 
surveillance for early case detection and treatment formed the core of the control 
initiatives. Sadly, the disease showed a dramatic re-emergence during early 
independence as control programmes became a victim of political instability and 
their own success [58, 59]. Renewed efforts have seen case numbers falling once 
again [59, 60]. However, in contrast to successful historical models of sleeping 
sickness management, current control strategies are almost entirely reactive, only 
coming into play in response to major epidemics [61].   
 
According to Molyneux et al. [62], those afflicted by sleeping sickness have been 
failed by the public health and scientific communities alike. Public health policy 
makers and practitioners have failed to sustain simple, proven methods of control. As 
for the scientific community, the priorities for research towards improved control 
have changed very little over the last half century (cheap, point-of-care diagnostics 
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and effective, non toxic drugs for late stage disease) but progress towards these 
targets has been impeded by the diversion of research efforts into scientifically 
impressive investigations into trypanosome and tsetse biology that are remote from 
the needs of the patient. Molyneux et al. summarise the problems and future 
requirements in the following statement, “Today we are able to undertake the most 
elaborate scientific experimentation on tsetse and trypanosomes, yet we are barely 
able to manage sleeping sickness during the comfort afforded by the present inter-
epidemic period. The huge rise in philanthrocapitalist investments that has been 
welcome in the past decade now needs to translate into practical solutions for rural 
peoples to manage this devastating disease [17]. Investments that we have seen in 
genetics and genomics may reap rewards in years to come, but in the meantime, 
funds must be provided to sustain effective, if unsexy, control strategies.” 
 
Having noted that control is realistic, control strategies are now described in more 
detail.  
 
1.2.5.1 Differences in control strategies for Gambian and 
Rhodesian sleeping sickness 
Control strategies for Gambian and Rhodesian sleeping sickness differ. Control of 
Gambian sleeping sickness relies on early case detection and treatment to reduce the 
anthroponotic parasite reservoir. Active screening is necessitated by the long 
asymptomatic preclinical stage during which infected individuals are likely to 
transmit disease without seeking treatment. Control of Rhodesian sleeping sickness 
requires additional strategies to reduce the parasite population in its zoonotic 
reservoir. Active case finding is less important; the acute nature of the disease mean 
that cases are more likely to self-present at health centres [34]. The requirement for 
and effects of targeting the livestock reservoir of T. b. rhodesiense in south east 
Uganda have been quantified [61], and are discussed in more details in Section 
1.2.5.3 (Control in the animal host) below.    
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1.2.5.2 Control in the human host 
Case detection and subsequent curative treatment in the human host prevents onward 
transmission. However, both case detection and treatment remain difficult and 
inadequate. Quantification of the level of under detection of T. b. rhodesiense 
sleeping sickness during an epidemic in Uganda [63] found that only 20 % of 
sleeping sickness cases present with early stage disease and that for every fatality 
another twelve go undetected. Furthermore, 85 % of undetected deaths remain 
undiagnosed despite having entered the health system. Therefore, diagnostic delays 
can be attributed to the service providers as well as the care seekers. These delays 
worsen the prognosis at treatment and increase the likelihood of onward transmission 
[64]. Specific diagnostics and their limitations are described below (Section 1.3).  
 
Current chemotherapy for human sleeping sickness also remains unsatisfactory. 
Problems include a limited and ancient repertoire of effective drugs, high frequency 
of severe adverse events, complex drug administration typically requiring 
hospitalization and drug resistance [65]. At least for now the constant threat to 
sustainable drug production (due to low profitability) has been overcome, since the 
pharmaceutical industry agreed to provide drugs for free [62]. 
 
Treatment depends upon the infecting parasite and the stage of disease progression. 
There are four registered drugs to choose from. Table 1.2 outlines the treatment 
options.
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Table 1.2. Chemotherapy of human African trypanosomiasis [66, 67].   
Effective against (Drug of 
choice for) 
Drug Adverse events Administration 
(Preferred 
method) Infecting parasite Stage  
Suramin Generally well tolerated. Intravenous 
injection over 15-
30 days 
T. b. rhodesiense, 
T. b. gambiense 
Early  
Pentamidine Generally well tolerated. Intramuscular 
injection or 
intravenous 
infusion over 7-10 
days. 
T. b. gambiense Early  
Melarsoprol Drug induced 
encephalopathy in 5-
10% of patients (70% 
fatal). Exfoliative 




T. b. rhodesiense, 
T. b. gambiense 
Early, 
late  




Orally every 6 
hours for 14 days. 
Or intravenous 
infusion. 






Reduced side effects 
compared to DFMO 
alone. 
Oral nirfutimox 





T. b. gambiense Late  
 
The drugs for human sleeping sickness have been in use for several decades and new, 
less toxic drugs are urgently needed.  Suramin, which was introduced in 1920, is 
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effective against first stage Gambian and Rhodesian sleeping sickness. However 
pentamidine, introduced in 1940, is preferred for the Gambian form because 
administration is more simple and rapid. Melarsoprol, introduced in 1949, is an 
organo-arsenical compound.  In addition to the severe adverse events outlined above, 
it also gives rise to more minor skin reactions, pyrexia, headache and general malaise 
in nearly all patients. D,L-α-Diflouromethylornithine (DFMO) is a viable alternative 
for second stage Gambian sleeping sickness but it is often prohibitively expensive, 
and being only trypanostatic, is not effective in patients with compromised immune 
systems, for example, HIV positive individuals. Drug bioavailability is much better 
when administered by intravenous infusion. Melarsoprol and DFMO are not used to 
treat early stage disease because of their toxicity and expense respectively.  
 
Diminazene aceturate has been developed and registered for use against animal 
trypanosomes but has not been registered for human treatment. However, it has been 
applied intramuscularly against the first stage of both disease forms and appears to be 
effective. It is cheap and readily available but its toxicology in humans is unknown 
[67].  
 
Recently a new treatment regimen has been established. In 2009, the WHO added 
Nifurtimox- Eflornithine Combination Therapy (NECT) to their model list of 
essential medicines and began distribution, following a randomized trial comparing 
standard eflornithine to NECT [68]. WHO has signed an agreement with Bayer 
Schering Pharma for the free supply of 400, 000 doses of Nifurtimox, per year, for 
five years, adding to a pre-existing donation of eflornithine by Sanofi Aventis. 
Previously nifurtimox was registered for use against Chagas disease (American 
trypanosomiasis) but not for human African trypanosomiasis (HAT).  Compared to 
eflornithine treatment costs are reduced by half and hospitalization is reduced from 
14 to ten days. Side effects are reduced compared to both melarsoprol and 
eflornithine, and it is at least as efficacious as eflornithine monotherapy [69]. 
Although this is a real step forward in improving treatment options many problems 
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remain, including transportation of the drug to remote health posts, intravenous 
administration and the specialized medical care needed to monitor for side effects as 
well as follow up for relapsing cases [62]. Drug resistance is also a concern. The 
nitro drugs, including nifurtimox and fexinidazole (a clinical trial candidate) have 
been shown to rapidly acquire reciprocal cross resistance, without compromising 
parasite virulence. Neither should therefore be considered as a stand alone treatment 
[70].  
 
The discovery of a potent and selective N-myristoyltransferase inhibitor, currently 
designated DDD85646, that could cure experimental infections in mice with an oral 
dose administered over four days may well represent an opportunity for the 
development of a safe oral treatment against this neglected disease. Trypanosomes 
appear to be hypersensitive to inhibition of this enzyme. Further work is now 
underway to improve the CNS penetration and selectivity this model T. brucei N-
myristoyltransferase inhibitor [71]. 
 
1.2.5.3 Control in the animal host 
Mathematical modelling has clearly demonstrated that control of T. b. rhodesiense in 
the animal reservoir, in addition to early case detection and treatment in humans, is 
critical for the control of Rhodesian sleeping sickness [61]. Specifically, Welburn et 
al. [61] developed Rogers seminal mathematical model [72], which described the 
transmission of Trypanosoma brucei between two host populations by a single 
vector, to incorporate the effects of medical and veterinary interventions [34], and 
then parameterised the model using field-based estimates from south east Uganda 
[61]. Welburn et al. calculated that cattle account for 92 % of the total transmission 
potential for T. b. rhodesiense. Further, they calculated that mass chemoprophylactic 
treatment which reaches 86 % of cattle can prevent outbreaks of Rhodesian sleeping 
sickness [61]. (This estimate is relatively insensitive to the percentage of humans 
receiving treatment). In short, in the absence of the cattle reservoir the basic 
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reproductive number (R0) (which is the number of secondary infections arising from 
one infectious individual entering a fully susceptible host population) of T. b. 
rhodesiense falls below zero and transmission cannot be maintained.  
 
Control of the human-infective parasite in the domestic livestock reservoir relies on 
three trypanocidal drugs, all of which have been in use for over 40 years. 
Isometamidium chloride has prophylactic as well as therapeutic properties, 
homidium salts have limited prophylactic use while diminazene aceturate is solely 
therapeutic. Drug resistance is a serious problem for animal trypanosomiases [73] 
and cross resistance is seen with drugs used to treat human disease [74]. Novel drug 
development is commercially unattractive. Therefore, these three established drugs 
should be used carefully and the prevalence and spread of drug resistance ought to be 
monitored. New methods to rapidly assess the drug susceptibility status of circulating 
trypanosomes are needed [74]. 
 
In Uganda there is a well-designed national policy for the trypanosomiasis control, 
including treatment of cattle at their point of origin or before sale. However it is clear 
that this policy has not been effectively implemented [75]. 
 
1.2.5.4 Control of the tsetse vector 
Controlling the tsetse population is a longstanding and well-established approach for 
trypansomiasis control. It has been well described elsewhere [58, 76]. Here it is 
sufficient to note that despite limited but notable success stories, such as the 
eradication of tsetse from Unjuga, Zanzibar, tsetse control is frequently 
unsustainable. For example, political unrest in Uganda in the 1970s interrupted a 
successful ground-spraying programme. Similarly, tsetse traps and targets have been 
shown to successfully control tsetse populations as part of government funded 
programmes, however, once left to the community they usually suffer the fate of the 
common good, and are not maintained. But tsetse control may yet be sustainably 
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achieved. The Stamp Out Sleeping Sickness programme has demonstrated that 
restricted application of insecticide to cattle has human and animal health benefits 
and by spraying cattle the common good problem is overcome [62]. 
 
1.3 Diagnosis of sleeping sickness 
WHO recommends that a positive diagnosis should be made when parasites can be 
detected in the lymph or blood by microscopy [77].  This is followed by staging of 
the disease to determine the appropriate course of therapy. Staging guidelines are 
described in Section 1.3.5.  
 
The differences in clinical progression seen with T. b. gambiense and T. b. 
rhodesiense necessitate the use of different diagnostic protocols. Although definitive 
diagnosis for both diseases relies on parasitological detection in the blood, or lymph, 
the steps preceding parasitological confirmation differ. For T. b. gambiense active 
serological screening and/or clinical signs are used to identify suspect cases whereas 
T. b. rhodesiense suspect cases are identified by the presence of trypanosomes in 
blood or CNS and associated clinical features.  
 
1.3.1 Clinical suspicion 
Clinical diagnosis of T. brucei infection is not possible in humans or cattle. In 
humans sensitive and specific diagnosis of sleeping sickness is not possible using 
clinical features alone but these features can be used to indicate that parasitological 
diagnosis is necessary [78, 79]. Cattle infected with T. brucei s.l. rarely show overt 
clinical signs [80] and other techniques are required to demonstrate the presence of 
the human infective parasite. 
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1.3.2 Serological screening 
Several different techniques have been developed to detect trypanosome specific 
humoral responses in blood, serum and CSF samples, the most important of which is 
the card agglutination test for trypanosomiasis (CATT) [81]. CATT is a rapid, simple 
agglutination assay for anti-T. b. gambiense antibodies, which uses an antigenic 
reagent based on T. b. gambiense Variable Antigen Type LiTat 1.3. The CATT test is 
used to screen for T. b. gambiense in most endemic areas. During field surveys, the 
subjects are first screened using freshly collected heparinized whole blood. This is 
followed by further tests on blood, plasma or serum dilutions for blood test positive 
individuals. Seropositivity does not necessarily indicate current infection since 
antibodies can persist for up to three years post cure [82]. Therefore, CATT cannot 
be used as an indication of cure after treatment [83]. 
 
CATT false negatives have been observed in parasitologically positive cases in 
Cameroon and north western Uganda [84, 85]. Some CATT false positives might 
arise where the LiTat 1.3 gene is absent in circulating strains of T. b. gambiense [84, 
86]. However, the CATT false negative cases in Uganda were LiTat 1.3 positive by 
PCR suggesting that LiTat 1.3 might not always be expressed, or may be expressed 
at a later stage in infection [85]. CATT false negatives can also result from 
complement-mediated inhibition, particularly at lower concentrations of sample [87]. 
To overcome this problem an improved version of CATT was developed, in which 
EDTA (which has anti-complement properties) is added to the dilution buffer [88]. 
 
CATT false positives are also likely. CATT false positives can occur in patients with 
malaria and transient infection with non-human-infective trypanosomes [81]. In the 
Cameroonian Fontem focus patient serum from CATT positive individuals failed to 
lyse LiTat 1.3 VAT trypanosomes, strongly indicating that CATT positivity can arise 
from cross reactivity [84]. Finally, high numbers of aparasitaemic serological 
suspects are observed. This might reflect a lack of CATT specificity or failure of the 
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parasitological parasitological tests in the face of weak or fluctuating parasitaemia 
[89, 90]. Perhaps, even, the patient’s immune response is effectively controlling the 
parasite [91]. Attempts to validate CATT against molecular PCR tests have 
generated more questions than answers [92]. 
 
Other limitations include: (i) the complexity of antigen production which requires the 
extraction of trypanosomes from infected rat blood [78]; (ii) the requirement for a 
team of well trained personnel, and the transportation of bulky equipment; (iii) 
CATT tests are not available in an individual format; and (iv) the onerous follow up 
associated with the high number of observed CATT positive, but aparasitaemic 
individuals. 
 
Modifications of CATT have been made for use with blood samples stored on filter 
paper, for example the Testryp micromethod [93] and CATT-FP [94]. These 
techniques require much lower quantities of CATT reagent, and could facilitate 
serological surveillance in particularly remote areas.  
 
More recently a new format of CATT has been developed and shown to be 
comparable to the existing CATT in subjects from a highly endemic area of the 
Democratic Republic of Congo. The new format (CATT-D10) is based on a 
thermostable lyophilisation medium and is produced in 10 unit vials. It might be 
more suitable for use in peripheral health care facilities, which may lack cold chain, 
and may not see sufficient suspect cases to justify opening a traditional 50 unit vial 
of CATT antigen [95].  
 
The LATEX/T. b. gambiense has been developed as a field alternative to CATT [96], 
and uses a combination of three surface antigens (LiTat 1.3, 1.5 and 1.6) coupled 
with suspended latex beads. The procedure is similar to that for CATT. In several 
field studies it was more specific, but less sensitive than CATT [78]. 
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Immunoflourescence assays, ELISA and immune trypanolysis methods for anti-
trypanosome antibody detection are also useful where there are good laboratory 
facilities, such as for the remote analysis of samples collected during large scale 
epidemiological surveys, but are not practical for application in the field [78]. 
 
There is no equivalent to CATT for serological screening for T. b. rhodesiense [97]. 
 
1.3.3 Parasitological diagnosis 
Microscopic parasite detection, upon examination of the lymph, blood or 
cerebrospinal fluid of the human patients, provides direct evidence for parasite 
infection. Cervical lymph node (CLN) palpitation ought to be performed on all 
CATT positive T. b. gambiense suspect cases. When the CLN are enlarged, lymph 
node aspiration for direct examination is mandatory. Detection of circulating T. b. 
rhodesiense parasites is relatively easy, however, the numbers of circulating T. b. 
gambiense can range from 10,000 ml-1 to less than 100 ml-1, which falls below the 
threshold of even the most sensitive methods [97].  
 
Most simply parasites can be viewed in wet blood films, whereby blood is spotted 
onto the slide underneath a coverslip and examined. Thick blood smears enhance 
detection sensitivity compared to a wet blood film. The blood droplet is smeared, air 
dried out of direct sunlight, and fixed with Giemsa or field stain, before viewing.  
 
Several concentration techniques have been developed to improve the diagnostic 
sensitivity of parasitological diagnosis. Triple centrifugation of blood was described 
by Yorke in 1938 [98]. Centrifugation of the blood sample in a capillary tube 
concentrates the trypanosomes in the white blood cell layer, which can then be 
examined using a normal light microscope (haematocrit centrifugation technique – 
HCT) [99] or a dark-ground or phase contrast microscope (buffy coat technique) 
[100]. The quantitative buffy coat technique combines centrifugation and fluorescent 
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detection using acridine orange [101]. The mini anion exchange centrifugation 
technique (mAECT) uses miniature anion exchange columns for the separation of 
trypanosomes from red blood cells prior to centrifugation [102]. 
 
The most sensitive techniques for the detection of parasites in lymph and blood are 
direct examination and mAECT respectively and when these two techniques were 
used in parallel sensitivity was improved further [103]. Recently an improved model 
for mAECT was developed by FIND and their partners in which several test 
components were redesigned. Most notably, a new collector tube and viewing 
chamber have made microscopic examination simpler for both tests [104].  
 
Finally, in vitro isolation has been developed for isolation of trypanosomes under 
field conditions [105] but requires examination over several weeks.  
 
Traditional microscopic methods for diagnosis are rapid and can be performed in the 
field. However, it is not possible to discriminate T. b. gambiense and T. b. 
rhodesiense by microscopy, and microscopy is insensitive when compared to 
molecular methods [106]. Table 1.3 describes the detection sensitivities of some of 
these parasitological methods.  
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Table 1.3. Comparative detection sensitivities of various parasitological 
diagnostic techniques [79] 
 
1.3.4 Molecular diagnosis 
PCR assays have been developed to detect and differentiate trypanosomes at the 
species and subspecies levels. For T. brucei s.l. PCR targeting a 177bp repeat region 
can detect a DNA concentration equivalent to what is present in a single 
trypanosome [107]. For T. b. rhodesiense PCR assays targeting the single copy SRA 
gene have been developed. Of particular note is a multiplex reaction, which includes 
an internal control, to verify the presence of sufficient DNA for single copy gene 
detection. This assay can discriminate T. b. brucei from T. b. rhodesiense for a single 
trypanosome in most cases [108]. PCR based identification of T. b. gambiense is also 
possible, using primers designed to amplify the single copy T. b. gambiense specific 
glycoprotein (TgsGP) gene. Single round and nested PCR assays have been 
developed. The best reported detection limit is 10 trypanosomes per ml-1 [32, 109]. 
The SRA and TgsGP genes are discussed in more detail in section 1.5. 
 
Hence, molecular methods are significantly more sensitive than microscopy. In our 
laboratory PCR is applied routinely to blood samples collected and stored onto 
Whatman FTA cards. Whatman FTA cards contain a chemically treated fibre matrix 
that lyses cells, inactivates proteins and immobilises DNA, making them suitable for 
long term storage of blood samples.  This approach enables accurate species-specific 
trypanosome identification for large-scale epidemiological surveillance at distant 
Technique Sensitivity (trypanosomes/ml) 
Wet blood film 10,000 
Thick blood film 5000 
Haematocrit centrifugation 500 
Mini anion exchange centrifugation 100 
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field sites. For example, this approach has been used to monitor the prevalence of T. 
b. brucei and T. b. rhodesiense in domestic livestock following the Stamp Out 
Sleeping Sickness campaign in Uganda (see www.sleepingsickness.org).  
 
Despite the reliability of these molecular techniques and their use as research tools, 
they are of no practical use as bed-side or pen-side diagnostic tools to direct 
treatment decisions. Nor are they useful for in-country monitoring. Several factors 
limit the usability of PCR in resource-poor field settings, including the need for a 
thermocycler and a reliable electricity source, as well as a gel tank and UV trans-
illuminator for visualising the outcome of the reaction. Therefore there is a need to 
develop more practical methods for use in the field. Loop-mediated isothermal 
amplification (LAMP) is one such method that may prove practical for field-based 
molecular diagnostics. 
 
1.3.5 Staging tools 
If parasites are detected in the blood or lymph disease staging must be performed, 
which requires examination of the CSF. CSF is obtained by lumbar puncture. 
According to WHO recommendations [77] the patient is in stage 1 if the white cell 
count in the CSF is ≤ 5 μl-1 and if trypanosomes cannot be observed. Stage 2 is 
characterised by the presence of trypanosomes and/or a white blood cell count of  ≥ 
20 μl-1. There is an intermediate stage when trypanosomes are not observed and the 
cell count falls between these values. Patients in this category may or may not 
require stage 2 treatment. 
 
Concentration techniques can be used to improve the sensitivity of trypanosome 
detection in the CSF. Centrifugation has been recognised to improve parasite 
detection since the early 1900s [110]. Double centrifugation (DC) was introduced in 
1988 [111]. After the first centrifugation the sediment is taken up in micro-
haematocrit tubes for a second centrifugation step. Although this increases the 
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sensitivity of detection it is not widely practised given the number of manipulations 
and the requirement for two centrifuges [112]. In 2000, the modified single 
centrifugation technique (MSC) was introduced [112]: 2 ml CSF is taken into a 
sealed Pasteur pipette (as prepared for mAECT) and centrifuged for 10 min at 600 g. 
The sediment is examined for trypanosomes by light microscopy using a mAECT 
viewing chamber. MSC is at least as sensitive as DC, and is easier to perform. 
 
Staging is complicated. Most national programmes use different cell count 
thresholds, and may not consider an intermediate category. Thresholds are difficult to 
define and justify. Progress in defining new biological stage specific markers is being 
made [113, 114].  
 
1.3.6 FIND and the search for new sleeping sickness 
diagnostics  
FIND are working across all areas of sleeping sickness diagnosis including 
microscopy, sero-diagnosis, molecular diagnostics and disease staging tools.  
 
1.3.6.1 Microscopy 
Work done by FIND and their partners to improve mAECT has been previously 
mentioned. Also, in collaboration with Carl Zeiss (www.zeiss.com) FIND have also 
developed a simple LED based fluorescence microscope using acridine orange for 
parasite staining [115]. Finally, they have revived an old method using ammonium 
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1.3.6.2 Serodiagnosis 
FIND have recently signed an agreement with Standard Diagnostics Inc., Korea for 
the commercial development of rapid, point-of-care, dipstick style test for detection 
(but not discrimination) of T. b. rhodesiense and T. b. gambiense. This follows work 
done by FIND and partners to identify candidate antigens for detection of anti-
trypanosome antibodies in patient sera. It is intended for screening in remote settings 
(http://www.finddiagnostics.org/media/press/100223.html; accessed 18th August 
2010). In addition to FIND and their partners are also seeking novel antigen 
detection tests. Particularly, FIND is collaborating with the University of Brussels to 
look at nanobody technology and with the Seattle Biomedical Research Institute 
(SBRI) to apply single chain variable fragment (scFv) antibody engineering.  See 
(www.finddiagnostics.org) 
 
Nanobodies are small (15 kDa) antibody fragments derived from camelid 
conventional heavy chain antibodies. They bind antigen via one single chain variable 
domain, encoded by a 350 bp gene. They can be generated after immunisation of 
camelids with antigen, by purifying the camelid lymphocytes followed by RT-PCR, 
cloning in a phage display library and selection of the antigen specific antibodies. 
Once generated, they can be easily and economically produced and purified using 
bacterial, yeast or plant expression systems.  They bind their target with high affinity 
and are small and stable with a long shelf life. It is relatively easy to produce larger 
bivalent or bispecific constructs, or nanobodies coupled to other protein carriers and 
they can be humanised by altering specific amino acid sequences to reduce the risk 
of inducing anti-nanobody antibodies [116, 117].  
 
This technology has begun to be applied for the diagnosis of sleeping sickness.  
Stijlemans et al. [118] generated a nanobody which targets the conserved Asn-linked 
carbohydrate of trypanosome VSG and demonstrated its diagnostic potential for 
parasite detection with fluorescent microscopy. The entire surface of viable parasites 
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were stained, indicating that these small antibody fragments can penetrate the VSG 
coat to reach otherwise inaccessible constant epitopes.  
 
More recently, Saerens et al. [119] generated several additional anti-VSG 
nanobodies using  trypanosome infection of camelids (in place of antigen 
inoculation). 
 
Two different antigen detection test formats are now under development using 
trypanosome specific nanobody technology. Firstly, a VSG specific dipstick format 
assay demonstrated an initial detection limit of 10 parasites ml-1 in a proof of 
principle study. Secondly, a novel diagnostic test using the PickPen (BioNobile) is 
also under development. This uses nanobody coated magnetic bead capture for 
antigen ‘fishing’ followed by detection  using a second complementary nanobody 
[116].  
 
Single-chain variable fragment (scFv) antibodies are one of the most popular 
recombinant antibody formats. Like nanobodies, they have many advantages in 
comparison to full length conventional monoclonal antibodies. In particular, their 
small size enables them to access targets which cannot be reaches by full size 
antibodies.  They can also be produced economically, are open to genetic 
manipulation and have been engineered into larger, multivalent, bi-specific and 
conjugated forms [120].  FIND and SBRI are using yeast display systems to generate 
high affinity scFv for T. brucei proteins 
(http://www.finddiagnostics.org/export/sites/default/media/newsletters/old_issues/ne
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1.3.6.3 Molecular diagnostics 
In October 2008 FIND signed a development agreement with Eiken Chemical 
Company, who originally developed LAMP (see below) to develop LAMP for 
sleeping sickness (http://www.finddiagnostics.org/media/press/081027.html; 
accessed 18th August 2010). To date FIND and their partners have been involved in 
the development of two LAMP assays for sleeping sickness, one targeting the 
Trypanozoon specific RIME element, and one targeting the T. b. rhodesiense specific 
SRA gene [121, 122]. Notably LAMP is the only isothermal DNA amplification 
technique that is being developed and evaluated by FIND for sleeping sickness. It is 
not the only isothermal DNA amplification technique that has been developed (see 
Section 1.5). 
 
1.3.6.4 Disease staging tools 
The methods for and difficulties associated with staging sleeping sickness were 
described in Section 1.3.5. At present staging requires investigation of the CSF, 
which is obtained by a painful and risky lumbar puncture procedure. To overcome 
this problem FIND and their partners have sought blood-based biomarkers for 
disease staging, but with little success.  However, they have determined a panel of 
three brain damage marker proteins which can be used to discriminate stage 2, and 
could be of use in developing improved CSF staging tests [113]. FIND have also 
been involved in reformatting the latex/IgM card agglutination test into a more stable 
individual kit format for staging by CSF IgM quantification.  
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human 
sleeping sickness: towards a point-of-care diagnostic test 
Chapter 1. Introduction 32 
1.4 Loop-mediated isothermal amplification (LAMP): A novel 
diagnostic technology for use in developing countries? 
Loop-mediated isothermal amplification (LAMP) is a DNA amplification technique 
developed in Japan by Eiken Chemical Company [123]. It is rapid, efficient and 
specific and has several advantages over traditional PCR. Most importantly, it does 
not require a high precision thermal cycler and gel-free amplicon detection systems 
can be used. Thus neither amplification nor detection requires equipment that would 
restrict its use to resource rich laboratory environments. As such it is being 
advocated as a suitable tool for low resource settings e.g. [124].    
 
1.4.1 The LAMP reaction 
1.4.1.1 Primers 
LAMP requires a minimum of four primers, two inner primers and two outer 
primers, which recognise six distinct regions on the target sequence. The forward and 
backward outer primers, F3 and B3 respectively, are the same as regular PCR 
primers. F3 binds its complementary sequence (denoted F3c) on one strand of the 
DNA, while B3 binds its complementary sequence (denoted B3c) on the other strand. 
The inner primers each contain two segments and bind to both the sense and 
antisense strands of the target DNA. The forward inner primer (FIP) comprises two 
segments denoted F2 and F1c. The F2 segment binds to its complementary region 
(F2c) on the one strand, and the F1c segment binds to F1 region on the opposing 
strand. Likewise the backward inner primer (BIP) comprises two segments denoted 
B2 and B1c. This is depicted in Figure 1.1. 
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Figure 1.1. LAMP primers and their binding sites on the target DNA  
Adapted from http://loopamp.eiken.co.jp/e/lamp/primer.html and ‘A Guide to LAMP 
primer designing (PrimerExplorer V4)’, Eiken Chemical Co. Ltd. 
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Once the inner and outer primers have been generated, two additional, optional ‘loop 
primers’ can be designed. These contain sequences complementary to the single 
stranded loop region in the starting material (see section 1.2.1.3. Mechanism). The 
forward loop primer (LF) binds between F1 and F2 and the backward loop primer 
(LB) binds between B1 and B2. This increases the number of starting points for 
DNA synthesis, and improves both the specificity and efficiency of the LAMP 
reaction [125]. 
 
1.4.1.2 Reaction conditions, reagents and templates 
The reaction proceeds under isothermal conditions, typically between 60 and 65˚ C. 
It requires primers as described above, Bst DNA polymerase (which has strand 
displacement activity), betaine, buffer solution, template DNA and water to make up 
the reaction to a standard volume.  
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LAMP does not require purified DNA for efficient DNA amplification. In the 
literature LAMP reactions have been performed using extracted DNA and directly 
from heat treated blood samples, as well as CSF and native serum [126, 127]. This 
reduces the overall time and cost in comparison to systems in which DNA extraction 
is required. It has been suggested that Bst DNA polymerase is less susceptible than 
Taq to blood based PCR inhibitors such as heme [128]. LAMP may also be used 
with an RNA target by adding reverse transcriptase to the reaction mix. This is 
known as reverse transcription coupled LAMP (RT-LAMP) [129]. 
 
1.4.1.3 Mechanism 
The mechanism of the LAMP reaction is summarised in Figure 1.2. It is also well 
described in an animation produced by Eiken Chemical Company 
(http://loopamp.eiken.co.jp/e/lamp/anim.html).  It proceeds in two main stages: first 
the production of a stem loop structure and second the cycling amplification stage. It 
is dependent on the special design of the outer, inner primers and loop primers and 
upon the strand displacement activity of Bst DNA Polymerase.  
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Figure 1.2. The mechanism of the LAMP reaction  
 
Figure taken from Mori et al. [130] 
 
In the starting material producing step, the inner primers bind first to the target 
sequence. The outer primers are present at a much lower concentration in the 
reaction mix and so hybridise more slowly to the target sequence. Once an outer 
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primer is bound it initiates strand displacement DNA polymerisation generating a 
single stranded DNA, to which the other inner and outer primers bind (reactions 1-5 
in Figure 1.2). This first stage generates a stem loop structure (Structure A) which 
acts as the starting material for the cycling amplification step. Once the starting 
material has been generated the outer primers play no further role in the reaction. 
During the cycling amplification step the inner primers bind the loop structure 
(reaction 6), generating a complementary stem loop (Structure B) and a new stem 
loop (reaction 10) whose stem is twice as long. A cyclic reaction between structures 
A and B is established (reactions 6-9). The elongated products (Structures C-F) are 
produced from the intermediate products formed during this cyclic reaction 
(reactions 10-12 and 13-15). The inner and loop primers bind the loop regions of the 
extended stem loops to generate these elongated products. Where loop primers are 
not included in the reaction strand displacement DNA synthesis is initiated from 
fewer loops at a time. 
 
Since the target sequence is recognised by several independent sequences in all three 
stages of the reaction amplification is highly specific.  
 
1.4.1.4 Detection 
There are a variety of high and low technology methods in the literature for detecting 
positive LAMP amplification reactions. LAMP products may also be visualised 
directly by traditional gel electrophoresis and UV trans-illumination appearing as a 
ladder of bands [123]. Unlike PCR, for which the size of the amplicon can be used to 
confirm reaction specificity, the LAMP ladder indicates only that amplification has 
occurred, and provides no guarantee that the primers bound their intended target.  
  
To confirm LAMP amplification of the correct target it is possible to sequence the 
LAMP product from a single band of the ladder excised after electrophoresis. 
Sequence specific visual detection of LAMP products is also possible using 
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fluorescently labelled DNA probes and low molecular weight polyethylenimene 
(PEI). A LAMP amplicon-PEI precipitate forms, incorporating the fluorescent 
labelled probes which can be visualised by UV light [131]. Finally endonuclease 
restriction and melting curve analysis e.g. [121] are sometimes used to confirm 
LAMP product specificity. Typically though, once a LAMP assay has been designed, 
optimized and validated positive amplification is assumed to be specific.  
 
The simplest method of endpoint detection is optical turbidity assessment. Turbidity 
is derived from magnesium pyrophosphate formation as a by product of DNA 
polymerization, and is sufficient to be picked up by the naked eye for many LAMP 
reactions [124]. For a less subjective result this can be quantified by an endpoint 
turbidimeter, or monitored throughout by a real-time turbidimeter. Real time 
turbidimetry is particularly useful during assay design and optimization, enabling 
comparisons of the speed and efficiency of the reaction under different conditions.  
 
Several colour change methods for reading the result within the reaction tube have 
also been developed, including (i) DNA intercalating dyes: Quant-iT PicoGreen 
[132], SYBR green [133, 134] and propidium iodide [134] and (ii) metal ion 
indicator methods: calcein alone [135], calcein with MnCl2 [136] and, most recently, 
hydroxynaphthol blue [137].  Metal ion indicators provide a simpler approach than 
the intercalating dyes; they are added alongside the other reagents, before incubation, 
so that amplification and detection are combined in a single processing step, within a 
closed tube system.  The colour changes can be visualised by eye, without special 
lighting, and are inexpensive.  
 
Methods which do not require the reaction tube to be opened after the amplication 
phase are favoured because they minimize the number of processing steps, and 
reduce the potential for laboratory contamination with LAMP products which would 
jeopardize the reliability of future tests.  
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1.4.2 Applications and uptake of LAMP technology  
Since the first description of LAMP in 2000, there has been an explosion of LAMP 
publications describing its application as a molecular diagnostic for a wide range of 
pathogenic agents including Mycobacterium tuberculosis, Plasmodium falciparum, 
Influenza and measles viruses, Salmonella and Eschericia coli to name but a few 
[138].  The original publication describing the LAMP technique has been cited 319 
times (on August 18th 2010), including 275 articles and 32 reviews.  
 
Figure 1.3. Citations per year following the original publication of the 





















Analysis of these citations by subject area reveals LAMP has been applied for the 
detection of bacteria, viruses and parasites, as well as for other diagnostic purposes 
such as sexing. LAMP citations are found within the infectious disease, veterinary 
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sciences, plant sciences, tropical medicine, environmental health, food sciences, 
fisheries and marine biology literature. 
In addition several kits have been developed by Eiken Chemical Company (see 
http://loopamp.eiken.co.jp/e/products/index.html). These kits are summarised in 
Table 1.4. 
 
Table 1.4. Loopamp Detection Kits (developed and marketed by Eiken 
Chemical Company, Japan) 
Field of use Specific application 
Environmental health Legionella detection  
Salmonella detection  
Verotoxin-producing Eschericia coli detection 
Verotoxin typing  
Eschericia coli 0157 detection  
Listeria monocytogenes detection  
Food safety 
Campylobacter detection  
Animal husbandry Bovine embryo sexing  
Research use only Norovirus GI/GII detection  
 
Despite this abundance of activity it remains to be seen whether this will translate 
into uptake and adoption in medical and veterinary public health and clinical 
practise. LAMP is being pursued as a potential clinical tool for tuberculosis and 
sleeping sickness diagnosis, especially by FIND (see section 1.3.6.3). 
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1.4.2.1 Applications of LAMP for identification of African 
trypanosomes 
The LAMP method has already been applied to the detection of African 
trypanosomes. Successful reactions have been reported using purified DNA [139], 
treated blood, serum and cerebrospinal fluid (CSF) samples [127] and dried blood on 
filter papers [140]. Table 1.5 summarises the applications of LAMP technology to 
African trypanosomes. 
 
Table 1.5. LAMP assays developed for the detection of African 
trypanosomes 
Parasite specificity Target gene Reference Year 
Trypanozoon PfrA (paraflagellar rod 
protein A) 
[140] 2003 




T. b. gambiense 5.8S rRNA-ITS2 [141] 2007 
T. evansi RoTat1.2 [141] 2007 
T. b. rhodesiense SRA (serum resistance 
associated gene) 
[122] 2008 
T. congolense P0 (Ribosomal subunit) [140] 2003 
T. congolense 18S rRNA [141] 2007 
 
1.5 Other isothermal amplification techniques 
Despite its prominence in the literature LAMP is not the only isothermal DNA 
amplification method to have been developed in recent years. Here the various 
methods are briefly described and compared, and some relevant applications are 
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highlighted. Many of these systems have been commercially developed into specific 
pathogen detection kits.  
Figure 1.4. Timeline illustrating the development of isothermal 
amplification, and its application to T. brucei s.l.  
1990 2000 2010





1991:Publication of  
NASBA method
1998: Publication of 
RCA as a DNA 
amplification system as 
a sequence specific 
detection assay
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Development of isothermal amplification technologies
2003:Publication of 
NEAR method
2003: LAMP for 
T. brucei s.l., targeting 
the single copy PfrA
gene





(i) LAMP for T. 
brucei s.l. (targeting 
the multicopy RIME 
element 
(ii) LAMP for T. b. 
rhodesiense
targeting the single 
copy SRA gene
(iii) Real time 
NASBA assay for T. 
brucei s.l.
2009: NASBA-OC for T. brucei s.l.




1.5.1 Isothermal, transcription based amplification  
In 1990 the first isothermal and one step transcription based nucleic acid 
amplification system was described [142]. The system generates antisense single 
stranded RNA from a single stranded RNA target via a cDNA intermediate using 
ribonuclease H, reverse transcriptase and DNA dependent RNA polymerase 
(enzymes normally used for retroviral replication). It was named 3SR.Ten million 
fold amplification occurs within 1-2 hours. The method has since been developed 
into the transcription mediated amplification (TMA) and the nucleic acid sequence 
based amplification (NASBA) approaches [143].  
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1.5.1.1 Transcription mediated amplification  
The transcription mediated amplification (TMA) approach is a commercial 
development of the transcription-based system described above. Gen-Probe Inc. have 
developed several high through put TMA assays including the APTIMA COMBO 2 
® Assay for detection and differentiation of Chlamydia trachomatis and Neisseria 
gonorrhoea and the AMPLIFIED MTD ® Assay for Mycobacterium tuberculosis. 
Together with Novartis Vaccines and Diagnostics they have also developed TMA 
based assays for viral infections including the PROCLEIX ® HIV-1/HCV Assay, the 
PROCLEIX ® ULTRIO ® Assay for HIV-1, Hep C and Hep B and the PROCLEIX 
® WNV Assay for West Nile Virus. Gen-Probe Inc have not made general purpose 
reagents commercially available, so at present the TMA approach is restricted to use 
of these kits by high throughput clinical and reference testing centres. 
 
1.5.1.2 Nucleic acid sequence based amplification 
The nucleic acid sequence based amplification (NASBA) method is also based on a 
transcription-mediated mechanism. It was first published in 1991 [144]. The three 
enzymes required (reverse transcriptase, RNAse H and T7 RNA polymerase) are 
available from bioMérieux, in their NucliSense basic kit. Since the start of this study 
NASBA has been applied (by others) to T. brucei s.l. [145, 146]. This assay is 
described as a potential competitor for LAMP based sleeping sickness diagnosis in 
Chapter 9.  
 
1.5.2 Strand displacement amplification  
The strand displacement amplification (SDA) system was first reported in 1992 [147, 
148]. It has been developed into a high throughput DNA amplification assay for 
Chlamydia trachomatis and Neisseria gonorrhoaea by Becton Dickinson and Co. 
(BD ProbeTec™ ET System) for high volume molecular testing in large clinical and 
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reference laboratories (see http://www.bd.com/ds/productCenter/MD-
ProbetecEt.asp) 
 
Thus, SDA and TMA provide evidence that there is a market for, and acceptance of, 
high throughput isothermal amplification systems for molecular testing in large 
clinical and research laboratories, for some diseases. However, neither Becton 
Dickinson nor Gen-Probe Inc have opted to commercialise general purpose reagents, 
which limits the further development and application of these technologies for other 
infectious agents.  
 
1.5.3 Rolling circle amplification 
In 1995 small, single-stranded circular DNAs were first shown to behave as catalytic 
templates for DNA synthesis, in a process that became known as rolling circle 
amplification (RCA), which can occur under isothermal conditions [149, 150]. 
Subsequently this process was developed for sequence specific amplification 
detection [151, 152].  
 
1.5.4 NEAR  
NEAR is a patented technology belonging to Ionian Technologies, which was first 
described by the company’s founder in 2003 [153] (see http://www.ionian-
tech.com/index.html). It can be used to detect DNA or RNA targets, and the 
amplification products can be visualised using a variety of standard methods 
including real-time and endpoint fluorescence, agarose gel electrophoresis and mass 
spectroscopy. It proceeds at 60 ˚C and takes only 5 min. It has a single base 
resolution, with multiplex capabilities. Ionian Technologies are also developing a 
proprietary dipstick method for the detection of amplification products. According to 
their website, they are developing battery operated portable detectors for biothreat 
detection as well as rapid point of care diagnostics with lyophilised reagents stable at 
37 ˚C and 42 ˚C, and requiring minimal sample preparation. In 2008, Ionian 
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Technologies were awarded a Bill & Melinda Gates Foundation grant to develop 
point-of-care diagnostic tests for the developing world with an initial focus on 
Neisseria gonorrhoeae, Chlamydia and Mycobacterium tuberculosis.  
 
1.5.5 Helicase dependent amplification 
Helicase dependent amplification (HDA) [154, 155] was developed by BioHelix 
Corporation (see www.biohelix.com). HDA proceeds by the same mechanism as 
PCR, except that a helicase enzyme is used instead of heat to melt the double 
stranded DNA. BioHelix Corp. have developed 2 product lines: (i) HDA-Inside 
which is a general purpose reagent and (ii) IsoAmp® On Demand Detection Kits for 
the detection of Staphylococcus aureus and Staphylococcus aureus mecA in research 
samples. Endpoint detection is via real-time flourescence detection. Therefore, 
although the amplification reaction itself is isothermal, isothermal incubation 
systems capable of real-time flourescence detection are not commercially available. 
In this format HDA does not constitute a low technology alternative to real-time, or 
traditional, PCR. However, real time detection is not necessary, and a light scanner 
could be used for endpoint detection. Work is also underway to develop a disposable 
lateral flow detection device into which a HDA reaction could be placed directly 
from a heating block. This would enable direct transfer of amplicon onto the strip in 
an enclosed setting, thus reducing the risk of laboratory contamination by the 
reaction products. 
 
1.5.6 Recombinase polymerase amplification  
The recombinase polymerase amplification (RPA) method was first published in 
2006 [156]. It is a proprietary technology of TwistDx (see www.twistdx.co.uk). 
Unlike Gen-Probe Inc and Becton Dickinson and Co., TwistDx have commercialised 
general purpose reagents which can be applied by end users for specific assay 
development. These reagents are supplied in a dried stable format. Although 
TwistDx still recommend refrigeration for long-term storage, a strict cold chain is not 
required during transport, or in the short term.  In addition TwistDx are also 
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developing pathogen specific detection kits for clinical diagnostics, biodefense and 
agriculture. 
 
The reaction uses Bacillus subtillis Pol I (Bsu). DNA purification is not required, but 
amplification can be performed directly on crude samples, e.g. blood. RNA targets 
can also be amplified by addition of reverse transcriptase. The reaction proceeds at 
37 ˚C and exponential amplification is achieved within 5-10 minutes. Several 
endpoint detection methods are possible, including standard gel electrophoresis, 
lateral flow strip detection and real-time and endpoint fluorescence using TwistDx 
fluorescent probe systems. This method has the capacity for multiplex detection. 
 
1.6 Evaluating diagnostics  
Before it can be usefully applied a diagnostic must be properly evaluated. However, 
concerns have been raised about the lack of rigorous and transparent evaluation for 
diagnostic tests, particularly those for use in developing countries. Many countries do 
not have regulatory standards for diagnostic tests, which means they can often be 
sold in the developing world without any formal evaluation of their performance and 
effectiveness [2, 3].  
 
1.6.1 The evaluation process 
Diagnostic evaluation is a several step process. Three distinct phases can be defined. 
In Phase 1 proof of principle studies are performed to provide evidence that the test 
detects the intended target. In Phase 2 the candidate test is evaluated in a case control 
study. These studies might make use of fresh patient, or archived samples. In Phase 3 
the test is validated in the target population using a large-scale prospective study.  
 
Several different characteristics need to be evaluated. First, test performance is 
critical. This is assessed by calculating the sensitivity and specificity, as well as the 
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positive and negative predictive values of a test. In addition to test performance the 
ease and conditions of use, the conditions of storage and the shelf life are key factors 
that must be evaluated. Finally, it is important to assess the reliability of any test. 
 
1.6.1.1 Sensitivity and specificity 
Sensitivity is the proportion of true positives that are detected. It represents the 
probability that the test will produce a true positive result when used on an infected 
population as compared to a reference or ‘gold standard’.   
Specificity is the proportion of true negatives that are detected by the test. It 
represents the probability that the test will produce a true negative result, compared 
to the ‘gold standard’, when used on a non-infected population.  
Sensitivity and specificity are innate test characteristics that do not vary with 
prevalence. However, sensitivity and specificity estimates may vary among 
populations and subpopulations depending on the distribution of influential 
covariates. In practice sensitivity and specificity tend to be estimated as average 
values across non-homogenous populations. In reality, stratum-specific estimates 
might be more informative [5]. 
 
1.6.1.2 Predictive values 
The positive predictive value (PPV) of a test is the probability that a person is 
infected when a positive test result is observed. The negative predictive value (NPV) 
is the probability that a person is not infected when a negative test result is observed. 
Unlike sensitivity and specificity, the predictive values of a test vary depending upon 
the prevalence of the condition being tested for in a specific population.  
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1.6.1.3 Kappa: a chance adjusted measure of agreement 
Cohen’s kappa statistic (κ) [157] can be used to quantify the level of agreement 
between the diagnostic and the gold standard. This gives a better indication of the 
concordance between the two techniques than percentage agreement, since it 
accounts for the agreement expected by chance.   
 
1.6.1.4 Reliability 
The reliability of a test can be defined as ‘a measure of the extent to which replicate 
analyses using identical procedures agree with each other’ [3]. Kappa, as described 
above, provides a useful measure for such agreement. Several different types of 
reproducibility might need to be evaluated. The intrinsic repeatability of the test itself 
is foremost. Once this has been established it is important to investigate 
reproducibility with different operators, at different test sites, with different kit lots 
and on different days. Ideally, reproducibility should be evaluated in a blinded study. 
The reliability of borderline diagnoses might be particularly important.  
 
The calculation of sensitivity, specificity, positive and negative predictive value and 
Cohen’s kappa statistic are described in the general methods (Chapter 2). 
 
1.7 Identification and discrimination of the T. brucei s.l. sub-
species: a historical overview 
This thesis focuses on molecular detection of the human-infective African 
trypanosomes. It is therefore important to understand the background and discovery 
of key molecular markers in these organisms.  
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1.7.1 Discovery of the T. brucei s.l. subspecies 
Trypanosoma brucei was discovered in 1895, among wild and domestic animals in 
Zululand, by Sir David Bruce [158, 159]. Trypanosome infection of man was later 
discovered in the blood of a steam boat captain on the River Gambia [160] and 
named T. gambiense. In 1903, trypanosomes were shown to be the causal agents of 
sleeping sickness with Glossina palpalis incriminated as the vector. Later, another 
human-infective trypanosome was identified from a sleeping sickness patient in 
Rhodesia [161], and named T. rhodesiense. These two were later reclassified as T. b. 
gambiense and T. b. rhodesiense. At first they were determined to be separate species 
based on morphological differences and transmission via different Glossina species 
[162]. However, they are now considered to be morphologically indistinguishable. At 
first T. brucei and T. rhodesiense were thought to be one species, however 
differences in the distribution of human and animal infections soon convinced many 
that these were different parasites [163]. Overtime several different experimental 
approaches have been used to determine the taxonomic relationship between these 
trypanosomes, and to find a consistent differentiation methodology. 
 
1.7.2 The discovery and characterisation of the SRA gene 
for the identification of T. b. rhodesiense 
From 1934 to 1955, during what was known as the Tinde experiment, T. b. 
rhodesiense was passaged through a series of experimental hosts over several years. 
The human infectivity of the passaged strains was periodically retested by 
inoculation into human ‘volunteers’ and proved to be an unstable, but persistent, 
characteristic of T. b. rhodesiense [164]. Following the Tinde experiment, in 1970, 
Rickman and Robson [165] developed the Blood Incubation Infectivity Test (BIIT) 
to assess the human infectivity of T. brucei s.l. strains. Using this test resistance to 
human serum was again shown to be an unstable characteristic which varies with 
strain passage [166]. In addition human serum resistance was shown to vary with the 
antigenic type of a given strain [167, 168].  
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It became possible to search for the difference between sensitive and resistant lines at 
a genetic level. By comparing the cDNA of human serum sensitive and serum 
resistant clones which expressed the same VSG a single, differentially expressed, 
gene was identified. This became known as the serum resistance associated, or SRA 
gene [24]. Later the same gene was independently isolated from a different T. b. 
rhodesiense strain [169].  
 
SRA alone was shown to confer human serum resistance to T. b. brucei [170]. This 
together with an accidental infection of T. b. brucei transfected with the SRA gene 
[171] provided conclusive evidence for the role of SRA in human serum resistance in 
T. brucei rhodesiense. The mechanism by which the SRA protein confers this 
resistance was discovered later; in 2003 Vanhamme et al. demonstrated that SRA is a 
lysosomal protein whose amino terminal alpha helix interacts strongly with the 
carboxy terminal alpha domain of apolipoprotein L1 [28]. Since the SRA gene is 
found in a VSG expression site [170], it is only expressed when the resistance 
expression site (R-ES) is active. This explains the variability human serum resistance 
observed with antigenic variation. 
 
The SRA gene appears to have arisen as a result of a 378 bp deletion within what was 
originally a VSG gene and the putative breakpoints for this deletion are conserved. 
[172, 173]. This has implications for primer design. Ideally primers should span the 
deletion site in order to be specific for SRA [108]. 
 
Since its discovery several PCR assays targeting SRA have been developed and have 
demonstrated its presence in all T. b. rhodesiense strains tested [33, 52, 54, 174-176]. 
At present there is no definitive marker for T. b. brucei, and therefore it is difficult to 
prove that SRA is absent in this species, however the SRA gene is conspicuously 
absent in strains known, or presumed, to be T. b. brucei [171]. Thus the SRA gene is 
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considered to be a ubiquitous and reliable diagnostic marker for T. b. rhodesiense as 
tested throughout its host and geographic ranges.  
 
We now know that there are two main SRA variants; the ‘northern’ and ‘southern’ 
sequences [52, 54, 169, 172] which correlate with previously observed clinical 
differences [47, 54]. Despite slight variation between these sequences the SRA 
sequence is generally conserved across its geographic range, with less than 3 % 
sequence variation observed in isolates from disease foci spread across Ethiopia, 
Kenya, Tanzania, Uganda and Zambia [52]. The genomic position of the SRA gene is 
similarly conserved, downstream of ESAG 5, but again there is slight variation 
between the northern and southern SRA sequences.  
 
The observed sequence and positional conservation contrasts with the extensive 
genetic variability seen with biochemical strain analysis. This has led to the 
suggestion that SRA arose once by a deletion event, and subsequently spread into 
different T. b. brucei genetic backgrounds by genetic exchange [171]. 
 
1.7.3 The discovery and characterisation of the TgsGP gene 
for the identification of T. b. gambiense 
Following the discovery of the SRA gene it was proposed that another similar 
truncated VSG might similarly be responsible for human infectivity in T. b. 
gambiense. To test this hypothesis reverse transcriptase linked PCR (RT-PCR) was 
used to identify VSG like transcripts from T. b. gambiense LiTat 1.3 RNA.  Two 
cDNAs carrying the 14 nucleotide VSG signature were obtained; regular VSG and a 
smaller transcript, subsequently named TgsGP. In the same publication the authors 
demonstrated that TgsGP encodes a 47kDa protein with a GPI-anchored VSG N-
terminal domain, but without a typical VSG C terminal domain. They identified 
remarkable sequence similarity between amino acids 1-376 of TgsGP and the N-
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terminal domain of T. brucei ILTat 1.23 VSG as well as between the next 27 amino 
acids of TgsGP and a C terminal section of T. brucei MITat 1.1 VSG [25].  
 
However, TgsGP does not confer resistance to lysis by normal human serum. 
Although its exact function is unknown, several features suggest that it is a surface 
receptor which interacts with host components. It is surface exposed and 
concentrated at the flagellar pocket, has a similar structure to the trypanosome 
surface receptor, transferrin, and like other known components of the endocytotic 
machinery, is modified by the addition of pNAL [25]. 
 
In 2002 Radwanska et al. developed a PCR for the TgsGP gene [109]. Primers were 
designed avoiding the region which shares sequence similarity with the T. b. brucei 
IlTat 1.23 VSG gene  and were carefully targeted to bind at the 3’ end, where 
similarity to possible ancestral/ related genes is lost [109, 177]. Since the TgsGP 
sequence is well conserved in Group 1 T. b. gambiense, regardless of geographic 
origin, making it an ideal target for molecular detection of this parasite [177]. Using 
DNA extracted from trypanosome isolates the PCR was specific for conventional 
fully serum resistant T. b. gambiense  (it successfully detected TgsGP in 13 Group 1 
T. b. gambiense isolates, but not in two Group 2 T. b. gambiense or 58 other non T. b. 
gambiense isolates). The PCR was further validated using total DNA extracted from 
92 sleeping sickness patients from Côte d’Ivoire. The results corresponded exactly to 
parasite detection by mAECT. A single round PCR could detect down to 1000 
trypansomes ml-1 and this was improved to 10 trypanosomes ml-1 when a nested 
approached was used. 
 
The assay was further developed and applied by Picozzi et al. [32], who developed a 
nested PCR protocol with additional outer primers, spanning the Radwanska target.   
 
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human 
sleeping sickness: towards a point-of-care diagnostic test 
Chapter 1. Introduction 52 
In humans TgsGP PCR has been used to investigate seropositive aparasitaemic 
patients. The TgsGP PCR was not consistent for these subjects and results did not 
agree with serological or parasitological detection. The utility of TgsGP PCR as a 
clinical diagnostic remains unclear. More fundamentally, the existence of a PCR 
positive, but otherwise indetectable reservoir of T. b. gambiense remains an 
unproven hypothesis, with significant potential epidemiological implications [45, 
92]. 
 
TgsGP PCR has also been applied to animal populations, for example peridomestic 
livestock in Equatorial Guinea [178]. In this study, livestock were shown to harbour 
T. b. gambiense in some but not all disease foci. Again this has implications for our 
understanding of the epidemiology of Gambian sleeping sickness. 
 
1.8 Prospects for point-of-care molecular diagnosis of sleeping 
sickness  
Molecular diagnosis of Gambian and Rhodesian sleeping sickness is possible, by 
well established PCR assays, thanks to the discovery of the SRA and TgsGP genes. 
However, PCR is not suitable for point-of-care diagnosis. It is restricted to use in 
resource rich, often remote, research laboratories. LAMP is being promoted as a low 
technology DNA amplification technique suitable for the detection and identification 
of many and varied disease agents in low resource settings. LAMP assays for 
sleeping sickness have been published but have not been validated, either as 
epidemiological surveillance, or clinical diagnostic tools. There is a need to define 
the user requirements and performance standards for a high impact sleeping sickness 
diagnostic. If LAMP can fulfil these user requirements and performance standards it 
could be useful as a clinical diagnostic. LAMP may also be useful for remote 
epidemiological surveillance of sleeping sickness, as a cheaper, quicker, more 
sensitive alternative to PCR. The current trend for point-of-care diagnostics is 
towards a handheld or disposable device, with minimal to no additional 
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instrumentation requirements. In its current format LAMP technology does not meet 
these standards. However innovation is constant and many are striving to incorporate 
LAMP into a handheld device e.g. [179-181]. LAMP holds great potential as an 
improved molecular diagnostic for sleeping sickness. 
 
With all of the above in mind the principle aims of this study are outlined below. 
 
1.9 Thesis Aims 
1. To determine whether LAMP assays for Trypanozoon detection might be a 
useful and simpler alternative to PCR as part of remote epidemiological 
surveillance studies of zoonotic parasites in the cattle reservoir. 
2. To validate the published LAMP primers and assay for T. b. rhodesiense by 
comparison to the multiplex PCR for SRA as a reference test. 
3. To design novel LAMP primers targeted to SRA accounting for its similarity 
to VSG genes. 
4. To validate the published LAMP primers and assay for T. b. gambiense by  
comparison to the nested PCR for the TgsGP gene as a reference test. 
5. To apply simple methods of LAMP endpoint detection to LAMP HAT 
assays. 
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2 Chapter 2: Materials and Methods 
2.1 Samples 
Three different types of DNA samples were used.  These were: (i) commercially 
available human and cattle genomic DNA; (ii) DNA extracted from cryopreserved 
trypanosome isolates and (iii) DNA eluted from human and cattle blood stored on 
Whatman FTA cards.  
 
2.1.1 Commercially available human and cattle genomic 
DNA 
Genomic DNA from human placenta (D4642, Sigma, UK) and unsheared genomic 
DNA from calf thymus (D4764, Sigma, UK) were used as templates to check for 
cross reactions of trypanosome specific LAMP assays with host DNA. Dilution 
series in water were prepared from these DNA samples. For the human DNA 1 ml of 
water was added to 0.25 A260 units of DNA, to give a solution 0.0125 mg ml-1.  
(One A260 unit is equivalent to 50 μg DNA). A tenfold dilution series was made and 
1 μl of these dilutions was used to seed each LAMP reaction. By taking 1 μl of the 
0.0125 mg ml-1 solution, 12.5 ng of DNA was added to the reaction mix.  
 
For the cattle DNA 1 ml of water was added to 1 A260 unit of DNA. Given that there 
are approximately 20 A260 units per μg DNA, 1 unit is equivalent to 0.05 mg DNA. 
Therefore we have a 0.05 mg ml -1 solution. Taking 1 μl of this solution provides us 
with 50 ng DNA. A ten fold dilution series was made from this starting solution and 
1 μl of these dilutions was used to seed each LAMP reaction.  
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2.1.2 Cryopreserved trypanosome samples 
In total 86 samples were recovered from storage in liquid nitrogen. They were kept at 
-80 °C until processing (approximately 1 week). The sample set was chosen to 
include Trypanosoma brucei brucei, Trypanosoma brucei gambiense and 
Trypanosoma brucei rhodesiense. The isolates were either procyclic cultures frozen 
in Cunningham’s media, with glycerol, or were bloodstream forms preserved in PSG 
Glycerol [182]. Although the majority of the isolates had been passaged through 
mice several times before their DNA was obtained, some were original isolates from 
the field. The samples were taken from cattle, humans, pigs and flies between 1968 
and 1998. Individual sample details are given in Appendix 1. Twelve of these 
samples were taken from stocks that had been previously described as T. b. 
gambiense in the published literature (samples 5, 12, 17, 18, 19, 21, 22, 23, 58, 61, 
62 and 75), of which nine belonged to Group 1 (samples 5, 12, 17, 18, 21, 22, 23, 58, 
and 62).   A summary of the published isoenzyme analyses upon which the Group 1 
and 2 identifications have been made can be found in Appendix 11. 
 
In addition T.congolense ((Fly148) and T. vivax (TREU 1722) DNA that had been 
previously extracted from cryopreserved blood stream form trypanosomes using the 
Qiagen DNAeasy Blood and Tissue Kit (QIagen, UK), were used in Chapter 3 to 
assess the specificity of LAMP RIME and LAMP PfrA. 
 
Frozen T. b. brucei (But135) and T. b. rhodesiense (DO) procyclic cultures were also 
used to obtain purified DNA for the initial screening of novel LAMP primers for T. 
b. rhodesiense (Chapter 4). But135 was isolated from a cow in Buteba village, 
Uganda in 1990 [183]  while DO was isolated from a human patient in Southeast 
Uganda in 1990 [184].  
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2.1.2.1 DNA extraction from cryopreserved samples 
DNA was extracted from the samples using a commercial kit (QIAamp DNA Blood 
Midi Kit, QIAGEN). First the samples were allowed to thaw at room temperature, 
before being transferred to screw-top tubes for washing and resuspension in 
phosphate buffered saline (PBS) as follows: centrifugation (3000 rpm, 5 minutes), 
removal of the supernatant and resuspension in 1 ml of PBS, followed by a second 
spin (3000 rpm, 5 minutes) and the final supernatant removal and pellet resuspension 
in 1 ml PBS. Pellets were not always visible, in which case only 80 % of the 
supernatant was removed and PBS was added to make the final volume of the sample 
back up to 1 ml. 
 
The extraction protocol was performed according to the manufacturer’s protocol. The 
cells within the prepared samples were lysed by adding the 1 ml samples to 100 µl of 
QIAGEN protease followed by 1.2 ml of Buffer AL. The mixture was shaken 
vigorously, incubated at 70 °C in a water bath for at least 10 minutes, 1 ml of ethanol 
was then added and the mixture shaken vigorously again. The sample DNA was then 
bound to the QIAamp Midi Column membrane by spinning the solution at 3000 rpm 
for 3 min, in a QIAamp Midi Column, placed in a 15 ml centrifuge tube. The filtrate 
was discarded and 2 ml of Buffer AW1 were added to the Midi column and the tubes 
were span at 5000 rpm for 1 min, before adding 2 ml Buffer AW2 and spinning 
again, at 5000 rpm for 15 min. Buffers AW1 and AW2 were both used to wash the 
DNA bound to the membrane and the filtrate from these two spin steps was 
discarded. The QIAamp Midi Columns were placed in fresh 15 ml collection tubes. 
Finally, to elute the DNA from the QIAamp midi column membrane, 200 µl of 
Buffer AE was pipetted onto the membrane and left to incubate at room temperature 
for 5 min. DNA was collected by spinning at 5000 rpm for 2 min. To maximize the 
DNA yield this elution process was then repeated, with fresh Buffer AE and a second 
spin step (5000 rpm, 2 min) before the DNA from the collection tube was transferred 
to a smaller, screw top tube, for transportation and storage. Samples were stored in 
the refrigerator. No special arrangements were made to keep the samples cool during 
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transport to Japan. During the flight they were transported in the hold and the journey 
was made during winter, so there was little opportunity for them to experience warm 
temperatures. 
 
DO and But135 DNA, used in Chapter 4, were purified using the Qiagen DNeasy kit 
by following the manufacturer’s protocol: ‘Purification of Total DNA from Animal 
Blood or Cells (Spin-Column Protocol)’ (Qiagen). First the stock solutions were 
allowed to thaw at room temperature and diluted by the addition of 1 ml of water. 
The sample was lysed by the addition of proteinase K, and the buffering conditions 
were optimised so that DNA bound onto the DNeasy mini spin column membrane 
during the subsequent centrifugation step. Two wash steps ensured the removal of 
contaminants from the membrane before the DNA was eluted. 
 
2.1.2.2 Molecular characterisation of DNA extractions 
The DNA concentration in each sample was measured using a NanoDrop 
spectrophotometer (Thermo Fisher Scientific). The 86 samples were then subject to 
the TCS PCR for the detection of Trypanosoma congolense savannah, TBR PCR for 
Trypanozoon detection, the nested TgsGP PCR for identification of T. b. gambiense 
and the multiplex SRA PCR for the identification of T. b. rhodesiense as described 
below. 
 
In addition the ITS1 rDNA PCR [185] was performed to give a positive 
identification of the Fly 148 and TREU 1722 DNA samples used in Chapter 3  as T. 
congolense or T. vivax. 
 
2.1.3 FTA card samples 
Whatman FTA cards contain a chemically treated fibre matrix that lyses cells, 
inactivates proteins and immobilises DNA, making them suitable for long term 
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storage of blood samples. In this study both human and cattle blood samples that had 
been stored on FTA cards were used. Our standard laboratory protocol for 
preparation of these samples is described. It is based on the protocol published by 
Becker et al [186]. 
 
The first step in the preparation of these samples for PCR or LAMP was to take 
punches using either (i) a Harris Micro Punch (Whatman BioSciences Ltd) on a filter 
paper and cutting mat backing, or (ii) a Plier Craft Punch (Woodware).The number 
and diameter of the punches varied according to the particular experiment, as 
described in the methods sections of the subsequent chapters. Punches were placed in 
Eppendorf tubes. Five blank punches were made on filter paper between each sample 
and discarded, to avoid carry over of FTA card sample material between samples. 
Blank filter paper punches were also taken as negative controls for the FTA card 
preparation process. 
 
Each set of punches was washed twice, with agitation, for 15 minutes each in 1 ml 
FTA purification reagent (Whatman) in order to remove blood intrinsic PCR 
inhibitors. This was followed by two further 15 min wash steps, with agitation, in 1 
ml TE buffer (10 mM Tris-HCL pH 8.0; 1 mM EDTA pH 8.0) in order to remove the 
FTA purification reagent, which also inhibits the PCR reaction. The washed punches 
were transferred to open PCR tubes and allowed to dry for 30 min at 37 ˚C. DNA 
was eluted by adding 50 μl of 5 % (w/v) Chelex suspension to each sample, and 
heating at 90˚C for 30 minutes. Eluted DNA was stored at -20 ˚C. Five microliters of 
eluted DNA was used to seed a PCR or LAMP reaction.  
 
2.1.3.1 FTA card samples used in Chapter 3 
Two sets of cattle blood samples stored on Whatman FTA cards were used in 
Chapter 3. The first set were collected in 2008, as part of ongoing epidemiological 
studies on the prevalence of T. brucei s.l. in Uganda, during the Stamp Out Sleeping 
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Sickness campaign [187] and were used to compare LAMP PfrA, LAMP RIME and 
TBR PCR. These samples comprised 100 μl venous blood, collected from the ear of 
the cattle and stored on Whatman FTA cards. Blood was collected after cattle were 
cast to the ground by their owners. At the end of the day, or as soon as time 
permitted, the cards were stood out to dry before being packed into envelopes with 
silica gel desiccant for storage and transport. 
 
The second set (105 samples) were taken from our laboratory archives for checking 
the specificity of LAMP RIME and LAMP PfrA. They had been collected in Zambia 
in 1997 and 1998, and were stored on Whatman FTA cards. Previously species 
identification PCR assays had been performed for: (i) T. congolense savannah [188]; 
(ii) T. congolense forest [188]; (iii) T. congolense Kilifi [188]; (iv) T. congolense 
Tsavo [189]; (v) T. vivax (3 distinct PCR assays)  [188, 190, 191]; (v) Trypanozoon 
(2 distinct PCR assays) [107, 192]. Each PCR assay had been seeded with a single 2 
mm FTA card disc, which had been washed according to the usual protocol.  
 
For both sets, five 3 mm punches were washed and dried and the DNA was eluted 
into 100 μl chelex (5 % w/v) suspension. DNA was prepared as described above. All 
PCR and LAMP reactions were seeded with 5 µl DNA eluted from the FTA card 
cattle blood samples.  
 
2.1.3.2 FTA card samples used in Chapter 7 
DNA was eluted from 52 human blood samples that were collected onto Whatman 
FTA cards between 2004 and 2006 from South East Uganda.  Samples were 
collected from parasite positive patients (as determined by microscopy) as part of 
routine surveillance in conjunction with the Ugandan Ministry of Health. Three 2 
mm punches were washed and dried according to usual protocol (Section 2.1.3) and 
the DNA was eluted into 100 μl chelex solution.   
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DNA was also eluted from 48 cattle blood samples collected onto Whatman FTA 
cards in central Uganda, October 2008 as part of ongoing monitoring of trypanosome 
prevalence in cattle for the SOS campaign (see 
www.stampoutsleepingsickness.com). Five 3 mm punches were taken, they were 
washed and dried according to usual protocol (Section 2.1.3) and the DNA was 
eluted into 100μl chelex solution.   
 
2.2 PCR reactions 
Four different standard PCR assays for the detection of Trypanosoma congolense 
savannah, Trypanozoon, T. b. gambiense and T. b. rhodesiense DNA were used 
throughout this work. All three are published methods and the primers are described 
in Table 2.1 below. 
 
2.2.1 Trypanosoma congolense PCR reaction 
PCR confirmation of T. congolense savannah DNA was made using the TCS PCR 
primers [188] which target a 369 bp satellite repeat sequence, first identified by 
restriction digest analysis and estimated to constitute approximately 5 % of the T. 
congolense nuclear DNA [107] . The reaction composition and cycling conditions 
were as follows: each 25 μl reaction contained 16 mM (NH4)2SO4, 67 mM Tris-HCl 
(pH 8.8 at 25 oC), 0.01% Tween-20, (collectively 10x NH4 Reaction Buffer, Bioline), 
1.5 mM MgCl2 (Bioline), 1 U REDTaq (Bioline), 200 μM of each of the four dNTPs 
(Bioline), and 1 μM of each primer (TCS1 and TCS2). Thermal cycling was carried 
out as follows: 94 oC for 3 min followed by 30 cycles of 94 oC for 1 min, 55 oC for 2 
min and 72 oC for 2 min, with a final extension step of 72 oC for 5 min. The expected 
band size was 316 bp.  
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2.2.2 Trypanozoon specific PCR reaction 
Throughout this thesis PCR identification of Trypanozoon DNA was made using the 
TBR PCR primers [107] which target a 177 bp satellite repeat sequence [193, 194] of 
which there are 10000 copies per haploid genome. Twenty years after being first 
described in the literature this PCR assay remains the method of choice for the 
molecular detection of Trypanozoon parasites, having been successfully applied in 
several large-scale epidemiological studies [32, 195] using DNA from blood samples 
collected onto Whatman FTA cards. It is sensitive to as little as 0.01 pg of DNA.  
 
The reaction composition and cycling conditions were as follows: each 25 μl reaction 
contained 16 mM (NH4)2SO4, 67 mM Tris-HCl (pH 8.8 at 25 oC), 0.01 % Tween-20, 
(collectively NH4 Reaction Buffer, Bioline), 1.5 mM MgCl2 (Bioline), 0.7 U 
REDTaq (Bioline), 200 μM of each of the four dNTPs (Bioline), and 0.8 μM of each 
primer (TBR1 and TBR2). Thermal cycling was carried out as follows: 94 oC for 3 
min followed by 35 cycles of 94 oC for 1 min, 55 oC for 1 min and 72 oC for 30 s, 
with a final extension step of 72 oC for 5 min. The expected band size was 173 bp.  
 
2.2.3 T. b. gambiense specific PCR reaction 
PCR identification of T. b. gambiense was made using a nested PCR designed to 
target the TgsGP gene [32]. At the first round each 25 μl reaction contained 1.5 U 
HotStar Taq (Qiagen), 1 x NH4 buffer (accompanying buffer for HotStar Taq 
(Qiagen)) containing 1.5 mM MgCl2, 200 μM each of the four dNTPs (Bioline) and 
1 μM each primer (TgsGPf1 and TgsGPr1). The reaction was initiated with a 15 min 
denaturation step at 95 ˚C, followed by 40 cycles of 94 ˚C for 40 seconds, 56 ˚C for 
45 seconds and 72 ˚C for 45 seconds, and finally a 10 min extension step at 72 ˚C. 
The second round of PCR was always seeded with 1 μl of the first round product. 
Each 25 μl reaction contained 2.5 U HotStarTaq (Qiagen), 1 x NH4 buffer with 1.5 
mM MgCl2, 5 μl of buffer Q (20 mM Tris-HCl pH 8.7, 100 mM KCl, 50 mM 
(NH4)2SO4), 200 μM of each dNTP and 0.5 μM of each primer. This second round 
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reaction was initiated with a 15 min denaturation step at 95 ˚C, followed by 40 cycles 
of 94 ˚C for 1 min, 64 ˚C for 1 min and 72 ˚C for 1 min, and finally a 10 min 
extension step at 72 ˚C. These are in accordance with the published protocols, except 
that in the first round the extension step was left for 10 rather than 5 min and in the 
second round a 64 ˚C 1 min step was used instead of a 63 ˚C 1 min step. This was in 
line with the protocol used in our laboratory. The expected band size was 308 bp. 
 
2.2.4 T. b. rhodesiense specific PCR reaction 
The published multiplex PCR reaction for amplification of the GPI-PLC and SRA 
genes was used for the identification of T. b. rhodesiense [174]. A GPI-PLC band 
indicates the presence of sufficient genomic material for the amplification of a single 
copy gene and amplification of SRA is diagnostic of T. b. rhodesiense. The reaction 
was performed according to the published protocol. Each 25 μl reaction contained 
1.5 U HotStar Taq, 1 x NH4 buffer (accompanying buffer for HotStar Taq (Qiagen)) 
1.25 μl Rediload dye (Invitrogen), 200 μM each dNTP, 3 mM MgCl2 (Qiagen) and 
0.2 μM each of four primers: SRA F, SRA R, PLC F and PLC R to amplify the SRA 
and PLC genes respectively. In some cases Rediload dye was not included, and the 
volume was made up to 25 μl using additional H20. The reaction was initiated with a 
15 min denaturation step at 95 ˚C, followed by 35 cycles of 94 ˚C for 30 s, 63 ˚C for 
90 s and 72 ˚C for 70 s, and finally a 10 min extension step at 72 ˚C. The expected 
band sizes for this multiplex PCR are 324 bp for a PLC amplicon, > 1kb for a VSG 
amplicon and 669 bp for an SRA amplicon. For T. b. rhodesiense one would expect 
all three bands to be present. For other T. brucei s.l. the VSG and PLC bands alone 
are expected. The PLC band is an internal control to check that the quality and 
quantity of DNA in the sample is adequate for PCR amplification of a single copy 
gene.  
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2.2.5 ITS PCR 
The ITS1 rDNA PCR [185] was performed to give a positive identification of the 
DNA samples as T. congolense or T. vivax. This single PCR can detect and identify 
all pathogenic trypanosomes.  Each transcribed unit comprises 18S, 5.8S and 28S 
rRNA genes separated by two internal transcribed spacer regions [196-198]. The CF 
and BR primers bind to the 18S and 5.8S rDNA respectively for amplification the 
ITS1 region, which varies in size, enabling discrimination between trypanosome 
species [185]. Each 25 μl reaction contained 0.5 U BioTaq (Bioline, UK), 1 x NH4 
buffer (Bioline, UK) containing16 mM (NH4)2SO4, 67 mM Tris-HCl (pH 8.8 at 25 
oC), 0.01 % Tween-20, 2 mM MgCl2 (Bioline, UK), 0.4 μM CF and BR primers, 
200 μM each dNTP and water. Thermal cycling was carried out as follows: 95 oC for 
5 min followed by 35 cycles of 94 oC for 4 min, 58 oC for 30 s and 72 oC for 90 s, 
with a final extension step of 72 oC for 2 min. A 700 bp band was expected for T. 
congolense savannah or forest, 250 bp for T. vivax and 480 bp for any member of the 
sub-genus Trypanozoon.   
 
2.2.6 Identifying PCR positive reactions 
Reaction products were held at 4 ˚C pending analysis. The reactions products were 
analysed by gel electrophoresis and UV illumination to detect the presence of an 
appropriately sized band corresponding to the size of the amplified fragment of 
DNA. Gel electrophoresis was performed at 100 V in a 1% TBE-agarose gel 
containing either ethidium bromide or GelRed (Biotium). The use of GelRed 
replaced ethidium bromide in our laboratory during the course of this work because it 
is a safer and more sensitive alternative that can be used with the same imaging 
system. For those reactions in which Rediload dye was not included in the reaction 
mix Gel Loading Buffer (Sigma) was mixed with the reaction products prior to 
loading into the gel.  
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Table 2.1. PCR primer sequences used for identification of 
Trypanosoma congolense savannah, Trypanozoon DNA and species 










TCS1 CGAGAACGGGCACTTTGCGA T. congolense 
savannah 
316 bp 
satellite TCS2 GGACAAACAAATCCCGCACA 
TBR1 CGAATGAATATTAAACAATGCGCAGT Trypanozoon 177 bp 




T. b. gambiense TgsGP 
TgsGPr2 GCCATCGTGCTTGCCGCTC 
SRA F GAAGAGCCCGTCAAGAAGGTTTG  SRA 
SRA R TTTTGAGCCTTCCACAAGCTTGGG 
PLC F CGCTTTGTTGAGGAGCTGCAAGCA 
T. b. rhodesiense 
PLC 
PLC R TGCCACCGCAAAGTCGTTATTTCG 
 
2.3 LAMP reactions 
Four different published LAMP assays for the detection of Trypanozoon, T. b. 
gambiense and T. b. rhodesiense DNA were used throughout this work and are 
described in more detail below. The primer sequences are given in Tables 2.2, 2.3 
and 2.4 below. 
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2.3.1 Trypanozoon specific LAMP  
Two Trypanozoon specific LAMP reactions have been used in this study, one 
targeting the single copy paraflagellar rod protein A (PfrA) gene (henceforth referred 
to as LAMP PfrA) [140] and a second targeting the multicopy RIME element 
(henceforth referred to as LAMP RIME) [121]. 
 
For LAMP PfrA each 25 μl reaction contained 8 U Bst DNA polymerase (New 
England Biolabs), 2.5 μl Thermopol reaction buffer I with additional MgSO4 (New 
England Biolabs) to give 20 mM Tris-Cl, 10 mM KCl, 10 mM (NH4)SO4, 0.1 % 
Triton X-100 and 8 mM MgSO4, 0.8 M betaine (Sigma Aldrich), 1.4 mM of each of 
the four dNTPs (Bioline), 1.6 μM of both FIP and BIP and 0.2 μM of both F3 and 
B3, the LAMP primers. When performed in a thermal cycler, or simple heating 
block, the reaction mix was incubated at 65 °C for 1 hour followed by termination at 
80 °C for 2 min. Reaction products were then held at 4 °C until analysis. When the 
reaction was performed in the Loopamp Real Time Turbidimeter (Eiken Chemical 
Co. Ltd.) the reaction was simply held at 65 °C for 90 min. Note that the detergent 
(Triton X-100) in the reaction buffer is different to the detergent in the reaction 
buffer used by the original authors (Tween 20). 
 
For LAMP RIME each 25 μl reaction contained 8 U Bst DNA polymerase (New 
England Biolabs), 2.5 μl Thermopol reaction buffer I (New England Biolabs) to give 
20 mM Tris-Cl, 10 mM KCl, 10 mM (NH4)SO4, 0.1 % Triton X-100 and 2 mM 
MgSO4, 0.8 M betaine (Sigma Aldrich), 200 µM of each of the four dNTPs 
(Bioline), 2 µM of both FIP and BIP, 0.2 µM of both F3 and B3 and 0.8 µM of both 
LF and LB. When performed in a thermal cycler, or simple heating block, the 
reaction mix was incubated at 62 °C for 1 h followed by termination at 80 °C for 4 
min. This follows the published protocol exactly. Reaction products were then held 
at 4 °C until analysis. When the reaction was performed in the Loopamp Real Time 
Turbidimeter (Eiken Chemical Co. Ltd.) the reaction was simply held at 62 °C for 90 
min. 
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2.3.2 T. b. rhodesiense specific LAMP  
When this work started in 2008 and at the time of writing a single published LAMP 
reaction designed to identify T. b. rhodesiense could be found in the literature [122]. 
This assay was performed in the current work according to this published protocol. 
Each 25 μl reaction contained 8 U Bst DNA polymerase (New England Biolabs), 2.5 
μl Thermopol reaction buffer I (New England Biolabs) to give 20 mM Tris-Cl, 10 
mM KCl, 10 mM (NH4)SO4, 0.1 % Triton X-100 and 2 mM MgSO4, 0.8 M betaine 
(Sigma Aldrich), 200 µM of each of the four dNTPs, 2 µM of both FIP and BIP, 0.2 
µM of both F3 and B3 and 0.8 µM of both LF and LB. When performed in a thermal 
cycler, or simple heating block, the reaction mix was incubated at 62 °C for 1 h 
followed by termination at 80 °C for 4 min. Reaction products were then held at 4 °C 
until analysis.   
 
2.3.3 T. b. gambiense specific LAMP  
Similarly, one published LAMP assay designed to identify T. b. gambiense could be 
found in the literature [141]. In the current work this assay was performed according 
to the published protocol, except for the use of Triton X-100 containing buffer in 
place of Tween-20 containing buffer. All other buffer constituents were identical. 
Each 25 μl reaction contained 8 U Bst DNA polymerase (New England Biolabs), 2.5 
μl Thermopol reaction buffer I with additional MgSO4 (New England Biolabs) to 
give 20 mM Tris-Cl, 10 mM KCl, 10 mM (NH4)SO4, 0.1 % Triton X-100 and 8 mM 
MgSO4, 0.8 M betaine (Sigma Aldrich),  1.4 mM of each of the four dNTPs, 1.6 μM 
of both FIP and BIP and 0.2 μM of both F3 and B3. When performed in a thermal 
cycler, or simple heating block, the reaction mix was incubated at 63 °C for 1 h 
followed by termination at 80 °C for 2 min. Reaction products were then held at 4 °C 
until analysis.  When the reaction was performed in the Loopamp LA-200 real time 
turbidimeter (Eiken Chemical Co. Ltd.) the reaction was simply held at 63 °C for 90 
min. 
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SRA FIP GGACTGCGTTGAGTACGCATCCGC 
AAGCACAGACCACAGC 
 BIP CGCTCTTACAAGTCTTGCGCCCTTCTGAGATGTGCCCACTG
 LF GCGGAAGCAAGAATGACC 
 LB TCTTACCTTGTGACGCCTG 
 F3 CGCGGCATAAAGCGCTGAG 
 B3 GCAGCGACCAACGGAGCC 
 
Table 2.4. LAMP primer sequences used for identification of T. b. 
gambiense 
Target gene Primer Sequence 
5.8S rRNA- 





 F3 AAGCTCTCTCGAGCCATC 
 B3 TGACATACACAATATGTGCGA 
 
2.3.4 Detecting LAMP products 
DNA amplification was assessed by electrophoresis in a 1% TBE - agarose gel 
containing either ethidium bromide or GelRed. The use of GelRed replaced ethidium 
bromide in our laboratory during the course of this work because it is a safer and 
more sensitive alternative that can be used with the same imaging system. Gel 
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Loading Buffer (Sigma) was mixed with the reaction products prior to loading into 
the gel. Reaction products were seen as a ladder of multiple bands under UV 
illumination, indicating the production of stem-loop DNAs containing varying 
numbers of inverted repeats of the target sequence. This usually had a smeared 
appearance.  
 
Other LAMP product detection methods included 
(i) the turbidity of the product in the reaction tube observed by eye  
(ii) real time turbidimetry using the time to reach a threshold turbidity 
measurement of 0.1 [130]. This is a standard value chosen to 
define a positive reaction in a real time turbidimeter e.g. [133]. 
(iii) colour change with Quant-iT PicoGreen. 2 μl or 5 μl is added 
post-incubation. Colour is then observed by eye under normal 
light, and fluorescence is observed under UV light  
(iv) colour change with hydroxynaphthol blue. Before incubation 120 
μM hydroxynaphthol blue was included in each 25μl reaction mix.  
Upon termination colour was assessed by eye, under normal light. 
(v) colour change with calcein and MnCl2. 25 μM calcein and 0.5 mM 
MnCl2 were included in each 25 μl reaction mix before 
incubation. Upon termination the colour was assessed by eye, 
fluorescence under UV observed 
(vi) 1 μl Loopamp Flourescence Detection Reagent (Eiken, Japan) 
added to the reaction mix prior to incubation. An orange to green 
colour change was assessed by eye, and the fluorescence under 
UV was observed. 
.  
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2.4 Novel LAMP primer design 
LAMP primers are designed against a target sequence. LAMP requires a minimum of 
four primers, two inner primers and two outer primers, recognising six distinct 
regions on the target sequence. The forward and backward outer primers, F3 and B3 
respectively, are the same as regular PCR primers. The inner primers each contain 
two segments and bind to both the sense and antisense strands of the target DNA. 
The forward inner primer (FIP) comprises two segments denoted F2 and F1c. 
Likewise the backward inner primer (BIP) comprises two segments denoted B2 and 
B1c. This is shown in Figure 2.1. 
 
Once the inner and outer primers have been generated, two additional, optional ‘loop 
primers’ can be designed. These contain sequences complementary to the single 
stranded loop region in the starting material. The forward loop primer (LF) binds 
between F1 and F2 and the backward loop primer (LB) binds between B1 and B2. 
Loop primers are not required for LAMP amplification, but they can improve both 
the specificity and efficiency of the reaction [125] by increasing the number of 
starting points for DNA synthesis. 
 
After the choice of an appropriate target sequence there are four key factors in the 
design of successful LAMP primers: the melting temperature (Tm), stability at the 
primer ends, GC content and secondary structure. The distance between primers is 
also important. The importance of these factors, and their incorporation into the 
design process is discussed in ‘A Guide to LAMP primer designing (PrimerExplorer 
V4)’ produced by Eiken Chemical Co. Ltd and available through their website. 
LAMP primers can be designed using the PrimerExplorer V4 software 
(http://primerexplorer.jp/elamp4.0.0/index.html) which automatically accounts for 
each factor. This requires a minimum length target sequence of 200 bp.  
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Using the PrimerExplorer V4 software the Tm is designed to be in the range 64-66 ˚C 
for F1c and B1c, 59-61 ˚C for F2, B2, F3 and B3 and 64-66 ˚C for the loop primers. 
The software uses the nearest-neighbour method to calculate Tm, for standard 
experimental conditions of 0.1 μM oligos, 50 mM Na + ions, 4 mM Mg 2+ ions. 
However these conditions are often changed during LAMP primer assay 
optimization. 
 
The stability of the primer ends is important because they provide the starting point 
for DNA synthesis. Hence, the primers are designed to so that the 3’ ends of F2, B2, 
F3, B3, LF and LB and the 5’ ends of F1c and B1c have a free energy change (ΔG) -
4 kcal mol-1 or less. The more negative the ΔG, the more often the primer anneals to 
the template.  
 
The GC content of the primers is designed to be in the range 40-65 %. Primer design 
also aims to prevent the formation of secondary structures and primer dimers.  The 
distance between the 5’ ends of F2 and B2 should be in the range 120-160 bp, the 
distance between the 5’ ends of F2 and F1 (or B2 and B1) should be in the range 40-
60 bp and the distance between the 3’ end of the outer primer and the 5’ end of the 
inner primer should be between 0-60 bp.  
 
Most simply the Primer Explorer V4 software designs primers across the whole 
target region. However, the user can specify the binding site of any given primer. In 
addition mutations on the target sequence can be highlighted in order that specific, or 
common, primers can be designed.  
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Figure 2.1. LAMP primers and their binding sites on the target DNA  
F2F3 B1c B2c B3c
B3
F1











0 – 60 bp
120 – 160 bp
40 – 60 bp
 
Adapted from http://loopamp.eiken.co.jp/e/lamp/primer.html and ‘A Guide to LAMP primer 
designing (PrimerExplorer V4)’, Eiken Chemical Co. Ltd 
 
2.4.1 LAMP primer design for novel T. b. rhodesiense 
specific assays 
Two methods were used to design the LAMP primer sets. Firstly the location of F1, 
F2, F3, B1, B2 or B3 was fixed to bind from position 571-590. For each, the 
automatic judgment parameter set and the default design options were selected. First 
the basic design option was used. When this did not generate any primer sets the AT 
rich parameter setting was selected within the detailed settings. Since this generated 
numerous primer sets the easy sorting rule was applied to select the best of the 
candidate sets. Primer information files were used to design loop primers. Where 
several loop primer sets were generated the first in the list was selected for testing 
(see summary Tables 2.5 and 2.6). 
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Table2.5.  Design process for SRA specific LAMP primers 







(ii) Detailed settings; 
AT rich parameter; 
no sorting rule 
(iii) Detailed settings; 
AT rich parameter; 
easy sorting rule 
SRALAMP_a B3 0 1000 2 
SRALAMP_b B1 1 Not done Not done 
SRALAMP_c F3 0 549 2 
SRALAMP_d F2 0 234 1 
SRALAMP_e B2 0 108 1 
SRALAMP_f F1 0 398 1 
 
Table 2.6  Loop primer design for SRA specific LAMP primers 
ID Number of loop primers generated 
 LF LB Sets 
SRALAMP_a-[6] 17 63 222 
SRALAMP_a-[1] 7 63 60 
SRALAMP_b 0 0 0 
SRALAMP_c-[6] 1 64 0 
SRALAMP_c-[1] 30 12 312 
SRALAMP_d 0 15 0 
SRALAMP_e 12 27 27 
SRALAMP_f 42 12 41 
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Secondly primer design software was used to design specific primers to recognise a 
mutation at position 581. Again automatic judgment setting was selected. The 
mutation was set at position 581.  Using basic design settings, no primer sets were 
generated but when the AT rich parameter was chosen 18 primer sets were 
generated. The recognition site was located at the 5’ end of the F1c segment for six 
sets, and at the 3’ end of the F2 segment for 12 sets.  
 
The primer sets were compared (Appendix 6) and five were selected for testing 
(SRALAMP7.1, SRALAMP7.2, SRALAMP7.3, SRALAMP7.10 and 
SRALAMP7.13) - where primer sequences were identical or very similar they were 
not ordered in duplicate. Primers sets were constructed using some common primers 
and differ slightly from the primer sets generated (Appendix 6, Table 3). No loop 
primers sets could be designed for any of these primer sets.  
 
The sequences and binding sites of all primers in all novel primer sets designed, in 
relation to the position of the SRA specific internal deletion, are shown in Appendix 
7. 
2.4.2 LAMP primer design for novel T. b. gambiense specific 
assays 
Primers were designed using the TgsGP sequence with accession number AJ277951.  
Five sets of LAMP primers were generated using the automatic judgement default 
setting of the primer design software.  No modifications were made to any of the 
parameter settings. Five sets of LAMP primers were generated (see Appendix 14).  
Primers sets 22, 11, 18 and 28 bind towards the front end of the TgsGP sequence 
whereas primer set 59 binds in the same region of the gene as the nested TgsGP PCR 
primers (shown in Appendix 15 and summarised in Figure 2.2 below). 
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Figure 2.2.  Relative target regions of the TgsGP PCR [75] and LAMP 
primers within TgsGP gene AJ277951  
264                      474
289                    502
387                          617
420                      617










Primer set 59 was selected for further investigation as it was considered less likely to 
give rise to non-specific amplification with other T. brucei VSG genes (henceforth 
referred to as LAMP TgsGP).  The sequences and other key characteristics of the 
TgsGP LAMP primers are summarised in Table 2.7.  The binding sites of all LAMP 
TgsGP primers relative to TgsGP PCR primers are shown in more detail in Appendix 
15. 
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Table 2.7. Characteristics of the LAMP TgsGP primers 
Primer 5’  to 3’ 
position 











18 60.89 -4.18 -7.36 0.56 TTAACGCAGACACCGCCT 
FIP 
 





40     
TCCAAATTGACGGGGACAACGG-
GCCGTTCCTGTGCAGTTG 
F2 838-856 19 60.79 -5.23 -4.67 0.58 CGATGTCGCTGCTGTGTTC 
F1c 896-916 21 65.33 -5.20 -4.27 0.57 GATCCCGCCTGCTGTGGTTTT 
B2 997-1014 18 60.74 -6.68 -4.66 0.61 GCCGTTCCTGTGCAGTTG 
B1c 948-969 22 65.10 -4.53 -5.94 0.55 TCCAAATTGACGGGGACAACGG 
 
2.5 Development of novel LAMP assays 
2.5.1 Initial trial of primers for T. b. rhodesiense 
Nine primer sets were selected for the initial trial (Table 2.8). All novel primers 
designed for the SRA gene were initially tested under the following reaction 
conditions: 62 ˚C for 1 h followed by a 4 min termination step at 80 ˚C and held at 4 
°C using a thermocycler until analysis.  A reaction volume of 25 μl was used with 1 
µl template DNA and containing 8 U Bst DNA polymerase (New England Biolabs), 
2.5 μl Thermopol reaction buffer I (New England Biolabs) to give 20 mM Tris-Cl, 
10 mM KCl, 10 mM (NH4)SO4 and 2 mM MgSO4, 5 μl Q buffer (Qiagen), 200 µM 
dNTPs, 2 µM of both FIP and BIP, 0.2 µM of both F3 and B3 and 0.8 µM of both LF 
and LB. Additional MgSO4  was used to adjust the final concentration to test these 
primer sets over a range of MgSO4 concentrations (Table 2.8). Where loop primers 
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human 
sleeping sickness: towards a point-of-care diagnostic test 
Chapter 2. Materials and Methods 77 
were not included water was added to make up the reaction volume, all other 
conditions were kept the same.  
 
Initial screening of the novel primers was carried out using purified DNA extracted 
from frozen stocks of parasites But135 (T. b. brucei) and DO (T. b. rhodesiense). 
 
Table 2.8. Summary of primer sets trialled for SRA specific LAMP 





SRALAMP_a B3 Yes 2 mM 
SRALAMP_b B1 No 2, 4, 6 and 8 mM 
SRALAMP_e B2 Yes 2, 4, 6 and 8 mM 
SRALAMP_f F1 Yes 2, 4, 6 and 8 mM 
SRALAMP7.1 F1c No 2, 3, 3.5, 4, 4.5 and 5 mM 
SRALAMP7.2 F2 No 2, 4, 6 and 8 mM 
SRALAMP7.3 F2 No 2, 4, 6 and 8 mM 
SRALAMP7.10 F1c No 2, 4, 6 and 8 mM 
SRALAMP7.13 F1c No 2, 4, 6 and 8 mM 
 
2.5.2 Adaptation of the novel assay for T. b. rhodesiense for 
use with the real time turbidimeter 
Three modifications were made to the LAMP reaction mix for use with the real time 
turbidimeter. LAMP buffer was altered to contain Tween-20 in place of Triton X-
100, the concentration of MgSO4 was increased from 2 mM to 8 mM and the 
concentration of dNTPs were simultaneously increased from 0.2 mM to 1.4 mM. 
These changes were tested using four SRA PCR positive samples (32, 36, 64, 65 and 
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68) and two SRA negative samples (24 and 28) and the changes were tested for 
LAMP reactions run using both heating block followed by gel electrophoresis, and 
using a real time turbidimeter.  
2.5.3 Application of the novel assay for T. b. rhodesiense to 
the complete sample set using a heating block  
The SRALAMP_a assay was also applied to the 86 samples using a thermocycler to 
incubate the reaction at 62 ˚C for 60 min, followed by a 4 min 80 ˚C termination 
step. The reactions were then held at 4 ˚C until they were assessed. Assessment was 
made by optical turbidity assessment, and by gel electrophoresis with subsequent UV 
illumination for all samples. This full sample set screen was performed three times. 
For these reactions the reaction mix was the same as with the  real time turbidimeter 
screen described above, except that the reaction buffer contained 0.1 % Triton X-100 
in place of 0.1 % Tween-20. The reactions were seeded with 1 μl of the DNA 
sample. 
 
2.5.4 Application of the novel assay for T. b. rhodesiense to 
the complete sample set using the real time 
turbidimeter 
The SRALAMP_a assay was applied to all 86 samples using a real time turbidimeter. 
The reaction mix contained 8 U Bst DNA polymerase, 1 X LAMP buffer (20 mM 
Tris-HCl, 10 mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4, 0.1% Tween-20), plus 
additional MgSO4 to give a final concentration of 8 mM MgSO4 0.8 M betaine, 1.4 
mM dNTPs, 2 µM FIP and BIP, 0.8 µM LF and LB, 0.2 µM F3 and B3 and H20 to 
make the reaction volume up to 25 μl. The temperature was set at 62 ˚C for 90 min, 
and the time to a threshold turbidity of 0.1 was noted. The reactions were seeded 
with 1 μl of the DNA sample. 
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2.5.5 Optimisation of reaction conditions including loop 
primer concentration and temperature 
To see whether the time to reach the turbidity threshold could be reduced, and to 
make the reaction as sensitive as possible, loop primer concentration and incubation 
temperature were tried over a range of reasonable values. 
 
Since loop primers can improve LAMP reaction efficiency, the SRALAMP_a assay 
was trialled without the loop primers, with the loop primers 0.8 μM (intermediate 
between the inner and outer primer concentrations as usual) and at 2.4 μM (in excess 
of the inner primers). The effect of different loop primer concentrations was assessed 
by performing the assay on a dilution series of sample 86 in a real time turbidimeter. 
The concentration of this sample was 11.7 ng μl-1 as measured with a NanoDrop 
Spectrophotometer.  
 
Secondly the assay was re-applied to the total sample set using both 2.4 and 0.8 μM 
loop primers. For economy, 1 in 10 dilutions of the DNA samples were used to seed 
the reaction.  
 
The effect of temperature on reaction efficiency and sensitivity was assessed by 
performing the assay on a dilution series of sample 86 in a real time turbidimeter at 
58, 60, 62, 64 and 65 ˚C.  
 
2.5.6 Initial trial of primers for T. b. gambiense 
A trial using the TgsGP LAMP primers was made using T. b. gambiense TgsGP PCR 
positive samples 5 and 17, and non - T. b. gambiense TgsGP PCR negative samples 
1, 2 and 3.  The assay was run at 63 ˚C for 1 hr in a heating block, followed by 2 min 
at 80 ˚C to halt the reaction.  After gel electrophoresis the products were visualised 
under UV light.  
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Final concentrations of 2 mM, 4 mM, 6 mM and 8 mM MgSO4 were all attempted, 
as previous work with novel SRALAMP primers showed that the concentration of 
MgSO4 affects the LAMP reaction. Otherwise the reaction mix contained: 8 U Bst 
DNA polymerase, 1 X LAMP buffer (20 mM Tris-HCl, 10 mM KCl, 10 mM 
(NH4)2SO4, 2 mM MgSO4, 0.1% Tween 20), 0.8 M betaine, 0.2 mM dNTPs, 2 µM 
FIP and BIP, 0.8 µM LF and LB, 0.2 µM F3 and B3 and H20 to make the reaction 
volume up to 25 μl. The reactions were seeded with 1 μl of the DNA sample. 
 
2.5.7 Adaptation of the novel assay for T. b. gambiense for 
use with a real time turbidimeter 
This was repeated using the same samples and reaction mix, at 63 ˚C for 90 minutes 
in the turbidimeter, with a final concentration of 8 mM MgSO4 in the reaction mix.  
This was trialled with either 0.2 mM or 1.4 mM dNTPs.  A reaction termination step 
was not included when using the real time turbidimeter.  
 
2.5.8 Application of the novel assay for T. b. gambiense to 
the complete sample set using the real time 
turbidimeter 
The LAMP TgsGP assay was applied to all 86 samples using a real time 
turbidimeter.  The reaction mix contained 8 U Bst DNA polymerase, 1 X LAMP 
buffer (20 mM Tris-HCl, 10 mM KCl, 10 mM (NH4)2SO4 2 mM MgSO4, 0.1% 
Tween 20), plus additional MgSO4 to give a final concentration of 8 mM MgSO4 0.8 
M betaine, 1.4 mM dNTPs, 2 µM FIP and BIP, 0.8 µM LF and LB, 0.2 µM F3 and 
B3 and H20 to make the reaction volume up to 25 μl. Temperature was set at 63 ˚C 
for 90 minutes, and the time to a threshold turbidity (Tt) of 0.1 was noted.  Reactions 
were seeded with 1 μl of the DNA sample. 
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2.5.9 Application of the novel assay for T. b. gambiense to 
the complete sample set using a heating block 
The LAMP TgsGP assay was also applied to the 86 samples using a thermocycler to 
incubate the reaction at 63 ˚C for 60 minutes, followed by a 2 min 80 ˚C termination 
step.  The reactions were then held at 4 ˚C until they were assessed.  Assessment was 
made by optical turbidity assessment, and by gel electrophoresis with subsequent UV 
illumination for all samples. This full sample set screen was performed three times. 
For these reactions the reaction mix was the same as with the real time turbidimeter 
screen described above, except that the reaction buffer contained 0.1% Triton X-100 
in place of 0.1% Tween 20.  The reactions were seeded with 1 μl of the DNA sample. 
 
2.5.10 Absolute sensitivity of LAMP versus PCR 
A two times and a ten times dilution series were made for three T. b. gambiense 
samples (5, 18 and 58) whose DNA concentration was first quantified using a 
NanoDrop 2000 (Thermo Scientific).  One μl of each dilution was used to seed both 
the TgsGP PCR and TgsGP LAMP assays.  The result was determined both by 
turbidity in the reaction tube, and by gel electrophoresis and UV visualization. 
  
2.6 Statistical analyses 
Two by two contingency tables were made to allow comparisons between any two 
given tests. From these sensitivity, specificity, positive and negative predictive 
values and Cohen’s kappa statistic were calculated as described below. In order to 
assist the interpretation of Cohen’s kappa statistic the prevalence and bias indices, 
the 95 % confidence intervals and the maximum attainable kappa were also 
calculated as described below. 
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2.6.1 Sensitivity and Specificity 
Sensitivity is the proportion of true positives that are detected by the diagnostic test 
in question. It represents the probability that the test will produce a true positive 
result when used on an infected population as compared to a reference or ‘gold 
standard’.  Conversely the specificity of a test is the proportion of true negatives that 
are detected by the test, representing the probability that it will produce a true 
negative result, again as compared to the ‘gold standard’, when used on a non-
infected population. Table 2.9 describes the possible outcomes of any diagnostic test, 
and the formulae for calculating sensitivity and specificity in comparison to a 
reference standard. 
 
2.6.2 Positive and Negative Predictive Values 
The positive predictive value of a test is the probability that a person is infected when 
a positive test result is observed whereas the negative predictive value is the 
probability that a person is not infected when a negative test result is observed. 
Unlike sensitivity and specificity, the predictive values of a test vary depending upon 
the prevalence of the condition being tested for in a specific population. Table 2.9 
describes the possible outcomes of any diagnostic test, and the formulae for the 
positive and negative predictive values for any diagnostic test in comparison to a 
reference standard. 
 
2.6.3 Cohen’s kappa  
Cohen’s kappa statistic (κ) [157] was used to quantify the level of agreement 
between two tests. This gives a better indication of the concordance between the two 
techniques than percentage agreement, since it accounts for the agreement expected 
by chance. The formula for the calculation of kappa is given in Table 2.9. A kappa 
value of one implies perfect agreement; values less than one imply less than perfect 
agreement. A negative kappa value indicates that the two tests agree less than would 
be expected by chance. A rough guide to the interpretation of kappa values has been 
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given by Altman [199] and has been summarised in Table 2.10 below. However, 
interpretation of the magnitude of kappa is not straightforward. Benchmarks and 
thresholds are inevitably arbitrary [200, 201] and the actual magnitude of kappa can 
be influenced by the prevalence, bias and non independence of ratings [202]. 
Therefore in this study we follow the recommendations given by Sim and Wright 
(2005) [202] for the interpretation of kappa: (i) report the bias and prevalence 
alongside the obtained value of kappa; (ii) relate the magnitude of kappa to the 
maximum attainable kappa for the contingency table as well as to one in order to 
provide an indication of the effect of imbalance in the marginal totals; (iii) construct 
a confidence interval around the obtained value of kappa to reflect sampling error; 
(iv) be cautious when comparing the magnitude of kappa when prevalence or bias 
indices differ.  
 
The prevalence index is calculated as the absolute difference between the number of 
true positive and true negative observations, divided by the total number of 
observations (Table 2.9) [202]. If the prevalence of a positive rating is either very 
high, or very low, the prevalence index is high, chance agreement is high and kappa 
is reduced [200]. The effect of prevalence on kappa is greater for large values of 
kappa than for small values [203]. It is important to note that the prevalence index 
itself is affected by both the true prevalence of positives in the population being 
tested, and by the behaviour of the test or reader.  
 
Bias is the extent to which the two tests, or two raters disagree on the proportion of 
positive or negative observations. The bias index is calculated as the absolute 
difference between the number of false positive and false negative observations, 
divided by the total number of observations (Table 2.9) [202]. When there is a large 
difference in the number of false positive and false negative observations the bias 
index is high and kappa is increased. This effect is greater when kappa is small [203]. 
Therefore, we are faced with two paradoxical situations: (i) kappa is lowered when 
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the prevalence index is high and (ii) kappa is increased when the bias index is high 
[204]. 
 
The maximum attainable kappa (κmax) is calculated using the same formula as for 
Cohen’s kappa, however, before the calculation is made the marginal probabilities 
and the cell frequencies are adjusted to obtain the greatest possible agreement. 
Therefore the difference between the observed kappa and κmax is the unachieved 
agreement beyond chance within the constraints of the marginal totals. 
 
95 % confidence intervals for kappa were calculated from the contingency table 
using the GraphPad Quick Calcs online calculator 
(http://www.graphpad.com/quickcalcs/kappa1.cfm).  
 
Finally kappa assumes that errors are independent [205]. Non- independence 
increases kappa. Hence, factors affecting the independence of kappa were considered 
during the interpretation of kappa.  
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Table 2.9. Possible outcomes of a diagnostic test and associated 
formulae. 
True status Test status Total 
 Positive Negative  












    
Total TP+FP FN+TN TP+FN+FP+TN 
Sensitivity = TP / (TP + FN) 
Specificity = TN / (TN + FP) 
Positive Predictive Value =  TP / (TP + FP) 
Negative Predictive Value = TN / (TN + FN) 
κ = (Total number of agreements-Expected number of agreements)/(Total number of 
observations-Expected number of agreements) 
Prevalence index = ( | TP – TN | )/ (TP+FN+FP+TN) 
Bias index = ( | FP – FN | )/ (TP+FN+FP+TN) 
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Table 2.10. The interpretation of Cohen’s kappa statistic [199]  
Kappa value Level of agreement 
<0.00 Less than would be expected by 
chance 
0.00 – 0.20 Poor agreement 
>0.20 – 0.40 Fair agreement 
>0.40 – 0.60 Moderate agreement 
>0.60 – 0.80 Good agreement 
>0.80 – 1.00 Very good agreement 
 
2.7 Multi observer study  
Thirty-three observers each scored all 60 samples as positive or negative by 
comparison with a positive and negative control, after training on a small batch of 
eight samples.  The participants were not chosen according to any specific criteria 
but were asked about their work background, previous experience of colour change 
assays and their impressions of these tests in light of their previous experience.  
Observers were asked to rank how easy they found differentiation of the colour 
differences (very easy, quite easy, quite difficult or very difficult), and how many of 
the samples were easy to rate as positive or negative (all, most, some, very few or 
none) for each method.  They were also asked which colour change method they 
found easiest to use.  Finally they were given the opportunity to make any general 
comments.  
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3 Chapter 3. Detection of human infective trypanosomes 
in the zoonotic reservoir using LAMP 
3.1 Introduction 
Mathematical modelling has clearly demonstrated that control of T. b. rhodesiense in 
the animal reservoir, in addition to early case detection and treatment in humans, is 
critical for the control of Rhodesian sleeping sickness [34]. However, identification 
of T. b. rhodesiense in domestic livestock is difficult for two reasons: (i) T. brucei s.l. 
infection in domestic livestock is not usually clinically apparent [206] and (ii) 
microscopically T. b. rhodesiense cannot be differentiated from  non-human-
infective T. b. brucei, which may be circulating among the same reservoir host 
species. Morphological differentiation of T. brucei from T. congolense and T. vivax 
also remains difficult, insensitive and error-prone [207, 208]. 
 
Following the discovery of the SRA gene (which uniquely identifies T. b. rhodesiense 
at the DNA level) it has been possible to detect and quantify human-infective 
parasites in the unaffected livestock reservoir.  In areas endemic for human sleeping 
sickness one in three T. brucei s.l. infections in cattle can be identified as T. b. 
rhodesiense [209]. Assuming this ratio is constant it should now therefore be 
possible to indirectly quantify circulating human parasites, using a generic T. brucei 
s.l. diagnostic. To this end, molecular techniques have come to the forefront of 
trypanosome detection technologies. Early work made use of DNA probes for the 
detection of Trypanozoons, targeting a 177 bp satellite repeat sequence [193]  and the 
Trypanozoon ingi element [210, 211].  The next significant advance came with the 
development of PCR, which was first applied to trypanosomes in 1989 by Moser 
[107]  whose designed primers to the same 177 bp satellite repeat sequence described 
above (of which there are 10000 copies per haploid genome). Twenty years on this 
Trypanozoon specific PCR remains the method of choice for the molecular detection 
of these parasites. It is sensitive to as little as 0.01 pg of DNA; equivalent to one 
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tenth of a trypanosome and has been successfully applied in several large-scale 
epidemiological studies [32, 195] that have screened DNA from cattle blood samples 
collected onto Whatman FTA cards.  These FTA cards provide an ideal matrix for 
sample collection and transport from remote, ill-equipped field sites, as well as for 
long-term sample storage without the requirement for refrigeration or any other 
special storage facilities. In addition, two different loop-mediated isothermal 
amplification (LAMP) assays have recently been developed for the detection of 
Trypanozoon DNA: one targeting  the single copy PfrA gene [140] and the other 
targeting the multi-copy RIME element [121]. 
 
RIME is a mobile genetic element first described in a ribosomal DNA clone from T. 
brucei in 1984 [212]. Mobile genetic elements can be classified according to their 
transposition mechanism, sequence structure and insertion site specificity. RIME is a 
random, non-long terminal repeat, retrotransposon; thus it moves randomly through 
the trypanosome genome via an RNA intermediate. It is the most common mobile 
genetic element in trypanosomes making up approximately 5 % of the trypanosome 
genome and being present at about 400 copies [210, 213, 214]. Although it lacks 
strict insertion site specificity, it is clustered, particularly within the rRNA genes and 
the telomeres of chromosome one [215-217].  Before development of the LAMP 
RIME assay, the RIME element had been exploited for strain typing of T. brucei s.l. 
via an MGE-PCR assay [218-220]. Mobile genetic elements are often well suited for 
strain typing because their location and length may vary between strains. 
 
The LAMP RIME primers were designed by Njiru et al. [121], who used RIME 
sequences from T. b. brucei (accession number EF567426), T. b. rhodesiense 
(accession number EF567426) and T. evansi (accession number EF567425) as their 
templates. These were sequences were generated from PCR products amplified using 
primers designed from the original RIME sequence (accession number K01801; 
[212]).  
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The PfrA (paraflagellar rod protein A) gene (accession number X14819) of T. brucei 
was first identified and sequenced by Schlaeppi et al. in 1989 [221]. At that time the 
authors believed that PfrA and PfrB were two identical, tandemly linked genes, 
found at a single locus in the trypanosome genome, which both coded for a 600 
amino acid protein via distinct mRNAs. The paraflagellar rod (PFR) was first 
identified in 1962 [222]. It is a major component of kinetoplastid and euglenoid 
flagellae alongside the microtubular axoneme in these flagellate organisms. Early 
studies identified two major protein components of the paraflagellar rod, PFR1 and 
PFR2. More recent work has identified over 40 additional proteins associated with 
the PFR [223]. Schlaeppi et al. suggested that PFR1 and PFR2 were encoded by one 
gene with the observed differences being due to protein folding [221]. However 
genome sequencing of T. brucei, Trypanosoma cruzi and Leishmania major 
identified distinct (though related) genes encoding PFR1 and PFR2 which are present 
in separate tandem arrays and have arisen via a single gene duplication event [215, 
224, 225]. Note that the Pfr1 and Pfr2 genes were sequenced after the development 
of the LAMP PfrA assay. They are available via GenBank under accession numbers 
XM_838928 and XM_842234 respectively. 
 
In this study the LAMP PfrA [140] and LAMP RIME [121] assays were compared to 
the well established TBR PCR [107] for the detection of members of the subgenus 
Trypanozoon in cattle blood samples collected onto Whatman FTA cards. This study 
was performed in order to determine whether LAMP might be a useful and simpler 
alternative to PCR as part of remote epidemiological surveillance studies. 
 
3.2 Aims 
Initially there were two main aims to this study: 
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1. To compare the sensitivity of LAMP PfrA, LAMP RIME and TBR PCR 
assays for detecting members of the subgenus Trypanozoon from cattle blood 
samples collected as part of ongoing epidemiological surveillance. 
2. To compare the cost of LAMP PfrA, LAMP RIME and TBR PCR assays for 
detecting members of the subgenus Trypanozoon. 
 
As analysis of results arising from this section work began it became apparent that 
LAMP RIME detected an excess of Trypanozoon positive samples. The further aims 
of the study were then defined as follows: 
 
3. To investigate the possibility of LAMP positive reactions from non-
Trypanozoon DNA 
a. Using Trypanosoma congolense and Trypanosoma vivax  DNA 
b. Using cattle blood samples with a high T. congolense infection rate 
c. Using host genomic DNA 
d. By sequence analysis of the primer binding sites 
4. To design an improved LAMP assay for detecting members of the subgenus 
Trypanozoon 
 
3.3 Study outline  
Firstly, blood samples from Ugandan cattle were used for the detection study which 
compared LAMP RIME [121], LAMP PfrA [140] and TBR PCR [107]. Prior to this 
study no other characterisation of these samples had taken place, nor did they come 
from animals identified as cases or controls. Therefore, this molecular data could 
only be analysed in isolation, without reference to any external gold standard. 
Initially, the results from the LAMP PfrA and LAMP RIME assays were compared 
to the results from the TBR assay, which is considered as the current reference 
standard for the molecular diagnosis of Trypanozoon parasites.  Sensitivity, 
specificity, negative and positive predictive values, Cohen’s kappa statistic with 95 
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% confidence intervals, prevalence and bias indices and the maximum attributable 
kappa were calculated. Next, an extended reference standard was defined that 
incorporated the results from all three assays.  Samples that generated a positive 
signal using any of the three assays were considered positive. Sensitivity measures 
were calculated for each assay against this reference standard. Sensitivity was also 
calculated for the use of two assays in parallel, where the combination was taken as 
positive if either one, or both, gave a positive signal. The chi-squared test was used 
to analyse whether the differences seen in the sensitivity arising with the different 
molecular approaches were statistically significant.   
 
Secondly, the costs of the reagents required for the three assays were compared. The 
present cost (at the time of writing) for each reagent was noted from the appropriate 
supplier website or from our previous order information where pricing was not 
publicly available. The quantity of each reagent required for 100 reactions was 
calculated to determine the total cost for 100 reactions of each assay. The cost 
calculations are shown in Appendix 3.  
 
Having observed an excess of LAMP RIME positive reactions, in comparison to the 
TBR PCR, with the Ugandan cattle blood samples, it was deemed necessary to revisit 
the LAMP PfrA and LAMP RIME assays. So, thirdly, the specificity of these LAMP 
assays was scrutinized using: (i) T. congolense (Fly148) and T. vivax (TREU 1722) 
DNA extracted previously from procyclic trypanosome cultures using the Qiagen 
DNAeasy Blood and Tissue Kit (Qiagen,UK); (ii) 105 Zambian cattle blood samples 
with a high known prevalence of T.  congolense savannah infection and (iii) 
commercially available human and cattle genomic DNA.  
 
For (i) both the ITS1 rDNA PCR and the TBR PCR were performed once on a 
tenfold dilution series of each DNA, using 1 μl template DNA. The LAMP RIME 
and LAMP PfrA assays were performed in triplicate on the tenfold dilution series of 
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DNA, and then an additional ten times on the strongest concentration. For (ii) the 
LAMP RIME assay was applied to all 105 samples. For (iii) eight negative control 
samples (seeded with H20) and one positive Trypanozoon DNA sample were ran 
alongside LAMP RIME and LAMP PfrA.  
 
Fourthly a BLAST (Basic Local Alignment Search Tool; 
http://blast.ncbi.nlm.nih.gov/Blast.cgi) [226] search was performed for EF567424, 
EF567425, EF567426 and X14819 (LAMP RIME and LAMP PfrA primer target 
sequences) to identify similar non-Trypanozoon sequences. Hits were considered 
according to the following criteria: (i) inclusion of the full LAMP primer binding 
region; (ii) percentage sequence identity. When the entire primer binding region was 
included and sequence identity was high the precise primer binding locations were 
mapped within the BLAST hit.  
 
Finally, attempts were made to design a Trypanozoon specific LAMP assay targeting 
the same 177 bp sequence used for TBR PCR primer design using the Primer 
Explorer V4 software (http://primerexplorer.jp/elamp4.0.0/index.html).  
 
3.4 Results 
3.4.1 Comparative detection study 
The two LAMP assays (RIME and PfrA) and the TBR PCR were applied to 428 
cattle blood samples. Seventy two samples were TBR PCR positive, 23 samples were 
LAMP PfrA positive and 145 samples were LAMP RIME positive. In total 189 
samples were positive by one or more of the assays. 
 
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human 
sleeping sickness: towards a point-of-care diagnostic test 
Chapter 3. Detection of human infective trypanosomes in the zoonotic reservoir 
using LAMP 
 93 
3.4.1.1 Comparison to current reference standard 
The TBR PCR is considered to be the gold standard for the molecular diagnosis of 
Trypanozoon parasites and is routinely applied to cattle blood samples collected onto 
Whatman FTA cards to screen for T. brucei s.l.. Therefore, data analysis began with 
the comparison of LAMP PfrA and LAMP RIME to TBR PCR. 
 
LAMP PfrA showed less agreement than would be expected by chance alone with 
TBR PCR (κ = - 0.02; 95 % CI -0.209 – 0.169) while LAMP RIME showed fair 
agreement with the TBR PCR (κ = 0.233; 95 % CI 0.123 – 0.344). With LAMP PfrA 
the majority of the discordant results were false negatives, while for LAMP RIME 
they were false positive. The contingency table and summary statistics are shown 
below (Tables 3.1 and 3.2).  
 
These comparisons are also summarised graphically below (Figure 3.1).  
 
Table 3.1. Contingency tables for the comparison of the LAMP reactions 
with the current standard TBR PCR 
 LAMP PfrA LAMP RIME 
TBR PCR + - Total + - Total 
+ 3 69 72 44 28 72 
- 20 336 356 101 255 356 
Total 23 405 428 145 283 428 
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Table 3.2. Comparative summary statistics when the two LAMP assays 
were compared to the TBR PCR assay 
 LAMP PfrA LAMP RIME 
Kappa 






(95 % CI) 
4.17 % 
(0.94 – 12.03 %) 
61.11 % 
(49.55 – 71.55 %) 
Specificity 
(95 % CI) 
94.38 % 
(91.44 – 96.38 %) 
71.63 % 
(66.73 – 76.07 %) 
N P V 
(95 % CI) 
82.96 % 
(78.98 – 86.32 %) 
90.11 % 
(86.03 – 93.11 %) 
P P V 
(95 % CI) 
13.04 % 
(3.69 – 32.97 %) 
30.34 % 
(23.43 – 38.27 %) 
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Figure 3.1. Kappa, sensitivity and specificity estimates for LAMP PfrA 
and LAMP RIME compared to TBR PCR, with 95 % confidence intervals 










To aid interpretation of kappa the prevalence and bias indices were calculated, as 
well as the maximum attributable kappa, for the agreement between LAMP PfrA and 
TBR PCR, as well as for LAMP RIME and TBR PCR (Table 3.3). The maximum 
attributable kappa fell well short of 1 for both comparisons, and the prevalence index 
was high. Therefore, kappa may be artificially deflated by the skew in the data 
towards samples that are negative by both tests being compared.  
 
Table 3.3. Prevalence and bias indices, and the maximum attributable 
kappa for LAMP PfrA and LAMP RIME versus TBR PCR 
 LAMP PfrA LAMP RIME 
κmax 0.438 0.566 
Prevalence index 0.778 0.493 
Bias index 0.114 0.171 
 
3.4.1.2 Comparison to the extended reference standard  
According to the results described in Table 3.1 above LAMP RIME signals were 
detected in 101/356 TBR negative samples (28.37 %; 95 % CI 23.93 – 33.27 %). 
LAMP PfrA signals were also detected in 5.62 % TBR negative samples (n = 20/356; 
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95 % CI 3.62 – 8.56 %). Therefore an extended reference method was defined: a 
sample was considered to contain Trypanozoon DNA if it was positive by any one or 
more of the three assays. This standard assumes that all three targets are perfectly 
specific, and that disagreements arise because they target different regions of the 
trypanosome genome. 
 
TBR PCR identified 38.10 % (n = 72/189; 95 % CI 31.47 – 45.19 %) of the samples 
defined as positive in this study. This was more sensitive than LAMP PfrA which 
detected only 12.17 % (n = 23/189; 95 % CI 8.19 – 17.66 %). However, LAMP 
RIME assay was more sensitive than the PCR, detecting 76.72 % (n = 145/189; 95 % 
CI 70.18 – 82.20 %) of the positive samples.  
 
When the results from more than one assay were combined the sensitivity was 
improved. The best combination, and most sensitive measure overall, was seen when 
the results from the PCR and LAMP for RIME assays were combined. Here, 91.53 % 
(n = 173/189; 95 % CI 86.61 – 94.83 %) of positive samples were identified.  
 
The χ 2 results indicate a strong association between the type of assay, or 
combination of assay results, and the detection sensitivity. Table 3.4 displays the 
sensitivity seen with each approach, alongside the χ 2 statistics.  
 
Finally, the less sensitive assays detected some positive samples not identified by the 
more sensitive assays. Therefore a more sensitive assay cannot be relied upon to 
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Table 3.4. Sensitivity of each method relative to the total number of 
positive samples identified in the study 
Method Sensitivity  
( 95 % CI) 
χ 2 
Single assay 
PCR 38.10 % 
(31.47 – 45.19 %) 
LAMP for PfrA 12.2% 
(8.19 – 17.66 %) 
LAMP for RIME 76.7% 
(70.18 – 82.20 %) 
 




PCR plus LAMP for PfrA 48.68 % 
(41.65 – 55.76 %) 
PCR plus LAMP for RIME 91.53 % 
(86.61- 94.83 %) 
LAMP for RIME plus LAMP for PfrA 85.19 % 
(79.37 – 89.59 %) 
 




3.4.1.3 Cost comparison 
The TBR PCR assay was the cheapest, in terms of reagents alone, costing £21.57 for 
100 reactions. LAMP RIME, which costs £31.09 for the reagents required for 100 
reactions, is cheaper than LAMP PfrA, which costs £42.40 for the reagents required 
for 100 reactions. LAMP PfrA is more expensive than LAMP RIME owing to the 
higher concentration of dNTPs required, and the addition of MgSO4 to the reaction.  
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3.4.2 Non - specific LAMP RIME reactions  
Above, the sensitivity of single and parallel testing with TBR PCR, LAMP PfrA and 
LAMP RIME were compared to an extended reference standard. As noted, the 
validity of these comparisons depends on the specificity of these molecular assays. 
However, it is possible that the LAMP positive signals detected in TBR PCR 
negative samples were false positives. To investigate this possibility LAMP RIME 
and LAMP PfrA were applied to: (i) T. congolense and T. vivax DNA; (ii) Zambian 
cattle blood samples with a high known prevalence of T.  congolense savannah 
infection and (iii) commercially available human and cattle genomic DNA. 
 
3.4.2.1 With T. congolense and T. vivax DNA 
The identity of the T. congolense (Fly 148) and T. vivax (TREU 1722) DNA samples 
were confirmed by the ITS1 rRNA PCR. Neither of these DNA samples were 
Trypanozoon positive, either according to the ITS1 PCR or the TBR PCR. When the 
LAMP RIME and PfrA assays were applied in triplicate to each dilution series, one 
LAMP RIME positive reaction was observed for T. congolense, and 15 for T. vivax 
(Table 3.5). Thirteen of the T. vivax LAMP RIME positives were observed for 
dilutions from which no trypanosome DNA was detected by the ITS1 rDNA PCR. 
No LAMP PfrA positives were observed. 
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Table 3.5. LAMP and PCR performed on dilution series of T. congolense 
and T. vivax DNA 
T. congolense T. vivax 
Number of 
positive LAMP 
signals (n = 3) 
Number of 
positive LAMP 




RIME PfrA  
TBR ITS1 
rDNA 
RIME PfrA  
1 X - 700 bp 1 0 - 250 bp 2 0 
1 X 10-1 - 700 bp 0 0 - - 1 0 
1 X 10-2 - - 0 0 - - 3 0 
1 X 10-3 - - 0 0 - - 3 0 
1 X 10-4 - - 0 0 - - 1 0 
1 X 10-5 - - 0 0 - - 2 0 
1 X 10-6 - - 0 0 - - 3 0 
 
LAMP RIME and PfrA assays were then performed ten times each on the most 
concentrated T. congolense and T. vivax DNA. Again, all LAMP PfrA reactions were 
negative. However two LAMP RIME positives were observed; one with T. 
congolense and one with T. vivax. These results are shown in Table 3.6. 
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Table 3.6. LAMP and PCR performed on T. congolense and T. vivax 
DNA 
Number of positive LAMP signals (n 
= 10) 
 TBR ITS1 
rDNA 
RIME PfrA 
1 X T. congolense - 700 bp 1 0 
1 X T. vivax - 250 bp 1 0 
 
3.4.2.2 With Zambian cattle blood samples 
The sample set contained 105 samples, of which 70 had previously been identified as 
PCR positive for T. congolense savannah, ten as PCR positive for the sub-genus 
Trypanozoon, and one as PCR positive for T. vivax. This includes five T. brucei – T. 
congolense savannah mixed infections, and one T. vivax – T. congolense savannah 
mixed infections. Overall, in this study, eight samples were LAMP RIME positive.  
 
The distribution of these LAMP RIME positives is shown in Table 3.7 below. 
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Table 3.7. LAMP RIME positive samples among the Zambian cattle 
blood samples 
PCR identification LAMP RIME 
 
 Positive (%) Negative (%) Total 
T. brucei  0 5 5 
T. congolense Savannah 3 61 64 
T. brucei & T. congolense 1 4 5 
T. vivax & T. congolense 1 0 1 
No PCR positive ID 3 27 30 
Total 8 (7.62%) 97 (92.38 %) 105 
All trypanosome positive 5 (6.67%) 70 (93.33 %) 75 
All trypanosome positive, Trypanozoon negative 4 (6.15%) 61 (93.85%) 65 
 
LAMP RIME identified Trypanozoon positive samples with 10.00 % sensitivity (n = 
1/10; 95 % CI 0.00 – 42.60 %) and 92.63 % specificity (n = 88/95; 95 % CI 85.33 – 
96.62 %). The agreement between LAMP RIME and TBR PCR is poor [199] (κ = 
0.029; 95 % CI -0.409 – 0.467). Tables 3.8 and 3.9 summarise the agreement and 
agreement statistics for the comparison between LAMP RIME and TBR PCR.  
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Table 3.8. Contingency table for the agreement between LAMP RIME 
and TBR PCR 
  LAMP RIME 
  + - Total 
+ 1 9 10 
- 7 88 95 
TBR PCR 
Total 8 97 105 
 
Table 3.9. Kappa statistic for the agreement between LAMP RIME and 
TBR PCR 
Kappa (95 % CI) 0.029(-0.409, 0.467) 
Prevalence index 0.829 
Bias index 0.019 
κmax 0.879 
 
Some (n= 4/65; 6.15 %) LAMP RIME positive reactions were seen among T. 
congolense positive – Trypanozoon negative samples. However, widespread false 
positives were not seen. LAMP RIME detected only a small proportion (n = 5/70; 
7.14 %) of T. congolense savannah PCR positive samples and agreement between 
LAMP RIME and the T. congolense savannah PCR is less than would be expected by 
chance [199] (κ = -0.01; 95% CI -0.152 – 0.133). Tables 3.10 and 3.11 summarise 
the agreement between LAMP RIME and the PCR for T. congolense savannah. 
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Table 3.10. Contingency table for the agreement between LAMP RIME 
and TCS PCR 
  LAMP RIME 
  + - Total 
+ 5 65 70 
- 3 32 35 
TCS PCR 
Total 8 97 105 
 
Table 3.11. Kappa statistic and sensitivity for the agreement between 
LAMP RIME and TCS PCR 
Kappa (95 % CI) -0.01 (-0.152 – 0.133) 
Prevalence index 0.257 
Bias index 0.590 
κmax 0.08 
Sensitivity (95 % CI) 7.14 % (2.72 – 16.02 %) 
 
3.4.2.3 With commercially available human and cattle genomic 
DNA 
Positive reactions were observed for LAMP PfrA and LAMP RIME assays when the 
most concentrated host DNA was used (12.5 ng human placental DNA, or 50 ng calf 
thymus DNA added to a single 25 μl reaction).  No further LAMP PfrA positive 
results were seen. Two additional LAMP RIME positives were observed in an 
uneven distribution across the human DNA dilution series and four additional LAMP 
RIME positives were observed in an uneven distribution across the cattle DNA 
dilution series (Table 3.12). 
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Table 3.12. LAMP PfrA and RIME results performed on dilution series of 
human and cattle DNA 
 Calf thymus DNA Human placental DNA 
Dilution LAMP PfrA LAMP RIME LAMP PfrA LAMP RIME 
1 X + + + + 
1 X 10-1 - + - - 
1 X 10-2 - - - + 
1 X 10-3 - - - - 
1 X 10-4 - + - - 
1 X 10-5 - + - + 
1 X 10-6 - + - - 
1 X 10-7 - - - - 
 
3.4.3 Sequence analysis 
In order to take the investigation of LAMP PfrA and LAMP RIME specificity a step 
further a BLAST search was made for the Trypanozoon sequences which were used 
for LAMP primer design. (For LAMP RIME primer design these were EF567424 (T. 
b. rhodesiense), EF567425 (T. evansi) and EF567426 (T. b. brucei); for LAMP it 
was X14819). Matches to the LAMP RIME primer template sequences were seen in 
Trypanosoma cruzi and Schistosoma mansoni. None of these T. cruzi sequences 
contained the entire LAMP primer binding region, therefore non-specific binding to 
this parasite was discounted. However, potential LAMP RIME primer binding sites 
were identified within S. mansoni.  
 
Out of the five Schistosoma mansoni hits, four were located in a genome sequence 
supercontig (Smp_scaff010453, accession number: FN367744.1) and the fifth was 
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located in a hypothetical protein mRNA (Smp_186500, accession number 
XM_002570283.1). One of these fragments included the entire LAMP primer 
binding sequence and has 99 % sequence identity with EF567424 and EF567426. 
The LAMP RIME primer binding sites could be located in this fragment with only 
one 1 bp sequence mismatch observed in the F1c primer. These five hits, and the 
LAMP RIME primer binding sites in Schistosoma mansoni FN367744.1 are shown 
in Appendix 4.  
 
Several non-Trypanozoon sequences were identified by BLAST performed on 
X14819, the sequence used for LAMP PfrA primer design (Table 3.13). However, of 
those that contained the LAMP PfrA primer binding region none had more than 85 % 
sequence identity with X14819. Therefore it was considered unlikely that LAMP 
PfrA primers would initiate false LAMP amplification for these species. 
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Table 3.13. BLAST hits against the sequence used for LAMP PfrA 
primer design 
Non- Trypanozoon organism Number of hits by BLAST 
Trypanosoma cruzi 18 
Leishmania 22 
Crithidia fasciculata 2 
Herpatomonas megaseliae 2 
Phacus smulkowskianus 2 
Total  46 
 
3.4.4 Designing novel Trypanozoon specific LAMP primers 
for the 177 bp TBR PCR target sequence 
It was not possible to design a set of LAMP primers for the same sequence targeted 
by the Trypanozoon specific TBR PCR. LAMP primer design software requires a 




This is the first reported use of the LAMP methodology for the detection of 
Trypanozoon from cattle blood samples.  More than 400 cattle blood samples 
collected onto Whatman FTA cards were used to compare a well established PCR 
methodology against two published LAMP reactions – LAMP RIME and LAMP 
PfrA. 
 
The LAMP RIME reaction detected far more ‘Trypanozoon positive’ samples than 
the well established PCR protocol. However, LAMP PfrA detected far fewer 
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‘Trypanozoon positive’ samples than the well established PCR protocol. The 
detection sensitivity was significantly improved when results from more than one 
assay were combined – a parallel testing approach. LAMP RIME with the PCR was 
the most sensitive combination and most sensitive measure overall.  
 
The different sensitivities may be attributed to the different DNA targets of the three 
assays, and the different reaction mechanisms by which PCR and LAMP proceed. 
The PCR primers target a 177 bp repeat of which there are 10000 copies per haploid 
genome [107, 193, 194]. RIME is a mobile genetic element present at up to 400 
copies in the T. brucei genome [219]. Thus, though less prolific than the PCR target, 
the LAMP for RIME assay also uses a multi-copy sequence.  In contrast the LAMP 
for PfrA primers target the single copy PfrA gene [140].  The LAMP reaction 
proceeds by a very different mechanism to traditional PCR [123].  It can generate a 
much higher amplicon concentration in a shorter time frame and is therefore 
typically more sensitive than PCR.  The reaction is particularly efficient when loop 
primers are included [125], as is the case for LAMP for RIME.  Indeed, the absolute 
sensitivities for these assays reported by the original authors match the hierarchy of 
relative sensitivities reported in this study. The LAMP for RIME assay is reported to 
be 100 times more sensitive than the PCR with a detection limit of 0.0001 pg of 
DNA, whereas the LAMP for PfrA requires a minimum of 1 pg of DNA, equivalent 
to 10 trypanosomes ml-1. 
 
These different approaches also differ in cost. Considering reagents alone the cost 
per 100 reactions is cheapest for the PCR assay (£21.57 for 100 reactions) and most 
expensive for the LAMP PfrA assay (£42.40 for 100 reactions).  Therefore, while 
LAMP RIME is apparently more sensitive than the equivalent PCR, it is more 
expensive. However, if the application of LAMP continues to grow (see Chapter 1) it 
is likely that the price of Bst DNA polymerase will fall. The cost of this polymerase 
accounts for more than half the cost of the LAMP reaction (Appendix 3). According 
to the Bioline customer services helpline the cost of Taq polymerase (catalogue 
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number 21060) has been unchanged for the last five years at £350. Using the retail 
price indices (RPI) for July 2005 (758.2) and July 2010 (884.1) it is possible to 
calculate that £350 in 2005 is equivalent to £408.18 today. In effect therefore the 
price of Taq has fallen, as one might expect Bst to do also.  A thermal cycler, 
necessary for PCR reactions, is an extra cost compared to the water bath required for 
LAMP assays.  Thermal cyclers range in price according to functional specification 
and supplier.  A quick web search found that one UK supplier quotes £1965.00 for 
the cheapest available thermal cycler (25 Well Thermal Cycler, TC-300; catalogue 
number MB0530; www.appletonwoods.co.uk) compared to £242.05 for the least 
expensive dry heating block (Labnet Accublock, single dry block heater with 20 
wells; catalogue number HE1 501; www.appletonwoods.co.uk).  Therefore the 
additional cost of the PCR machine (£1723) is equivalent to the extra cost for 18000 
reactions LAMP RIME - after 18000 samples have been processed the cost of the 
thermal cycler is offset and PCR becomes the cheaper option.  
 
Given the excess of LAMP RIME positive results over and above the detection of 
TBR PCR positives, sensitivity differences might not be the only difference between 
the assays. It was important to check the specificity of the LAMP reaction. Non-
specific LAMP RIME amplification with other bovine infective trypanosomes, as 
well as non-specific amplification from host DNA were investigated.  The results 
were not encouraging. LAMP RIME amplified Trypanosoma congolense and 
Trypanosoma vivax DNA, as well as human and cattle genomic DNA. LAMP PfrA 
positive reactions were also seen with most concentrated host genomic DNA 
samples. One can consider what this might mean for user contamination in the 
laboratory. Recall that a tenfold dilution series was made and that the most human 
DNA added to the LAMP assays (with the 1 X dilution) was 12.5 ng. This is more 
than 1000 times the DNA content of a human cell (estimated at 7.2 -7.5 pg [227]). 
However, LAMP RIME positive amplification was seen with human DNA 
equivalent to less than that seen in a single human cell. Therefore the technician 
could easily contaminate the LAMP assay via skin shedding or during handling. 
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What is more, small amounts of human DNA are very likely to contaminate the FTA 
card, unless gloves are strictly worn.  In addition LAMP RIME positive reactions 
were seen with T. congolense savannah PCR positive-Trypanozoon PCR negative 
cattle blood samples. Notably, the results presented in this chapter contradict the 
original study, in which LAMP RIME specificity was assessed against DNA samples 
(approx 1 ng) human, tsetse, bovine, camel, Plasmodium falciparum, T. congolense 
savannah, T. congolense kilifi, T. congolense forest, T. simiae, T. simiae tsavo, T. 
godfreyi, T. vivax and T. lewisi and in which no positive reactions were reported for 
any of these samples [121].  
 
Finally, the BLAST search results give rise to real concern that LAMP RIME could 
amplify DNA from Schistosoma mansoni.  S. mansoni is one of five main species of 
trematode worm that cause Schistosomiasis – a chronic parasitic disease infecting 
207 million people worldwide, 85 % of whom live in sub-Saharan Africa 
(http://www.who.int/mediacentre/factsheets/fs115/en/index.html). For example, in 
Uganda, in 2003,  20.4 % of the population were estimated as infected [228].  
Although the focus of this study is the use of LAMP RIME for the detection of 
Trypanozoons in cattle, others are evaluating the use of LAMP RIME for the 
detection of Trypanozoons in humans [229].  Cross reactivity of the LAMP RIME 
assay with S. mansoni would seriously undermine its specificity in its target human 
population.  
 
The LAMP PfrA assay was published in 2003.  In the seven years since its 
publication it has been applied in only three additional research publications: (i) a 
study in which LAMP PfrA was compared to alternative diagnostic approaches for 
Trypanosoma evansi (Surra) in pigs [139]; (ii) a study assessing the thermostability 
of LAMP reagents and its amplification efficiency on crude trypanosome DNA 
templates [230] and (iii) a comparison of the analytical sensitivity of LAMP RIME 
and LAMP PfrA [121].  Firstly, LAMP PfrA specifically detected T. evansi in 
experimentally infected pigs, with high sensitivity, which exceeded that of PCR and 
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microscopy, and was second only to mouse inoculation [139].  Secondly, storage of 
LAMP reagents at 25 ˚C, 37 ˚C or -20 ˚C did not affect the detection sensitivity of 
LAMP PfrA and, although the detection sensitivity was poor when fresh blood was 
used to directly seed the LAMP PfrA reaction, hemolysed blood provided a suitable 
template for LAMP amplification [230].  Thirdly, LAMP PfrA required a 50 fold 
higher concentration of Trypanozoon DNA for successful amplification as compared 
to LAMP RIME [121].  
 
The LAMP RIME assay was published more recently, in 2008, having been 
developed by FIND (Foundation for Innovative New Diagnostics) with its academic 
partners at Murdoch and Obihiro Universities [115]. By selecting a gene with a high 
copy number, they hoped to improve the analytical sensitivity of Trypanozoon 
detection, in comparison to the LAMP PfrA assay. They succeeded. FIND continue 
to advocate the use of LAMP RIME as a potential new diagnostic for HAT 
(http://www.finddiagnostics.org/programs/hat/find_activities/molecular_diagnosis.ht
ml).  However, this study suggests that this improvement in analytical sensitvity 
brings an unacceptable cost in terms of reduced specificity.  
 
Recently, the LAMP RIME and a LAMP assay specific for the detection of T. b. 
rhodesiense (LAMP SRA [122]) have been compared to an SRA PCR [231] protocol 
also using human patient blood spotted onto FTA cards [229]. There are several key 
differences between the methodology and key findings of this paper, and the study 
reported here, which are worthy of note.  Firstly, the samples were collected from 
human patients, confirmed as trypanosome positive by microscopy. Hence specificity 
could not be assessed, rather the study focused on sensitivity. Second, LAMP RIME 
was not compared to TBR PCR, which detects all members of the subgenus 
Trypanozoon by targeting the multicopy 177 bp satellite repeat sequence. Rather, 
both LAMP reactions were compared to an SRA PCR, which has a single copy gene 
target. The study demonstrated that LAMP RIME and LAMP SRA are both more 
sensitive than the SRA PCR protocol used, and, further, that LAMP RIME and 
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LAMP SRA show very good agreement with one another (κ = 0.85, 95% CI 0.64-1).  
As the authors themselves note, a case control study is a key next step, in which 
LAMP RIME and LAMP SRA are applied to trypanosome negative as well as 
trypanosome positive blood samples. However, the results shown in this chapter 
suggest that as a research community we need to be much more confident about the 
specificity of the RIME assay before such steps forward are taken. Strategies to 
investigate LAMP RIME specificity further are urgently required, and will be 
discussed in Chapter 9.  Finally, as noted elsewhere [232], this study highlights the 
variety of PCR protocols in circulation, and the lack of a unified standard against 
which LAMP might be compared.  
 
Since its publication in 1989 the TBR PCR has enjoyed widespread use. It has been 
applied:  
(i) for the detection and identification of trypanosomes in tsetse  [39, 233-235]), 
(ii) to incriminate animal reservoirs of T. b. gambiense e.g. [236] and T. b. 
rhodesiense e.g. [33], 
(iii) for post treatment follow up of T. brucei in cattle [237, 238], 
(iv) during investigation of fatal post treatment reactive encephalopathies in 
human patients [239], 
(v) as a diagnostic for T. b. gambiense sleeping sickness, particularly as a follow 
up to CATT where there is discrepancy between parasitological detection and 
serology [86, 91, 92, 240], 
(vi) to detect Trypanosoma evansi in camels [241], other mammals [242], and 
even an atypical human infection [23], 
(vii) to detect Trypanosoma equiperdum in horses [243], 
(viii) as a putative stage determining diagnostic in sleeping sickness patients 
[244]  and (viiii) for diagnosis from archived human blood slides [39].  
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This list is not exhaustive, yet it highlights the utility of a molecular diagnostic that is 
capable of sensitive and specific detection of the Trypanozoons. In addition the TBR 
PCR is routinely used in our laboratory to monitor the prevalence of T. brucei s.l. as 
part of the Stamp Out Sleeping Sickness Campaign 
(www.stampoutsleepingsickness.com). The World Organisation for Animal Health 
(OIE) do not prescribe any particular test for tsetse transmitted animal 
trypanosomiases for the purposes of international trade. 
 
Here we ask: does LAMP offer a useful alternative to TBR PCR for remote 
epidemiological surveillance of cattle blood samples collected onto Whatman FTA 
cards? In this context the thermostability of LAMP reagents is largely irrelevant.  
 
At present we have serious concerns about both Trypanozoon LAMP reactions, 
particularly the sensitivity of LAMP PfrA and the specificity of LAMP RIME. 
Further, both LAMP reactions are more expensive than TBR PCR (for reagents 
alone).  
 
Unfortunately, attempts here to design LAMP primers to the sequence targeted by 
the TBR PCR were unsuccessful. Should an improved LAMP assay be developed, 
whose sensitivity and specificity is comparable, or even better than the TBR PCR, 
LAMP might be useful for more local monitoring of disease prevalence in cattle. 
LAMP ought to be a better suited technology for use in a less well resourced 
laboratory. Heating blocks are less expensive than PCR machines, or a water bath 
could be used and end product visualization can be achieved by addition of a cheap 
colour change reagent such as hydroxynaphthol blue (see also Chapter 8).  
 
If LAMP does not currently provide a suitable alternative to PCR for surveillance of 
T. brucei s.l. in cattle, might it be a useful tool for human diagnoses? Here, cross 
reactivity with T. congolense and T. vivax would be less relevant, since these species 
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are not typically human-infective. However at least one mixed T. brucei – T. 
congolense human infection has been reported [40]. Further, it is plausible that T. 
congolense or T. vixax DNA might persist in the human blood stream for long 
enough to be detected after lysis of these parasites. The apparent amplification of 
host DNA is also important. According to the Qiagen DNeasy Blood and Tissue Kit 
(Qiagen, UK) 3-6 μl DNA can be purified from 100 μl mammalian blood 
(approximately equivalent to the volume of  blood spotted onto an FTA card) into 
100 μl elution buffer, to give a DNA concentration of 0.03 – 0.06 μg μl-1. By 
comparison our starting concentrations of human and cattle genomic DNA were 
0.0125 and 0.05 μg μl-1 respectively. Clearly, these concentrations are similar to that 
one might expect in a human or cattle blood sample. The possibility that the 
technician might contaminate the reaction has also been discussed above, and one 
must not forget the potential problem of S. mansoni co-infection and cross reactivity 
with LAMP RIME. 
 
While detection of all members of the subgenus Trypanozoon by LAMP seems 
inadequate other species specific LAMP assays also show promise. It is these to 
which we turn in the subsequent chapters, returning to a more general discussion of 
the suitability of LAMP technology per se in the final chapter.  
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4 Chapter 4. LAMP assays for the specific detection of 
Trypanosoma brucei rhodesiense 
4.1 Introduction  
The demand for new and improved diagnostics for T. b. rhodesiense is well 
illustrated by the Ugandan situation. Uganda alone reported more than half of the 
new cases of Rhodesian sleeping sickness in 2006; a total of 245 out of 486 cases 
(note that under-detection and under-reporting are major issues and any reported 
figures are deceptively low). Also in Uganda, if the northwards trade of infected 
animals continues unchecked the human T. b. gambiense and T. b. rhodesiense foci 
of sleeping sickness are predicted to merge, which would further complicate both 
diagnosis and treatment and compromise prognosis. Improved diagnostic tools for T. 
b. rhodesiense are therefore urgently required to improve case detection and 
treatment, to enable more accurate determination of disease burden for public health 
practitioners and policy makers at all levels and to enable targeted application of 
therapeutic and prophylactic agents in domestic livestock and to make risk 
assessments [61]. Rational control of Rhodesian sleeping sickness requires 
diagnostics that can be used at local centres to distinguish T. b. gambiense and T. b. 
rhodesiense [32]. 
 
The first, and only, LAMP assay for the specific detection of T. b. rhodesiense was 
published in 2008 [122], with primers targeting the SRA gene (referred to hereon as 
LAMP SRA1).  
 
Four sequenced SRA genes are publically available for access through the GenBank 
database. Z37159 was the first sequenced, in 1994, from a Ugandan isolate [172]. 
Five years later AF097331 was independently identified in a Kenyan strain [169]. In 
2002, the SRA gene from an additional eight T. b. rhodesiense isolates were 
sequenced, including two of Tanzanian origin, two Kenyan, two Zambian, one 
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Ugandan and one Ethiopian. Two new sequences were identified AJ345057 (the so 
called ‘northern variant’) identical to the Tanzanian, Kenyan and Ugandan SRA 
genes, and AJ345058 (the ‘southern variant’) found to be identical to the Zambian 
and Ethiopian SRA genes [52]. When compared, these genes were 97.9-99.7 % 
homologous with only three minor sequence variants. Sequences AJ345057 and 
AJ345058 are similar to AF097331 rather than Z37159, which is now thought to 
represent a unique mutation in the clone or parental line from which it was 
sequenced [52].  
 
The LAMP SRA1 primers were designed using SRA sequence Z37159 and the assay 
was validated using DNA from 49 T. b. rhodesiense isolates (of which 14 were 
negative by a SRA PCR assay [52] and including isolates with the northern SRA gene 
and isolates with the southern variant SRA gene, as shown elsewhere [52]), five T. b. 
gambiense, six T. b. brucei, six T. evansi, three T. congolense, one T. vivax, one T. 
simiae, one T. simiae tsavo and one T. godfreyi. Njiru et al. [122] reported perfect 
diagnostic sensitivity and specificity, with a 1 pg detection limit.  
 
Here, the LAMP SRA1 assay has been re-evaluated. The binding sites of the primers 
were mapped to all four databased SRA gene sequences.  It was noted that these 
primers did not account for the deletion known to distinguish SRA from a multitude 
of similar VSG sequences.  In light of this, and the SRA PCR negative-LAMP SRA1 
positive results reported by Njiru et al. [122], the LAMP SRA1 assay was performed 
alongside the multiplex SRA PCR [108] reaction on 86 trypanosome DNA samples. 
The multiplex PCR is considered to be an improvement over previous PCR assays 
[32, 52] for SRA since it incorporates an internal amplification control that target the 
single copy trypanosomal GPI-PLC gene present in all T. brucei s.l.  Novel LAMP 
primers were also designed for the SRA gene that did span the deletion site. The 
binding sites of these primers were mapped to all four SRA gene sequences available 
on the Genbank database.   This chapter describes aspects of the molecular 
identification of DNA samples in this sample set, the re-evaluation of the published 
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LAMP assay for T. b. rhodesiense, and the design, optimisation and validation of a 
novel LAMP assay for T. b. rhodesiense.  
 
4.2 Aims  
1. To characterise the set of DNA samples using accepted PCR protocols as 
reference methods.  
2. To validate the published LAMP primers and assay for T. b. rhodesiense by 
comparison to the reference multiplex PCR for SRA. 
3. To design novel LAMP primers targeted to SRA accounting for its similarity 
to VSG genes. 
4. To optimize and validate the novel LAMP assay on the DNA samples. 
5. To review and compare sequenced SRA genes on database, mapping all 
LAMP primers to these genes in order to ensure the validity of these methods 
for all (northern and southern) T. b. rhodesienses.  
 
4.3 Study outline 
Firstly, the 86 DNA samples extracted from cryo-preserved procyclic and 
bloodstream form trypanosomes were subject to:  
- TCS PCR [188] as the standard molecular tool for the identification of 
T. congolense (savannah).  
- TBR PCR [107] as the standard molecular tool for the detection and 
identification of Trypanozoon DNA.  
- LAMP PfrA [140] as a positive control reaction for LAMP 
amplification of a single copy gene. 
- The multiplex SRA PCR reaction was used as the standard molecular 
diagnostic method for detection of T. b. rhodesiense [108]. 
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-  The published LAMP for T. b. rhodesiense [122] (referred to as 
LAMP SRA1) with endpoint detection by gel electrophoresis and UV 
illumination. 
 
A novel LAMP assay was designed to be specific for T. b. rhodesiense, by designing 
novel primers specific for the SRA gene and accounting for the deletion site 
compared with VSG.  Primers were trialed using But135 and DO DNA using a range 
of MgSO4 concentrations. After selection of the most appropriate primers the 
reaction mix was adapted for use in the real time turbidimeter by varying the 
concentration of dNTPs and MgSO4.  The assay was applied to the 86 samples in the 
real time turbidimeter before optimisation of the loop primer concentrations and 
reaction temperature were attempted.  
 
Two methods for endpoint detection were tried; Loopamp fluorescence detection 
reagent and calcein with MnCl2. Both were performed using 1/10, 1/100 and 1/1000 
dilutions of sample 86, using the optimised mastermix with 0.8 μM loop primers and 
Triton X-100 containing LAMP buffer in a heating block. The product was removed 
for gel electrophoresis and UV illumination to confirm the result. 
 
Cross tabulations were used to calculate sensitivity, specificity, negative and positive 
predictive values and Cohen’s kappa statistic, as well as 95 % confidence intervals, 
the prevalence and bias indices, and the maximum attributable kappa to aid the 
interpretation of kappa. These calculations were performed to compare the reference 
SRA PCR to: 
 
(i) the published LAMP SRA1assay  
(ii) the novel SRALAMP_a assay (assessed by real time turbidimeter)  
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(iii) the novel SRALAMP_a assay (assessed by heating block and gel 
electrophoresis, in triplicate, with the comparison made for each repeat 
of the LAMP assay);  
(iv) the novel SRALAMP_a assay with 0.8 and 2.4 μM loop primers on 1 in 
10 dilutions of the DNA samples (assessed by real time turbidimeter) 
 
Finally, the four databased SRA sequences (Z37159, AF097331, AJ345057 and 
AJ345058) were aligned using the ClustalW2 multiple sequence alignment program 
without making any changes to the default settings 
(www.ebi.ac.uk/Tools/clustalw2/index.html) [245] and the binding sites of the 
published and novel LAMP primers were mapped to the four aligned SRA sequences 
from the database by eye. 
 
4.4 Results 
4.4.1 Molecular assays 
The results of the molecular assays, excluding the novel SRALAMP_a assay, for all 
86 samples are shown in Appendix 8. The results of each assay and comparisons 
between them are shown in more detail in the following sections.  
 
4.4.1.1 Trypanozoon specific PCR reaction 
All samples, except for four, were positive by the TBR PCR. Samples 18, 21, 71, and 
85 were TBR PCR negative. Samples 49, 71 and 85 were T. congolense savannah 
(confirmed by the TCS PCR [188]) and were therefore expected to be TBR negative. 
There were three unexpected results: sample 49 is false positive and samples 18 and 
21 are false negative by TBR PCR. Since samples 18 and 21 are positive by the 
TgsGP PCR they are henceforth considered as T. b. gambiense despite their TBR 
negative status.  
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4.4.1.2 Trypanozoon specific LAMP reaction 
Eighty one samples were positive by LAMP PfrA. The average time to the turbidity 
threshold for LAMP PfrA positives was 38 min 59 s. Negative samples were 56, 62, 
71, 72 and 85. Again, sample 49 was positive. It may be a mixed infection, or it may 
have been cross-contaminated with Trypanozoon DNA during DNA extraction, 
handling or storage. T. congolense samples 71 and 85 were expected to be 
Trypanozoon negative. Samples 56, 62 and 72 were excluded from later analysis of 
the LAMP SRA assays.  
 
4.4.1.3 T. b. rhodesiense specific PCR reaction 
Multiplex SRA PCR gives rise to three bands. A band corresponding to VSG 
amplicon is observed at >1kb, a 669 bp band corresponds to specific amplification of 
the SRA gene and a 324 bp band corresponds to amplification of the GPI-PLC gene, 
as an internal control to confirm the presence of sufficient quality trypanosome DNA 
in the sample for PCR amplification of a single copy gene. PLC bands were observed 
for all but two of the samples (56 and 85). This seems to confirm that sample 56 
lacks sufficient DNA for amplification, as per the LAMP PfrA reaction. Sample 85 
was expected to be Trypanozoon negative which explains the lack of a PLC band. 
Samples 49 and 71 were also expected to be Trypanozoon negative, however weak 
PLC bands were seen for these samples suggesting that these DNA samples contain 
some T. brucei s.l. DNA as well as T. congolense savannah. VSG bands were seen 
for all but six of the samples (21, 22, 23, 56, 58, 85). Samples 21, 22, 23 and 58 were 
all confirmed T. b. gambiense Group 1. Thirty six of the 86 samples were SRA 
positive, of which two were unexpectedly positive for both the SRA and the TgsGP 
gene, one was unexpectedly SRA positive but not TgsGP PCR positive and one was 
unexpectedly SRA negative. These four anomalous results are summarised in Table 
4.1. Cohen’s kappa statistic demonstrates very good agreement (κ = 0.926; 95 % 
confidence interval 0.844 – 1.008; prevalence index 0.179; bias index 0.012) 
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between the SRA PCR and the 84 samples with known identity (see Appendix 2 for 
the identity and corresponding reference for all samples). Table 4.2 summarises the 
data from which this kappa statistic is calculated. Neither the prevalence nor bias 
indices suggest that this kappa value is artificially inflated or deflated. 
 
Table 4.1.  Anomalous SRA PCR and TgsGP PCR results 



















33. UGH [247] T. b. 
rhodesiense 




Table 4.2. The multiplex SRA PCR compared to previous identification 
as T. b. rhodesiense (see Appendix 2 for the identity and corresponding 
reference for all samples) 
  SRA PCR 
  + - Total 
+ 33 1 34 
- 2 48 50 
T. b. rhodesiense 
Total 35 49 84 
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4.4.2 Validation of the existing assay 
The LAMP SRA1 assay [122] showed very good agreement (κ = 0.901; 95 % CI 
0.807 – 0.996). The two by two table and summary statistics for the accuracy of 
LAMP SRA1 compared to the SRA PCR reference test are shown in Tables 4.3 and 
4.4. Neither the prevalence (0.157) nor the bias (0.024) indices suggest that this 
kappa value is artificially inflated or deflated. The maximum attributable kappa is 
0.951.  
 
Table 4.3. Two by two table summarising the agreement between LAMP 
SRA1 and SRA PCR 
  LAMP SRA1 
  + - Total 
+ 33 3 36 
- 1 46 47 
SRA PCR 
Total 34 49 83 
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Table 4.4. Summary statistics for the agreement between LAMP SRA1 
and SRA PCR 
Kappa 
(95 % CI) 
0.901 
(0.807 - 0.996) 
Sensitivity 
(95 % CI) 
91.67 % 
(77.43 – 97.87 %) 
Specificity 
(95 % CI) 
97.87 % 
(87.86 – 99.99 %) 
NPV 
(95 % CI) 
93.88 % 
(82.85 – 98.52 %) 
PPV 
(95 % CI) 
97.06 % 
(83.78 – 99.99 %) 
 
4.4.3 Development of the novel assay 
For the development of a novel assay several candidate primer sets were evaluated, 
of which one was taken forward for LAMP assay development. This included 
adaptation for use with a real time turbidimeter, optimisation, and evaluation on the 
complete sample set.  
 
4.4.3.1 Initial trial of novel primers 
The SRALAMP_b, SRALAMP7.2 and SRALAMP7.10 primers amplified neither T. 
b. rhodesiense nor T. b. brucei at any of the concentrations of MgSO4 at which they 
were tested.  
 
At 2 mM MgSO4, the SRALAMP_a primers specifically amplified T. b. rhodesiense 
but not T. b. brucei. Amplification occurred both with and without the loop primers, 
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using 1 μl of purified DNA as template. Without loop primers two out of three 
reactions seeded with DO (T. b. rhodesiense) were positive, however, when the loop 
primers were included all three were positive.  
 
LAMP products were much brighter under UV light, as assessed by eye, when the 
loop primers were included. Thus it seemed that the loop primers enhanced the 
amplification efficiency of the reaction. Figure 4.1 shows the electrophoresed LAMP 
product, as seen under UV light, generated by the SRALAMP_a primers with and 
without loop primers, in the initial screen. 
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human 
sleeping sickness: towards a point-of-care diagnostic test 
Chapter 4. LAMP assays for the specific detection of Trypanosoma brucei 
rhodesiense 
 124 
Figure 4.1.  SRALAMP_a primers at 2 mM MgSO4.   
            
1 2 3 4 5 6 7 8 1 2 43 5 6 7 8L L
Without loop primers With loop primers
 
Lanes 1-3 But135 (T. b. brucei); lanes 4-6 DO (T. b. rhodesiense); lanes 7, 8 negative 
controls; lanes labelled L contain a 1 kb ladder. 
 
The SRALAMP_e primers specifically amplified T. b. rhodesiense but not T. b. 
brucei at 2 mM, 4 mM, 6 mM and 8 mM MgSO4. The LAMP product, as seen under 
UV light, were brightest at 4 mM, 6 mM and 8 mM MgSO4, and were approximately 
equally bright at these concentrations.  
 
The SRALAMP_f primers specifically amplified T. b. rhodesiense but not T. b. 
brucei at 2 mM, 4 mM, 6 mM and 8 mM MgSO4. The ladders of bands were 
approximately equally bright at all these concentrations. 
 
In the initial screen, at 2 mM MgSO4, the SRALAMP7.1 primers neither amplified T. 
b. brucei nor T. b. rhodesiense. However, when the MgSO4 concentration was altered 
specific amplification of T. b. rhodesiense was observed. Positive results were 
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observed for all T. b. rhodesiense samples, but no T. b. brucei samples, at 3 mM, 3.5 
mM, 4 mM, 4.5 mM and 5 mM MgSO4. The LAMP product appeared brightest, 
under UV light, for 3 mM, 3.5 mM or 4 mM MgSO4 and less bright at 4.5 mM and 5 
mM MgSO4.  
 
The SRALAMP7.3 primer set specifically amplified T. b. rhodesiense in the initial 
screen at 2 mM, 4 mM, 6mM and 8mM, with optimal amplification observed at 4 
mM.  
 
The SRALAMP7.13 primer set specifically amplified T. b. rhodesiense in the initial 
screen at 2 mM, 4 mM, 6 mM and 8 mM, with optimal amplification observed at 4 
mM.  
 
SRALAMP_a was taken forward as a potentially T. b. rhodesiense specific LAMP 
primer set for full validation. Full validation was not performed simultaneously for 
all primer sets, even though several others showed promise, simply because the 
samples set was finite and time and resources were limited.  
 
4.4.3.2 Adaptation of SRALAMP_a for use with the real time 
turbidimeter 
When the concentration of MgSO4 and dNTPs were simultaneously increased to 8 
mM and 1.4 mM respectively, positive LAMP reactions were seen specifically for 
four SRA positive samples (32, 36, 64, 65 and 68) but not for two SRA negative 
samples (24 and 28) (both on a gel and using the turbidimeter). 
 
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human 
sleeping sickness: towards a point-of-care diagnostic test 
Chapter 4. LAMP assays for the specific detection of Trypanosoma brucei 
rhodesiense 
 126 
4.4.3.3 Optimisation of the reaction conditions for the novel assay 
To see if the time to reach the turbidity threshold could be reduced, and to make the 
reaction as sensitive as possible, the loop primer concentration and incubation 
temperature were tested over a range of reasonable values. 
 
When loop primers were included into the reaction at a 0.8 μM, which is a typical 
concentration for loop primers in a LAMP reaction, intermediate between the 
concentrations of the inner and outer primers, the LAMP reaction was more sensitive 
and more efficient than when no loop primers were used. The detection limit 
improved by a factor of five, from a 1/1000 dilution (0.0117 ng DNA) to a 1/5000 
dilution (0.0234 ng DNA) and the reaction was 23 min 36 s faster on average 
compared to when no loop primers were used. The detection limit and reaction 
efficiency were improved again when the loop primer concentration was increased to 
2.4 μM, which is in excess of the inner primer concentration. With 2.4 μM loop 
primers the detection limit improved from a 1/5000 dilution (0.0234 ng DNA) to a 
1/10000 dilution (0.00117 ng DNA) and the reaction was 7 min 47 s faster on 
average compared to when 0.8 μM loop primers are used. These data are shown in 




Loop-mediated isothermal amplification (LAMP) for the diagnosis of human 
sleeping sickness: towards a point-of-care diagnostic test 
Chapter 4. LAMP assays for the specific detection of Trypanosoma brucei 
rhodesiense 
 127 
Table 4.5. Effect of loop primers on the sensitivity and efficiency of the 
SRALAMP_a reaction 
Dilution factor Time taken to reach the turbidity threshold 
 Without loop primers Loop primers at 0.8 µM Loop primers at 
2.4 µM 
1/10 01:00:54 00:37:48 00:29:30 
1/50 01:02:30 00:38:30 00:31:30 
1/100 01:02:42 00:39:12 00:31:24 
1/500 01:09:36 00:42:18 00:32:54 
1/1000 01:15:06 00:55:00 00:39:42 
1/5000 - 00:58:00 00:59:06 
1/10000 - - 00:64:18 
 
Given the reductions seen in reaction time and detection limit when loop primers 
were used at 2.4 μM the assay was re-evaluated. Keeping everything else the same 
the assay was applied to 1/10 dilutions of the sample DNAs, firstly using 0.8 μM and 
secondly using 2.4 μM loop primers. Samples 21 and 72 were excluded from the 
analysis because they were LAMP PfrA negative at this dilution. When 2.4 μM loop 
primers were used the agreement with the reference PCR was reduced from κ = 
0.852 (very good) to κ = 0.354 (fair) and the specificity of the assay was largely lost, 
falling from 92.50 % to 42.50 %. Neither the prevalence nor bias indices suggest that 
this kappa value is artificially inflated or deflated, although the bias index is higher 
for the 2.4 μM screen. There is no overlap in the 95 % confidence intervals, which 
supports the conclusion that 2.4 μM loop primers worsens the agreement between the 
LAMP assay and the reference PCR. These calculations were made from the data 
shown in Table 4.6 below. The diagnostic accuracy summary statistics at both loop 
primer concentrations are shown in Table 4.7 below.  
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Table 4.6. Two by two table comparing SRALAMP_a with the reference 
PCR at two different concentrations of loop primers  
  SRALAMP_a 
  0.8 μM loop primers 2.4 μM loop primers 
  + - Total + - Total 
+ 27 2 29 28 1 29 
- 3 37 40 23 17 40 
SRA PCR 
Total 30 39 69* 51 18 69* 
*samples 2 and 73-86 were not done 
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Table 4.7. Summary statistics for SRALAMP_a using different 
concentrations of loop primers compared to the reference SRA PCR 
 0.8 μM loop primers 2.4 μM loop primers 
Kappa 






(95 % CI) 
93.10 % 
(76.97 – 99.15 %) 
96.55 % 
(81.37 – 99.99 %) 
Specificity 
(95 % CI) 
92.50 % 
(79.43 – 98.12 %) 
42.50 % 
(28.50 – 57.82 %) 
 NPV 
(95 % CI) 
94.87 % 
(82.21 – 99.48 %) 
94.44 % 
(72.35 – 99.99 %) 
PPV 
 (95 % CI) 
90.00 % 
(73.58 – 97.34 %) 
54.90 % 
(41.38 – 67.74 %) 
 
To aid interpretation of kappa the prevalence and bias indices and the maximum 
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Table 4.8. Prevalence and bias indices, as well as the maximum 
attributable kappa for the data in Tables 4.6 and 4.7. 
 
The reaction time was fastest at 60 ˚C or 62 ˚C depending on the concentration of 
DNA used as template for the LAMP reaction. Generally when higher concentrations 
of DNA were used the reaction was most efficient at 62 ˚C; at lower concentrations 
of DNA the reaction was most efficient at 60 ˚C. The reaction times at each 
temperature over the dilution series are shown in Table 4.9 below (the fastest 
reaction time at each DNA concentration is highlighted in red). Over the temperature 
range 58 ˚C to 62 ˚C the detection limit of the assay was not reached. At 64 ˚C and 
65 ˚C the detection limit is not clear cut, but these results suggest that the assay may 







 0.8 μM loop primers 2.4 μM loop primers 
κmax 0.970 0.407 
Prevalence index 0.145 0.159 
Bias index 0.014 0.319 
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Table 4.9. Effect of temperature on the efficiency and sensitivity of the 
SRALAMP_a assay  
Dilution 
factor 
Time taken to reach the turbidity threshold 
 58 ˚ C 60 ˚C 62˚ C 64˚ C 65˚ C 
1/10 00:51:30 00:43:12 00:42:00 00:48:12 01:05:06 
1/50 00:54:24 00:45:30 00:45:18 00:52:48 01:08:24 
1/100 00:54:36 00:47:36 00:46:48 00:55:00 01:03:42 
1/500 00:59:00 00:51:24 00:53:00 01:04:00 01:09:30 
1/1000 01:03:06 00:53:30 00:51:54 - 01:12:12 
1/5000 01:05:36 00:54:36 00:58:36 01:14:00 - 
1/10000 01:05:30 01:02:12 01:13:18 - 01:16:48 
 
4.4.3.4 Endpoint detection 
Figure 4.2 panel A shows the fluorescence, under UV illumination, when Loopamp 
Fluorescence Detection Reagent was used with SRALAMP_a. In panel A the 
fluorescence emitted by a negative control is compared to the fluorescence emitted 
from three positive reactions (a, b and c, which each contained a different 
concentration of template DNA). Regardless of the DNA concentration used to seed 
the SRALAMP_a reaction fluorescence appeared brighter than the negative control. 
Under ambient light a detectable colour change was also discernible by eye.  
 
In contrast, Figure 4.2 panel B shows the fluorescence, under UV illumination, when 
calcein and MnCl2 were used with SRALAMP_a. The gel electrophoresis results are 
adjacent. Clearly, all three reactions (a, b and c) are positive, and yet the fluorescence 
is difficult to distinguish from the negative control, particularly for tube c which was 
seeded with the lowest concentration of DNA.  
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Figure 4.2. Assessing the endpoint of the SRALAMP_a assay at 0.8 μM 
loop primers with Thermopol reaction buffer 
      A       
                   - a     b     c  
    B                    
a      b      c- - a   b   c
 
 Panel  A. Loopamp Flourescence Detection Reagent with a) 1/10 dilution of DO, b) 1/100 
dilution, c) 1/1000 dilution  and panel B. Calcein and MnCl2, as per Tomita , Mori et al. 
[136] with a) 1/10 dilution of DO, b) 1/100 dilution, c) 1/1000 dilution. 
 
4.4.4 Evaluation of the novel assays 
When it was performed and assessed using the real time turbidimeter the 
SRALAMP_a assay showed very good agreement (κ = 0.808; 95 % CI 0.681 - 
0.934) with the SRA PCR assay. The average time to the turbidity threshold was 39 
min 48 s. For true positives only the average time was 38 min 0 s. The average time 
for the false positives was 48 min 50 s.  Next, the SRALAMP_a was performed in 
triplicate, in a thermocycler, followed by optical turbidity and gel electrophoretic 
assessment. Tables 4.10 and 4.11 present the two by two comparison for 
SRALAMP_a versus SRA PCR using the real time turbidimeter and the heating 
block respectively.  
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Table 4.10.  SRALAMP_a versus SRA PCR (real time turbidimeter) 
  SRALAMP_a 
  + - Total 
+ 35 1 36 
- 7 40 47 
SRA PCR 
Total 42 41 83 
 
Table 4.11. SRALAMP_a, incubated in a thermocycler and assessed by 
gel electrophoresis, applied three times to the sample set, versus SRA 
PCR  
Replicate of SRALAMP_a 
1 2 3 
 
+ - Total + - Total + - Total 
+ 34 2 36 34 2 36 34 2 36 
- 2 45 47 5 42 47 11 36 47 
SRA PCR 
Total 36 47 83 39 44 83 45 38 83 
 
Table 4.12 presents the summary statistics comparing SRALAMP_a to the PCR for 
each test. When the SRALAMP_a, with the results read by gel electrophoresis, was 
compared to the SRA PCR results for these samples, the agreement, measured by 
Cohen’s kappa statistic, ranged from κ = 0.690 to κ = 0.902. There is considerable 
overlap between the 95 % confidence intervals for these three kappa values, 
supporting the hypothesis that this is a reliable assay.  
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Table 4.12. Summary statistics for the comparison of the index test, 
SRALAMP_a, and the reference test SRA PCR 
 
To aid interpretation of kappa the prevalence and bias indices and the maximum 
attributable kappa were also calculated (Table 4.13). 
Gel electrophoresis  Real time 
turbidimetry Repeat of SRALAMP_a 
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Table 4.13. Prevalence and bias indices, as well as the maximum 
attributable kappa for the data in Tables 4.11 and 4.12. 
 
Overall the best performance of the SRALAMP_a assay was the first screen of the 
sample set in the thermocycler, as assessed by gel electrophoresis when very good 
agreement (κ = 0.902) was seen, with the LAMP test being 94.44 % sensitive and 
95.57 % specific as compared to the PCR. All the results from the SRALAMP_a 
assay on the total sample set are given in Appendix 9. An assessment of the 
reliability of this assay, using these results is addressed in Chapter 7 and the 
usefulness of turbidity as a simple visual endpoint detection method is analysed and 
discussed in Chapter 8. 
 Real time turbidimetry Gel electrophoresis 
  1 2 3 
κmax 0.856 1 0.927 0.786 
Prevalence index 0.060 0.133 0.096 0.024 
Bias index 0.072 0 0.036 0.108 
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Figure 4.3. Kappa, sensitivity and specificity estimates, with 95 % CI for 








































SRALAMP_a (rtt) is performed using the real time turbidimeter; SRALAMP_a (gel) is 
incubated in a thermocycler with endpoint detection via gel electrophoresis and UV 
illumination, this was repeated three times (i, ii and iii) 
 
4.4.5 Multiple sequence alignment of databased SRA 
sequences 
Multiple sequence alignment of the four databased SRA sequences using the 
ClustalW2 program (www.ebi.ac.uk/Tools/clustalw2/index.html) [245] is shown in 
Figure 1, Appendix 10. There were 28 mismatches across the total sequence. 
 
4.4.6 Comparison of LAMP primer binding sites with 
northern and southern variant SRA sequences 
4.4.6.1 Published LAMP primers 
Perfect consensus was seen between the published LAMP primers, which were 
designed using the original Ugandan SRA gene Z37159, to northern variant SRA gene 
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AJ345057. However two separate single nucleotide mismatches were observed when 
the same primers were compared to the southern variant SRA gene sequence 
AJ345058, of which one was located in the F3 primer, and one was located in the 
FIP primer (Figure 2, Appendix 10). 
 
4.4.6.2 Novel LAMP primers 
Perfect consensus was seen between the novel LAMP primers, designed for the SRA 
gene AF097331, to northern variant SRA gene AJ345057 and southern variant SRA 
gene AJ345058 (Figure 3, Appendix 10).  
 
4.5 Discussion 
In 1989 the gene which confers human infectivity in T. b. rhodesiense – the SRA 
gene – was discovered [24] (independently confirmed in 1998 [170]). The SRA gene 
has proved to be a ubiquitous and conserved genetic marker for T. b. rhodesiense 
[52]. Its discovery and characterisation has enabled sensitive and specific molecular 
detection of this parasite, which in turn has greatly enhanced our understanding of 
the epidemiology of Rhodesian sleeping sickness. In particular cattle have been 
identified as important reservoir hosts, with a role in spreading disease into new 
geographic areas [32, 33].  
 
Several PCR assays have been developed for T. b. rhodesiense, each with primers 
that target the SRA gene [33, 52, 108, 175]. When designing PCR primers for SRA it 
is critical that they account for the deletion characteristic [108]: the SRA gene has 
apparently arisen as a result of a 378 bp deletion within what was originally a VSG 
gene and the putative breakpoints for this deletion are conserved [172, 173]. If this is 
not taken into consideration primers will likely bind VSG genes also present in other 
T. brucei s.l. species. This is made apparent by the amplified VSG band in the 
multiplex SRA PCR [108]. 
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For this study the multiplex PCR [108] was chosen for use as the reference standard 
for the molecular detection of T. b. rhodesiense. This multiplex PCR reaction 
includes contains an internal control which indicates whether sufficient genomic 
material is present for detection of a single copy T. brucei gene. The multiplex SRA 
PCR showed very good agreement (κ = 0.926) with previous identification as T. b. 
rhodesiense (these previous identifications were made according to a variety of 
methods, as described and referenced in Appendix 2). Two false positives (both 
supposed to be T. b. gambiense) and one false negative were observed. One of the 
false positives (sample 12) was previously SRA PCR positive using a different DNA 
extraction, so this is probably a true identification. The false negative might also be a 
correct identification. This isolate was identified as T. b. rhodesiense according to 
RFLP analysis, however, human serum sensitivity in vitro has not been tested for this 
isolate, which was collected from a cow.   Despite discrepancies it was reasonable to 
use the PCR as a molecular test against which to validate the published and new 
LAMP assays for T. b. rhodesiense.  
 
In 2008 a LAMP assay for the specific detection of T. b. rhodesiense was developed, 
whose primers were targeted to the SRA gene [122]. However, these primers bind 
upstream of the conserved SRA specific deletion site. Therefore, it was feared that the 
assay might also amplify T. b. brucei and T. b. gambiense DNA. Amplification of an 
unintended target is potentially more serious with LAMP than with traditional PCR 
since the majority of LAMP endpoint detection methods are not sequence specific. 
PCR products are usually confirmed by the size of the amplified fragment, which is 
seen upon UV illumination of the reaction products after they have been separated by 
gel electrophoresis.  However LAMP readout is typically positive or negative. When 
LAMP products are separated by gel electrophoresis, a ladder of bands is seen, but it 
is the presence rather than the shape of the ladder that is usually used for detection.  
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Sequence mismatches were also observed within the F3 and FIP primers when 
compared to the southern variant SRA sequence. Together these observations 
justified re- validation of the assay using a different set of DNA samples.  
 
The published assay for T. b. rhodesiense showed very good agreement (κ = 0.901) 
with the multiplex SRA PCR, detecting 92 % of SRA positive samples and showing 
98 % specificity. It was not possible to fully validate its application to the ‘southern’ 
T. b. rhodesiense as samples were not available.  
 
Although the published assay unexpectedly showed very good agreement with the 
multiplex SRA PCR reaction, novel primers were also designed which accounted for 
the SRA specific internal deletion site.  
 
Initially all novel primers were tested on one T. b. rhodesiense and one T. b. brucei 
DNA sample. The same reaction conditions were selected that had been used for the 
LAMP SRA1 assay (62 ˚C for 1 h followed by 4 min at 80 ˚C) and the composition 
of the reaction mix was the same as for the published LAMP RIME [121] and SRA1 
[122] reactions (Chapter 2). However, after the SRALAMP_a assay was selected for 
further validation this was modified with supplementary MgSO4, and additional 
dNTPs, so that these reagents were present in the same concentrations as in the 
published LAMP PfrA and TBG1 reactions [140, 141] in order to use turbidity for 
endpoint detection, both visually and using a real time turbidimeter. The sample set 
was screened four times using the SRALAMP_a assay. Firstly the assay was 
performed in the real time turbidimeter, which incubates the reaction, and gives a 
readout signal which indicates the time at which turbidity surpasses a predefined 
threshold. Then the assay was performed three times in a heating block after which 
the endpoint was detected by a visual assessment of the turbidity, and by gel 
electrophoresis with UV illumination.   
 
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human 
sleeping sickness: towards a point-of-care diagnostic test 
Chapter 4. LAMP assays for the specific detection of Trypanosoma brucei 
rhodesiense 
 140 
Using the real time turbidimeter, the SRALAMP_a assay showed very good 
agreement (κ = 0.808) with the multiplex SRA PCR assay. It detected 97 % of SRA 
PCR positives and was 85 % specific. Noticeably, the agreement between the novel 
LAMP assay and the PCR is less good than for the published assay and the PCR. The 
novel assay is more sensitive, but less specific. In other words it is detecting more 
true positives, but also more false positives.  
 
The average time to reach the turbidity threshold was approximately the same as for 
the LAMP PfrA assay on the same samples, but is not so fast as some reported 
LAMP assays (e.g. less than 30 minutes [125]). Attempts to improve the reaction 
efficiency were made during this study; variations in the concentration of loop 
primers and the incubation temperature were both trialled. At first it seemed that by 
increasing the concentration of loop primers the efficiency might be dramatically 
improved, however this came with an unacceptable decrease in reaction specificity. 
The temperature remained optimal at 62 ˚C. It might still be possible to further 
improve the efficiency of the reaction: small alterations in the primer binding site 
have been shown to have dramatic effects on reaction efficiency during the 
development of other LAMP assays (Chie Nakajima, personal communication). 
Finally, small adjustments in the composition of the reaction mix, or the incubation 
temperature might also improve the efficiency of the reaction. 
 
Since the LAMP SRA1 assay was not assessed in the turbidimeter it is not possible to 
make direct comparisons of reaction efficiency for these two assays.  
 
The first time the SRALAMP_a assay was applied to the full sample set using a 
heating block the results showed very good agreement with the multiplex SRA PCR 
(κ = 0.902).  This agreement was comparable to that seen with the published LAMP 
reaction, and was an improvement over the same assay performed and assessed by 
real time turbidimeter. Furthermore, the sensitivity and specificity were both high (94 
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% and 95 % respectively). Fewer false positives are detected when DNA amplicon is 
visualised directly via gel electrophoresis, than by turbidity, which is a by-product of 
DNA amplification.  
 
Repeatability of both the published and novel assays are analysed and discussed in 
Chapter 7. However, here at first glance alone we can see that the agreement of the 
novel SRALAMP_a assay over several repeats is far from perfect. This is possibly 
due to degradation of the DNA samples and the increasing likelihood of cross 
contamination between samples over time and with repeated use.  
 
Njiru et al. report that their LAMP assay (LAMP SRA1) is 100 times more sensitive 
than PCR for the SRA gene [122]. Using 10 fold serial dilutions of 100 ng DNA, pre 
heated at 96 ˚C for 1 min, they could reliably detect 1 pg DNA with the LAMP SRA1 
but only 100 pg DNA by PCR [52] (not the multiplex SRA PCR used in this study). 
The multiplex PCR can reliably differentiate between the T. brucei subspecies using 
genomic DNA diluted to the equivalent of one trypanosome (0.12 pg) [108]. The 
novel SRALAMP_a assay here could detect up to 1.17 pg diluted genomic DNA 
(approximately equivalent to 10 trypanosomes). Therefore, the novel LAMP assay is 
roughly equivalent to the published assay. Following the approach of Njiru et al. 
[122] sensitivity of SRALAMP_a might be improved by pre-heating the template.  
 
Simple, closed tube, endpoint detection would constitute an enormous benefit for a 
diagnostic intended for use in a resource poor, low technology setting. Turbidity was 
not reported for the published LAMP SRA1 assay, nor were any other closed tube 
detection methods applied to the LAMP SRA1 assay in the original study. In this 
study, turbidity ‘by-eye’ was possible for SRALAMP_a. Its accuracy compared to 
the results by gel electrophoresis for the same LAMP amplifications is described, 
analysed and discussed in Chapter 8. In summary, 79 % of positive SRALAMP_a 
reactions could be detected by turbidity, without any false positives. However, 
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turbidity assessment is not objective, but depends upon the reader’s interpretation of 
what they see, and here, turbidity assessments were made by one relatively 
experienced observer. An observer who selected a less stringent threshold for scoring 
a reaction as turbid would be likely to detect more false positives. Also, the 
agreement between turbidity, ‘by-eye’ and gel electrophoresis, was not consistent. 
Therefore, although ‘by-eye’ turbidity might be useful as a quick and dirty, 
technology-free method for reading LAMP results it is too subjective and insensitive 
to be used for definitive diagnosis. It is possible that simple yet quantitative endpoint 
turbidity measurement might be useful in field settings. Further work measuring the 
turbidity of LAMP reactions, followed by receiver operating curve analysis, would 
be useful to determine whether quantitative endpoint turbidimetry could be reliably 
used to discern LAMP positive and negative reactions.  
 
The small amount of preliminary work performed here suggested that the 
commercially available Loopamp flourescence detection reagent would enable 
discrimination of positive and negative endpoints for SRALAMP_a by a colour 
change that is visible by eye and according to fluorescence under UV. However this 
was only performed on a very few samples, and requires further validation. 
According to the manufacturers it should be stored at -20 ˚C, which may act as a 
barrier to use in HAT endemic areas owing to the cold chain requirement. Endpoint 
detection is discussed in detail in Chapter 8. 
 
4.5.1 Conclusions 
Both the published and novel LAMP assays designed to specifically detect T. b. 
rhodesiense enabled very good, but imperfect, agreement with the reference standard 
molecular diagnostic, the multiplex SRA PCR assay. Using data generated from the 
first full screen of the total sample set for each assay, performed in a thermocycler, 
followed by gel electrophoresis with UV visualisation, agreement with the reference 
standard PCR was almost identical for the two assays, the sensitivity was marginally 
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higher with the novel assay, whereas the specificity of the published assay was 
slightly better (Table 4.16).  
 
Table 4.16. Comparing the diagnostic sensitivity and specificity of the 
two T. b. rhodesiense LAMP assays 
 LAMP assay 
 SRALAMP_a (novel) LAMP SRA1 (published) 
Kappa 0.902 0.901 
Sensitivity 94.44 % 91.67 % 
Specificity 95.57 % 97.87 % 
 
However this comparison hides a lack of LAMP assay reproducibility which is 
assessed in more detail in Chapter 7 and makes direct comparison of the two assays 
difficult. Each assay has its own advantages. The published assay probably has a 
lower detection limit, whereas the novel assay has been optimised to enable simple 
endpoint discrimination by eye, using turbidity. Since the published assay does not 
give rise to turbidity in the reaction tube of positive reactions it might be difficult to 
perform in a real time turbidimeter. Given that the novel assay can be performed in a 
real time turbidimeter it is in a better position for further optimisation. Both assays 
have potential for further development as field friendly molecular diagnostic tools for 
T. b. rhodesiense. The future of these assays depends on further validation studies, 
and improvements to sample preparation and endpoint visualisation.  
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5 Chapter 5. Evaluation of a LAMP protocol [141] 
designed for the specific detection of Trypanosoma 
brucei gambiense 
5.1 Introduction 
T. b. gambiense classically falls into two groups first  differentiated by isoenzyme 
and restriction fragment length polymorphism analysis [248, 251-256] and later 
distinguished by unique microsatellites [257-259] and sequence polymorphisms 
within the 5.8S rRNA ITS region [249].  Most T. b. gambiense that have been 
isolated are from the genetically homogenous Group 1 type [248, 256, 260-262] with 
the remainder classified as Group 2.  
 
The number of reported cases for T. b. gambiense fell to 9877 by 2009 [59], the 
currently available diagnostics for T. b. gambiense remain far from perfect (see 
Chapter 1).   
 
At the start of this study the only LAMP assay for the specific detection of T. b. 
gambiense was published in 2007 [141].  This targeted the 5.8S rRNA - internal 
transcribed spacer 2 (ITS2) gene using primers that were designed for the sequence 
with accession number AF306777 (referred to as LAMP TBG1).  
 
The AF306777 sequence spans the ITS-1, ITS-2 and intervening 5.8S rRNA of a T. 
b. gambiense group 2 isolate known as TH2 (78E) originating from a human 
infection in Koudougou, Côte d’Ivoire. This region is supposed to be largely non 
functional and to be under minimal selective pressure. It was sequenced as part of a 
study conducted by Agbo et al. in 2001 [249], to investigate whether polymorphisms 
in this region could be used to differentiate T. b. brucei and T. b. gambiense. Agbo et 
al. used restriction fragment length polymorphisms (RFLP) (on six T. b. brucei and 
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seven T. b. gambiense isolates, of which one was Group 2) and sequence analysis (on 
four T. b. brucei and four T. b. gambiense isolates, of which one was Group 2). The 
RFLP analysis supported segregation of the isolates into three groups; one containing 
five T. b. brucei isolates, a second containing six T. b. gambiense Group 1 isolates 
and a third containing the one T. b. gambiense Group 2 isolate.  Sequence alignments 
identified a unique four base pair C3A insertion in the 5.8S rRNA gene of all four T. 
b. gambiense isolates.  
 
Thekisoe et al. [141], validated LAMP TBG1 using DNA extracted (by a standard 
method [250]) from in vitro parasite cultures of nine T. b. gambiense strains (five 
Group 1 and four Group 2 strains), one T. b. brucei, one T. b. rhodesiense, two T. 
congolense, one T. cruzi and nine T. evansi.  Several non-trypanosomal parasite 
cultured samples were also used (Babesia bovis, B. bigemina, B. caballi, B. equi, 
Theleria orientalis, T. parva, Toxoplasma gondii and Neospora caninum).  With this 
sample set, the LAMP TBG1 primers were shown to be highly specific for T. b. 
gambiense and could detect as little as 1 fg of T. b. gambiense DNA.  Both the 
sensitivity and specificity assays were reported to be consistent when repeated in 
pentaplicate [141]. 
 
In the present work, LAMP TBG1 was applied to a larger set of Trypanozoon DNA 
samples in comparison to TgsGP PCR as a reference test for this subspecies.  
 
5.2 Aims 
There were initially two main aims to this study: 
1. To screen the sample set with the reference PCR for the specific detection of 
Group 1 T. b. gambiense.  
2. To validate the published LAMP primers and assay for T. b. gambiense on a 
larger set of Trypanozoon DNA samples. 
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As the results were analysed it became apparent that it was also necessary to: 
3. Investigate the causes of observed non specificity in the published primers. 
 
5.3 Study outline 
Firstly, the 86 DNA samples extracted from cryo-preserved procyclic and 
bloodstream form trypanosomes were subject to:  
- TCS PCR [188] as the standard molecular tool for the identification of 
T. congolense (savannah).  
- TBR PCR [107] as the standard molecular tool for the detection and 
identification of Trypanozoon DNA.  
- TgsGP PCR [32, 109] reaction as the standard molecular diagnostic 
method for detection of T. b. gambiense.  
- LAMP PfrA [140] as a positive control reaction for LAMP 
amplification of a single copy gene.  
- LAMP TBG1[141] performed twice per sample; once in a  heating 
block and once in a real time turbidimeter 
 
Cross tabulations were then used to calculate sensitivity, specificity, negative and 
positive predictive values and Cohen’s kappa statistic, as well as 95 % confidence 
intervals, the prevalence and bias indices, and the maximum attributable kappa to aid 
the interpretation of kappa. These calculations were performed to compare: 
 
(i) Published identity as a Group 1 T. b. gambiense against TgsGP PCR 
(ii) Published identity as T. b. gambiense (Group 1 or Group 2) against  
a. LAMP TBG1 (assessed by gel electrophoresis) 
b. LAMP TBG1 (assessed by real time turbidimetry); 
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(iii) TgsGP PCR against 
a. LAMP TBG1 (assessed by gel electrophoresis) 
b. LAMP TBG1 (assessed by real time turbidimetry); 
(iv) LAMP TBG1 (assessed by gel electrophoresis) against LAMP TBG1 
(assessed by real time turbidimetry).  
 
Thirdly, the LAMP TBG1 primers were compared to their target sequence in four T. 
b. brucei and four T. b. gambiense sequences for the target region which were 
described by Agbo et al. [249] (Accession numbers AF306770, AF306771, 
AF306772, AF306773, AF306774, AF306775, AF306776 and AF306777). The 
position of the primers in relation to the T. b. gambiense specific C3A insertion was  
also determined.  
 
5.4 Results 
The results of the four molecular assays (TBR PCR, LAMP PfrA, TgsGP PCR and 
LAMP TBG1), for all 86 samples are fully tabulated in Appendix 12. The results 
from the TBR PCR and LAMP PfrA were fully described in Chapter 4.  A key point 
to note here is that three samples (56, 62 and 72) were excluded from all analyses 
because they were LAMP PfrA negative, despite being TBR PCR positive. The 
results from TgsGP PCR and LAMP TBG1 as well as the comparisons between 
made between them are described in detail in the following sections.  
 
5.4.1 T. b. gambiense specific PCR reaction 
TgsGP PCR was positive for nine samples but these were not all the same nine 
classified as in Group 1 T. b. gambiense in the scientific literature [246, 248, 252] 
(see Appendix 11).  A two by two table is shown below (Table 5.1) which excludes 
LAMP PfrA negative samples. TgsGP PCR shows good agreement [199] (κ = 0.803; 
95 % CI 0.585-1.022) with previous identification as Group 1 T. b. gambiense and is 
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highly specific (97.3%; 95 % CI 90.23-99.83 %), though less sensitive (87.5%; 95 % 
CI 50.78-99.89 %). The confidence interval for sensitivity is wide, owing to the 
small number of T. b. gambiense samples. The prevalence index is high (0.795), 
again because of the small number of T. b. gambiense samples, which may lead to an 
artificial reduction in kappa. However, the bias index is low (0.012).  
 
Table 5.1. TgsGP PCR agreement and earlier speciation of the isolates 
 TgsGP PCR 
Published identity + - Total 
Group 1 T. b. gambiense 7 1 8 
Not Group 1 T. b. gambiense  2 73 75 
Total 9 74 83 
 
Information about the discrepant samples is given in Table 5.2. This includes one 
false negative (highlighted in green) and two false positive samples (blue), as well as 
one LAMP PfrA negative sample which may also be a false negative (pink), and a 
fifth sample which was correctly identified by the TgsGP PCR assay, but was also 
positive by the SRA PCR. 
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Table 5.2. Discrepancies between the TgsGP PCR and published 
sample identities.  




5. Dal069 [246] T. b. gambiense Human; Côte d’Ivoire; 
1981 
+ + 
12. Biyamina [248] T. b. gambiense Human; Sudan; 1982 + - 
20. Katerema 311 [247] T. b. brucei Cattle; Uganda; 1990  - + 
33. UGH [247] T. b. rhodesiense Human; Uganda ; 1988 + + 
62. Muraz 15 
IM47a 
[248] T. b. gambiense Human; Burkina 
Faso;1980 
- - 
a LAMP PfrA negative, so may be inadequate quantity/quality DNA in this extraction for 
molecular analysis 
5.4.2 T. b. gambiense specific LAMP reaction 
Excluding the LAMP PfrA negative Trypanozoon samples leaves 83 samples, of 
which 68 were positive when the assay was performed in a real time turbidimeter.  
The average time to turbidity for the positive samples was 1 h 15 min 38 s.  The 
average time to turbidity for true positives (defined by previous published identity of 
the same stocks) was 1 h 14 min 41 s, while the average time to turbidity for false 
positives was 1 h 15 min 47 s.  When the reaction was performed in a heating block 
and the result assessed by gel electrophoresis 21 fewer samples were positive.  Of the 
three LAMP PfrA negative samples, 56 and 72 were negative for LAMP TBG1 by 
both methods, whereas 62 was negative when LAMP TBG1 was assessed by gel, but 
positive when assessed with the real time turbidimeter.  
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5.4.3 Agreement between real time turbidimetry and gel 
electrophoresis for LAMP TBG1 
A two by two table quantifying the agreement and disagreement between real time 
turbidimetry and gel electrophoresis results is shown below (Table 5.3). From this 
table Cohen’s kappa statistic was calculated. Poor agreement [199] (κ = 0.184; 95 % 
CI -0.043 – 0.411) was seen between the gel and turbidimetric assessed reactions. 
The prevalence index was 0.386 and the bias index was 0.253. The maximum 
attributable kappa was 0.447. The majority of the discordant results are for reactions 
which were positive by turbidity, but not by gel electorphoresis. 
 
Table 5.3. Two by two table summarising the agreement between real 
time turbidimetry and gel electrophoresis for LAMP TBG1  
 Gel 
Turbidimeter + - Total 
+ 42 26 68 
- 5 10 15 
Total 47 36 83 
 
5.4.4 Detection of T. b. gambiense by LAMP TBG1 
The LAMP TBG1 assay for the detection of T. b. gambiense (Groups 1 and 2 
according to previous identification of these stocks in the literature) was assessed 
with gel electrophoretic read out. By gel, LAMP TBG1 showed less agreement than 
would be expected by chance (κ = -0.098; 95 % CI -0.290 – 0.094) with the 
published identity of the samples and was less than 50 % sensitive and specific. 
Secondly, when the outcome was assessed by real time turbidimetry the agreement 
was poor (κ = 0.009; 95 % CI -0.128 – 0.145).  Sensitivity was improved to 81.82 % 
with the longer run time, but with specificity reduced to 20.83 % (Tables 5.4 and 
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5.5).  The confidence intervals are particularly wide for the sensitivity estimates, 
since so few T. b. gambiense samples were available. 
 
Table 5.4. Two by two table summarising the agreement between LAMP 
TBG1 and published identity as T. b. gambiense (Group 1 and Group 2) 
LAMP TBG1  
Gel electrophoresis Real time turbidimetry 
Published identity + - Total + - Total 
T. b. gambiense 4 7 11 9 2 11 
Not T. b. gambiense 43 29 72 57 15 72 
Total 47 36 83 66 17 83 
 
Table 5.5. LAMP TBG1 compared to published T. b. gambiense identity 
(Group 1 and Group 2) 
 LAMP TBG1 
 Gel electrophoresis Real time turbidimetry 
Kappa 
(95 % CI) 
- 0.098 
(-0.290 – 0.094) 
0.009 
(-0.128 – 0.145) 
Sensitivity 
(95 % CI) 
36.36 % 
(14.98 – 64.81 %) 
81.82 % 
(51.15 – 96.01 %) 
Specificity 
(95 % CI) 
40.28 % 
(29.71 – 51.83 %) 
20.83 % 
(12.94 – 31.68 %) 
NPV 
(95 % CI) 
80.56 % 
(64.67 – 90.55 %) 
88.24 % 
(64.41 – 97.97 %) 
PPV 
(95 % CI) 
8.51 % 
(2.83 – 20.46 %) 
13.64 % 
(7.12 – 24.15 %) 
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To aid interpretation of kappa the prevalence and bias indices and the maximum 
attributable kappa were also calculated (Table 5.6). 
 
Table 5.6. Prevalence and bias indices, as well as the maximum 
attributable kappa for the data in Tables 5.4 and 5.5. 
 
5.4.5 Comparing LAMP TBG1 and TgsGP PCR. 
LAMP TBG1 showed less agreement than would be expected by chance with the 
standard PCR method for the detection of T. b. gambiense, regardless of the method 
used to determine the output of the reaction (gel electrophoresis, κ = -0.049; real time 
turbidimetry, κ = -0.044).  When assessed by gel electrophoresis the LAMP assay 
was less than 50 % sensitive and specific compared to the PCR. When the reaction 
was run for longer in the real time turbidimeter, sensitivity was improved to 66.67 %, 
but specificity fell to 16.22 % (Tables 5.7 and 5.8).  Confidence intervals are 
particularly wide for the sensitivity estimates, since so few T. b. gambiense samples 
were available. 
 LAMP TBG1 
 Gel electrophoresis Real time turbidimetry 
κmax 0.210 0.076 
Prevalence index 0.301 0.072 
Bias index 0.434 0.663 
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Table 5.7.  Agreement between the LAMP TBG1 and TgsGP PCR assays  
  LAMP TBG1 
  Gel electrophoresis Real time turbidimetry 
  + - Total + - Total 
TgsGP PCR + 4 5 9 6 3 9 
 - 43 31 74 62 12 74 
 Total 47 36 83 68 15 83 
 
Table 5.8. Summary statistics comparing LAMP TBG1 with TgsGP PCR  
 
To aid interpretation of kappa the prevalence and bias indices and the maximum 
attributable kappa were also calculated (Table 5.9).  
 LAMP TBG1 
 Gel electrophoresis Real time turbidimetry 
Kappa 
(95 % CI) 
-0.048 
(-0.240 – 0.145) 
-0.044 
(-0.162 – 0.074) 
Sensitivity 
(95 % CI) 
44.44 % 
(18.84 – 73.37 %) 
66.67 % 
(35.09 – 88.27 %) 
Specificity 
(95 % CI) 
41.89 % 
(31.32 – 53.27 %) 
16.22 % 
(9.37 – 26.40 %) 
NPV 
(95 % CI) 
86.11 % 
(70.87 – 94.39 %) 
80.00 % 
(54.05 – 93.70 %) 
PPV 
(95 % CI) 
8.51 % 
(2.83 – 20.46 %) 
8.82 % 
(3.78 – 18.27 %) 
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Table 5.9. Prevalance and bias indices, as well as the maximum 
attributable kappa for the data in Tables 5.7 and 5.8. 
 
Figure 5.1 shows kappa, sensitivity and specificity (with their respective 95 % 
confidence intervals) for all the comparisons made above. 
 LAMP TBG1 
 Gel electrophoresis Real time turbidimetry 
κmax 0.170 0.052 
Prevalence index 0.325 0.566 
Bias index 0.458 0.675 
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Figure 5.1. Kappa, sensitivity and specificity estimates, with 95 % CI for 
all comparisons made between LAMP TBG1 and the reference methods 































LAMP TBG1 (rtt) was performed using the real time turbidimeter; LAMP TBG1 (gel) was 
incubated in a thermocycler with endpoint detection via gel electrophoresis and UV 
illumination; pub ID is the identity of these samples according to previous analyses recorded 
in the literature and PCR is TgsGP PCR 
 
5.4.6 Sequence alignment of primers to the target region 
The LAMP TBG1 primers were not specific for T. b. gambiense, whether compared 
to the previously published identity of these stocks, or to the standard PCR method 
for the detection of T. b. gambiense (the TgsGP PCR, whose use is restricted to 
identification of Group 1 T. b. gambiense). The LAMP TBG1 primer sequences were 
aligned to the 5.8S rRNA gene from four T. b. brucei and four T. b. gambiense 
sequences in order to investigate this poor specificity. Several interesting 
observations were made. Firstly, the primers do not span the T. b. gambiense specific 
C3A insertion. Secondly, the primers do not show unique and perfect consensus with 
T. b. gambiense. Thirdly, there is intraspecific variation within the primer binding 
sites for T. b. gambiense and T. b. brucei. These observations are discussed in more 
detail below. Tables 5.10 and 5.11 summarise the sequence mismatch between the 
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primers and these sequences. The primer binding sites on each of the T. b. brucei and 
T. b. gambiense ITS1 – 5.8S –  ITS2 gene sequences are shown in Appendix 13. 
 
5.4.6.1 The FIP primer 
The F2 section of the FIP primer does not show any sequence mismatch with the 
eight sequenced T. b. brucei and T. b. gambiense isolates. The F1c section aligns 
perfectly to all of the T. b. gambiense sequences and one of the four T. b. brucei 
sequences, but shows slight mismatch with three of four T. b. brucei sequences. This 
suggests that the FIP primer will show limited specificity to T. b. gambiense.  
 
5.4.6.2 The BIP primer 
The B2 section of the BIP primer shows similar amounts of sequence mismatch for 
T. b. brucei and T. b. gambiense (it is not a perfect match for any of the sequences 
except the single T. b. gambiense isolate it was designed against). The B1c section 
matches three of four T. b. brucei sequences and two of four T. b. gambiense 
sequences (including the one it was designed to). The BIP primer does not show 
specificity for T. b. gambiense. 
 
5.4.6.3 The F3 primer 
The F3 primer sequence matches all T. b. brucei and T. b. gambiense isolates 
sequenced here. It does not provide specificity for T. b. gambiense. 
 
5.4.6.4 The B3 primer 
B3 primer shows similar sequence mismatch for T. b. brucei and T. b. gambiense (it 
is not a perfect match for any of the sequences except the one T. b. gambiense isolate 
it was designed to).  It is unlikely that it could be specific for T. b. gambiense. 
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Table 5.10. A summary of the differences between the binding sites for 
the TBG1 LAMP primers for T. b. brucei isolates (see also Appendix 13) 
 
 Primer 
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Table 5.11. A summary of the differences between the binding sites for 
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No difference No difference 
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5.5 Discussion 
5.5.1 T. b. gambiense specific PCR 
Several PCR assays have been developed for T. b. gambiense [109, 263, 264] of 
which the TgsGP PCR is considered the best [177]. Since the first publication of the 
assay it has been modified into a more sensitive nested PCR reaction [32].  In the 
present work it was chosen as the best currently available PCR for the molecular 
identification of T. b. gambiense. Notably though it is only useful for detection of 
Group 1 T. b. gambiense. Although Group 1 isolates do comprise the majority of T. 
b. gambiense the inability to detect Group 2 T. b. gambiense is a short coming of this 
PCR for the present study. A Group 2 T. b. gambiense specific PCR is not known to 
be available.  
 
The TgsGP PCR showed very good agreement with published identity as a Group 1 
T. b. gambiense isolate. One false negative result was seen compared to what was 
expected based on identification of these samples in the literature.  This was the 
sample known as Biyamina, which was instead noted to be SRA positive. This 
concurs with previous unpublished observations in our laboratory (Kim Picozzi, 
personal communication).  Two false positive results were also seen. These may be 
due to cross contamination of these samples with T. b. gambiense DNA, or 
contamination of second round PCR reaction tubes with first round PCR product 
from a T. b. gambiense positive sample. The nested PCR increases the opportunities 
for handling errors to be made by increasing the number of manipulations that need 
to be performed.  This is a disadvantage that must be offset against the improvement 
in sensitivity that is obtained via the nested approach. It is also possible, but less 
likely, that these isolates (a human isolate from South East Uganda, and a cattle 
isolate) actually contained T. b. gambiense parasites at the time of collection.  
 
Despite these discrepancies, given the good agreement between the observed TgsGP 
PCR result and the identity of these isolates as described in the literature, TgsGP 
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PCR was considered a reasonable molecular test against which to validate the LAMP 
TBG1. 
 
5.5.2 Real time turbidimetry for LAMP TBG1 
LAMP assays can be performed in a heating block, thermocycler or water bath. 
Positive amplification reactions can be visualised by UV illumination after gel 
electrophoresis of the reaction products. This approach gives rise to a ladder of 
bands, which may appear as a more degenerate smear if the electrophoresis is ran 
more quickly, or through a less stringent gel. Alternatively LAMP reactions can be 
performed in a real time turbidimeter, typically for 90 minutes, after which the time 
taken to reach a pre determined turbidity threshold is recorded. If turbidity is noted 
the reaction is considered positive. Real time turbidimetry allows quantitative 
objective assessment of turbidity. It is often favoured by researchers developing 
LAMP reactions since the effect of any changes to primer design or reaction 
composition on the efficiency of the reaction can be quantified. Furthermore the 
reaction tube does not need to be opened. A closed tube system is preferred so that a 
laboratory does not become contaminated with LAMP products, which might 
compromise future work. 
 
In this study, an additional 21 positive results were seen when the LAMP TBG1 
assay was performed using a real time turbidimeter, rather than a heating block 
(when the reaction was performed in a heating block results were visualised by gel 
electrophoresis and UV illumination). Agreement between these two different 
methods of performing the same assay was poor, most likely as the reaction was 
incubated for longer in the real time turbidimeter.  Indeed, only one sample reached 
the turbidity threshold in less than one hour. This could also be because the turbidity 
threshold which was chosen was inappropriate. However, spurious turbidity must not 
be ruled out. Differences could also be due to actual amplification differences 
between the two repeats of the reactions, rather than differences in the detection 
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methods per se. The disagreement seen here serves as a warning for development and 
validation studies for other LAMP primer sets. Firstly, are all, or certain, LAMP 
reactions intrinsically unreliable, such that two screens of any sample set will never 
produce congruent results? (addressed in Chapter 7). Secondly, is the disagreement 
seen between the gel and turbidimeter results here a problem for other LAMP primer 
sets? Thirdly, is the disagreement here due to poor calibration of the real time 
turbidimetry threshold? In this study the choice of the turbidity threshold was 
arbitrarily chosen as a typical value used by other researchers for development of 
LAMP assays.  Perhaps a threshold ought to be specifically chosen for a given 
LAMP assay by comparison to gel electrophoresis results?  
5.5.3 Validation of LAMP TBG1 
LAMP TBG1 analysed by gel showed less agreement than would be expected by 
chance with published identity as T. b. gambiense.  This comparison was made 
against published identity as either Group 1 or 2 T. b. gambiense, since LAMP TBG1 
was validated for identification of both groups in the original publication. LAMP 
TBG1 by gel also showed less agreement than would be expected by chance with 
results from the TgsGP PCR which is specific for T. b. gambiense Group 1.  
 
When LAMP TBG1 results from the real time turbidimeter assays were compared to 
published identity as T. b. gambiense (Group 1 and 2) there was almost no agreement 
beyond what would be expected by chance. The sensitivity was improved compared 
to the gel electrophoresis results, but the specificity was markedly worse. This 
reflects the general observation that more samples are positive by real time 
turbidimeter.  
 
When LAMP TBG1 results from the real time turbidimeter were compared to the 
TgsGP PCR results there was less agreement than would be expected by chance, 
sensitivity was better than that seen by gel, but specificity was worse. This reflects 
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the observation that more samples are positive, in a non-specific manner, by real time 
turbidimetry. 
 
Although LAMP TBG1 was not described as being specific for Group 2 T. b. 
gambiense, the specific sequence of the target gene used during the primer design 
process was from a Group 2 T. b. gambiense isolate.  In the analyses LAMP TBG1 
was compared to both Group 1 and 2 T. b. gambiense isolates since the assay was 
originally published for use with both of these groups. However, given that primers 
were designed using a sequence from a Group 2 isolate it is not surprising that 
marginally better agreement was seen when the assay was compared to all T. b. 
gambiense, as identified in the literature, as opposed to TgsGP PCR positives as 
defined in this study.  
 
A closer look at the binding sites of the LAMP TBG1 primers for four T. b. brucei 
and three Group 1 T. b. gambiense sequences as well as the Group 2 T. b. gambiense 
sequence used for primer design was enlightening. LAMP TBG1 primers did not 
account for the C3A insertion previously reported to be unique and specific for T. b. 
gambiense in this region. The FIP primer shows limited specificity for T. b. 
gambiense for these sequenced isolates. None of the other primers look to be T. b. 
gambiense specific, however one LAMP primer may be sufficient to confer 
specificity on a whole assay. The intra subspecies variability in the primer binding 
sites is also a concern since it might reduce the sensitivity of these primers. 
 
5.5.4 Conclusions 
The results described here do not support the use of the LAMP TBG1 assay for T. b. 
gambiense specific molecular detection and identification. This work highlights areas 
for concern when performing LAMP assays using real time turbidimetry rather than 
incubation followed by gel electrophoresis and UV visualisation of LAMP products. 
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human 
sleeping sickness: towards a point-of-care diagnostic test 
Chapter 5. Design and evaluation of a novel LAMP protocol for the specific 
detection of Group 1 Trypanosoma brucei gambiense 
 163 
 
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human 
sleeping sickness: towards a point-of-care diagnostic test 
Chapter 6. Design and evaluation of a novel LAMP protocol for the specific 
detection of Group 1 Trypanosoma brucei gambiense 
 164 
6 Chapter 6. Design and evaluation of a novel LAMP 
protocol for the specific detection of Group 1 
Trypanosoma brucei gambiense 
6.1 Introduction 
In Chapter 5 a LAMP assay for T. b. gambiense (LAMP TBG1) [141] was evaluated 
using 86 trypanosome DNA samples (including nine from Group 1 T. b. gambiense 
isolates). Regardless of the method used for assay incubation and read out, and 
regardless of whether results were compared to the previously published identity or 
TgsGP PCR results for these DNA samples, LAMP TBG1 showed poor agreement 
(Cohen’s kappa statistic (κ) = 0 – 0.2) or less agreement than would be expected by 
chance (κ < 0) [199].  Hence, LAMP TBG1 protocol does not provide an accurate 
diagnostic tool for T. b. gambiense and there remains a requirement for the design of 
a sensitive and specific LAMP assay for T. b. gambiense.  
 
The broad spectrum LAMP RIME [121] and LAMP PfrA [140] assays, which detect 
all members of the subgenus Trypanozoon, could be used for the diagnosis of T. b. 
gambiense, but fail to differentiate T. b. gambiense from T. b. rhodesiense.  
Clinically this would be problematic if a patient had travelled within endemic foci of 
both diseases, or if the foci of these two separate diseases merge.  Since the 
convergence of T. b. gambiense and T. b. rhodesiense endemic foci in Uganda is 
becoming increasingly likely, the need for a discriminatory diagnostic test for these 
two subspecies is becoming increasingly urgent [32].  Generic Trypanozoon 
diagnostics might also detect DNA from abortive or transient T. b. brucei infections 
[39, 91, 92]. Separate concerns regarding the sensitivity and specificity of currently 
available LAMP assays for Trypanozoons are discussed in Chapter 3. 
 
Here is a description of the design, development and validation of a novel LAMP 
assay for Group 1 T. b. gambiense.   The TgsGP gene was selected as the target for 
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this novel assay. TgsGP was discovered in 2001 and encodes a T. b. gambiense 
specific glycoprotein [25]. It is well conserved in Group 1 T. b. gambiense, 
regardless of geographic origin and PCR assays have been developed (see Chapter 1, 
Section 1.7.3). Recall that since TgsGP like genes have been identified in other T. 
brucei s.l. isolates [25, 109, 265] with consensus to the 5’ end of TgsGP, TgsGP 
specific primers should be targeted to the 3’ end, where similarity to possible 
ancestral/ related genes is lost [109, 177]. 
 
Here LAMP for TgsGP was validated using 86 trypanosome samples of DNA that 
were previously used to evaluate the LAMP TBG1 assay. The absolute sensitivity of 
this novel assay is also determined, and simple endpoint detection by reaction tube 
turbidity is established.  The reliability of the assay is analysed and described in 
Chapter 7.   
 
6.2 Aims 
1. To design LAMP primers targeted to the TgsGP PCR gene. 
2. To develop a LAMP assay for amplification of T. b. gambiense. 
3. To validate the LAMP assay on a large set of Trypanozoon DNA samples. 
 
6.3 Study outline 
Firstly, a novel LAMP assay was designed to be specific for T. b. gambiense and was 
trialled with a small sub set of T. b. gambiense and non T. b. gambiense DNAs using 
a typical LAMP reaction mix, over a range of MgSO4 concentrations. 
Secondly the assay was adapted for use in the real time turbidimeter.  
Thridly, it was applied to the 86 DNA samples, once using a real time turbidimeter 
and once in a heating block followed by gel electrophoresis and turbidity assessment 
by eye. These analyses were in addition to all previous molecular characterisations 
performed on these samples. 
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Cross tabulations were used to calculate sensitivity, specificity, negative and positive 
predictive values and Cohen’s kappa statistic, as well as 95 % confidence intervals, 
the prevalence and bias indices, and the maximum attributable kappa to aid the 
interpretation of kappa. These calculations were performed to compare:  
(i) Published identity as Group 1 T. b. gambiense against  
a. LAMP TgsGP (assessed three times by gel electrophoresis) 
b. LAMP TgsGP (assessed once by real time turbidimetry); 
(ii) TgsGP PCR against 
c. LAMP TgsGP (assessed three times by gel electrophoresis) 
d. LAMP TgsGP (assessed once by real time turbidimetry); 
(iii) LAMP TgsGP (assessed by gel electrophoresis) against LAMP TgsGP 
(assessed by real time turbidimetry) 
Fourthly, the absolute sensitivity of LAMP was established in comparison to PCR. 
 
6.4 Results 
6.4.1 Molecular assays 
The results of the PCR assays and the LAMP PfrA for all 86 samples are tabulated in 
Appendix 12 and described in detail in Chapters 4 and 5.  Key points to note here are 
that (i) three samples (56, 62 and 72) were excluded from all analyses because they 
were LAMP PfrA negative, despite being TBR PCR positive and (ii) the TgsGP PCR 
showed very good (although imperfect) agreement (κ = 0.803) with identity as Group 
1 T. b. gambiense according to the literature.  
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6.4.2 Initial trial and adaptation for use with a real time 
turbidimeter 
In the initial trial, positive LAMP endpoints were seen for TgsGP PCR positive but 
not TgsGP PCR negative samples at 4 mM, 6 mM and 8 mM MgSO4.  With 2 mM 
MgSO4 positive LAMP amplification was not observed. Specific LAMP positive 
endpoints were also seen when the reaction was performed in the real time 
turbidimeter.   In the real time turbidimeter the time to threshold turbidity (Tt) was 
much quicker when 1.4 mM dNTPs were included (Table 6.1).  
 
Table 6.1. Effect of dNTP concentration on the efficiency of the LAMP 
TgsGP reaction 
Sample Sub-species Tt 
  0.2 mM dNTPs 1.4 mM dNTPs 
5. T. b. gambiense 73 min 54 s 37 min 30 s 
17. T. b. gambiense 78 min 0 s 40 min 0 s 
1. T. b. brucei No amplification No amplification 
3. T. b. rhodesiense No amplification No amplification 
 
6.4.3 Application of the TgsGP LAMP assay to 86 
trypanosome DNA samples 
Firstly, the assay was applied to the 86 samples using a real time turbidimeter (see 
full results in Appendix 16, Table 1).  In summary, nine TgsGP samples reached the 
turbidity threshold in 90 minutes, of which six were true positive (positive by both 
TgsGP PCR and in the literature) and three were false positive (negative by both 
TgsGP PCR and in the literature).  The average time to reach the turbidity threshold 
was 60 min 31 s.   For the six true positive results the average time to turbidity was 
51 min 6 s, whereas for the three false positive results the average time to turbidity 
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was 79 min 6 s.  There is a marked difference in the time to turbidity between true 
and false positive samples.   
 
Secondly, the same assay was applied to the same samples using a thermocycler. 
Samples were incubated for 60 (rather than 90) minutes, and endpoint detection was 
performed by standard gel electrophoresis with UV illumination and by visualisation 
of endpoint turbidity.  The second method was performed three times for the full 
sample set (full results are shown in Appendix 16, Table 2).  
 
6.4.3.1 Accuracy of the TgsGP LAMP assay 
a) Incubation and readout using a real time turbidimeter 
When a real time turbidimeter was used for incubation and readout, the LAMP 
TgsGP showed moderate agreement with the TgsGP PCR assay (κ = 0.504; 95 % CI 
0.177 – 0.832) and good agreement with published identity as a Group 1 T. b. 
gambiense isolate (κ = 0.672; 95 % CI 0.394 – 0.951).  Table 6.2 presents a two by 
two comparison of the real time turbidimeter results for the TgsGP LAMP versus 
TgsGP PCR and published identity as Group 1 T. b. gambiense.  Table 6.4 shows the 
summary statistics for these comparisons. 
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Table 6.2. Agreement of TgsGP LAMP (by real time turbidimeter) with (i) 
published identity as Group 1 T. b. gambiense and (ii) TgsGP PCR  
 Published identity as Group 1 
T. b. gambiense 
TgsGP PCR 
LAMP TgsGP + - Total + - Total 
+ 6 3 9 5 4 9 
- 2 72 74 4 70 74 
Total 8 75 83 9 74 83 
 
Table 6.3. Summary statistics comparing LAMP TgsGP (by real time 
turbidimeter) with (i) published identity as Group 1 T. b. gambiense and 
(ii) TgsGP PCR 
 
 Published identity as 
Group 1 T. b. gambiense 
TgsGP PCR 
Kappa 
(95 % CI) 
0.672 
(0.394 – 0.951) 
0.504 
(0.177 – 0.832) 
Sensitivity 
(95 % CI) 
75.00 % 
(40.09 – 93.69 %) 
55.56 % 
(26.63 – 81.16 %) 
Specificity 
(95 % CI) 
96.00 % 
(88.42 – 99.10 %) 
94.59 % 
(86.50 – 98.28 %) 
NPV 
(95 % CI) 
97.30 % 
(90.10 – 99.82 %) 
94.59 % 
(86.50 – 98.28 %) 
PPV 
(95 % CI) 
66.67 % 
(35.09 – 88.27 %) 
55.56 % 
(26.63 – 81.16 %) 
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To aid interpretation of kappa the prevalence and bias indices and the maximum 
attributable kappa were also calculated (Table 6.4). 
 
Table 6.4. Prevalence and bias indices, as well as the maximum 
attributable kappa for the data in Tables 6.2 and 6.3. 
 
b) Incubation followed by gel electrophoresis 
The LAMP TgsGP reaction was performed in triplicate, in a thermocycler followed 
by endpoint turbidity and gel electrophoretic assessment.  An assessment of the 
reliability of this assay, using these results, is addressed in Chapter 7 and the use of 
turbidity as a simple method for readout, using these results, is discussed in Chapter 
8.  Here, analysis is focussed on the accuracy of the LAMP TgsGP assay. 
 
When the TgsGP LAMP, with the results read by gel electrophoresis, was compared 
to the published identity of these isolates, the agreement, as measured by Cohen’s 
kappa statistic, ranged from 0.467 to 0.862. The two by two comparisons and 
summary statistics are shown in Tables 6.5 and 6.6 respectively. 
 
 
 Published identity as 
Group 1 T. b. gambiense 
TgsGP PCR 
κmax 0.934 1 
Prevalence index 0.795 0.783 
Bias index 0.012 0 
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Table 6.5. TgsGP LAMP, incubated in a thermocycler and assessed by 
gel electrophoresis, applied three times to the sample set, versus 
published identity as Group 1 T. b. gambiense 
 Replicate of LAMP TgsGP 
 1 2 3 
Published identity + - Total + - Total + - Total 
Group 1 T. b. gambiense 7 1 8 5 3 8 7 1 8 
Non- Group 1 T. b. gambiense 1 74 75 6 69 75 8 67 75 
Total 8   75 83 11 72 83 15 68 83 
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Table 6.6. Summary statistics comparing the three LAMP TgsGP 
replicates (incubated in a thermocycler and assessed by gel 
electrophoresis) versus published identity as Group 1 T. b. gambiense 
 
To aid interpretation of kappa the prevalence and bias indices and the maximum 
attributable kappa were also calculated (Table 6.7). 
 
 Replicate of LAMP TgsGP 
 1 2 3 
Kappa 
(95 % CI) 
0.862 
(0.672 – 1.051) 
0.467 
(0.138 – 0.796) 
0.552 
(0.276 – 0.829) 
Sensitivity 
(95 % CI) 
87.50 % 
(50.78 – 99.89 %) 
62.50 % 
(30.38 – 86.51 %) 
87.50 % 
(50.78 – 99.89 %) 
Specificity 
(95 % CI) 
98.67 % 
(92.13 – 99.99 %) 
92.00 % 
(83.32 – 96.59 %) 
89.33 % 
(80.10 – 94.74 %) 
NPV 
(95 % CI) 
100 % 
(94.09 – 100 %) 
95.83 % 
(87.97 – 99.06 %) 
98.53 % 
(91.37 – 99.99 %) 
PPV 
(95 % CI) 
87.50 % 
(50.78 – 99.89 %) 
45.45 % 
(21.25 – 72.01 %) 
46.67 % 
(24.80 – 69.89 %) 
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Table 6.7. Prevalence and bias indices, as well as the maximum 
attributable kappa for the data in Tables 6.5 and 6.6. 
 
When the TgsGP LAMP, with the results read by gel electrophoresis, was compared 
to the TgsGP PCR results for these samples, the agreement, as measured by Cohen’s 
kappa statistic, ranged from 0.546 to 0.934.  The two by two comparisons and 
summary statistics are shown in Tables 6.8 and 6.9 respectively. 
 
Table 6.8. TgsGP LAMP, incubated in a thermocycler and assessed by 
gel electrophoresis, applied three times to the sample set, versus 
TgsGP PCR.  
 Replicate of LAMP TgsGP 
 1 2 3 
Published identity + - Total + - Total + - Total 
Group 1 T. b. gambiense 8 1 9 6 3 9 8 1 9 
Non- Group 1 T. b. gambiense 0 74 74 5 69 74 7 67 74 
Total 8 75 83 11 72 83 15 68 83 
 
 Replicate of LAMP TgsGP 
 1 2 3 
κmax 1 0.822 0.652 
Prevalence index 0.807 0.771 0.723 
Bias index 0 0.036 0.084 
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Table 6.9. Summary statistics comparing the three LAMP TgsGP 
replicates (incubated in a thermocycler and assessed by gel 
electrophoresis) with TgsGP PCR 
 
To aid interpretation of kappa the prevalence and bias indices and the maximum 
attributable kappa were also calculated (Table 6.10). 
 
 Replicate of LAMP TgsGP 
 1 2 3 
Kappa 
(95 % CI) 
0.934 
(0.807 – 1.062) 
0.546  
(0.247 – 0.845) 
0.614  
(0.360 – 0.868) 
Sensitivity 
(95 % CI) 
88.89 %  
(54.33 – 99.99 %) 
66.67 % 
(35.09 – 88.27 %) 
88.89 %  
(54.33 – 99.99 %) 
Specificity 
(95 % CI) 
100 % 
(94.09 – 100 %) 
93.24 % 
(84.79 – 97.43 %) 
90.54 % 
(81.46 – 95.62 %) 
NPV 
(95 % CI) 
98.67 % 
(92.13 – 99.99 %) 
95.83 % 
(87.97 – 99.06 %) 
98.53 % 
(91.37 – 99.99 %) 
PPV 
(95 % CI) 
100 % 
(62.78 – 100 %) 
54.55 % 
(27.99 – 78.75 %) 
53.33 % 
(30.11 – 75.20 %) 
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Table 6.10. Prevalence and bias indices, as well as the maximum 
attributable kappa for the data in Tables 6.9 and 6.10. 
 
Overall the best performance of the TgsGP PCR assay was the first screen of the 
sample set in the thermocycler (as assessed by gel electrophoresis) and compared to 
the TgsGP PCR, where the two assays showed very good agreement (κ = 0.934), 
with the LAMP test being 89.89 % sensitive and 100 % specific as compared to the 
PCR (see Figure 6.1). 
 
 Replicate of LAMP TgsGP 
 1 2 3 
κmax 0.934 0.886 0.711 
Prevalence index 0.795 0.759 0.711 
Bias index 0.012 0.024 0.072 
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Figure 6.1. Kappa, sensitivity and specificity estimates, with 95 % 
confidence intervals for all comparisons made between LAMP TgsGP 









































LAMP (rtt) is LAMP TgsGP performed using the real time turbidimeter; LAMP 
(gel) is LAMP TgsGP incubated in a thermocycler with endpoint detection via gel 
electrophoresis and UV illumination; pub ID is the identity of these samples 
according to previous analyses recorded in the literature and PCR is TgsGP PCR. 
 
6.4.4 Agreement between real time turbidimetry and gel 
electrophoresis for LAMP TgsGP 
A two by two table quantifying the agreement and disagreement between real time 
turbidimetry and gel electrophoresis results (for the first of the three screens only) is 
shown in Table 6.11.  From this table Cohen’s kappa statistic was calculated and 
moderate agreement [199] (κ = 0.541; 95 % CI 0.216 – 0.867) was observed between 
the gel and turbidimeter assessed reactions.  The prevalence index was 0.795 and the 
bias index was 0.012.  Given that the prevalence index is high the kappa might be 
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artificially decreased.  The maximum attributable kappa was 0.934 and the majority 
of the discordant results were almost exactly evenly distributed.  
 
Table 6.11. Two by two table summarising the agreement between real 
time turbidimetry and gel electrophoresis for LAMP TgsGP  
 Gel 
Turbidimeter + - Total 
+ 5 4 9 
- 3 71 74 
Total 8 75 83 
 
6.4.5 Absolute sensitivity of LAMP versus PCR 
TgsGP PCR was more sensitive than LAMP TgsGP. This is shown in Table 6.12 
below, which summarises the results when two fold and ten fold dilution series were 
made from three samples, each with a distinct starting DNA concentration. In all 
instances the LAMP reaction amplified a 1 in 10, but not a 1 in 100, dilution, 
whereas the PCR reaction detected T. b. gambiense DNA up to, but not beyond, a 1 
in 100,000 dilution.  
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TgsGP PCR on dilution 
series 
LAMP TgsGP on dilution 
series 
  2 fold 10 fold 2 fold 10 fold 
5 27.3 ng μl-1 No limit 1 in 100,000 1 in 64 1 in 10 
18 27.4 ng μl-1 No limit 1 in 100,000 1 in 32 1 in 10 
58 14.7 ng μl-1 No limit 1 in 10,000 1 in 8 1 in 10 
 
6.5 Discussion 
Here a novel LAMP assay for the detection and identification of Group 1 T. b. 
gambiense has been developed and evaluated.  The TgsGP gene was selected as the 
target for this assay because it is a well accepted diagnostic marker gene for Group 1 
T. b. gambiense [109, 177].  Online LAMP primer design software was used to 
design LAMP primers for TgsGP that specifically targeted the 3’ end of the gene.  
 
The novel LAMP primers were initially tested on two T. b. gambiense Group 1 DNA 
samples which were both positive by the TgsGP PCR assay, and three non-T. b. 
gambiense samples, including two T. b. brucei and one T. b. rhodesiense.  The same 
reaction conditions were selected that had been used for the LAMP TBG1 assay (63 
˚C for 1 h followed by 2 min at 80 ˚C).  At first, the composition of the reaction mix 
was the same as the published LAMP RIME [121] and SRA1 [122] reactions (see 
Chapter 2).  However, this was modified with supplementary MgSO4, and additional 
dNTPs, so that these reagents were present in the same concentrations as in the 
published LAMP PfrA and TBG1 reactions [140, 141].  When the real time 
turbidimeter was used the reaction buffer was chosen to contain Tween-20, otherwise 
a reaction buffer containing Triton X-100 was used. Under the modified conditions, 
T. b. gambiense specific LAMP amplification was seen for this subset of samples 
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using the real time turbidimeter and by heating block and gel electrophoresis, and the 
assay was applied to the total set of samples.  
 
The LAMP TgsGP assay was applied to all samples, firstly using a real time 
turbidimeter, and secondly using a thermocycler.  In the real time turbidimeter the 
samples were incubated for 90 min, without a termination step, and the result was 
counted as positive if turbidity surpassed the threshold value of 0.1 within 90 min.  
With the thermocycler the reaction was incubated for 1 h, followed by a 2 min 
termination step.  The reaction was counted as positive if a ladder/smear of DNA 
could be seen upon UV illumination of the products run through an agarose gel.  The 
turbidity of the reaction at the end time was also assessed by eye.  With the 
thermocycler the full set of samples was screened three times.  
 
With the real time turbidimeter, the average time to the reach the turbidity threshold, 
was considerably slower for the false positive reactions, than for the true positives. 
The turbidity threshold that was used was not calibrated for this reaction but was 
simply chosen as a value typically used when developing LAMP reactions.  If 
incubation had been limited to one hour these false positives could be properly 
interpreted as negative results without affecting any of the true positives.  
Alternatively, selection of a different turbidity threshold might also have eliminated 
the false positives seen here. This demonstrates the importance of calibration of the 
turbidity against gel electrophoresis, when developing any novel LAMP assay.   It 
would be useful to apply the LAMP TgsGP assay using a dilution series of TgsGP 
positive and negative samples with different turbidity thresholds and for different 
time points, in order to determine the best endpoint for the assay.  
 
The average time to reach the turbidity threshold was slower, even when considering 
the true positive results alone, than for the LAMP PfrA reaction.  This suggests that 
the LAMP TgsGP reaction is less efficient. Several approaches for improving the 
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efficiency of the reaction could be made; firstly the primers themselves could 
undergo slight adjustments so that they bind in slightly different positions. Small 
alterations in the primer-binding site have been shown to have dramatic effects on 
reaction efficiency during the development of other LAMP assays (Chie Nakajima, 
pers. com.). Secondly the relative concentrations of the inner, outer and loop primers 
could be modified. Again, this has been shown to affect reaction efficiency during 
the development of other LAMP assays (Chie Nakajima, personal communication). 
Finally, small adjustments in the composition of the reaction mix, or the incubation 
temperature might improve the efficiency of the reaction. Having demonstrated the 
potential of this primer set in this work, further improvements could be worthwhile.  
 
With the real time turbidimeter LAMP TgsGP showed moderate agreement (κ = 
0.501; 95 % CI 0.177 – 0.832) with the TgsGP PCR assay but good agreement with 
published identity as a Group 1 T. b. gambiense isolate (κ = 0.672; 95 % CI 0.394 – 
0.951).  This difference arises from discrepancies between the TgsGP PCR results 
and the published identity of three of the samples.  The basis on which a sample was 
categorised as Group 1 is summarised in Appendix 11 and TgsGP PCR results are 
shown in Appendix 16.  Sample 12 which is a Group 1 T. b. gambiense according to 
isoenzyme analyses the literature [248] was negative by the TgsGP PCR but positive 
by the LAMP TgsGP (with the turbidimeter).  Samples 20 and 33 are TgsGP PCR 
positive, but are not T. b. gambiense according to the literature (see Appendix 2). 
Both are LAMP TgsGP negative in the turbidimeter.  The wide confidence intervals 
of both kappa estimates overlap considerably and one cannot confidently conclude 
that the difference in agreement is significant. 
The results were initially very promising when the reaction was performed with the 
thermocycler, with read out by UV illumination after gel electrophoresis. For the first 
screen, the LAMP TgsGP was 88.89 % sensitive (95 % CI 54.33 – 99.99 %) and 100 
% specific (95 % CI 94.09 – 100 %) compared to TgsGP PCR. Although the 95 % 
confidence interval around the sensitivity estimate is wide, owing to the small 
number of T. b. gambiense samples that were available, it remains well above zero so 
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one can be confident that agreement exceeds that expected by chance alone. Here the 
LAMP assay appeared more favourable when compared to the TgsGP PCR assay 
rather than the published identity of the isolates, although the difference was 
insignificant given the overlap in the confidence intervals. Again the differences are 
due to samples 12, 20 and 33, as summarised in Table 6.13 below. The different 
results seen for these three samples explain what first appeared to be the strange 
observation that with the real time turbidimeter the TgsGP LAMP assay agreed more 
strongly with published identity whereas when the reaction was performed using a 
thermocycler and assessed by gel electrophoresis with UV illumination, the assay 
agreed more strongly with the TgsGP PCR results. 
 
Table 6.13. Discrepant results for samples 12, 20 and 33 
Sample Published 
identity 
Ref TgsGP PCR 
(this study) 
LAMP TgsGP 
- real time 
turbidimeter 
LAMP TgsGP- 
thermocycler and gel 
electrophoresis (1st 
repeat) 
12 Group 1 T. b. 
gambiense 
[248] - + - 
20 T. b. brucei [247] + - + 
33 T. b. 
rhodesiense 
[247] + - - 
 
The results from the first screen in the thermocycler (assessed by gel electrophoresis) 
were also compared to the results when the assay was performed in the real time 
turbidimeter. These two data sets showed moderate agreement, which contrasts with 
the poor agreement seen in Chapter 5 when real time turbidimeter and themocycler 
results were compared for the LAMP TBG1 assay. Most importantly an excess of 
false positive results was not observed for LAMP TgsGP with the real time 
turbidimeter. This reinforces the utility of the turbidimeter if an appropriate turbidity 
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threshold is selected. Here, the selection of an appropriate turbidity threshold was 
largely serendipitous.  The remaining discrepancies are not unexpected given that the 
repeatability of the assay was imperfect even when performed under identical 
conditions (see Chapter 7).  However, at first glance alone we can see that the 
agreement over several repeats is far from perfect. This is possibly due to 
degradation of the DNA samples and the increasing likelihood of cross 
contamination between samples over time and with repeated use.  
 
LAMP is often promoted as being more sensitive than PCR, however, here the 
TgsGP nested PCR is 1,000 to 10,000 times more sensitive than the LAMP reaction.  
It is possible that the sensitivity of this LAMP assay might be improved by small 
adjustments to the reaction composition and conditions.  
 
The use of turbidity as a simple method for LAMP TgsGP readout is discussed in 
more detail in Chapter 8.  In short, visual turbidity was less sensitive than gel 
electrophoresis but was 100 % specific for gel positive endpoints, as assessed by a 
single, experienced reader.  Therefore, turbidity could be useful quick method for 
reading LAMP results. 
 
In conclusion, novel LAMP primers for T. b. gambiense were designed to target the 
same region of the TgsGP gene as the nested TgsGP PCR [32] and the results shown 
here are promising.  At best, Cohen’s kappa statistic for the agreement between the 
LAMP and PCR assays was 0.934. The LAMP assay detected 88.89% of the PCR 
positive samples, and no false positives were seen.  Given these strong results the 
process was repeated in order to assess the reliability of this assay. However, when 
the assay was repeated both sensitivity and specificity were reduced and the assay 
was observed to be less than perfectly reliable (see Chapter 7). In addition to 
considering diagnostic sensitivity it is also important to consider the absolute 
sensitivity of any molecular diagnostic. LAMP is promoted as being more sensitive 
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that PCR.  However, this novel LAMP assay was consistently less sensitive than the 
equivalent PCR.  In part this may be attributed to the nested nature of the PCR, 
though it also highlights the possibility to further improve the sensitivity of this 
promising new LAMP assay. Finally, it is important to note that the evaluation 
performed here was unfortunately limited by the number of T. b. gambiense isolates 
available. Thus confidence limits around the sensitivity estimates, as well as Cohen’s 
kappa statistic are rather wide. 
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human 
sleeping sickness: towards a point-of-care diagnostic test 
Chapter 7. The reliability of LAMP 184 
7 Chapter 7. The reliability of LAMP 
7.1 Introduction 
In the previous chapters the focus has been upon the validity and accuracy of various 
published and novel LAMP assays for Trypanozoon parasites.  A valid test is one 
that measures what it claims to measure.  Accuracy is the extent to which this 
measurement is correct and is quantified by sensitivity and specificity.  However, the 
value of a test also depends upon its reliability.  A reliable test generates the same 
result over several repeats under the same test conditions [266].  Here, the terms 
reliability and repeatability are used interchangeably.  Reproducibility refers to a 
similar but subtly different concept.  While reliability assessment considers the 
closeness of test results when the conditions of measurement are constant, 
reproducibility is a measure of the closeness of test results when the conditions for 
testing or measurement are changed [267].  Changes may include the operator (inter-
observer reproducibility), test site, kit lot or run day, for example.  
 
Neither the repeatability nor the reproducibility of the various published LAMP 
assays for Trypanozoons, have been well addressed in the scientific literature.  
Reliability was not addressed during publication of the LAMP PfrA [140] assay or 
the LAMP TBG1 [141] assay (which been shown to be non specific see Chapter 5).  
In the original LAMP SRA1 [122] study the assay was performed in triplicate on 
dilution series of infected mouse blood when determining the analytical sensitivity of 
the assay: reliability was not reported to be a problem, but neither was it explicitly 
quantified.  The authors did not report any problems with repeatability for LAMP 
RIME [121]; the results were identical for dilution series of infected mouse blood 
when performed in a thermocycler or water bath, and there was total agreement 
between replicates for clinical samples.  However the number of replicates applied 
was not clear.  
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Follow up reports, in which evaluation of LAMP SRA1 and LAMP RIME 
diagnostics have been extended to clinical samples, have also focussed upon validity 
assessment [268]. This is not unusual; Guthmann et al. [269] noted a similar bias 
during early evaluations of rapid diagnostic tests (RDTs) for malaria.  Yet, reliability 
is critical and must be analysed and reported.  Referring to rapid diagnostic tests for 
malaria, it has been noted elsewhere that, ‘RDTs must provide consistently accurate 
tests and be seen to do so. ’ [270]. 
 
Therefore, here the reliability of several LAMP assays is explicitly addressed.  The 
assays under consideration are: LAMP RIME [121], LAMP PfrA [140], LAMP SRA1 
[122], SRALAMP_a (see Chapter 4) and LAMP TgsGP (see Chapter 6).  Reliability 
is assessed using control DNA samples as well as human and animal blood samples.  
 
Here, the endpoint of all LAMP reactions was assessed by gel electrophoresis and 
UV illumination.  The reproducibility of endpoint detection methods is a separate 
issue that is addressed in Chapter 8.  
 
7.2 Aims 
1. To quantify the reliability of LAMP assays for Trypanozoon (LAMP RIME 
and LAMP PfrA), for T. b. gambiense (LAMP TgsGP) and T. b. rhodesiense 
(LAMP SRA1 and SRALAMP_a) on the same DNA extractions used for 
validity analyses throughout this thesis. 
2. To quantify the reliability of LAMP RIME, LAMP PfrA in comparison to the 
TBR PCR on human and cattle blood samples. 
3. To quantify the reliability of the two LAMP assays for T. b. rhodesiense in 
comparison to the multiplex SRA PCR on human and cattle blood samples. 
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7.3 Study outline 
Firstly LAMP RIME [121] and LAMP PfrA [140] for Trypanozoons, LAMP TgsGP 
for T. b. gambiense (see Chapter 6)  and two LAMP reactions for T. b. rhodesiense 
(LAMP SRA1 [122] and SRALAMP1 (see Chapter 4) were performed in triplicate on 
all 86 control DNA samples. Cohen’s kappa statistic was used to compare each 
repeat screen (i, ii and iii) of the total sample set for each assay against the relevant 
reference PCR (i.e. LAMP PfrA and LAMP RIME were compared to the TBR PCR, 
while LAMP SRA1 and SRALAMP_a were compared to the SRA PCR).  Cohen’s 
kappa statistic was also used to quantify test-retest agreement for all three 
combinations of the three screens by each assay (eg. for LAMP RIME repeat i was 
compared to repeat ii and repeat iii; repeats ii and iii were also compared to one 
another). 
 
 Secondly, the same assays were performed in pentaplicate on a subset of the control 
DNA samples. The number of samples for which all three (or five) replicates were all 
positive, or all negative were summed and this was calculated as a percentage of the 
total number of observations (n = 86) to give the overall percentage agreement. The 
method of Fleiss, Levin et al. [271] was used to quantify the agreement across the 
five replicates for the subspecies specific LAMP assays (LAMP SRA1, SRALAMP_a 
and LAMP TgsGP). Hereon this is referred to as Fleiss’ kappa 
 
Mostly, repeats were performed serially and the time lag between replicates is 
summarised here. LAMP PfrA replicates were made over two days.  LAMP RIME 
and SRALAMP_a replicates spanned a three-week time period.  The first three 
replicates of the LAMP TgsGP assay were performed within nine days, but the 
additional two repeats were not performed until one month later.  Finally, the longest 
time lapse between repeats was seen for the LAMP SRA1 assay.  The first full screen 
of the 86 samples took place five months in advance of the remaining replicates, 
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which were performed within a three week period. In between the samples were 
stored in a refrigerator. 
 
Thirdly, the LAMP assays for Trypanzoon and T. b. rhodesiense (LAMP RIME, 
LAMP SRA1 and SRALAMP_a) were performed in triplicate on Whatman FTA card 
samples   
(i) 52 T. b. rhodesiense human patient blood samples, alongside triplicate 
repeats of the TBR and SRA PCR assays (each assay was performed 
simultaneously within 24 hours of DNA preparation) 
(ii) 48 cattle blood samples, as well as triplicate repeats of the TBR and SRA 
PCR assays (the TBR PCR and LAMP RIME assays were performed 
simultaneously within 24 hours of DNA preparation which was then 
frozen and thawed once before the SRA PCR, LAMP SRA1 and 
SRALAMP_a reactions were performed simulataneously on the DNA 
samples) 
 
The number of samples for which the three replicates were all positive or all negative 
was calculated as a percentage of the total number of observations to provide the 
overall percentage agreement.  Cohen’s kappa statistic was used to quantify test-
retest agreement for all three combinations of the three screens by each assay.  The 
magnitude and range of these kappa values for each assay could be compared to one 
another. Firstly, calculations were made separately for cattle and human sample 
results, then, in order to increase sample size and reduce confidence intervals 
calculations were performed on data pooled for all Whatman FTA card field samples.  
For the SRA PCR kappa was calculated from a three by three contingency table, 
including ‘insufficient DNA present’ as the third category, where a GPI-PLC band 
was not seen.  
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7.4 Results  
7.4.1 Control DNA samples 
The results from the repeated application of the five LAMP assays to the 86 DNA 
samples can be found alongside the reference PCR results, tabulated in Appendix 17.  
 
7.4.1.1 Agreement between LAMP and the equivalent PCR assays 
Having applied LAMP assays to all 86 control DNA samples, in triplicate, the first 
analysis to be made was a comparison of each repeated application of a particular 
assay to the appropriate reference PCR (see Figure 7.1 for a graphical results 
summary).  Agreement was quantified by Cohen’s kappa statistic.  The values of 
κmax, the prevalence and bias indices and the 95 % confidence intervals for κobserved 
were calculated to aid interpretation and comparison of κobserved.  Results of these 
calculations and the contingency tables from which they were made are shown in 
Appendix 18.  
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 LAMP RIME and LAMP PfrA were compared to the TBR PCR; LAMP TgsGP was 
compared to the TgsGP PCR; and LAMP SRA1 and SRALAMP_a were compared to the 
SRA PCR. Error bars show the 95 % confidence intervals for each of the kappa statistics. 
7.4.1.2 LAMP test-retest agreement  
Secondly, the repeatability of each LAMP assay was assessed.  Two measures are 
considered.  Firstly, the overall percentage agreement was calculated for each assay 
and secondly the agreement between any two repeats of an assay was calculated 
using Cohen’s kappa statistic.   
 
Table 7.1 shows the overall percentage agreement for each LAMP assay.  For the 
Trypanozoon identification LAMP RIME was better than LAMP PfrA.  For T. b. 
rhodesiense, LAMP SRA1 was better than SRALAMP_a. 
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Table 7.1. Overall percentage agreement for each LAMP assay applied 
in triplicate to 86 DNA samples 
LAMP Overall percentage agreement 
RIME 97.67 % 
PfrA 77.91 % 
TgsGP 83.72 % 
SRA1 89.53 % 
SRALAMP_a 80.23 % 
 
Figure 7.2 shows a summary of the agreement (quantified by Cohen’s kappa statistic) 
for all test-retest combinations of each assay.  The values of κmax, the prevalence and 
bias indices and the 95 % confidence intervals for κobserved were also calculated to aid 
interpretation and comparison of κobserved.  The results of these calculations and the 
contingency tables from which they were made are shown in Appendix 19.  
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LAMP RIME i-ii indicates that the first repeat screen with the LAMP RIME assay was 
compared to the second repeat screen with the LAMP RIME assay, etc. Error bars show the 
95 % confidence intervals for each of the kappa statistics. 
 
7.4.1.3 Pentaplicate repeats for a subset of samples 
Evaluation of LAMP assay reliability on control DNA samples was then extended by 
looking at the repeatability of the tests performed five times on a subset of samples.  
Table 7.2 shows the results when the LAMP assays were repeated five times 
alongside the reference PCR results (performed once to confirm the molecular 
identification of these samples).  LAMP RIME detected all samples (all 
Trypanozoons) with 100 % sensitivity, while LAMP PfrA gave two false negative 
results out of five repeats for one T. b. gambiense sample. LAMP TgsGP was 
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perfectly specific but failed to identify T. b. gambiense on four occasions.  Finally, 
the LAMP assays for SRA were perfectly sensitive but both picked up false positives.  
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Table 7.2. Number of positive LAMP reactions out of five repeats 
 PCR  Positive LAMP assays (n= 5) 
Sample  TBR SRA TgsGP RIME PfrA TgsGP SRA 
LAMP_a 
SRA1
1. Tira 24 + - - 5 5 0 1 1 
2. Sikuda 28 + - - 5 5 0 0 1 
6. Papol 33 + - - 5 5 0 1 0 
7. Bumanda 146 + - - 5 5 0 0 0 
8. Papol 264 + - - 5 5 0 0 0 
5. Dal069 IM52 + + + 5 5 5 1 0 
17. TH149 + - + 5 5 4 0 0 
18. Bida 3CloneA - - + 5 5 5 3 0 
20. Katerema 311 + - + 5 3 3 0 0 
21. Musikia 
CloneA 
- - + 5 5 4 0 1 
3. UGC + + - 5 5 0 5 5 
4. UGI + + - 5 5 0 5 5 
9. UGA 88 + + - 5 5 0 5 5 
14. Papol 103 + + - 5 5 0 5 5 
80. Rose Akinare + + - 5 5 0 5 5 
Samples highlighted in green are T. b. brucei, in yellow are T. b. gambiense and in pink are 
T. b. rhodesiense. 
 
Table 7.3 (below) shows the overall percentage agreement of each LAMP assay with 
this subset of samples, calculated using the results tabulated above (see Table 7.2). 
Only LAMP RIME was perfectly reliable on these control DNA samples.  However 
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since this subset did not contain non-Trypanozoons, it was not possible to assess the 
reliability of LAMP RIME for generating true negative results.  
 
Table 7.3. Overall percentage agreement for each LAMP assay in 
pentaplicate (15 DNA samples) 
LAMP Overall percentage agreement 
RIME 100 % 
PfrA 93.33 % 
TgsGP 80 % 
SRA1 80 % 
SRALAMP_a 73.33 % 
 
Fleiss’ kappa [271] was used to quantify the agreement across the five replicates for 
the subspecies specific LAMP assays (LAMP SRA1, SRALAMP_a and LAMP 
TgsGP) (see Table 7.4). This gives a chance corrected measure of agreement. 
Accordingly, the novel assay for T. b. rhodesiense was most reliable, while the two 
novel assays were less reliable, but none show perfect agreement.  
 
Table 7.4. Fleiss’ kappa statistic for agreement across five repeats 
LAMP Assay SRALAMP_a SRA1 TgsGP 
Kappa  0.753 0.829 0.769 
 
7.4.2 LAMP and PCR assay reproducibility when applied to 
field samples 
Having considered the repeatability of LAMP on control DNA samples, reliability 
was then assessed using human patient and cattle blood samples stored on Whatman 
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FTA cards. Table 7.5 summarises the results seen when the TBR PCR, SRA PCR, 
LAMP RIME, LAMP SRA1 and SRALAMP_a assays were applied in triplicate to 
cattle and human patient blood samples.  
 
Table 7.5. Repeatability of PCR and LAMP assays applied to cattle 
blood samples  











 All + 21 0 4 1 1 
All - 23 0 18 32 44 
All insufficient 
DNAa  
 36    
Total  48 48 48 48 48 
 % agreement 91.66  75.00  45.83  68.75  93.75  











 All + 52 27 41 34 3 
All - 0 1 0 5 20 
All insufficient 
DNAa  
 4    
Total  52 51 52 52 52 
% agreement 100  62.74  78.85  75.00  44.23  
 aThis category refers to the SRA PCR only 
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Figure 7.3 presents a graphical summary of the agreement for all test-retest 
combinations of the TBR PCR and LAMP RIME assays on the cattle samples.  There 
were no a priori expectations about the outcome of these tests (i.e. the infection 
status of these samples was unknown). Agreement was quantified by Cohen’s kappa 
statistic.  The values of κmax, the prevalence and bias indices and the 95 % confidence 
intervals for κobserved were also calculated to aid interpretation and comparison of 
κobserved.  The results of these calculations and the contingency tables from which they 
were made are shown in Appendix 20. The same analysis is not shown for the SRA 
PCR, LAMP SRA1 and SRALAMP_a since only two of the cattle samples were SRA 
PCR positive for at least one of the three repeats. Therefore the confidence intervals 
of any kappa estimates would be extremely wide. 
 
Figure 7.3. LAMP and PCR test-retest agreement using DNA prepared 
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TBR PCR i-ii indicates that the first repeat screen with the TBR PCR assay was compared to 
the second repeat screen with the TBR PCR assay, TBR PCR i-iii indicates that the first 
repeat screen with the TBR PCR assay was compared to the third repeat screen with the 
same assay and TBR PCR ii-iii indicates that the second repeat screen with the TBR PCR 
assay was compared to the third repeat screen with the same assay. Test-retest comparisons 
were also made for LAMP RIME repeats (first to second (i-ii), first to third (i-iii) and second 
to third (ii-iii)).  Error bars show the 95 % confidence intervals for each of the kappa 
statistics. 
 
Figure 7.4 presents a graphical summary of the agreement for all test-retest 
combinations of the SRA PCR, LAMP SRA1 and SRALAMP_1 assays when these 
were performed simultaneously on the human patient blood samples.  All human 
samples were from parasite positive individuals.  The TBR PCR identified all the 
samples as positive (see Table 7.5).  None of these three molecular assays for the 
SRA gene generated consistent positive signals for all samples.  Agreement was 
quantified by Cohen’s kappa statistic.  The values of κmax, the prevalence and bias 
indices and the 95 % confidence intervals for κobserved were used to aid interpretation 
and comparison of κobserved.  The results of these calculations and the contingency 
tables from which they were are shown in Appendix 21.  
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Figure 7.4. LAMP and PCR test-retest agreement using DNA prepared 































































































SRA PCR i-ii indicates that the first repeat screen with the SRA PCR assay was compared to 
the second repeat screen with the SRA PCR assay, SRA PCR i-iii indicates that the first 
repeat screen with the SRA PCR assay was compared to the third repeat screen with the same 
assay and SRA PCR ii-iii indicates that the second repeat screen with the SRA PCR assay was 
compared to the third repeat screen with the same assay. Test-retest comparisons were also 
made for LAMP SRA1 and SRALAMP_a repeats (first to second (i-ii), first to third (i-iii) 
and second to third (ii-iii)).   Error bars show the 95 % confidence intervals for each of the 
kappa statistics. 
 
TBR PCR and LAMP RIME were also applied to these human samples. As 
mentioned above and in Table 7.5 all the TBR PCR were positive, whereas the 
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LAMP assay for Trypanozoons (LAMP RIME) showed only poor to fair test-retest 
agreement (κ = 0.071 to 0.305) with all 95 % confidence intervals including zero (see 
Appendix 21).  
 
The data from the human and cattle blood samples was then pooled to increase the 
sample size, in order to make more confident statements about assay reliability. 
Using pooled data test-retest agreement was very good for the TBR PCR (κ = 0.893 
to 0.973) and fair to moderate for LAMP RIME (κ = 0.370 to 0.518).  SRA PCR 
showed good test-retest agreement (κ = 0.605 to 0.635).  Similarly the published 
LAMP assay for T. b. rhodesiense (LAMP SRA1) showed moderate to good test-
retest agreement (κ = 0.580 to 0.680), but SRALAMP_a showed only poor to 
moderate test-retest agreement (κ = 0.191 to 0.443).  
 
Figure 7.5 presents a summary of the agreement for all test-retest combinations of 
the TBR and SRA PCR and the LAMP RIME, LAMP SRA1 and SRALAMP_a 
assays when all the data from cattle blood samples and human patient blood samples 
were pooled. Agreement was quantified by Cohen’s kappa statistic. The values of 
κmax, the prevalence and bias indices and the 95 % confidence intervals for κobserved 
were also calculated to aid interpretation and comparison of κobserved. The results of 
these calculations and the contingency tables from which they were made are shown 
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Figure 7.5. LAMP and PCR test-retest agreement pooling all data from 













































































































































TBR PCR i-ii indicates that the first repeat screen with the TBR PCR assay was compared to 
the second repeat screen with the TBR PCR, TBR PCR i-iii indicates that the first repeat 
screen with the TBR PCR assay was compared to the third repeat screen with the same assay 
and TBR PCR ii-iii indicates that the second repeat screen with the TBR PCR assay was 
compared to the third repeat screen with the same assay. Test-retest comparisons were also 
made for LAMP RIME, SRA PCR, LAMP SRA1 and SRALAMP_a repeats (first to second 
(i-ii), first to third (i-iii) and second to third (ii-iii)).  Error bars show the 95 % confidence 
intervals for each of the kappa statistics. 
 
7.5 Discussion 
This study was performed in order to explicitly evaluate the reliability of LAMP tests 
for the sleeping sickness parasites.  Pan-Trypanozoon and sub-species specific T. b. 
gambiense and T. b. rhodesiense LAMP assays were considered.  Firstly, two LAMP 
assays for Trypanozoons (LAMP RIME and LAMP PfrA) and three subspecies 
specific assays (LAMP TgsGP for T. b. gambiense and LAMP SRA1 and 
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SRALAMP_a for T. b. rhodesiense) were applied in triplicate to 86 control DNA 
samples for test-retest analysis and comparison to the reference PCRs.  This was 
extended to five repeats for a subset of the control DNA samples. Secondly, 
reliability was assessed using cattle and human blood samples that were 
representative of those that might be collected in the field as part of an 
epidemiological survey.  They were screened in triplicate by the reference PCRs as 
well as LAMP RIME, LAMP SRA1 and SRALAMP_a.  Unfortunately suitable 
samples for a similar reliability study of LAMP TgsGP were not available.  
 
7.5.1 Reliability of the LAMP assays upon three repeated 
applications to the 86 control DNA samples 
The published LAMP assay for T. b. rhodesiense (LAMP SRA1) consistently showed 
very good agreement (κ > 0.8), both with the reference PCR for the SRA gene, and in 
test-retest scenarios.  Repeatability is apparent from the narrow range of kappa 
values which for test retest reliability varied by only 0.025, and for agreement to the 
reference PCR varied by only 0.046. Neither the prevalence nor bias indices give 
reason for concern that these kappa values might be artificially inflated or deflated 
and the confidence intervals were relatively narrow.  However agreement was 
imperfect even when the marginal totals were accounted for; κobserved did not reach 
κmax.  
 
The agreement between each replicate of the novel LAMP assay for T. b. 
rhodesiense (SRALAMP_a) with the reference PCR was less consistent, with kappa 
varying over a range of 0.204. Kappa values for the test-retest reliability were also 
less strong and more variable than for LAMP SRA1. However even at its worst, test-
retest reliability remained ‘good’ at κ = 0.7.  Again, the confidence intervals were 
reasonably narrow, neither the prevalence nor bias indices give reason for concern 
that these kappa values might be artificially inflated or deflated and agreement was 
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imperfect, even when the marginal totals were accounted for; κobserved did not reach 
κmax. 
 
The published LAMP assay for T. b. gambiense (LAMP TgsGP) did not show 
consistent agreement with the reference PCR for the TgsGP gene. Although at the 
first run it showed very good agreement (κ = 0.935) with the PCR, at the second and 
third repeats this fell to κ = 0.548 and 0.554 respectively.  Hence kappa varied by 
0.387. Test-retest agreement was moderate in each instance.  Notably, however the 
prevalence indices were high, both for agreement with the reference PCR and for 
test-retest calculations, reflecting the underlying asymmetry of the sample set, which 
contains a low proportion of T. b. gambiense samples.  High prevalence indices can 
generate artificially low kappa values, and so this test might well be better than these 
statistics suggest.  It would be useful to perform further validation studies on a larger 
sample set, or one that contains a higher proportion of T. b. gambiense samples.  This 
would improve the precision of the kappa values, which at present have very wide 
95% confidence intervals.  Sample size guidelines are available in the literature 
[202].  They were not adhered to here with respect to T. b. gambiense since no more 
samples were available at the time of the study.  
 
Similarly the distribution of Trypanozoon and non-Trypanozoon DNAs makes the 
sample set ill-suited for kappa based reliability measures of LAMP RIME and 
LAMP PfrA. Instead, we can consider the overall percentage agreement. Unlike 
kappa this does not measure true agreement, since it does not account for agreement 
that would occur by chance alone.  However, it is useful here as a crude measure.  
Across three repeated applications to the 86 DNA samples perfect agreement was 
seen for LAMP RIME (all three results positive, or all three negative) for 84 
samples, giving an overall percentage agreement of 97.67 %. LAMP PfrA was less 
repeatable; perfect agreement was seen for 67 samples giving an overall percentage 
agreement of 77.91 %.  For the other three assays overall percentage agreement 
ranged from 80-90 %.  
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7.5.2 Reliability of the LAMP assays upon five repeated 
applications to a subset of 15 DNA samples 
When reliability was investigated further by performing additional retest assays on a 
subset of samples LAMP RIME was more reliable than LAMP PfrA (according to 
the overall percentage agreement). Since both these assays are Trypanozoon specific, 
and no non-Trypanozoon samples were included in the subset, this reliability can 
only be interpreted in terms of the ability of the assay to reproducibly detect true 
positives.  
For LAMP SRA1, SRALAMP_a and LAMP TgsGP agreement was described by 
overall percentage agreement and by Fleiss’ kappa statistic, which is a measure of 
agreement beyond that expected by chance alone. None of these assays were 
perfectly reliable. Across the 5 repeats LAMP SRA1 and SRALAMP_a were 
perfectly sensitive, but generated false positives, whereas LAMP TgsGP was 
perfectly specific but missed some true positives. However, the results were 
promising.  Particularly, the pentiplicate subset repeat data supports an improved 
interpretation of LAMP TgsGP reliability compared to when the same assay was 
repeated in triplicate for all 86 samples.  This reinforces the importance of having an 
appropriate distribution of samples within any sample set for any validity or 
reliability analyses.  The full sample set was not ideal for a reliability study of a T. b. 
gambiense specific assay, since it did not contain very many T. b. gambiense 
samples.  Unfortunately this was unavoidable within the limits of this study as there 
were no more T. b. gambiense samples available for use. 
 
7.5.3 Reliability of the assays when applied to FTA card 
samples  
The TBR PCR consistently showed very good agreement (κ > 0.8) when applied to 
cattle blood samples.  Consistency is apparent from the relatively narrow range of 
kappa values which for test-retest reliability varied by only 0.125.  When applied to 
human patient blood samples all the TBR PCR results for all the samples were 
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positive.  Thus the results were in perfect agreement even though kappa cannot be 
calculated when the total observed positive-positive, or negative-negative agreements 
equals zero.  
 
By contrast the LAMP assay for Trypanozoons, LAMP RIME, showed only poor to 
fair test-retest agreement both when it was applied to cattle blood samples and when 
it was applied to human patient blood samples.  For the human samples the 
prevalence index was quite high (0.769 – 0.865), so it is possible that kappa is 
artificially deflated for agreement between LAMP RIME repeats on these samples.  
However, the prevalence index is less of a concern for the cattle samples, and kappa 
remains low.  Furthermore, the observed kappa values fall far below their potential 
maximum values given the marginal totals.   
 
When the data from the human and cattle samples was pooled test-retest agreement 
was very good (κ = 0.893 to 0.973) for the TBR PCR, but was fair to moderate (κ = 
0.370 to 0.518) for LAMP RIME.  By pooling the data the confidence intervals 
became less broad and do not include zero.  Hence, agreement exceeds that expected 
by chance alone but LAMP RIME is less reliable than the TBR PCR. 
 
The majority of the cattle blood samples did not contain sufficient DNA for the 
detection of a single copy gene, such as SRA, by PCR.  Therefore reliability analyses 
were not specifically performed for the SRA molecular detection assays on this 
sample set. However, when applied to human patient blood samples the SRA PCR 
showed fair to moderate test-retest agreement.  Although again the confidence 
intervals are broad, they do not include zero, so we can be confident that agreement 
exceeds that expected by chance alone.  Having noted that the SRA PCR might be 
more reliable for human patient blood samples, than cattle blood samples, one can 
consider the reliability when these data sets were pooled.  In this case the confidence 
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intervals were much narrower, and the kappa for test- retest agreement was 
consistently good.  
 
When the LAMP SRA1 and SRALAMP_a assays for T. b. rhodesiense were applied 
to the DNA eluted from the human blood samples, LAMP SRA1 was more reliable.  
The prevalence indices were moderately high for both, so again, kappa might be 
artificially deflated.  The confidence intervals did not include zero for LAMP SRA1, 
in contrast to SRALAMP_a.  When the data were pooled LAMP SRA1 was the most 
reliable again.   
 
Repeatability was worse on real sample material compared to the control DNA 
samples. For LAMP SRA1 test-retest reliability ranged from κ = 0.857 to κ = 0.880 
on the control DNA samples.  On the field derived FTA card samples this fell 
considerably and kappa ranged from 0.580 to 0.680. For SRALAMP_a a similar 
pattern was seen.  With the control DNAs kappa ranged from 0.676 to 0.835, 
whereas with the field samples kappa ranged from 0.191 to 0.443.  It is possible that 
the repeatability of these LAMP reactions on real samples might be improved if 
samples were collected, stored, and prepared for molecular analysis by another 
method.  However, FTA cards provide an unrivalled sample collection and storage 
system.  They contain a chemically treated fibre matrix that lyses cells, inactivates 
proteins and immobilises DNA, making them suitable for long term storage of blood 
samples without a cold chain or additional reagents. However, sparse parasite 
material may be unevenly distributed on the card, so that even for a positive sample 
taking just a few punches might not include parasite DNA [272].  In this study the 
fewer and smaller punches of FTA card material were used from the human samples 
compared to the cattle blood samples. The number and size of punches used with 
cattle samples has been optimized in a previous study (Heba Ahmed, PhD Thesis, 
University of Edinburgh).  The protocol used with human samples has not been 
optimized, but given that parasite DNA is known to be much higher in T. b. 
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rhodesiense patients, and given the finite nature of these precious samples, it was 
deemed appropriate to use less material.  
 
7.5.4 Reliability requirements for clinical diagnostic tests 
Ideally, diagnostics would be perfectly reliable (as well as being perfectly accurate). 
However, this is not always true, and an imperfect test might still be the test of 
choice. Where diagnostics are imperfect, algorithms can be designed to reduce 
uncertainty.  For example, in the UK, national standard methods exist which define 
the testing algorithms for HIV and Chlamydia trachomatis (VSOP 11 and VSOP 37, 
respectively. See http://www.hpa-standardmethods.org.uk/pdf_sops.asp#virology). 
Screening for HIV is by a fourth generation immunoassay which combines detection 
of the HIV p24 antigen and HIV antibody detection in the same test.  When the 
specimen is unreactive, repeat screening depends upon the patient’s history of likely 
exposure.  When the sample is reactive screening is always repeated, first on the 
same sample, and then on a second sample. Chlamydia testing uses one of several 
commercially available nucleic acid amplification tests.  Again, the testing algorithm 
requires confirmation of a positive result by repeat testing.  The testing algorithm 
also defines the course of action in the face of intermediate or invalid results.  
 
7.5.5 Conclusion 
LAMP is not a perfectly reliable test and repeatability worsens when real samples are 
used. However, the reliability measures determined here cannot necessarily be 
extrapolated to samples processed differently.  If and when LAMP is developed as a 
bedside diagnostic tool, reliability must not be taken for granted but should be 
quantified under that system.  If might be necessary to perform more than one test 
per individual if LAMP does not prove to be sufficiently reliable. In terms of 
epidemiological surveillance and other research, perfect reliability might not be 
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necessary.  However, the degree of unreliability must be quantified so that results are 
meaningful and comparable.  
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8 Chapter 8. Comparing simple methods for reading the 
results of LAMP reactions  
8.1 Introduction 
Loop-mediated isothermal amplification (LAMP) is promoted as a low technology 
alternative to traditional PCR that might be useful in resource poor settings [138]. To 
this end accurate and reliable interpretion of the LAMP is vital.  
 
The LAMP reaction generates a mixture of stem loop DNAs of various stem lengths 
containing multiple loops of inverted repeats of the target sequence [123] (see Figure 
1.2). These products can be detected in a variety of ways, the majority of which are 
not sequence-specific, as described in Chapter 1.  
 
 
Visible turbidity was reported as a means to discern positive LAMP PfrA results 
[140], but  not for the RIME [121] or SRA assays [122].  The LAMP PfrA assay 
contains 8 mM MgSO4, whereas the RIME and SRA assays contain only 2 mM 
MgSO4.  The SRALAMP_a (Chapter 4) and LAMP TgsGP (Chapter 6) assays were 
designed to contain 8 mM MgSO4 to facilitate turbidity based endpoint assessments.  
 
Quant-iT PicoGreen [132] is a DNA intercalating dye that can be added to the 
LAMP reaction tube post-incubation. In the presence of LAMP amplified DNA the 
dye shows an orange to green colour change and fluoresces under UV light.  While 
simple, addition of the dye is an extra processing requirement and further opening of 
reaction tubes may expose the laboratory to contamination by LAMP products; this 
contrasts with calcein, MnCl2, and hydroxynaphthol blue that are added before 
incubation.  
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Calcein is a metal ion indicator, which responds to alterations in the chemical 
composition of the reaction mix as DNA amplification proceeds.  Calcein and MnCl2 
are reported to produce an orange to green colour change, and to fluoresce under UV 
light in the presence of LAMP products [136].  Calcein and MnCl2 are added 
alongside the other reagents before incubation. Initially, manganese ions combine 
with calcein to quench its fluorescence, and the reaction solution is orange.   When 
the LAMP reaction proceeds in the presence of target DNA, the pyrophosphate ion 
by-product binds the manganese ions, releasing calcein.  Calcein then binds to 
residual magnesium ions, the fluorescence increases and the reaction mix is green by 
eye.  
 
Hydroxynaphthol blue is also a metal ion indicator which produces a violet to sky 
blue colour change in the presence of LAMP products [137].  It is added alongside 
the other reagents before incubation.  The mechanism by which the colour change is 
generated is simpler than that described for calcein with MnCl2 above.  As the 
reaction progresses and pyrophosphate ion binds magnesium ions, the concentration 
of magnesium ions falls. Hydroxynaphthol blue acts as an indicator by directly 
responding to this change in magnesium ion concentration. 
 
Here, turbidity, Quant-iT PicoGreen, hydroxynaphthol blue and calcein with MnCl2 
were evaluated for use with HAT specific LAMP reactions and were assessed using 
both well-characterised control DNA samples and human patient blood samples on 
Whatman FTA cards.  Evaluation moved on to consider inter-observer reliability, 
which is particularly important when read out is subjective.  
 
8.2 Aims 
1. To establish the ease of use, sensitivity and cost of four simple endpoint 
detection methods with four HAT-specific LAMP assays 
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2. To compare turbidity (assessed by eye) with gel electrophoresis and UV 
illumination for LAMP PfrA, LAMP TgsGP and SRALAMP_a using 86 
control DNAs 
3. To determine the inter-rater reliability of two metal ion indicator methods for 
assessing LAMP endpoints. 
 
8.3 Study outline  
Firstly, purified trypanosome DNA was used to establish the ease of use and 
sensitivity of four simple endpoint detection methods (turbidity assessed by eye, 
colour change and fluorescence under ambient and UV light respectively with Quant-
iT PicoGreen,  colour change under ambient light with hydroxynapthol blue and 
colour change and fluorescence under ambient and UV light respectively with 
calcein and MnCl2 ) using four LAMP assays (LAMP PfrA, LAMP RIME, LAMP 
SRA1 and SRALAMP_a). These were performed using a 10-fold dilution series of 
sample 86 whose concentration was measured using a NanoDrop (ThermoScientific) 
spectrophotometer. 
 
For evaluating turbidity, each assay was performed once on the T. b. rhodesiense 
DNA dilution series.  After turbidity assessment reaction products were subject to gel 
electrophoresis. LAMP PfrA and SRALAMP_a assays, were performed with Triton 
X-100 in the reaction buffer (minor modification to the published LAMP PfrA 
format).  LAMP RIME and LAMP SRA1 were first performed according to their 
published protocols, then the concentration of dNTPs was increased from 0.2 to 1.4 
mM and the concentration of MgSO4 was increased from 2 to 8 mM in line with the 
reaction mix composition for LAMP PfrA.  
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For Quant-iT PicoGreen, LAMP PfrA, LAMP RIME, LAMP SRA1 and 
SRALAMP_a were all performed in duplicate on the T. b. rhodesiense dilution series 
described above with Triton X-100 in the reaction buffer (a minor modification to the 
published LAMP PfrA format).  After the full LAMP reaction incubation time 5 μl of 
the LAMP product was aliquoted for gel electrophoresis.  Then, 2 μl Quant-iT 
PicoGreen was added to one replicate and 5 μl Quant-iT PicoGreen was added to the 
second.   
 
For hydroxynaphthol blue, LAMP PfrA, LAMP RIME, LAMP SRA1 and 
SRALAMP_a were performed once on the T. b. rhodesiense dilution series described 
above with Triton X-100 in the reaction buffer (a minor modification to the 
published LAMP PfrA format) with hydroxynaphthol blue. Products were also 
subject to gel electrophoresis.  
 
For calcein with MnCl2, LAMP PfrA, LAMP RIME, LAMP SRA1 and SRALAMP_a 
were all performed in triplicate on the T. b. rhodesiense dilution series described 
above with both reaction buffer compositions (Triton X-100 and Tween-20). 
Products were also assessed by gel electrophoresis  
 
Secondly, 86 control DNA samples (Appendix 2) were used to validate the use of 
turbidity as a simple visual endpoint discrimination method for LAMP PfrA, 
SRALAMP_a and LAMP TgsGP. For LAMP PfrA the results were analysed for all 
86 samples. For SRALAMP_a and LAMP TgsGP the statistical analysis excluded 
LAMP PfrA negative samples 56, 62 and 72, in line with other analyses made for 
these assays on this sample set. 
 
Thirdly, a multi-observer study was performed in order to investigate the inter-
observer reliability of the two metal ion indicator methods – colour change with 
hydroxynaphthol blue and colour change with calcein and MnCl2. These methods 
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were chosen for their advantages as low cost, closed system methods. The study used 
sixty blood samples from human sleeping sickness patients spotted on to Whatman 
FTA cards. The SRALAMP_a assay was performed, in duplicate, for each sample,   
firstly including reaction included hydroxynaphthol and secondly with calcein and 
MnCl2 using Tween-20 instead of Triton X-100. Products were subject to gel 
electrophoresis. The results from each observer were compared to the status of each 
sample, as defined by gel electrophoresis and UV illumination.  The agreement 
between each observer and the gel result was quantified using Cohen’s kappa 
statistic (κ) [157].  The overall level of agreement between all observers was then 
quantified [271] for both colour change detection methods.  
 
8.4 Results 
8.4.1 Ease of use and sensitivity of four simple endpoint 
detection methods 
Four simple endpoint detection methods were assessed using four LAMP assays: 
LAMP PfrA, LAMP RIME, LAMP SRA1 and SRALAMP_a.  
 
8.4.1.1 Turbidity 
Positive LAMP PfrA reactions were detectable by visible turbidity up to and 
including a 1 x 10-4 dilution of the T. b. rhodesiense DNA. This was equal to the 
detection limit seen when the same reaction products were visualised by UV 
illumination after gel electrophoresis. Similarly, positive SRALAMP_a reactions 
were detectable by visible turbidity up to and including a 1 x 10-3 dilution of the T. b. 
rhodesiense DNA. This was equal to the detection limit seen when the same reaction 
products were visualised by UV illumination after gel electrophoresis.  
 
Visible turbidity detection is not reported to be possible for LAMP RIME or SRA1.  
However, when the dNTP and MgSO4 concentrations were simultaneously increased 
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turbidity could be observed up to and including a 1 x 10-4 dilution of the T. b. 
rhodesiense DNA for both assays. This was equal to the detection limit seen when 
the same reaction products were visualised by UV illumination after gel 
electrophoresis. Therefore, turbidity was as sensitive as gel electrophoresis for 
detecting LAMP positive end-points for all four assays and no false positives were 
observed.  These results are shown alongside the detection limits with other endpoint 
readout formats (see Table 8.1). 
 
8.4.1.2 Quant-iT PicoGreen  
Addition of 2 μl or 5 μl Quant-iT PicoGreen allowed positive reactions to be 
discerned under ambient and UV light for all four LAMP assays. Quant-iT 
PicoGreen was not tested for LAMP TgsGP. The detection limit for each assay with 
these formats is shown in Table 8.1. For LAMP RIME, LAMP SRA1 and 
SRALAMP_a colour and fluorescence showed perfect agreement with gel 
electrophoresis regardless of the volume of Quant-iT PicoGreen. For LAMP PfrA 
with 2 μl Quant-iT PicoGreen, colour and fluorescence based detection disagreed 
with the results by gel electrophoresis in two instances. Gel positive, but colour 
change and fluorescence negative endpoints were seen with the 1 x 10-4 dilution and 
gel negative but colour change and fluorescence positive endpoints were seen with 
the 1 x 10-5 dilution. However, no disagreements were seen when 5 μl Quant-iT 
Picogreen were used. An example of the colour change seen with Quant-iT 
PicoGreen can be seen in Figure 8.1.    
 
8.4.1.3 Hydroxynaphthol blue   
Hydroxynaphthol blue also allowed positive reactions to be discerned under ambient 
light for all four LAMP assays (Table 8.1).  Hydroxynaphthol blue induced colour 
change showed perfect agreement with detection by gel for all assays except 
SRALAMP_a when one gel positive assay (corresponding to the 1 x 10-4 dilution) 
appeared violet (negative). No false positives were seen with hydroxynaphthol blue 
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versus the gel.  For the LAMP PfrA, RIME and SRALAMP_a assays, inclusion of 
hydroxynaphthol blue had no effect on the detection limit. However the sensitivity of 
the LAMP SRA1 was reduced when hydroxynapthol blue was added compared to 
those results seen with turbidity or Quant-iT PicoGreen (see Table 8.1).  An example 
of the colour change seen with hydroxynaphthol blue can be seen in Figure 8.1.  
 
8.4.1.4 Calcein and MnCl2  
The calcein and MnCl2 method was found to give results of variable quality. An 
example of the colour change seen with calcein and MnCl2 can be seen in Figure 8.1.  
No positive LAMP amplification was seen with the RIME assay, with either reaction 
buffer, despite running each assay in triplicate for the full dilution series. Neither 
were any LAMP positive endpoints seen for the LAMP PfrA or LAMP SRA1 
reactions with 0.1% Triton X-100 containing LAMP buffer, despite running each 
assay in triplicate for the full dilution series.  However, amplification was seen when 
0.1% Tween-20 was used with the LAMP PfrA, SRALAMP_a and LAMP SRA1 
reactions.  The detection sensitivity for each of these assays varied over the three 
repeats and colour changes and fluorescence were sometimes ambiguous and did not 
always agree with the result determined by gel electrophoresis. SRALAMP_a 
amplification was seen for both reaction buffer compositions.  Therefore this was the 
only reaction for which LAMP amplicons were detected when Triton X-100 was 
included with calcein and MnCl2.  Again the detection limit was inconsistent and did 
not always agree with the colour change and fluorescence observations (see 
Appendix 23).  
 
Furthermore, the inclusion of calcein and MnCl2 seemed to reduce the absolute 
sensitivity of the assay as compared to results seen with turbidity or Quant-iT 
Picogreen, where extra reagents were not added to the reaction mix.  
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Table 8.1. Sensitivity with different assays and detection methods with 
a 10 fold dilution series of 13.6 nM T. b. rhodesiense DNA.  
  PfrA RIME SRA1 SRALAMP_a
Turbidity 1 x 10 -4 1 x 10 -4 1 x 10 -4 1 x 10 -3 Turbidity 
Gel 1 x 10 -4 1 x 10 -4 1 x 10 -4 1 x 10 -3 
Colour 1 x 10 -3 1 x 10 -5 1 x 10 -4 1 x 10 -3 
Fluorescence 1 x 10 -3 1 x 10 -5 1 x 10 -4 1 x 10 -3 
Quant-iT 
PicoGreen (2 μl) 
Gel 1 x 10 -4 1 x 10 -5 1 x 10 -4 1 x 10 -3 
Colour 1 x 10 -4 1 x 10 -5 1 x 10 -4 1 x 10 -4 
Fluorescence 1 x 10 -4 1 x 10 -5 1 x 10 -4 1 x 10 -4 
Quant-iT 
PicoGreen (5 μl) 
Gel 1 x 10 -4 1 x 10 -5 1 x 10 -4 1 x 10 -4 
Colour 1 x 10 -5 1 x 10 -5 1 x 10 -3 1 x 10 -3 Hydroxynaphthol 
blue Gel 1 x 10 -5 1 x 10 -5 1 x 10 -3 1 x 10 -4 
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Figure 8.1.  Colour change reactions with hydroxynaphthol blue, calcein 
with MnCl2 and Quant-iT Picogreen.   
A B C
 
Panel A shows the colour change seen with hydroxynapthol blue, panel B shows the colour 
change seen with calcein and MnCl2 and panel C shows the colour change seen with Quant-
iT PicoGreen. 
8.4.2 Turbidity for LAMP PfrA, SRALAMP_a and LAMP 
TgsGP 
Turbidity was compared to detection by gel electrophoresis for three repeat screens 
of the total sample set for LAMP PfrA, SRALAMP_a and LAMP TgsGP. The results 
of these comparisons are given in two by two tables in Appendix 24, from which 
summary statistics were calculated (see Tables 8.2, 8.3 and 8.4 and Figure 8.2). 
 
For LAMP PfrA kappa ranged from 0.554 to 0.765.  The confidence intervals around 
these estimates are wide, reflecting the scarcity of LAMP PfrA negative samples in 
the set.  Despite this none of the confidence intervals span zero, supporting the 
hypothesis that agreement between turbidity and gel electrophoresis is significantly 
better than would be expected by chance.  For SRALAMP_a kappa ranged from 
0.475 to 0.951 and for LAMP TgsGP from 0.751 to 0.868.  The confidence intervals 
are generally slightly narrower for LAMP TgsGP kappa, and most narrow for 
SRALAMP_a kappa, reflecting the distribution of T. b. gambiense and T. b. 
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rhodesiense samples in the set.  Again these confidence intervals do not span zero.   
In all but one instance (the second repeat screen with LAMP PfrA) turbidity detects 
gel positive LAMP endpoints with 100 % specificity. Sensitivity is variable both 
within and between assays.  
 
Table 8.2. Turbidity by eye compared to UV visualisation of LAMP 




 Repeat 1 Repeat 2 Repeat 3 
Kappa 
(95 % CI) 
0.765 
(0.610 – 0.920) 
0.554 
(0.057 – 1.050) 
0.589 
(0.239 – 0.989) 
Sensitivity 
(95 % CI) 
88.06 % 
(77.91 – 94.08 %) 
97.59 % 
(91.12 – 99.85 %) 
93.90 % 
(86.18 – 97.70 %) 
Specificity 
(95 % CI) 
100 % 
(80.21 – 100 %) 
66.67 % 
(20.24 – 94.37 %) 
100 % 
(45.41 – 100 %) 
NPV 
(95 % CI) 
70.37 % 
(51.35 – 84.32 %) 
50.00 % 
(15.00 – 85.00 %) 
44.44 % 
(18.84 – 73.37 %) 
PPV 
(95 % CI) 
100 % 
(92.69 – 100 %) 
98.78 % 
(92.76 – 99.99 %) 
100 % 
(94.30 – 100 %) 
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Table 8.3. Turbidity by eye compared to UV visualisation of LAMP 
products after gel electrophoresis for SRALAMP_a  
 
 Repeat 1 Repeat 2 Repeat 3 
Kappa 
(95 % CI) 
0.475 
(0.275 – 0.676) 
0.951 
(0.885 – 1.018) 
0.928 
(0.847 – 1.008) 
Sensitivity 
(95 % CI) 
44.44 % 
(29.53 – 60.43 %) 
94.87 % 
(82.21 – 99.48 %) 
93.33 % 
(84.02 – 97.73 %) 
Specificity 
(95 % CI) 
100 % 
(90.98 – 100 %) 
100 % 
(90.42 – 100 %) 
100 % 
(89.07 – 100 %) 
NPV 
(95 % CI) 
70.15 % 
(58.29 – 79.82 %) 
95.65 % 
(84.66 – 99.61 %) 
92.68 % 
(79.88 – 98.17 %) 
PPV 
(95 % CI) 
100 % 
(77.31 – 100 %) 
100 % 
(88.80 – 100 %) 
100 % 
(90.01 – 100 %) 
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Table 8.4. Turbidity by eye compared to UV visualisation of LAMP 
products after gel electrophoresis for LAMP TgsGP 
 
To aid interpretation of kappa the prevalence and bias indices and the maximum 
attributable kappa were also calculated (Table 8.5). 
 Repeat 1 Repeat 2 Repeat 3 
Kappa 
(95 % CI) 
0.751 
(0.474 – 1.028) 
0.752 
(0.515 – 0.989) 
0.868 
(0.721 – 1.015) 
Sensitivity 
(95 % CI) 
62.50 % 
(30.38 – 86.51 %) 
63.64 % 
(35.19 – 85.02 %) 
80.00 % 
(54.05 – 93.72 %) 
Specificity 
(95 % CI) 
100 % 
(94.16 – 100 %) 
100 % 
(93.93 – 100 %) 
100 % 
(93.60 – 100 %) 
NPV 
(95 % CI) 
96.15 % 
(88.84 – 99.14 %) 
94.74 % 
(86.84 – 98.33 %) 
95.77 % 
(87.81 – 99.04 %) 
PPV 
(95 % CI) 
100 % 
(51.09 – 100 %) 
100 % 
(59.56 – 100 %) 
100 % 
(71.8 – 100 %) 
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Table 8.5. Prevalence and bias indices, and the maximum attributable 
kappa for turbidity versus gel electrophoresis with LAMP PfrA, 
SRALAMP_a and LAMP TgsGP 






 1 2 3 1 2 3 1 2 3 
κmax 0.765 0.851 0.589 0.475 0.951 0.928 0.751 0.752 0.868 
Prevalence 
index 
0.465 0.919 0.849 0.373 0.084 0.048 0.843 0.819 0.675 
Bias index 0.093 0.012 0.058 0.241 0.024 0.036 0.036 0.048 0.036 
 
Figure 8.2. Kappa, sensitivity and specificity, with 95 % confidence 
intervals for the agreement between turbidity and endpoint detection by 
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8.4.3 Multi-observer study 
Inter-reader reliability of the hydroxynaphthol blue and calcein with MnCl2 methods 
were evaluated using a multi-observer study with the SRALAMP_a assay applied to 
human patient blood samples stored on Whatman FTA cards.  
 
8.4.3.1 Participants  
Thirty three volunteers participated in this study. There was a strong occupational 
bias towards the biomedical sciences. Eighteen participants self-defined as biological 
scientists, six were veterinarians (of which, three also described themselves as 
biologists) and one was a medical doctor. Nine participants did not place themselves 
into any of the above categories.  Nine participants reported some previous 
experience with diagnostic tests, which require a colour or colour change to be 
observed, although in most cases this experience was limited.  Twenty one of the 
participants were female, twelve were male. Age was not surveyed. 
 
8.4.3.2 Questionnaire 
All observers said that they found the violet to blue colour change, seen with 
hydroxynaphthol blue, easier to use than the orange to green colour change seen with 
calcein and MnCl2.  
 
When asked, ‘In your opinion, how easy is it to see the violet to sky blue /orange to 
green colour difference?’ 73 % of observers found the colour change with 
hydroxynaphthol blue quite easy to see, whereas 94 % of the observers found the 
colour change with calcein and MnCl2 very difficult to see.  
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When asked ‘In your opinion, using this colour change, how many of the samples 
were easy to rate as positive or negative?’ all participants found most or some of the 
samples easy to score with hydroxynaphthol blue.  
 
All participants found very few or no samples easy to score with calcein and MnCl2.  
 
Of those who had some previous experience interpreting diagnostic tests both 
methods were generally considered to be less easy to interpret than their previous 
experiences. 
 
Eight observers commented on a difference in turbidity between the positive and 
negative controls for the calcein and MnCl2 method. Two participants found it easier 
to score the samples using this turbidity difference than with the colour difference 
seen with hydroxynaphthol blue. The participants were not closely questioned as to 
how they made their decision; it is possible that several more made their judgements 
on a similar basis. 
 
8.4.3.3 Individual observer agreement with reference standard 
method  
Cohen’s kappa statistic (κ)  was used to compare the agreement of observers with the 
results according to gel electrophoresis. For hydroxynaphthol blue agreement ranged 
from κ = 0.145 (95 % CI -0.139 – 0.429) to κ = 0.870 (95 % CI 0.726 – 1.013). For 
calcein and MnCl2 agreement ranged from κ = -0.533 (95 % CI -0.747 – -0.319) to κ 
= 0.930 (95 % CI 0.834 – 1.026).  The range of kappa for the agreement between gel 
and colour change is summarised in Figure 8.3 below.  This agreement is much more 
variable for calcein with MnCl2 than for hydroxynaphthol blue, as seen by the total 
range, and more importantly the interquartile range.  
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In 66.67 % of observers the agreement between the hydroxynaphthol blue colour 
change and the results seen by gel electrophoresis were better than agreement 
between calcein MnCl2 colour change and gel (n = 22/33; 95 % CI 49.52 – 80.34 %).  
 
Since colour blindness is more prevalent among males the data were analysed for 
gender specific differences.  The range of kappa for the agreement between gel and 
colour change is summarised in Figure 8.3 below. As well as showing the differences 
between hydroxynaphthol blue and calcein with MnCl2, this box plot also breaks 
down the data by sex.  For hydroxynaphthol blue the spread seems slightly increased 
for females, both in terms of the interquartile and absolute range.  For calcein with 
MnCl2 the absolute range has a greater spread for males, but the interquartile range is 
slightly wider for females. There are no large differences between the sexes for either 
method.  
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Figure 8.3 Agreement between the endpoint assessed by colour change 
(hydroxynapthol blue or calcein-MnCl2) and gel electrophoresis for 
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HNB is hydroxynapthol blue, CM is calcein with MnCl2.  
 
8.4.3.4 Inter-observer agreement 
The method of Fleiss, Levin et al. [271] was used to quantify the agreement of all 
observers for each method (Fleiss’ kappa).  For hydroxynaphthol blue, the Fleiss’ 
kappa value of 0.693 was significantly different from zero - or no agreement, 
(P<0.0001).  For calcein and MnCl2 the Fleiss’ kappa value of 0.209 was seen. This 
was also significantly different from zero (P<0.0001).  Agreement between many 
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8.4.4 Reagent costs  
Quant-iT PicoGreen was the most expensive of the methods used.  When 5μl of this 
reagent is added per reaction the cost is £116.00 for 100 reactions.  By sharp 
contrast, the costs of turbidity, hydroxynaphthol blue and calcein with MnCl2 are all 
less than £0.001 for 100 reactions (see Tables 8.6 and 8.7). 
 
Table 8.6 Reagent costs and suppliers at the time of the study (2009) 
Reagent Supplier Catalogue number Cost 
Quant-iT PicoGreen Invitrogen, UK P7581 £252 for 1 ml 
Hydroxynaphthol 
blue 
Sigma Aldrich, UK 33936 £33.70 for 10 g 
Calcein Sigma Aldrich, UK C0875 £77.30 for 5 g 
MnCl2 Sigma Aldrich, UK M8054 £25.80 for 100 g 
 
Table 8.7. Reagent costs per 100 reactions (based on the costs 
described in Table 8.6 above)  
Method of endpoint detection Cost per 100 reactions 
Quant-iT PicoGreen £116.00 
Turbidity £0.00 
Hydroxynaphthol blue £0.0006 
Calcein and MnCl2 £0.00073 
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LAMP is promoted as a low technology diagnostic tool for resource poor settings 
[138] and simple visual discrimination of the test result is perceived as an important 
factor for recommending the method as a straightforward diagnostic [137].   
 
However, LAMP results can be read in a variety of ways.  Complex sequence 
specific [131] and high technology, real-time turbidimetry [130] approaches are 
useful during assay design and optimisation. LAMP products may also be visualised 
directly following gel electrophoresis by UV trans-illumination. More simply, 
turbidity can be generated as a by-product of DNA amplification [124].  Several 
colour change methods for reading the result within the reaction tube have also been 
developed, including the use of DNA intercalating dyes: Quant-iT PicoGreen [132], 
SYBR green [133, 134] and propidium iodide [134] and the metal ion indicator 
methods: calcein alone [135], calcein with MnCl2 [136] and, most recently, 
hydroxynaphthol blue [137].  The metal ion indicators have provided the simplest 
approach to date; they are added alongside the other reagents, before incubation, so 
that amplification and detection are combined in single processing step, within a 
closed tube system.  The colour changes can be visualised by eye, without special 
lighting, and they are inexpensive.  
 
In the present work Quant-iT PicoGreen was the most expensive of the methods 
used. When 5 μl of this reagent is added per reaction the cost is £116.00 for 100 
reactions.  In contrast, the costs of turbidity, hydroxynaphthol blue and calcein with 
MnCl2 are all less than £0.001 for 100 reactions. 
 
None of the methods assessed here confirm that LAMP amplification corresponds to 
its intended target. It is assumed that all LAMP amplicons arise from the target 
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region.  As stated by Mori et al. [130] ‘The LAMP method uses four primers that 
recognize six regions on the target nucleic acid, so that specificity is extremely high.  
For this reason, in the LAMP method, detection can be done without checking the 
amplification product during or after the amplification’.  Melt curve analysis 
supports this hypothesis, as demonstrated, for example, during the development of 
the LAMP RIME and SRA1 assays [121, 122].  However the possibility of mis-
priming remains.  By contrast, mis-priming during PCR can be easily detected since 
it will almost always give rise to a different size product which can easily be 
distinguished by gel electrophoresis.  
 
Turbidity enabled sensitive and specific endpoint discrimination for LAMP PfrA and 
SRALAMP_a but is not visible for LAMP RIME or LAMP SRA1 using published 
protocols.  However, by adjusting the concentration of dNTPs and MgSO4, turbidity 
could also be visualised for both LAMP RIME and LAMP SRA1, though the effect 
of these changes on the sensitivity and specificity of these assays has not been 
quantified and further validation work would be required before these changes could 
be applied.  Since other simple methods, principally the hydroxynaphthol blue 
format, can be used with both these assays, more extensive turbidity validation for 
LAMP RIME and LAMP SRA1 was not performed. 
  
Quant-iT PicoGreen enabled easy visual endpoint discrimination for all assays; the 
colour and fluorescence were more easily assessed when 5 μl (rather than 2 μl) of 
this reagent but the extra cost is significant for this expensive assay.  Simple, 
sensitive and specific endpoint discrimination was also possible for all assays using 
the hydroxynaphthol blue method.  For LAMP RIME, PfrA and SRALAMP_a 
inclusion of hydroxynapthol blue did not reduce the assay sensitivity, confirming 
previous work [137] that this reagent does not inhibit the LAMP reaction.  However, 
a ten fold reduction in the detection limit was observed for the LAMP SRA1 assay 
with hydroxynaphthol blue compared to LAMP SRA1 without any additional 
reagents in the reaction mix. Goto et al. [137] also reported Mn2+ inhibition of  
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LAMP, which may explain the total inhibition of LAMP RIME, and partial 
inhibition of LAMP PfrA, SRA1 and SRALAMP_a assays found in the present work 
when calcein and Mn2+ was added.  
  
When turbidity was compared to gel electrophoresis for LAMP PfrA, SRALAMP_a 
and LAMP TgsGP sensitivity, specificity, negative and positive predictive values 
and kappa were all variable across the three repeat screenings (this compromising 
variation was observed by a single reader, but it is not clear whether this is intra-
reader variability or intrinsic variability of turbidity). Generally, turbidity was seen 
specifically for gel positive endpoints for all three assays, but the sensitivity of 
turbidity was lower and more variable. It should be noted that this might be more a 
reflection of the individual observer than the characteristics of the turbidity detection 
format.  Since visual turbidity is a subjective assessment each observer will make his 
or her own threshold at which they define a reaction tube as cloudy enough to be 
counted as positive.  A high threshold will predispose the reader towards recognizing 
positive reactions specifically but with low sensitivity.  It should be noted that the 
confidence intervals around kappa and the accuracy estimate vary for each assay 
(they are much wider for LAMP PfrA) owing to the composition of the sample set, in 
which the proportions of LAMP positive and negative results are not equal for the 
three assays. 
 
This work shows that each detection method should be validated for any given 
LAMP assay.  This is particularly important for the turbidity and metal ion indicator 
approaches, which detect changes in the chemical composition of the reaction mix 
rather than amplified DNA.  From initial work hydroxynaphthol blue was found to 
be the better of the two metal ion indicator methods tested, while the calcein and 
MnCl2 method reduced LAMP reaction sensitivity, and was sensitive to the LAMP 
reaction buffer composition. 
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Nevertheless both hydroxynapthol blue and calcein with MnCl2 were taken forward 
for assessment of inter-reader reliability.  These methods were chosen for their 
advantages as closed system methods and their low cost.  By contrast Quant-iT 
PicoGreen is expensive, and breaks the closed system. Turbidity was excluded 
because it is not possible for all published LAMP assays for HAT. 
  
Inter-reader variability is an issue that has been largely ignored in the LAMP 
literature to date, and should be addressed where subjective end points are involved. 
In previous work end point interpretations have been made by one observer and to 
our knowledge no large scale, multi-observer studies have been performed with any 
of the LAMP endpoint detection methods.  As Sadatsafavi et al. have emphasised, 
‘any attempt to generalize the performance of a subjective diagnostic method should 
take into account the sample variation in both cases and readers’ [273]; they further 
highlight the need for a large group of observers to be used. 
  
The agreement across all observers was better for hydroxynaphthol blue tests (κ = 
0.693) than for calcein with MnCl2 (κ = 0.209), and, for 66 % of observers the 
hydroxynaphthol blue to gel agreement was better than the calcein-MnCl2 to gel 
agreement.  All observers said they found the hydroxynaphthol blue colour change 
easier to see.  Several observers commented on a turbidity difference between 
positives and negatives for the calcein-MnCl2 method.  Six of the 11 observers 
whose calcein-MnCl2 to gel agreement was better than that for hydroxynaphthol blue 
commented on this turbidity difference. The orange to green colour change may be 
less reliable than this report suggests. 
  
The present work has shown that hydroxynaphthol blue is the better of the two metal 
ion indicator methods tested.  Not only is it easier to see, but it also gives better inter-
reader reliability and more consistent agreement with the presence of the DNA 
amplicon, assessed by gel.  However, Cohen’s kappa statistic for the agreement 
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between colour change (assessed by an individual observer) and the presence of 
DNA amplicon (assessed by gel) ranged from κ = 0.145 to κ = 0.870. Therefore, 
hydroxynaphthol blue could be well suited as a tool to increase the efficiency of 
large scale screening and monitoring efforts but, when more than one individual is 
involved in LAMP screening, training and quality control will be necessary to reduce 
inter-observer variation.  This process might be aided by generating a colour swatch 
card against which assay results can be compared.  A quantitative colour measure, 
using some kind of spectrophotometric device would remove this variability, 
although this would need to be suitable for a low-resource, African setting.  
 
In conclusion, hydroxynaphthol blue was found to be the best method for easy, 
inexpensive, accurate and reliable interpretation of LAMP assays for human African 
trypanosomiasis. The violet to sky blue colour change was easy to see and was 
consistently interpreted by independent observers. A range of problems was found 
with the other methods.  Visible turbidity is not possible for all LAMP HAT assays.  
Quant-iT PicoGreen performed excellently, but opening the reaction tube exposes the 
laboratory to product contamination. It is also significantly more expensive than the 
other methods. With calcein and MnCl2 the four assays showed a range of partial to 
total inhibition and the colour change was difficult to see, leading to poor agreement 
between several independent observers.  
 
However, hydroxynaphthol blue is not perfect. Here, the agreement between 
amplicon detection by gel electrophoresis and colour change with hydroxynaphthol 
blue is variable and imperfect for different observers. Therefore while 
hydroxynaphthol blue is a promising method for rapid, low-technology LAMP 
endpoint detection, further work is required to develop methods that will assist 
different observers to make consistent interpretations of the same colour change. 
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9 Chapter 9. Discussion 
9.1 Background 
Accurate diagnostics are required to guide treatment decisions for sleeping sickness 
(human African trypanosomiasis – HAT) because symptoms are non-specific and the 
available drugs are either too toxic or too complex to administer to unconfirmed 
cases. Diagnostics are needed to direct both who and how to treat. T. b. rhodesiense 
and T. b. gambiense must be differentiated, as must the early and late stages of 
disease, since they demand different treatment protocols. Aside from case detection 
and management, accurate diagnostics are needed for disease surveillance, 
monitoring of public health interventions and epidemiological studies. Tools that 
enable surveillance, intervention monitoring and epidemiological studies of the 
zoonotic reservoir of T. b. rhodesiense are also urgently required to coordinate 
integrated disease control activities. The currently available diagnostics, and their 
shortcomings are fully described in Chapter 1. Suffice to say that improved 
diagnostics, which are sensitive, specific and applicable in poorly resourced, 
peripheral health care facilities, would be extremely useful in the continued fight 
against sleeping sickness.  
 
9.1.1 The development of LAMP diagnostics for sleeping 
sickness: a potted history 
In 2000 a novel nucleic acid amplification method, LAMP (loop-mediated-
isothermal amplification) was published [123] and LAMP was soon being promoted 
as a potential point of care diagnostic in the developing world:  
 
'By the use of turbidity measurement of the LAMP method a small, simple, 
economically feasible and safe DNA detection device could be established. The 
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development of such a device could realize the genetic point-of-care (gPOC) testing 
at the bedside or in underdeveloped nations in the near future.’[124]1  
 
In 2003 LAMP was first applied to human African trypanosomes in an assay 
designed to detect all members of the subgenus Trypanozoon [140]. Four months 
previously, the Foundation for Innovative New Diagnostics (FIND) had been 
launched. Initially FIND was focussed upon diagnostics for tuberculosis (TB) 
(agreement with Eiken for the development of a TB LAMP kit on 29th July 2005). 
On 6th February 2006 FIND and WHO announced a key collaboration to improve 
sleeping sickness diagnostics, supported by the Gates Foundation 
(http://www.finddiagnostics.org/media/press/). In 2007 a LAMP reaction purported 
to be specific for T. b. gambiense was first published [141].  In 2008, FIND and their 
academic partners published two novel LAMP HAT assays, one for the 
Trypanozoons, and one for the specific detection of T. b. rhodesiense [121, 122]. 







                                                 
1 Quotation from an employee of Eiken Chemical Company in their third LAMP-related publication, 
within two years of initial publication of the LAMP method. 
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Figure 9.1. Development timeline for LAMP diagnostics for human 
sleeping sickness 
2000 2005                     2010
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2003: LAMP for 
Trypanozoons., 
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the multicopy RIME element 
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The work described in this thesis began in September 2007 at which time a LAMP 
PfrA [140] assay and LAMP assay for T. b. gambiense [141] had been published. 
The LAMP RIME [121] and LAMP SRA [122] assays were published early in the 
course of the work. FIND was well established, but had only recently begun to apply 
its resources to sleeping sickness. Some LAMP tests for HAT were available, but 
validation work remained firmly within Phase 1 (proof of principle studies to 
confirm that the test detects the intended target).  This study focussed initially 
therefore on extended Phase 1 validation and early Phase 2 work, in which the tests 
could begin to be applied to ‘real’ samples. In 2008, the publication of two novel 
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simple LAMP readout systems was noted, and this study was extended to include 
application of these systems to LAMP HAT assays. The aims of this study can be 
summarised as follows,  
 
1. To determine whether LAMP assays for Trypanozoon detection might be a 
useful and simpler alternative to PCR as part of remote epidemiological 
surveillance studies of zoonotic parasites in the cattle reservoir. 
2. To validate the published LAMP primers and assay for T. b. rhodesiense by 
comparison to the multiplex PCR for SRA as a reference test. 
3. To design novel LAMP primers targeted to SRA accounting for its similarity 
to VSG genes. 
4. To validate the published LAMP primers and assay for T. b. gambiense by  
comparison to the nested PCR for the TgsGP gene as a reference test. 
5. To apply simple methods of LAMP endpoint detection to LAMP HAT 
assays. 
 
Subsequent objectives in response to observed findings included; 
 
6. The design and validate a novel LAMP assay for the specific detection and 
identification of T. b. gambiense by targeting the TgsGP gene. 
7. An assessment of the reliability of LAMP assays for HAT. 
 
9.3 Major findings and conclusions 
The experimental methods and results have been described in detail in the preceding 
chapters. Here, the main conclusions and the results from which they are drawn are 
outlined and discussed. 
 
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human 
sleeping sickness: towards a point-of-care diagnostic test 
Chapter 9. Discussion 235 
1. Neither of the two LAMP assays for the detection of Trypanozoon parasites 
(LAMP PfrA designed by Kuboki et al. in 2003 [140] and LAMP RIME designed by 
Njiru et al. in 2008 [121]) perform as well as the equivalent PCR protocol developed 
by Moser et al. in 1989 [107].  Therefore, at present LAMP does not offer an 
improved system for remote epidemiological surveillance of human infective 
trypanosomes in the zoonotic cattle reservoir.  
 
Cattle blood samples are routinely screened for the presence of T. brucei s.l. DNA, 
for monitoring the impact of the Stamp Out Sleeping Sickness programme (see 
www.stampoutsleepingsickness.com), and as part of other ongoing epidemiological 
studies.  When the LAMP PfrA, LAMP RIME and TBR PCR assays were applied 
simultaneously to DNA eluted from cattle blood samples (stored on Whatman FTA 
cards), positive signals were detected in 34 % (n = 145/428) by LAMP RIME, 17 % 
(n = 72/428) by TBR PCR and 5 % (n = 23/428) by LAMP PfrA. Compared to PCR, 
LAMP PfrA was very specific (94.38 %) but insensitive (4.17 %) whereas LAMP 
RIME was less specific (71.63 %) but more sensitive (61.11 %). Sensitivity was also 
calculated for each of the three reactions compared to a cumulative reference 
standard.  
 
However, subsequently the specificity of LAMP was brought into question. It is 
risky to compare the sensitivity of these assays to a reference standard, which does 
not represent a gold standard.  LAMP RIME specificity was undermined when it was 
seen to amplify T. congolense and T. vivax control DNA. It was further undermined 
when a BLAST search of the LAMP primer binding region revealed a region of the 
Schistosoma mansoni genome with high sequence identity to the RIME sequence. 
Although this is irrelevant for screening cattle blood samples, elsewhere the LAMP 
RIME tool is undergoing evaluation as a human diagnostic [268]. In summary, 
LAMP PfrA is insensitive compared to TBR PCR and LAMP RIME might be non-
specific. In light of these results neither of the currently available LAMP for 
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Trypanozoon assays is recommended as a replacement for TBR PCR for large-scale 
remote epidemiological surveillance of cattle blood samples.  
 
Although in this study the LAMP assays were applied to field derived naturally 
exposed samples, some of which were infected and some which were not, the 
absolute infection status of the cattle was unverified. Although TBR PCR was 
applied as a reference standard, but we do not know how many true infections it 
might miss.  
 
2. Both the LAMP SRA1 assay (designed by Njiru et al. in 2008 [122]) and the novel 
LAMP assay (designed in this study and which targets a separate region of the SRA 
gene) are sensitive and specific for T. b. rhodesiense.  
 
The LAMP SRA1 assay was published in 2008 [122]. Using primers designed to 
target the SRA gene, the authors intended that this assay would be specific for T. b. 
rhodesiense, but had failed to account for the fact that SRA arose from a deletion of a 
‘parent’ VSG gene. Since 2003 we have known that there are VSG genes with some 
sequence identity to SRA, but that SRA can be distinguished from these VSGs by a 
378 bp deletion [173]. Picozzi et al. recently exploited this to create a PCR for the 
SRA gene using primers spanning the deletion site [108]. Consequently, when T. b. 
rhodesiense DNA is present, a large (>1 kb) VSG fragment, and a smaller (324 bp) 
SRA fragment are amplified. When T. b. brucei DNA is used as the reaction template 
only the VSG fragment can be seen. In this study we mapped the LAMP primers 
designed by Njiru et al. to the SRA gene. The primers bind upstream of the deletion 
site, in a region which was expected to show a high level of sequence identity to 
several VSGs. This warranted a re-validation study of the LAMP SRA1 assay. 
Surprisingly, it specifically (98%) detected T. b. rhodesiense when tested on 36 SRA 
PCR positive and 47 SRA PCR negative samples. Sensitivity was estimated at 92 %.  
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A novel LAMP assay (SRALAMPa) was developed, designing LAMP primers that 
did account for the SRA specific deletion site. This assay was found to exhibit 94 % 
sensitive and 96 % specificity.  
 
The analytical sensitivity of both assays were similar (~ 1 pg DNA, equivalent to ten 
trypanosomes). Both were less sensitive than the multiplex SRA PCR, which can 
reliably differentiate between single T. brucei subspecies trypanosomes as well as 
genomic DNA diluted to the equivalent of one trypanosome [108].  
 
Turbidity can be used to discern LAMP amplification for the novel, but not from the 
published assay. This might make it more amenable to a poorly-resourced, or low- 
technology, setting.  
 
3. The LAMP TBG1 assay for the detection of T. b. gambiense (designed by 
Thekisoe et al. [141]) is not specific for this sub-species. 
 
The LAMP TBG1 assay was developed for detection of T. b. gambiense in 2007 with 
primers targetting the 5.8S rRNA-internal transcribed spacer 2 (ITS2) gene [141]. 
The primers were designed using the databased AF306777 gene sequence. This 
spans the ITS-1, ITS-2 and intervening 5.8S rRNA of a Group 2 T. b. gambiense 
isolate known as TH2 (78E), originating from a human infection in Koudougou, Côte 
d’Ivoire. It was sequenced by Agbo et al. in 2001[249], who identified  a unique four 
base pair C3A insertion in the 5.8S rRNA gene of T. b. gambiense isolates. Aside 
from the LAMP TBG1 assay, this gene region has not been exploited for nucleic acid 
amplification based diagnosis of T. b. gambiense. Rather, the TgsGP gene is 
considered to be the diagnostic indicator gene for T. b. gambiense (Group1) [25, 109, 
177]. PCR assays targeting this gene have been developed, including the nested 
protocol used in this study [32, 109].  
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In the original description of the LAMP TBG1 assay only one T. b. rhodesiense and 
one T. b. brucei were used to check for non-specific amplifications against with these 
two subspecies. This warranted a second evaluation of the LAMP TBG1 assay on a 
larger sample set. The assay was validated using the TgsGP PCR as the reference 
standard. Firstly, LAMP was performed in a real time turbidimeter, which incubates 
the reaction and provides a read out. Secondly, the reaction was incubated in a 
thermocycler, before the reaction products were assessed by gel electrophoresis and 
UV illumination. Regardless of the method used the LAMP TBG1 showed very poor 
agreement with the TgsGP PCR (κ < 0.01). Furthermore, analysis of the LAMP 
TBG1 primers then revealed that they did not bind to the C3A insertion. 
 
This assay is not fit for purpose as a T. b. gambiense specific assay and highlights the 
danger of inadequate diagnostic evaluations in which too few samples are used to 
check for false positive results. It also highlights how a badly chosen target can 
compromise the specificity of a reaction.  
 
4. A novel LAMP assay for T. b. gambiense, using primers designed in this study to 
target the TgsGP gene, showed very good agreement with a nested PCR protocol for 
the same gene [32] and the result of the assay could be simply visualised by turbidity 
in the reaction tube. However, concerns remain about the reliability of the assay.  
 
Given the poor sensitivity and specificity of the LAMP TBG1 assay for T. b. 
gambiense there remained a requirement for the design of a T. b. gambiense specific 
LAMP test. Hence, LAMP primers were designed for the TgsGP gene. Since similar 
genes have been observed in other T. brucei s.l. isolates with consensus to the 5’ end 
of TgsGP, the LAMP primers were specifically targeted to the 3’ end of this gene, in 
the same region as the TgsGP PCR primers. A protocol was developed which, when 
first screened using a thermocycler for incubation, followed by gel electrophoresis 
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and UV illumination for product detection, was highly sensitive (88.89 %) and 
specific (100%) compared to the TgsGP PCR. Positive endpoints became turbid, and 
this could be used as a readout system. Compared to the nested TgsGP PCR protocol 
used, the LAMP assay required a higher detection limit i.e. the TgsGP nested PCR is 
1,000 to 10,000 times more sensitive than the LAMP reaction. 
 
When the assay was performed in a real time turbidimeter the average time to reach 
the turbidity threshold was slower than had been seen with the LAMP PfrA reaction.  
 
It is possible that the sensitivity and efficiency of this LAMP assay might be 
improved by small adjustments to the reaction composition and primer design and 
this assay has real potential for further development as a T. b. gambiense specific 
LAMP assay. However, the main concern is the reliability of the assay. This is 
discussed in more detail under point 5 below.  
 
5. The reliability of the two LAMP SRA assays was imperfect, but consistently good 
when using purified DNAs from well characterised isolates. However, when the 
same assays were applied in triplicate to DNA eluted from human patient and cattle 
blood samples (on Whatman FTA cards) the results were less consistent. The LAMP 
RIME assay was also less reliable than the TBR PCR on the DNAs eluted from FTA 
cards. 
 
LAMP TgsGP reliability was only assessed using the purified DNAs. The picture 
here is unclear: with a small sample set (n = 15; including 5 T. b. gambiense), 
reliability across five repeats was strong; but when the sample set was extended (n = 
86, of which 9 samples were T. b. gambiense) agreement with the reference PCR, 
and in test-retest analyses was of concern.   
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Initially, reliability of LAMP SRA1, SRALAMPa and LAMP TgsGP were assessed 
by comparing three repeat screens of the 86 DNA samples used throughout the study. 
The published LAMP SRA1 (for T. b. rhodesiense) consistently showed very good 
agreement (κ > 0.8), both with the reference PCR for the SRA gene, and in test-retest 
analyses of the three repeats. The agreement between SRALAMPa (also for T. b. 
rhodesiense) and the reference PCR was slightly less strong and more varied, but did 
not fall below κ = 0.7. Kappa values for the test-retest reliability were also less 
strong and more variable with SRALAMP_a than with the LAMP SRA1 assay. 
However, even at its worst test-retest reliability did not fall below κ = 0.676, which is 
considered to be good agreement.  
 
In contrast LAMP TgsGP (for T. b. gambiense) did not show consistently good 
agreement with the reference PCR for the TgsGP gene. At first agreement was very 
good (κ = 0.935) but at the second and third repeats this fell to κ = 0.548 and 0.554 
respectively. Test-retest agreement was moderate in each instance. However this was 
probably skewed by the asymmetry of the sample set, which contained a low 
proportion of T. b. gambiense samples.   
 
Next, a subset of 15 samples was subject to additional retest assays to achieve a total 
of five repeats for each assay. Internal agreement for the three subspecies specific 
assays agreement was quantified using Fleiss’ kappa statistic. LAMP SRA1 was most 
reliable (κ = 0.829), then LAMP TgsGP (κ = 0.769), and lastly SRALAMP_a (κ = 
0.753). This suggests the reliability of LAMP TgsGP might have been 
underestimated in the first analysis by the nature of the sample set.  
 
LAMP RIME and LAMP PfrA were also performed in pentaplicate on this subset. 
The percentage agreement was better for LAMP RIME. However, this sample subset 
did not include non-Trypanozoons, so this agreement can only be interpreted in terms 
of reproducible detection of true positives. 
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The two LAMP SRA assays and the LAMP RIME were then applied in triplicate to a 
set of ‘field’ samples (48 cattle blood samples and 52 human patient blood samples, 
both spotted onto Whatman FTA cards). At the same time the TBR PCR and SRA 
PCR assays were also performed in triplicate on the same DNA elutions from the 
same samples.  
 
All human samples were positive by the TBR PCR as expected, and the test – retest 
agreement for TBR PCR on the cattle samples was very good (κ > 0.8) in each 
instance. By comparison the LAMP RIME was less reliable, showing only poor to 
fair agreement  in each test –retest analysis performed on cattle and human blood 
samples (κ = 0.024 – 0.383). 
 
Overall the field samples SRA PCR test-retest agreement was consistently good (κ = 
0.605 – 0.635) and LAMP SRA1 showed a comparable level of test-retest agreement 
(κ = 0.580 – 0.680). In contrast SRALAMP_a was less reliable, with only a poor to 
moderate agreement in test-retest analyses (κ = 0.191 – 0.443). 
 
Notably, the reproducibility of the LAMP SRA assays were worse when the field 
samples were used. LAMP SRA1 test-retest reliability ranged from κ = 0.857 to 
0.880 on the control DNAs, compared to κ = 0.580 to 0.680 on the field samples. A 
similar pattern was seen for SRALAMP_a. The control DNAs kappa ranged from 
0.676 to 0.835, whereas with the field samples kappa ranged from 0.191 to 0.443. It 
is possible that the reproducibility of these LAMP reactions on real samples might be 
improved if samples were collected, stored, and prepared for molecular analysis by 
another method. However, FTA cards provide an unrivalled sample collection and 
storage system. 
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So, LAMP is not always perfectly reliable and reproducibility worsens when real 
samples are used. However, the reliability measures here cannot necessarily be 
extrapolated to samples processed differently. If LAMP is developed as a clinical 
diagnostic, reliability must not be taken for granted but should be quantified under 
that system. Perfect reliability might not be a pre requisite for the application of 
LAMP as a clinical diagnostic, or as a research tool. For example, in a recent 
evaluation of a malaria rapid diagnostic test the intensity of the test line was not 
reproducibly read for five out of 19 samples, yet the authors concluded that it 
performed satisfactorily [274].  
 
6. Several simple endpoint detection systems have been developed that might 
facilitate the use of LAMP assays for HAT in low-technology settings. Turbidity is 
the most simple, but is not possible for all LAMP HAT assays. Quant-iT PicoGreen 
provides an obvious colour change but is expensive, and requires that the reaction 
tube is opened, exposing the laboratory to contamination with the LAMP product. 
Calcein with MnCl2 inhibits LAMP amplification and the colour change is difficult 
to see. Finally, hydroxynaphol blue (HNB) provides a simple, cheap, closed system, 
endpoint readout system. Several observers agreed that the HNB colour change was 
easier to see than that with calcein and MnCl2. However, the agreement between the 
true endpoint (as determined by gel electrophoresis) and the HNB endpoint was 
variable for different observers. Further work is required to develop methods that 
will assist different observers to make consistent interpretations of the same colour 
change. 
 
Several simple endpoint detection methods have been developed for LAMP. In this 
study four methods were applied and compared for LAMP HAT assays: (i) 
visualization of turbidity; (ii) hydroxynaphthol blue (HNB) added before incubation; 
(iii) calcein with MnCl2 added before incubation and (iv) Quant-iT PicoGreen added 
after incubation. Quant-iT PicoGreen was the most expensive of the methods used 
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costing £232.00 for 100 reactions (using 5 μl per reaction). The other methods all 
cost less than £0.001 for 100 reactions. 
 
Turbidity and the metal ion indicator methods (HNB and calcein) are the simplest 
readout systems to have been developed. Turbidity requires no additional reagents or 
technology. The metal ion indicators are added with the other reagents in the 
mastermix before incubation. For both, amplification and detection are combined in 
single processing step, within a closed tube system. The readout can be made by eye, 
without special lighting, and they are inexpensive.  
 
Turbidity is not visible for the LAMP RIME or SRA1 assays using published 
protocols. Both of these assays could be adjusted to obtain turbidity by simultaneous 
increase of MgSO4 and dNTPs. However, this has unknown consequences for the 
diagnostic sensitivity and specificity of these assays.  
 
Generally, when turbidity was compared to the true endpoint (as determined by gel 
electrophoresis) for LAMP PfrA, SRALAMP_a and TgsGP the positive predictive 
value of a turbid result was very high, but the negative predictive value was lower 
and more variable.  Agreement, quantified by Cohen’s kappa statistic, typically fell 
between 0.7 and 0.8, indicating good agreement. Clearly however, this agreement is 
imperfect and it varied for the three repeats of each assay on the same samples. This 
compromising variation was observed by a single reader, but it is not clear whether 
this is intra-reader variability or intrinsic variability of turbidity.  
 
A multi-observer study with 33 participants was used to investigate the reliability of 
the two metal ion indicator methods used in LAMP diagnostics. These methods were 
chosen as low cost, closed systems (c.f. Quant-iT PicoGreen). Turbidity was 
excluded because it is not visible for all HAT LAMP assays.  
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Hydroxynaphthol blue was the better of the two metal ion indicator methods tested. 
All observers said they found the hydroxynaphthol blue colour change easier to see. 
It showed better inter-reader reliability and more consistent agreement with the 
presence of the DNA amplicon (as determined by gel electrophoresis). 
 
However, Cohen’s kappa statistic for the agreement between the colour change 
(interpreted by a single observer) and the true endpoint (determined by gel 
electrophoresis) ranged from κ = 0.145 to κ = 0.870 depending upon the observer. 
Therefore if several people are involved in LAMP screening, training and quality 
control will be necessary to reduce inter-observer variation. This process might be 
aided by generating a colour swatch card against which assay results can be 
compared, along the lines of a litmus paper test for pH. Better still, a quantitative 
colour measure, using some kind of spectrophotometric device would remove this 
variability, although we must not forget that we are seeking to establish a LAMP 
endpoint detection format that is suitable in a low resource setting. 
 
Finally, it is critical to bear in mind that all the above methods are incapable of 
verifying that the LAMP product has been amplified from the intended target. For 
this, more complex approaches are required, such as sequencing. This issue has been 
discussed above in relation to the LAMP RIME assay.  
 
9.4 Further work 
9.4.1 Arising from Chapter 3  
Given the observed LAMP RIME non-specificity  (performed on only two non-
Trypanozoon control DNAs, and two commercially available host genomic DNAs) it 
would be useful to perform an extended Phase 1 proof  of principle trial to confirm, 
with finality, the specificity or otherwise of LAMP RIME. In this study we moved 
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directly to a Phase 2 evaluation of LAMP RIME and LAMP PfrA, since Phase 1 
appeared to have been completed in the original publications. An extended Phase 1 
proof of principle study ought to include more non-Trypanozoon DNAs. In the 
original study 13 non-Trypanozoon DNAs were used. No false positives were 
reported, corresponding to 100 % specificity (95 % confidence interval 73.41 – 100 
%). Table 9.1 below shows how this confidence interval might be narrowed by 
choosing a larger sample of non-Trypanozoons.  
 
Table 9.1. The effect of sample size on the confidence interval of a 
specificity measure 
Sample size Specificity (95 % CI) 
 0 false positives 1 false positive All false positive 
13 100 % (73.41 – 100 %) 92.31 % (64.58 – 99.99 %) 0 % (0 – 26.59 %)
30 100 % (86.53 – 100 %) 96.67 % (81.91 – 99.99 %) 0 % (0 – 13.47 %)
50 100 % (91.48 – 100 %) 98.00 % (88.53 – 99.99 %) 0 % (0 – 8.52 %) 
100 100 % (95.56 – 100 %) 99.00 % (94.01 – 99.99 %) 0 % (0 – 4.44 %) 
 
Other useful further work to investigate the observed non- specificity could include:  
(i) sequencing of LAMP RIME products where they arise from non-
Trypanozoon control DNA samples; 
(ii) sequencing of LAMP RIME products where they arise from 
simultaneously  TBR PCR negative cattle blood samples; 
(iii) restriction digest of LAMP RIME products (using NdeI which cuts 
between primers F1c and B1 [121]) where they arise from non-
Trypanozoon control DNA samples; 
(iv) restriction digest LAMP RIME products (using NdeI which cuts between 
primers F1c and B1 [121]) where they arise from simultaneously TBR 
PCR negative cattle blood samples; 
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(v) application of LAMP RIME to Schistosoma mansoni DNA. 
 
If LAMP RIME is validated as a specific assay, or a novel, Trypanozoon specific 
LAMP assay is developed which passes Phase 1 validation, then it would be useful to 
assess the assay using a no gold standard approach. No gold standard approaches are 
described in more detail in the supplement. In short, several frequentist and Bayesian 
latent class analysis methods have been developed to estimate the sensitivity and 
specificity of two or more index tests, in the absence of a gold standard. These 
approaches require that the tests are applied in more than one population.  
 
9.4.2 Arising from Chapter 4 
The next step for the SRA LAMP assays is Phase 2 evaluation. Phase 2 evaluation 
involves a case control study, ideally using fresh specimens. Archived samples can 
be used for Phase 2 trials, which may be quicker, cheaper and more convenient. 
However, the specimen quality may have been affected by storage, patient 
information may be limited and consent might be problematic [267, 275].  
 
Very recently a study was published in which LAMP SRA1 and LAMP RIME were 
compared to a PCR for the SRA gene using microscopy positive patient blood spotted 
onto FTA cards [268]. The PCR [231] against which the LAMP assays were 
compared was a nested protocol with different primers to the multiplex SRA PCR 
used throughout this study. This was a useful study, demonstrating that LAMP SRA1 
was 93.8 % sensitive (95 % CI 88.2 – 96.8 %) overall, and was significantly more 
sensitive that the PCR protocol. However, the analytical sensitivity of this particular 
PCR has not been reported in the literature. This highlights a more general problem: 
LAMP is rightly being compared to PCR, and yet, different studies are basing their 
comparisons on different PCR protocols. As has been pointed out elsewhere there is 
a plethora of in-house variations for any trypanosome PCR [232]. Ideally, before 
more authors set out to perform comparisons of the LAMP SRA assays to PCR, a 
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standard protocol ought to be agreed. Further, it would be very useful to have a 
standard specimen bank on which comparisons are made [232]. 
 
Returning to Phase 2 case control evaluation of the LAMP SRA assays, we face the 
problem of a reference standard. If LAMP is truly more sensitive than any previous 
parasitological detection method, then LAMP might detect true, but undetected, 
cases from within the control group. The TBR PCR could be the most appropriate 
reference standard, since it has a multi copy DNA target, making it a more sensitive 
target than the single copy SRA gene. However, the TBR PCR might detect DNA 
from abortive [91, 92] and/or transient [39] T. b. brucei infections. (This is discussed 
in more detail below in regard to the clinical significance of detecting trypanosome 
DNA.) Methods for diagnostic evaluation in the absence of a gold standard are also 
available and might be more appropriate. These are discussed in more detail in the 
supplement to this chapter. Notably, they require a different study design to the 
traditional case control study. In particular, they require that the index tests are 
compared in more than one population, which have different prevalences of disease. 
 
Prior to Phase 2 evaluation DNA sample preparation protocols need to be developed 
and properly validated. In the study discussed above patient samples from blood 
spots on FTA cards were used. This format is useful for remote epidemiological 
studies, but might be less appropriate if LAMP is to be applied at point-of-care. 
Elsewhere LAMP PfrA has been trialled using various DNA templates, including (i) 
genomic DNA extracted by the phenol-chloroform method; (ii) fresh blood applied 
directly to the reaction, (iii) haemolysed blood (prepared by dilution in distilled 
water, followed by centrifugation and re-suspension of the precipitate in TE buffer) 
and (iv) DNA eluted from FTA card samples. LAMP PfrA amplification sensitivity 
was consistently high (100 %) for serially diluted DNA (1000 pg to 1 pg) for all of 
the above DNA templates except fresh blood, for which the detection sensitivity fell 
as low as 43 % [230]. In another study heat treated blood samples were successfully 
used to seed a LAMP assay for Plasmodium falciparum [126]. The template 
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preparation protocol must also be designed to be compatible with the endpoint 
detection format. Thekisoe et al. rightly point out that turbidity cannot be visualised 
when fresh or haemolysed blood is used, and is difficult when FTA card eluate is 
used [230]. In this study two colour change methods for LAMP endpoint detection 
were trialled using FTA card eluate (Chapter 8 and discussed below).  
 
In summary, validation of the LAMP SRA assays is ready to move to Phase 2. 
Further work may need to be done to validate particular template preparation and 
endpoint detection formats in themselves before they are incorporated into a LAMP 
SRA Phase 2 trial. What is more, several different Phase 2 studies may need to be 
performed to validate different applications of the assay, which will likely use 
different sample preparation and endpoint detection formats (e.g. a case control study 
as a clinical diagnostic versus a case control study as remote epidemiological 
surveillance tool). It is critical that the objectives of any validation study are clearly 
defined from the outset. Sensitivity and specificity values cannot properly be 
extrapolated to include a different test protocol or application. 
 
9.4.3 Arising from Chapters 5 and 6 
Firstly, it might be possible to further optimize the primer design, reaction 
composition and incubation conditions in order to improve the sensitivity and 
efficiency of this assay. 
 
Secondly, it would be extremely useful to extend the validation across a much larger 
set of well characterised T. b. gambiense isolates from across the endemic range for 
this disease. In this study the novel LAMP TgsGP was validated on a relatively 
limited collection of available T. b. gambiense isolates (nine TgsGP PCR positive 
samples).  Earlier, the effect of sample size on the confidence limits surrounding 
specificity estimates was discussed. The same principle applies to sensitivity (Table 
9.2.). It is clear that as the number of true positives in the sample increases the 95 % 
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confidence interval around the sensitivity estimate decreases. For example, if one 
false negative result is seen with nine true positives (in this study nine TgsGP PCR 
positive samples were used) the confidence interval ranges from 60.63 to 99.17 %. If 
the number of true positives were to be increased to 30, the breadth of the confidence 
interval would be more than halved (for the same 1 false positive). 
 
Table 9.2. The effect of sample size on sensitivity and specificity 
estimates 
Sample size 
(of true positives for 
sensitivity, or true 
negatives for specificity) 
Sensitivity (with 1 false 
negative) or Specificity 
(with 1 false positive) 
95 % Confidence Interval 
9 88.89 % 60.63 % - 99.17 % 
30 96.67 % 81.91 % - 99.99 % 
50 98 % 88.53 % - 99.99 % 
100 99 % 94.01 % -  99.99 % 
 
Thirdly, the next step is to apply this assay to clinical samples, in a Phase 2 case 
control evaluation as described for the SRA LAMP assays above. All of the points 
made above regarding clinical evaluation of the SRA LAMP assays are pertinent 
here, including considerations of how best to evaluate a diagnostic in the absence of 
a gold standard. However, Phase 2 evaluation will not be appropriate until a more 
comprehensive Phase 1 evaluation has been completed.  
 
In addition there remains a diagnostic gap for Group 2 T. b. gambiense, which is not 
detected by the TgsGP PCR assay, nor this newly developed LAMP assay.  
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9.4.4 Arising from Chapter 7 
The reliability of any diagnostic is critical and the results in Chapter 7 are 
concerning. Of particular concern are (i) the reliability of the TgsGP LAMP on the 
purified DNA extractions, and (ii) the reduction in reliability seen when DNA is 
eluted from FTA card samples. 
 
As mentioned above, it would be useful to extend the set of DNA samples to include 
more T. b. gambiense isolates. This would improve the precision of the accuracy 
estimates for LAMP TgsGP (see future work arising from Chapters 5 and 6) as well 
as improving reliability estimation here.  
 
It would be useful to add endemic and non-endemic human control samples to this 
investigation of LAMP SRA reproducibility on human blood samples. It would also 
be natural to continue the assessment of LAMP TgsGP with a similar reliability 
study using human case and control blood samples.  
 
Similarly, LAMP RIME and LAMP PfrA reliability assessment would also be 
improved with additional testing on non-Trypanozoon control DNAs, as well as 
blood sample negative controls.  
 
Finally the reliability of LAMP using different DNA extraction formats would be 
useful. It might be that LAMP is inherently unreliable when applied to DNA eluted 
from FTA cards. It would be useful to ascertain whether LAMP is more reliable 
using, for example, haemolysed or heat treated blood samples, especially since these 
formats have been shown to provide a suitable LAMP template in other studies [126, 
230].  
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9.4.5 Arising from Chapter 8 
In order to improve LAMP readout in resource poor settings it would be useful to 
develop low technology methods to reduce the subjectivity of colour and turbidity 
assessment. This could include a colour matching chart for on site interpretation. 
Martinez et al. [276, 277] have considered the same problem (how to obtain 
diagnostically useful information in remote settings from subjective colorimetric 
assays). They proposed a telemedicine system in which the technician performs a 
basic test, photographs the results using a cell phone camera, and transmits the image 
trained medical professional. The diagnosis/ treatment and management protocol is 
then returned directly to the technician/ healthcare provider. Recent studies have 
successfully demonstrated that camera phones can be used to transmit diagnostic 
images for remote interpretations [278, 279]. This approach is appealing since 
phones, including camera phones, are becoming increasingly common. In 2009 the 
percentage of mobile phone subscriptions per 100 inhabitants rose to 57.9% in the 
developing world (http://www.itu.int/ITU-
D/ict/statistics/material/graphs/Mobile_cellular_98-08.jpg). However, the image 
itself will vary according to the phone itself, and the lighting conditions. This might 
be overcome in part by including a calibration chart into the photograph or with the 
development of more complex software for automatic image calibration. This 
approach might be useful for sleeping sickness, since treatment and management is 
not straightforward. 
 
9.5 LAMP as a future clinical diagnostic for sleeping sickness? 
Thus far the history of LAMP for sleeping sickness and the advances made in this 
study have been described. It is clear that LAMP has potential as a novel molecular 
diagnostic for HAT. However, it is much less clear whether this will translate into a 
field friendly clinical diagnostic, or whether LAMP will have a more restricted role 
as an (albeit useful) addition to an ever expanding tool box of molecular assays for 
use in sleeping sickness research. To address this question this discussion will move 
on to consider: (i) the political and economic factors shaping the drive to generate a 
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LAMP diagnostic for sleeping sickness; (ii) the operational feasibility of LAMP; (iii) 
competitors to LAMP and (iv) the clinical significance of identifying parasite DNA.  
 
9.5.1 Politics and economics 
In his book, ‘African Sleeping Sickness: Political Ecology, Colonialism, and Control 
in Uganda (Studies in African Health and Medicine)’ Jonathan Musere states 
 
‘It is not just enough to solely examine the scientific and medical basis of a disease, 
since in many cases the socio-political basis is the most important.’[280].  
 
Further, the development of loop-mediated isothermal amplification (LAMP) based 
diagnostics for sleeping sickness must be considered within historical, political and 
economic context under which they have been, and continue to be, developed. 
Biological factors are not alone in shaping the development of diagnostics.  
 
Sleeping sickness is a neglected tropical disease, but this has not always been the 
case. It has also been described as ‘the first media event epidemic in modern Africa’ 
[281]. In the early colonial period massive sleeping sickness epidemics swept across 
East and West Africa. The epidemics terrified the colonial powers and stimulated 
huge control programmes: as a consequence transmission was almost halted by the 
1960s. Yet in the post colonial era cases once again began to rise; by the late 1990s 
incidence had returned to levels seen in 1930s [59]. This resurgence has been 
attributed to declining surveillance [59] as well as to socio-economic upheaval [282]. 
And so, human African trypanosomiasis became a neglected tropical disease. 
 
The so called ‘neglected tropical diseases’ affect more than one billion people, and 
persist under conditions of poverty. They are neglected at all levels. At the 
community level the marginalised are often most affected and stigma keeps the 
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diseases hidden. The diseases themselves are mostly low mortality, high morbidity 
diseases, which cause severe and permanent disability. Consequently, at the national 
level, limited resources are allocated instead to high mortality, high priority diseases 
such as HIV and tuberculosis. At the international level they receive relatively little 
attention because they do not pose an immediate threat to western societies [60].  
 
In 1995 the World Health Organisation began to express concern about the rising 
incidence of sleeping sickness. In 1997 they passed a resolution in which they 
strongly advocated access to diagnosis and treatment and the reinforcement of 
surveillance and control [283]. According to Simarro et al. [59] there have been 
widespread improvements in HAT control since 1995 including technical and 
financial support from the WHO and high level political will which have increased 
the capacity for control. At the same time, access to diagnosis and treatment have 
been facilitated by declining social upheaval and an end to civil war in many 
endemic regions. In addition a free and sustainable drug supply was secured from 
industry. However, it was impossible to extend the provision of free drugs to include 
diagnostics, because commercially available diagnostics did not (and still do not) 
exist. Indeed, no diagnostic test for HAT has ever been manufactured under full 
registration by any regulatory agency and the tests that are currently available are 
produced by academic institutions [268]. 
 
To address this problem the Foundation for Innovative New Diagnostics (FIND; see 
www.finddiagnostics.org) was launched on 22nd May 2003 at the World Health 
Assembly as a spin off from the World Health Organisation (WHO). It is a non 
profit,  Swiss-based  foundation which ‘supports the development of diagnostic tests 
for diseases of poverty, including TB, HAT and malaria.’[268]. FIND have adopted a 
‘piggy backing’ approach: by developing technology platforms that are applicable to 
multiple diseases they have persuaded technology development companies to include 
neglected infectious diseases into diagnostic platforms for more commercially 
attractive diseases [284]. For example, FIND have developed a light-emitting diode 
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human 
sleeping sickness: towards a point-of-care diagnostic test 
Chapter 9. Discussion 254 
(LED) based fluorescence microscope with their industrial partner Zeiss. This 
technology was first developed to improve microscopy for TB, and then was applied 
to parasite detection for sleeping sickness. LAMP is the second example of FIND’s 
piggy backing approach to develop diagnostics for sleeping sickness. As described in 
Chapter 1, the LAMP technology was developed by Eiken Chemical Company in 
Japan [123]. Together FIND and Eiken developed and tested a prototype kit for 
LAMP based TB diagnosis using sputum samples [135] (also described in Chapter 
1). On 27th October 2008 FIND and Eiken announced their intention to extend this 
collaboration to work on HIV, malaria and sleeping sickness 
(http://www.finddiagnostics.org/media/press/081027.html). In the meantime FIND, 
working with academic partners at Murdoch and Obihiro Universities, developed the 
LAMP RIME and LAMP SRA assays for the detection of Trypanozoon and T. b. 
rhodesiense parasites respectively. Hence, LAMP was applied to sleeping sickness, 
because of a pre-existing collaboration with a particular technology development 
company. This approach was necessitated by the neglected status of human African 
trypanosomiasis, which renders it commercially unattractive. As stated elsewhere, 
‘The development of new diagnostic tools has been underfunded largely because 
neglected tropical diseases do not represent a significant market.’ [60]. 
 
HAT is now at its lowest level for 50 years and we are experiencing a long inter-
epidemic period. Only 9877 new cases were reported in 2009 
(http://www.who.int/neglected_diseases/integrated_media/integrated_media_hat_jun
e_2010/en/index.html).  However, these case reports are an underestimation of the 
true extent of sleeping sickness as under reporting is a known concern and it is 
possible (as suggested in Section 1.5.5 below), that latent T. b. gambiense may be 
circulating in unidentified foci. These figures are extremely low in comparison to 
other diseases such as malaria and tuberculosis, reinforcing how financially 
unattractive the development of HAT diagnostics are. In 2008, there were 9.4 million 
new cases of tuberculosis 
(http://www.who.int/tb/publications/2009/tbfactsheet_2009update_one_page.pdf ) 
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and 247 million cases of malaria causing nearly 1 million deaths 
(http://www.who.int/mediacentre/factsheets/fs094/en/index.html). Furthermore, as 
case numbers fall HAT diagnostics become less and less commercially viable. 
 
9.5.2 Operational feasibility 
As outlined in Chapter 1 there has been an explosion of LAMP research publications 
describing its application as a molecular diagnostic for a wide range of pathogenic 
agents. The original publication has been cited 317 times (on July 21st 2010), 
including 274 articles, 31 reviews, nine proceedings papers, two letters and one 
editorial. In addition several commercial kits have been developed by Eiken 
Chemical Company (see http://loopamp.eiken.co.jp/e/products/index.html), some of 
which have been adopted as the officially recommended methods for routine 
identification and surveillance of pathogens in Japan [138].     
 
With Public Private Partnerships come Public Private rivalries and conflicts and 
interests.  According to Mori and Notomi  (key players in the development of LAMP 
and employees of Eiken Chemical Company); 
 
‘the current direction of the development of LAMP is toward a simple diagnostic tool 
which can be routinely employed in the poorly resourced laboratories in rural areas 
of developing countries’ [138] 
 
FIND and Eiken together have developed and tested a prototype LAMP kit for the 
detection of TB from sputum smear samples in microscopy centres of developing 
countries [135]. Overall the study results were positive. After one week of training, 
technicians with no prior experience of molecular work were able to use the LAMP 
kit with a mean hands-on time of 54 minutes and with excellent inter-reader 
reliability, in a simple laboratory environment. The technicians were reported to have 
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been very satisfied with the interpretation of the LAMP result (using calcein as a 
colour change indicator) and sample processing was considered to be comparable to 
the process required for culture. However, the process required multiple 
manipulations and a specially designed heating and observation block. Furthermore, 
the technicians had reservations that it could be rolled out to more peripheral 
facilties. There was concern that the process might be too complex for less motivated 
and skilled staff, and that the LAMP process cannot be interrupted, for example, 
during a power cut, as can microscopy. Following this study LAMP and Eiken 
agreed to continue the development and simplification of the kit, and to extend 
performance testing.  
 
Others disagree that LAMP might be a useful tool in remote rural healthcare settings. 
Referring to the use of LAMP for sleeping sickness diagnosis, Deborggraeve and 
Büscher recently stated that;  
 
‘LAMP is being presented as a promising technique for point-of-care diagnosis of 
sleeping sickness. However, one should realise that diagnosis of this disease is most 
often done in very remote areas devoid of even basic facilities. LAMP requires DNA 
extraction, electricity, a cold chain, multiple manipulations, and sufficient 
infrastructural measures to prevent carry-over contamination. Therefore, we are not 
convinced of its future as a point-of-care diagnostic test.’ [232]2 
 
Deborrgraeve and Büscher highlight several important concerns about the use of 
LAMP, in its current research format, for application as a clinical diagnostic in 
sleeping sickness endemic areas. At present LAMP for HAT requires two heating 
blocks (one for the incubation at 60-65 ˚C, and one for the termination step), which 
                                                 
2 Notably, Deborggraeve and Busher work at the Institute of Tropical Medicine, Antwerp, where the 
exisiting diagnostic test that is supported and purchased by the WHO, the CATT test, was developed 
and is produced. 
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requires an electricity supply. The preparation of the reaction mix requires accurately 
calibrated pipettes, and disposable plastic ware (including pipette tips, PCR tubes, 
and e.g. an eppendorf tubes in which to make the master mix). The reagents 
themselves (Bst DNA polymerase, reaction buffer, MgSO4, betaine, dNTPs and 
primers) are also needed, though Thekisoe et al. have demonstrated that it might not 
be necessary to maintain a strict cold chain for their storage [230]. This is a long way 
from the simplicity of, for example, the rapid diagnostic tests for malaria (lateral 
flow dipstick tests which typically require a finger prick blood sample, and provide a 
diagnosis in 10-15 minutes). 
 
However, it would be short-sighted not to consider the ways in which the LAMP 
technology might be developed and simplified to make clinical diagnoses in resource 
poor settings possible. For example, the LAMP for TB prototype kit utilised a 
lyophilised reaction mix, which included the Bst polymerase. This both simplified 
the process (it was not necessary to accurately measure several small volumes of 
different reagents while keeping the whole mixture on ice) and overcame the need 
for a robust cold chain.  
 
Several other developments have been reported in the literature (and it is likely that 
given the commercial nature of LAMP other developments are being held firmly 
under wraps prior to patent applications). For example, a novel integrated isothermal 
device for real time turbidity measurement has been developed [180]. At present this 
system is only capable of processing one sample at a time, however the authors ‘hope 
to provide a multi-channel, portable, label-free, real time monitoring device for 
rapid identification and quantification of pathogenic organisms and point of care 
applications’ in the future. In a very different development LAMP and subsequent 
ultrafast electrophoretic analysis of the LAMP product have been integrated on a 
commercially available polymer biochip. However, at present this chip needs to be 
placed in a incubator for amplification and in a separate instrument for 
electrophoresis [285].  
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Since 2008 ten articles have been published in which lateral flow dipsticks (LFDs) 
have been developed for the detection of LAMP products. Recent pertinent examples 
include the development of LAMP-LFDs for Trypanosoma evansi strain B [286] and 
African Swine Fever virus [287]. However, while LFDs might offer a useful format 
for LAMP endpoint detection, they do not simplify the LAMP amplification process 
in itself. Rather they add manipulation steps, and the LAMP reaction tube must be 
opened, exposing the laboratory to amplicon contamination.  
 
9.5.3 A second isothermal nucleic acid amplification test for 
HAT 
Nucleic acid sequence based amplification (NASBA) is the second isothermal 
amplification technique to have been applied to sleeping sickness [145]. The assay, 
which targets the multicopy 18S rRNA, detects both T. b. rhodesiense and T. b. 
gambiense, but does not distinguish between the two. After an initial 2 min step 
heating step at 65 ˚C, the reaction is then held at 41˚C for 90 min which is more time 
consuming than LAMP. The assays had a detection limit of 10 parasites ml-1 which 
is comparable to the LAMP SRA assays. Unfortunately, cross reactivity against the 
Trypanosome subgenera Nannomonas and Duttonella were not assessed. Therefore 
this assay cannot be used for the specific detection of T. brucei s.l. in livestock, in 
which T. congolense and T. vivax also circulate in abundance, without further 
validation. The assay was tested on 59 blood samples from confirmed HAT cases, 
and 50 from controls and detected T. brucei s.l. in significantly more patient samples 
than microscopy alone. 
 
In 2009 this assay was coupled to an oligochromatographic dipstick detection format 
(NASBA-OC). Coloured lines appear, in the presence of amplified product, within 5 
-10 minutes of application to the dipstick, without compromising reaction sensitivity 
or specificity [146]. NASBA-OC was compared to a composite reference standard 
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(microcopy, microhaematocrit centrifugation with microscopy, or mAECT with 
microscopy) on 122 blood and CSF samples, and samples from Uganda (T. b. 
rhodesiense) and the Democratic Republic of Congo (T. b. gambiense). In brief, 
NASBA-OC was more sensitive than standard microscopy for blood samples but not 
for CSF. However, NASBA-OC requires less CSF than microscopy.  
 
In a Phase 2 case control study [288] NASBA-OC was more sensitive and specific 
than PCR-OC for the same gene [289]. However at a country level the data presented 
a more complex picture: the specificity of PCR-OC and the sensitivity of NASBA-
OC were both significantly higher in the Democratic Republic of Congo than 
Uganda which might be due to differences in sample transportation and storage 
conditions.  
 
Deborggraeve and Büscher raise similar concerns about the applicability of NASBA-
OC in a clinical setting as they did for LAMP.  
 
‘Although such strategies will definitely facilitate the implementation of molecular 
diagnostics in several control strategies for sleeping sickness, they are still too 
complex for general use in first-line diagnosis and management of patients.’[232] 
 
9.5.4 Other diagnostics for sleeping sickness 
Molecular techniques that do not include an amplification stage have also been 
proposed for sleeping sickness diagnosis, and it has been suggested that they might 
be more amenable to low-resource settings than the amplification based methods 
[232]. Two methods have been highlighted. First, Radwanska et al. developed a 
direct detection method using fluorescence in situ hybridization (FISH) with peptide 
nucleic acid probes [290]. The development of battery powered LED based 
fluorescence microscopes, by FIND and others, could make this a more field friendly 
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technique [232]. Secondly, Lorger et al. proposed a method of parasite visualization 
using RNA aptamers directed to the parasites surface coat [291]. However, for this 
technique to be sensitive a parasite concentration step would be required, such as 
microhaematocrit centrifugation for microscopy.  
 
Aside from molecular diagnostics, advances are also being sought, particularly by 
FIND, for better microscopic parasite detection, serodiagnosis and disease staging 
tools (http://www.finddiagnostics.org/programs/hat/find_activities/index.html).  
 
To improve direct parasite detection FIND have developed a simple LED based 
fluorescence microscope (with Carl Zeiss) using acridine orange for parasite staining. 
They are also improving the materials used in mAECT kits, particularly the gel 
columns, collection tubes, and viewing chambers, and to improve availability and 
procurement for screening programmes. Finally, they have revived an old method 
using ammonium chloride for red blood cell lysis prior to centrifugation which might 
be useful for parasite concentration. 
 
Following work done by FIND and their partners to identify candidate antigens for 
detection of anti- trypanosome antibodies in patient sera,  FIND have recently signed 
an agreement with Standard Diagnostics Inc., Korea for the commercial development 
of rapid, point-of-care test. The test will have a lateral flow format for detection of T. 
b. rhodesiense and T. b. gambiense (but will not discriminate between these two 
parasites), and is intended for screening in remote settings.  
 
In addition FIND are collaborating with the University of Brussels on the feasibility 
of camel heavy chain antibodies for parasite antigen detection, and with the Seattle 
Biomedical Research Institute to apply single chain variable fragment (scFv) 
antibody engineering to developed antibody probes.  
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Since the lumbar puncture (currently required to obtain CSF for disease staging) is 
painful and risky, FIND and their partners have sought blood based biomarkers for to 
discern early and late stage disease, but with little success. However, they have 
determined a panel of three brain damage marker proteins which can be used to 
discriminate stage 2, and could be of use in developing improved CSF staging tests 
[113]. FIND have also been involved in reformatting the latex/IgM card 
agglutination test into a more stable individual kit format for staging by CSF IgM 
quantification.  
 
9.5.5 Clinical significance of the detection of trypanosome 
DNA? 
So far we have considered the accuracy and reliability of LAMP assays for HAT. We 
have also discussed the operational feasibility of LAMP in a clinical setting. Yet we 
must also take a step back and ask ‘What is the clinical significance of the presence 
of parasitic DNA?’ 
 
This is a particularly pertinent question for diagnosis of T. b. gambiense, for which 
discrepancy between PCR and other diagnostic indicators have been previously 
noted [91, 92, 244, 292]. 
 
An investigation into a potential new focus of T. b. gambiense provides an excellent 
example of this uncertainty [292]. In late 2007 PCR analysis of human blood 
samples, from a previously ‘silent’ region around Lake Albert in western Uganda, 
generated positive signals for T. b. gambiense. Active screening (by CATT) was 
initiated in September 2008. All CATT whole blood positive individuals provided a 
second blood sample for CATT on 1/4, 1/8 and 1/16 plasma dilutions and for parasite 
detection by micro-haematocrit centrifugation and were examined for clinical signs 
by cervical lymph node palpitation. CATT positive whole blood was also spotted 
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onto Whatman FTA cards for PCR analysis (using both TBR PCR and TgsGP PCR 
for T. brucei s.l. and T. b. gambiense respectively) in the UK. 
 
Parasites were not found in the blood of any of the screened individuals by micro-
haematocrit centrifugation, nor did any of the individuals examined show enlarged 
lymph nodes. However several individuals were serologically positive by the CATT 
test (down to 1/16 plasma dilution) and several of the blood samples were positive 
for T. brucei s.l. parasite DNA by PCR. These were confirmed as T. b. gambiense in 
a sub set of samples. CATT seropositivity and PCR positivity did not agree. A follow 
up study of CATT whole blood positive cases was performed six months later, in 
which CATT was repeated, and the more sensitive mini-anion exchange 
centrifugation technique (mAECT) was used to detect parasites. Again, PCR 
positives were obtained, yet no parasites could be detected. The epidemiological 
picture became even more peculiar when these CATT and PCR results did not match 
those seen in the initial screening phase.  
 
Koffi et al. [92] noted similar discrepancies for TBR PCR compared both to CATT 
seropositivity and parasitological detection by mAECT in Côte d’Ivoire. Observing 
that these disagreements were worst among aparasitaemic serological subjects, they 
concluded that there might be a long lasting human reservoir of T. b. gambiense. The 
evidence for spontaneous cure and chronic state for T. b. gambiense has been 
carefully reviewed elsewhere [45].  These authors cautiously conclude that, while 
chromic carriage is biologically plausible, there is no current evidence that it does 
occur, but that there is some evidence for spontaneous cure from early stage disease.  
 
So, the questions remain 
What is the clinical significance of detecting parasite nucleic acids?  
Are we detecting pre-patent or transient T. b. gambiense infection?  
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Is this infection with non-pathogenic strains of T. b. gambiense?  
Are we detecting chronic carriage in trypanotolerant individuals?  
 
At present, we do not know the clinical significance of parasite DNA detection. If 
there are instances of human trypanotolerance, and/or non pathogenic T. b. 
gambiense strains in circulation, then the current epidemiological paradigm would 
need to be reworked with major implications for long term planning of disease 
control programmes. Further, Koffi et al. [92] note that the TBR PCR might be 
detecting persistent DNA from abortive T. b. brucei. infections, a suggestion that has 
also been made by Garcia et al. [91]. More recently transient T. b. brucei infection 
has also been demonstrated [39]. Hence, molecular assays for detection of 
Trypanozoon DNA, including LAMP [121, 140] and NASBA [146] as well as 
traditional [107] and real time PCR [186], need to be treated with caution. On the 
other hand, while multicopy T. b. gambiense and T. b. rhodesiense diagnostic 
indicator genes remain unavailable, multicopy Trypanozoon genes remain the most 
sensitive molecular targets for these trypanosomes.  
 
Deborggraeve and Buscher [232] suggest that T. brucei nucleic acids might be a 
marker for infection, but not disease, as has been observed for a PCR based 
Leishmania diagnostic [293]. They also suggest that T. brucei DNA might even be 
incorporated into the human genome giving rise to false positive PCR results.  
 
9.6 Evaluating diagnostics in the absence of a gold standard 
Ideally new diagnostics are evaluated by comparison to a perfect reference test. 
However, often such a ‘gold standard’ may be unavailable for some or all of the 
samples, or may be  imperfect or in some cases does not exist [294].  This leads to 
classification errors, which if ignored could bias accuracy estimates for the index test 
[295].  Consequently, latent class analysis methods have been developed to estimate 
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human 
sleeping sickness: towards a point-of-care diagnostic test 
Chapter 9. Discussion 264 
the sensitivity and specificity of two or more index tests, in the absence of a gold 
standard.  Latent class methods have been used for more than 30 years [296, 297].   
Both frequentist and Bayesian statistical approaches have been developed for latent 
class analysis and are outlined below.  
 
9.6.1 Frequentist approaches  
Hui and Walter [298] were the first to describe maximum likelihood analyses for 
latent class models. According to the Hui Walter paradigm two or more populations, 
with different disease prevalence in each population, are required to assess two tests. 
The properties of each test must be constant across these populations, and the tests 
must be conditionally independent given the true disease status. These assumptions 
are necessary to ensure that that the degrees of freedom of the observed data exceed 
the number of parameters to be estimated, i.e. to make the problem statistically 
identifiable [299]. Other frequentist approaches have also been described which 
make use of maximum likelihood methods for latent class analysis [300, 301].  All 
maximum likelihood based approaches require a large number of observations, since 
maximum likelihood theory is based on large sample theory. An excel based format 
to facilitate sample size calculations has been developed and is available online 
(www.epi.ucdavis.edu/diagnostictests) [302].  
 
9.6.1.1 A user friendly latent class analysis tool 
‘TAGS’, a program for the evaluation of test accuracy in the absence of a gold 
standard, was developed to promote the application of a maximum likelihood method 
to latent class analysis in a user friendly format. The programme can be implemented 
in the R and S-Plus statistical packages, and is also available in a web based 
interface, which in turn submits data to R. TAGS can be used with any statistically 
identifiable data set; data can be incorporated from several populations and multiple 
tests. Data from a reference population in which the true status is known can also be 
accounted for [303].  
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9.6.2 Bayesian models 
Bayesian models have also been developed for latent class based diagnostic 
evaluation where there is no gold standard.  The Bayesian approach allows prior 
scientific information to be incorporated into estimations of test accuracy and to 
solve otherwise statistically unidentifiable problems. 
 
Several Bayesian models for sensitivity and specificity estimation have been 
described: 
i) One test in one population 
ii) Two conditionally independent tests in two or more populations 
iii) Two correlated tests in two or more populations 
iv) Three tests in two or more populations, where two tests are 
correlated but jointly independent of the third test [304]. 
 
Some have questioned the legitimacy of Bayesian approaches to solve statistically 
unidentifiable problems.  Particularly, how is it possible to obtain prior sensitivity 
and specificity estimates if there is no gold standard [299]?  
 
Recently a Bayesian formulation of the Hui-Walter latent class model has been used 
to compare two PCR based molecular detection assays for T. brucei s.l. [305].  Given 
the limited sensitivity of current parasitogical detection methods a no gold standard 
approach might be best for evaluating LAMP in a clinical setting.  This would 
require a very different study design to a traditional Phase 2, case-control evaluation.  
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9.6.3 Limitations of latent class analysis   
In latent class models, individuals that are not detected by any of the available tests 
are assumed to be uninfected. This is an important limitation to all latent class 
models that has not been well addressed in the literature.  In order to avoid this 
problem it is important to use a range of tests covering the spectrum of biological 
responses to infection.  If this is not done, a group of infections may be missed, the 
sensitivity of other tests will be overestimated, and true prevalence underestimated 
[297, 303].  
 
9.7 Final words 
Numerous sensitive and specific molecular diagnostics have been developed for 
sleeping sickness [232]. They are invaluable as research tools and PCR is routinely 
applied in our laboratory for surveillance of T. b. rhodesiense in cattle, however 
molecular tools have not been adapted for clinical use, and do not directly benefit 
sleeping sickness patients. But now, LAMP is being developed and promoted as 
molecular diagnostic for clinical application and FIND have signed an agreement 
with Eiken Chemical Company to develop LAMP for sleeping sickness.  
 
In this study the published LAMP assays for Trypanozoon were evaluated for 
surveillance of T. brucei s.l. in cattle, and determined that they are unsuitable 
replacements for the current, well-established PCR protocol. There remains scope for 
the development of an improved LAMP assay for Trypanozoon detection. The 
published T. b. rhodesiense - and T. b. gambiense-LAMP assays were also evaluated, 
in addition to designing novel assays for both these subspecies.  
 
Contrary to expectation (given the primer design), the published LAMP for T. b. 
rhodesiense was sensitive, specific and reliable for purified DNAs, as was the novel 
assay. The novel T. b. gambiense LAMP (which targets the TgsGP gene), but not the 
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published assay (which targets the 5.8S rRNA gene) was sensitive and specific. 
However, the reliability of LAMP TgsGP, may be less than optimal and requires 
further assessment on an extended sample set.  
 
In summary this work has highlighted problems with some of the published LAMP 
assays for the detection of sleeping sickness parasites and, where possible, improved 
LAMP assays have been developed in their place. This work also emphasizes the 
importance of simple readout for LAMP tests, and evaluated several of the currently 
available methods. The colour change reagent hydroxynaphthol blue was identified 
as the best currently available method taking cost, ease of use and reliability into 
consideration but further work is required to ensure interpretation is consistent 
between multiple users. 
 
Simple and field-friendly sample preparation was not addressed in this study, but 
remains an important aspect in the development of LAMP, that has begun to be 
addressed elsewhere.  
 
The next steps in the development of LAMP as clinical diagnostics for sleeping 
sickness are Phase 2 evaluation and the development of an integrated protocol 
including sample preparation, amplification and readout. It remains to be seen 
whether such a protocol can be developed that is truly operationally feasible, cost-
effective and acceptable to end users. The recent collaboration between FIND and 
Eiken might make this possible. If not, it is reassuring that sleeping sickness 
diagnostic research is undergoing a small revival, and that LAMP is not the only tool 
under development. The most notable alternatives are NASBA (another isothermal 
nucleic acid amplification test) and dipstick style serological tests (being developed 
by Standard Diagnostics, in collaboration with FIND). In 2009 the number of 
reported cases of sleeping sickness fell below 10, 000 for the first time in 50 years. 
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Hopefully, improved diagnosis will assist in the continued fight against this 
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Appendix 1. Estimated impact of novel diagnostics for six 
major developing world diseases 
Table 1. Infrastructural requirements, performance characteristics, and 
impact of novel diagnostics for six major diseases of the developing 
world [306] 
 





Paediatric HIV (<12 
months) 
Minimal (90 %, 90 %) Save 180,000 -2.5 
million DALY’s over 
12 months assuming 
5% or 100% population 
access to ARTs 






Paediatric malaria None (90 %, 90 %) Avert 300,000 
childhood deaths 
annually 
Avert 450 million 
unnecessary treatments 
annually 
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Bacterial acute lower 
respiratory infections 








Minimal (90 %, 90 %) Save 2.8 million 
DALY’s annually 
Reduce prevalence of 
stunted growth by 
12.5% 
Syphillis Minimal (86 %, 72 %) Save 138 000 adjusted 
lives, and avert >148 
000 still births 
(assuming 100% 
treatment rates) 




Minimal (85 %, 90 %) Save 3 million DALYs 
Avert 12 million 
infections 
Prevent 161 000 related 
HIV infections in FSW 
over 4 years 
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Appendix 2. The sample set of control DNA samples 
Table 1. Identity of the 86 samples from which DNA was extracted 
Origin No. Name Species Procyclic/Bsf 
Host Date Country 
 
Ref 
1 Tira 24 T. b. bruceia Procyclic Cattle 1990 Uganda [247] 
2 Sikuda 28 T. b. bruceia Procyclic Cattle 1990 Uganda [247] 
3 UGC T. b. 
rhodesiensea 
Procyclic Human 1988 Uganda [247] 
4 UGI T. b. 
rhodesiensea 
Procyclic Human 1988 Uganda [247] 
5 Dal069 IM52 T. b. 
gambiense 
Procyclic Human 1981 Côte 
d’Ivoire 
[246] 
6 Papol 33 T. b. bruceia Procyclic Cattle 1990 Uganda [247] 
7 Bumanda 146 T. b. bruceia Procyclic Cattle 1988 Uganda [247] 
8 Papol 264 T. b. 
rhodesienseb 
Bsf Cattle 1990 Uganda [247] 
9 UGA 88 T. b. 
rhodesiensea 
Procyclic Human 1988 Uganda [247] 
10 E. Oketch T. b. 
rhodesienseb 
Procyclic Human 1990 Uganda [247] 
11 Papol 285 T. b. 
rhodesiensea 
Procyclic Cattle 1990 Uganda [247] 
12 Biyamina T. b. 
gambiense 
Bsf Human 1982 Sudan [248] 
13 Mela 3 T. b. bruceia Bsf Cattle 1988 Uganda [247] 
14 Papol 103 T. b. 
rhodesiensea 
Bsf Cattle 1988 Uganda [247] 
15 Mawero 66 T. b. 
rhodesiensea 
Bsf Cattle 1990 Uganda [247] 
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16 Mela 71 IM87 T. b. 
rhodesiensea 
Procyclic Cattle 1998 Uganda [247] 
17 TH149 T. b. 
gambiense 
Procyclic Human 1981 Côte 
d’Ivoire 
[246] 




Bsf Human 1968 Nigeria [252] 
19 TSW83 T. b. 
gambiense 
Procyclic Pig 1981 Côte 
d’Ivoire 
[246] 
20 Katerema 311 T. b. bruceia Bsf Cattle 1990 Uganda [247] 




Bsf Human 1982 Sudan [248] 
22 Suzena T. b. 
gambiense 
Bsf Human 1982 Sudan [248] 
23 Tsuaa T. b. 
gambiense 
Bsf Human 1968 Nigeria [252] 
24 Mawero 32 T. b. bruceic Procyclic Cattle 1990 Uganda [219] 
25 Papol 42 T. b. bruceia Procyclic Cattle 1988 Uganda [247] 
26 UGK T. b. 
rhodesiensea 
Procyclic Human 1988 Uganda [247] 
27 Papol 60 T. b. bruceia Procyclic Cattle 1990 Uganda [247] 
28 UR4 T. b. bruceib Procyclic Fly 1988 Uganda [247] 
29 F97 T. b. bruceib Procyclic Fly 1990 Uganda [247] 
30 Mawero 80 T. b. bruceic    Uganda [219] 
31 Papol 278 T. b. 
rhodesiensea 
Procyclic Cattle 1990 Uganda [247] 
32 URI T. b. 
rhodesiensea 
Procyclic Fly 1988 Uganda [247] 
33 UGH T. b. 
rhodesiensea 
Bsf Human 1988 Uganda [247] 
34 Mela Pig T. b. bruceia Bsf Pig 1988 Uganda [247] 
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35 Tira 22 T. b. bruceia Procyclic Cattle 1990 Uganda [247] 
36 Mela 66 T. b. 
rhodesiensea 
Bsf Cattle 1988 Uganda [247] 
37 Uganda B T. b. 
rhodesiensea 
Procyclic Human 1988 Uganda [247] 
38 Mela 24 T. b. bruceia Procyclic Cattle 1990/1988? Uganda [247] 
39 Iyolowa 125 T. b. bruceia Procyclic Cattle 1988 Uganda [247] 
40 Tira 168 T. b. bruceia Procyclic Cattle 1990 Uganda [247] 
41 Papol 12 T. b. bruceia Bsf Cattle 1990 Uganda [247] 
42 Mela 27 T. b. 
rhodesiensea 
Bsf Cattle 1988 Uganda [247] 
43 Poyem 11 T. b. bruceia  Cattle 1988 Uganda [247] 
44 Tira 4 T. b. bruceia Procyclic Cattle 1990 Uganda [247] 
45 Mela pig 2 T.  b. bruceic Bsf Pig 1990 Uganda [219] 
46 UGE T. b. 
rhodesiensea 
Procyclic Human 1988 Uganda [247] 
47 Katerema 72  Procyclic Cattle 1990 Uganda * 
48 Mawero 42 T. b. 
rhodesiensec 
Procyclic Cattle 1990 Uganda [219] 
49 Tira 34 T. 
congolensef 
 Cattle 1990 Uganda * 
50 H.Taka T. b. 
rhodesiensec 
Procyclic Human 1990 Uganda [219] 
51 Uganda A T. b. 
rhodesiensea 
Procyclic Human 1988 Uganda [247] 
52 A Kiburige T. b. 
rhodesiensed 
Procyclic Human 1990 Uganda * 
53 Uganda E T. b. 
rhodesiensea 
Procyclic Human 1988 Uganda [247] 
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54 Katerema 116 T. b. 
rhodesiensea 
Procyclic Cattle 1990 Uganda [247] 
55 Tira 43 T. b. bruceib Procyclic Cattle 1990 Uganda [247] 
56 Tira 92  Procyclic Cattle 1990 Uganda * 
57 Tira 75 T. b. bruceia Procyclic Cattle 1990 Uganda [247] 




Bsf Human 1982 Sudan [248] 
59 Iyolowa 116 T. b. bruceia Procyclic Cattle 1988 Uganda [247] 
60 Iyolowa 153 T. b. bruceia Procyclic Cattle 1988 Uganda [247] 
61 TH 112 IM56 T. b. 
gambiense 
Procyclic Human 1981 Côte 
d’Ivoire 
[246] 




Procyclic Human 1980 Burkina 
Faso 
[248] 
63 Mela 12 T. b. bruceia Procyclic Cattle 1990 Uganda [247] 
64 Mawero 31 T. b. 
rhodesiensec 
Bsf Cattle 1990 Uganda [219] 
65 F73 T. b. 
rhodesienseb 
Procyclic Fly 1990 Uganda [247] 
66 Tira 27 T. b. bruceia Bsf Cattle 1990 Uganda [247] 
67 Uganda L T. b. 
rhodesiensea 
Bsf Human 1988 Uganda [247] 
68 F48 T. b. 
rhodesienseb 
Procyclic Fly 1990 Uganda [247] 
69 Tira 68 T. b. bruceia Procyclic Cattle 1990 Uganda [247] 
70 Tira 30 T. b. bruceia Procyclic Cattle 1990 Uganda [247] 
71 Tira 29 T. 
congolensef 
Procyclic Cattle 1990 Uganda * 
72 Papol 371 T. b. bruceia Procyclic Cattle 1990 Uganda [247] 
73 Mawero 85 T. b. bruceic Procyclic Cattle 1990 Uganda [219] 
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74 Iyolowa 147 T. b. bruceia Bsf Cattle 1998 Uganda [247] 
75 Muraz 3 IM46 T. b. 
gambiense 
Procyclic Human 1979 Ivory 
Coast 
[248] 
76 Katerema 41 T. b. bruceia Procyclic Cattle 1990 Uganda [247] 
77 UGG 88 T. b. 
rhodesiensea 
Procyclic Human 1988 Uganda [247] 
78 Mela 2 T. b. 
rhodesiensea 
Bsf Cattle 1988 Uganda [247] 
79 Uganda M T. b. 
rhodesiensea 
Bsf Human 1988 Uganda [247] 
80 Rose Akinare T. b. 
rhodesiensee 
Procyclic Human 1990 Uganda * 
81 Uganda B T. b. 
rhodesiensea 
Procyclic Human 1988 Uganda [247] 
82 Papol 144 T. b. bruceia Procyclic Cattle 1990 Uganda [247] 
83 Uganda C T. b. 
rhodesiensea 
Procyclic Human 1988 Uganda [247] 
84 Sikuda 42.90 T. b. bruceia Procyclic Cattle 1990 Uganda [247] 
85 Sikuda 4 T. 
congolensef 
Procyclic Cattle  Uganda * 
86 D. Obwang T. b. 
rhodesiense 
Procyclic Human 1990 Uganda [184] 
a Species identifications made according to human serum resistance in vitro, RFLP 
analysis and if collected from a human host 
b Species identification made according to RFLP analysis and if collected from a 
human host 
c Species identified according MGE PCR analysis  
d Species identified as T. b. rhodesiense according to previously SRA positive and 
collection from a human host (Kim Picozzi, personal communication) 
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e Assumed to be T. b. rhodesiense according to collection from a human host 
f Sue Welburn, personal communication 
*No reference available but these were collected alongside other samples from the 
Busoga focus in South East Uganda as described in [247] 
 
Appendix 3. Cost comparison of LAMP PfrA, LAMP RIME and 
TBR PCR 
Table 1a. Reagent costs for LAMP PfrA 
Reagent Supplier 
(catalogue #) 
Price Quantity for 
100 reactions 



















250 μl £0.00 
Betaine Sigma Aldrich, 
UK (B0300) 
£14.80 for 1.5 
ml 
400 μl £3.95 
dNTPs  Bioline, UK 
(BIO-39029) 
£175.00 for 4 
x 500 ml 
140 μl £12.25 
MgSO4 New England 
Biolabs, UK 
(B9004S) 





150 μl £1.00 
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Water Sigma Aldrich, 
UK (W3500) 
£6.40 for 100 
ml 




13 p per base  £0.64 
Total    £42.40 
 

























FIP 42 £5.46 852 μla 
BIP 43 £5.59 722 μlb 
7220 μl 400 μl £0.61 
F3 19 £2.47 965 μlc 
B3 19 £2.47 965 μl 
9650 μl 50 μl £0.03 
Total      £0.64 
a These primers have not been ordered at the 100 nm scale from this company, so 
this number is taken as an estimate from the LAMP RIME FIP data 
b These primers have not been ordered at the 100 nm scale from this company, so 
this number is taken as an estimate from the LAMP RIME BIP data 
c These primers have not been ordered at the 100 nm scale from this company, so 
this number is taken as an estimate from the LAMP PfrA B3 data 
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Table 2a. Reagent costs for LAMP RIME 
Reagent Supplier Price Quantity 
required for 
100 reactions 







£49.00 for 1600 
units 







with Bst DNA 
polymerase 
250 μl £0.00 
Betaine Sigma Aldrich, 
UK (B0300) 
£14.80 for 1.5 
ml 
400 μl £3.95 
dNTPs Bioline,UK 
(BIO-39029) 
£175.00 for 4 x 
500 ml 
20 μl £1.75 
Water Sigma Aldrich, 
UK (W3500) 
£6.40 for 100 
ml 
880 μl £0.06 
Primers Integrated DNA 
Technologies 
13 p per base  £0.83 
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FIP 42 £5.46 852 μl 
BIP 41 £5.33 722 μl 
7220 μl 500 μl £0.75 
LF 18 £2.34 755 μl 
LB 18 £2.34 529 μl 
5290 μl 200 μl £0.05 
F3 19 £2.47 764 μl 
B3 20 £2.60 1035 μl 
7640 μl 50 μl £0.03 
Total      £0.83 
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Table 3a. Reagent costs for TBR PCR 
Reagent Supplier Price Quantity 
required for 
100 reactions 







£98.00 for 500 
units 
100 units £19.60 






250 μl £0.00 






75 μl £0.00 
dNTPs Bioline, UK 
(BIO-39029) 
£175.00 for 4 
x 500 ml 
20 μl £1.75 
Water Sigma Aldrich, 
UK (W3500) 
£6.40 for 100 
ml 




13 p per base  £0.10 
Total    £21.57 
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TBR1 26 £3.38 675 μl 
TBR2 24 £3.12 842 μl 
6750 μl 100 μl £0.10 
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Appendix 4. BLASTing the LAMP RIME primer binding region 
Table 1. Fragments of Trypanozoon RIME element and Schistosoma 







Gene fragment % Identity 
1-511 24152-23642 99 % 
7-254 16589-16836 95 % 
258-510 13639-13892 92 % 
258-511 
FN36744.1 
21589-21844 91 % 
EF567424 
15-365 XM_002570283 1-351 99 % 
1-507 24151-23642 98 % 
6-252 16589-16835 96 % 
260-507 13645-13892 93 % 
260-507 
FN36744.1 
21595-21844 90 % 
EF567425 
14-361 XM_002570283 1-351 98 % 
1-512 24152-23641 99 % 
7-254 16589-16836 95 % 
258-510 13639-13892 92 % 
258-511 
FN36744.1 
21589-21844 91 % 
EF567426 
15-365 XM_002570283 1-351 99 % 
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Table 2. Binding sites of LAMP RIME primers within Schistosoma 
mansoni FN36744.1 
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Appendix 5. BLASTing the LAMP PfrA primer binding region 
Table 1. BLAST hits against the PfrA gene, X14819, which contain the 
LAMP PfrA primer binding region 
Organism Gene Accession number % Identity 
Trypanosoma cruzi XM_809076.1 83 % 
 FJ222461.1 83 % 
 M97548.1 83 % 
 AF005195.1 72 % 
 AF005194.1 72 % 
 AF005193.1 72 % 
 XM_804737.1 72 % 
Leishmania infantum AM502234.1 84 % 
 XM_001464593.1 80 % 
 XM_001464594.1  85 % 
Leishmania major XM_001682174.1 79 % 
 XM_001682174.1 79 % 
Leishmania mexicana U45884.1 79 % 
Leishmania braziliensis AM494953.1 79 % 
 XM_001563700.1 79 % 
Crithidia fasciculata AY568293.1 79 % 
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Appendix 6. Novel LAMP primers for T. b. rhodesiense 
Table 1. SRALAMP primer sets, generated by instructing the primer 
design software to generate specific primers recognising a mutation at 
position 581, which span the deletion site in the F1c region. Different 
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Table 2. SRALAMP primer sets, generated by instructing the primer 
design software to generate specific primers recognising a mutation at 
position 581, which span the deletion site in the F2 region. Different 




































































SRALAMP7.18 F2 (605-628)- (651-671)- (545-562) (747-765) 
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Table 3. Composition of primer sets tested 
Primer set FIP BIP F3 B3 
SRALAMP7.1 7.1 7.1 7.1 7.1 
SRALAMP7.2 7.2 7.2 7.2 7.2 
SRALAMP7.3 7.3 7.2 7.3 7.3 
SRALAMP7.10 7.1 7.10 7.1 7.10 
SRALAMP7.13 7.1 7.13 7.1 7.10 
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Appendix 7. Binding sites of novel LAMP primers for the 
specific detection of T. b. rhodesiense 
Table 1. SRALAMP_a primers 











F3 ATCTCAGCGCTTTATGCC 18 
B3 GCCTTATTGCTACTGTTGTT 20 









LB AGTAATCGACATTCTGCAGCAG 22 
 
Figure 1. Binding sites of novel LAMP primers, coded SRALAMP_a, 
designed using SRA (AF097331) and the site of the internal deletion 
(between nucleotides 579 and 580) in SRA when compared with 
otherwise similar VSG (highlighted in red) 
 
AF097331     
   1 cgctattatt agaacagttt ctgtactata ttgaagacac acctctaaga atcacaatag 
  61 caaggcgaac cgaaagcgaa gcacagttaa cgtaacagca atgccccgaa attcgggccg 
 121 gacaacaagt accttggcgc tcgcgctggc cctaaagctg ctggcagtgc ctgtatcgcc 
 181 cagtggcacc gcctttgacg aagagcccgt caagaaggtt tgcaaagtag aaaaaaactt 
 241 agcagacgtc gcaggaatcg ctttggccaa aataaacaac ctgataaaac aagtatcggc 
 301 agcaaccgaa gcggaagcaa gaatgacctt ggccgccgca agcacagacc acagcaacat 
 361 ctcagcgctt tatgccgcgg cgtcaaacat agtgacaaga tgcgtactca acgcagtcca            
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        (F3)                                (F2) 
 421 cgctcttaca agtcttgcgc caatagcgtt aactgcagcg accaacggag ccaaaaccag 
                  (F1c)                                           (B1c) 
 481 tgggcacatc tcagaagtaa tcgacattct gcagcaggcg tcacaaggta agacagaagg 
                   (B2) 
 541 aaagtgcata gtgaaaagcg gcggcggtac aacaacagta gcaataaggc aactttacaa 
          (B3) 
 601 caaaataggg gacctagaaa aacaaacgac caacaactgc ggcaccagcg tgaccgaagt 
 661 actcgaacac attctaaaac aagaagcgct caaggaagcg ctactttcaa tcgtgaaaaa 
 721 accaaaaggg gcgccagaca aaacagcagc agatgaattg gtcaccgtgc ttatcaacgg 
 781 cgtggtgcca aacagcacag cacagaccca aaaattaaag gagaaaattc taaacacctt 
 841 ggtccccaag cttgtggaag gctcaaaaag ccaagtaaaa ctaaggattc tgaagtaccc 
 901 gggaaaaata cagaaaagca aactcgtatc aatccaagag ttaaaaaccc gagtggagcc 
 961 tgaatctagc actgaaagct gcaagcagca ggtcgccacc aaccaggcac aggaggcatt 
1021 ttgtaacgca attggcgacg acaaagacaa gggtaacaat gagacacgat gcagttacga 
1081 tgacagcaaa ggctcagaca aaaagtgcac atataatgcg gaaaaagcgg aagcaaatgg 
1141 ggcacctgca acgcaacctc aagggggagt gaacgaagca acaacaggaa attgtaaagg 
1201 gaaactggaa cccggatgca ccaaggcaca agaatacgaa tgggaaggaa aagaatccaa 
1261 agattcaagt tttcttgtgg atatgaaatt ggctctgaat atggttgctg cttttgtggc 
1321 ctttctgttt taattttcac ctcttttgaa agaactttgc tgtttcatat actttaacac 
1381 attttcatga atttgtgaa 
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Table 2. SRALAMP_b primers 












B3 CGAGTACTTCGGTCACGCT 19 
 
Figure 2. Binding sites of novel LAMP primers, coded SRALAMP_b, 
designed using SRA (AF097331) and the site of the internal deletion 
(between nucleotides 579 and 580) in SRA when compared with 
otherwise similar VSG (highlighted in red) 
AF097331     
   1 cgctattatt agaacagttt ctgtactata ttgaagacac acctctaaga atcacaatag 
  61 caaggcgaac cgaaagcgaa gcacagttaa cgtaacagca atgccccgaa attcgggccg 
 121 gacaacaagt accttggcgc tcgcgctggc cctaaagctg ctggcagtgc ctgtatcgcc 
 181 cagtggcacc gcctttgacg aagagcccgt caagaaggtt tgcaaagtag aaaaaaactt 
 241 agcagacgtc gcaggaatcg ctttggccaa aataaacaac ctgataaaac aagtatcggc 
 301 agcaaccgaa gcggaagcaa gaatgacctt ggccgccgca agcacagacc acagcaacat 
 361 ctcagcgctt tatgccgcgg cgtcaaacat agtgacaaga tgcgtactca acgcagtcca            
                                         
 421 cgctcttaca agtcttgcgc caatagcgtt aactgcagcg accaacggag ccaaaaccag 
                       (F3)                                   (F2)    
 481 tgggcacatc tcagaagtaa tcgacattct gcagcaggcg tcacaaggta agacagaagg 
          (F1c)      
 541 aaagtgcata gtgaaaagcg gcggcggtac aacaacagta gcaataaggc aactttacaa 
          (B1c) 
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 601 caaaataggg gacctagaaa aacaaacgac caacaactgc ggcaccagcg tgaccgaagt 
                                   (B2)                       (B3) 
 661 actcgaacac attctaaaac aagaagcgct caaggaagcg ctactttcaa tcgtgaaaaa 
  
 721 accaaaaggg gcgccagaca aaacagcagc agatgaattg gtcaccgtgc ttatcaacgg 
 781 cgtggtgcca aacagcacag cacagaccca aaaattaaag gagaaaattc taaacacctt 
 841 ggtccccaag cttgtggaag gctcaaaaag ccaagtaaaa ctaaggattc tgaagtaccc 
 901 gggaaaaata cagaaaagca aactcgtatc aatccaagag ttaaaaaccc gagtggagcc 
 961 tgaatctagc actgaaagct gcaagcagca ggtcgccacc aaccaggcac aggaggcatt 
1021 ttgtaacgca attggcgacg acaaagacaa gggtaacaat gagacacgat gcagttacga 
1081 tgacagcaaa ggctcagaca aaaagtgcac atataatgcg gaaaaagcgg aagcaaatgg 
1141 ggcacctgca acgcaacctc aagggggagt gaacgaagca acaacaggaa attgtaaagg 
1201 gaaactggaa cccggatgca ccaaggcaca agaatacgaa tgggaaggaa aagaatccaa 
1261 agattcaagt tttcttgtgg atatgaaatt ggctctgaat atggttgctg cttttgtggc 
1321 ctttctgttt taattttcac ctcttttgaa agaactttgc tgtttcatat actttaacac 
1381 attttcatga atttgtgaa 
 
Table 3. SRALAMP_e primers. 







F3 GACAAGATGCGTACTCAAC 19 
B3 AGGTCCCCTATTTTGTTGT 19 









LB CAGAAGGAAAGTGCATAGTGAAAAG 25 
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Figure 3. Binding sites of novel LAMP primers, coded SRALAMP_e, 
designed using SRA (AF097331) and the site of the internal deletion 
(between nucleotides 579 and 580) in SRA when compared with 
otherwise similar VSG (highlighted in red) 
 
AF097331     
   1 cgctattatt agaacagttt ctgtactata ttgaagacac acctctaaga atcacaatag 
  61 caaggcgaac cgaaagcgaa gcacagttaa cgtaacagca atgccccgaa attcgggccg 
 121 gacaacaagt accttggcgc tcgcgctggc cctaaagctg ctggcagtgc ctgtatcgcc 
 181 cagtggcacc gcctttgacg aagagcccgt caagaaggtt tgcaaagtag aaaaaaactt 
 241 agcagacgtc gcaggaatcg ctttggccaa aataaacaac ctgataaaac aagtatcggc 
 301 agcaaccgaa gcggaagcaa gaatgacctt ggccgccgca agcacagacc acagcaacat 
 361 ctcagcgctt tatgccgcgg cgtcaaacat agtgacaaga tgcgtactca acgcagtcca            
                                              (F3)               (F2) 
 421 cgctcttaca agtcttgcgc caatagcgtt aactgcagcg accaacggag ccaaaaccag 
                                                   (F1c)          
 481 tgggcacatc tcagaagtaa tcgacattct gcagcaggcg tcacaaggta agacagaagg 
            (B1c)      
 541 aaagtgcata gtgaaaagcg gcggcggtac aacaacagta gcaataaggc aactttacaa 
     (B2)                     (B3) 
 601 caaaataggg gacctagaaa aacaaacgac caacaactgc ggcaccagcg tgaccgaagt 
  
 661 actcgaacac attctaaaac aagaagcgct caaggaagcg ctactttcaa tcgtgaaaaa 
 721 accaaaaggg gcgccagaca aaacagcagc agatgaattg gtcaccgtgc ttatcaacgg 
 781 cgtggtgcca aacagcacag cacagaccca aaaattaaag gagaaaattc taaacacctt 
 841 ggtccccaag cttgtggaag gctcaaaaag ccaagtaaaa ctaaggattc tgaagtaccc 
 901 gggaaaaata cagaaaagca aactcgtatc aatccaagag ttaaaaaccc gagtggagcc 
 961 tgaatctagc actgaaagct gcaagcagca ggtcgccacc aaccaggcac aggaggcatt 
1021 ttgtaacgca attggcgacg acaaagacaa gggtaacaat gagacacgat gcagttacga 
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1081 tgacagcaaa ggctcagaca aaaagtgcac atataatgcg gaaaaagcgg aagcaaatgg 
1141 ggcacctgca acgcaacctc aagggggagt gaacgaagca acaacaggaa attgtaaagg 
1201 gaaactggaa cccggatgca ccaaggcaca agaatacgaa tgggaaggaa aagaatccaa 
1261 agattcaagt tttcttgtgg atatgaaatt ggctctgaat atggttgctg cttttgtggc 
1321 ctttctgttt taattttcac ctcttttgaa agaactttgc tgtttcatat actttaacac 
1381 attttcatga atttgtgaa 
 
Table 4. SRALAMP_f primers 







F3 GTGGGCACATCTCAGAAG 18 
B3 AAGTAGCGCTTCCTTGAG 18 









LB ACAACTGCGGCACCAGC 27 
 
Figure 4. Binding sites of novel LAMP primers, coded SRALAMP_f, 
designed using SRA (AF097331) and the site of the internal deletion 
(between nucleotides 579 and 580) in SRA when compared with 
otherwise similar VSG (highlighted in red) 
AF097331     
   1 cgctattatt agaacagttt ctgtactata ttgaagacac acctctaaga atcacaatag 
  61 caaggcgaac cgaaagcgaa gcacagttaa cgtaacagca atgccccgaa attcgggccg 
 121 gacaacaagt accttggcgc tcgcgctggc cctaaagctg ctggcagtgc ctgtatcgcc 
 181 cagtggcacc gcctttgacg aagagcccgt caagaaggtt tgcaaagtag aaaaaaactt 
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 241 agcagacgtc gcaggaatcg ctttggccaa aataaacaac ctgataaaac aagtatcggc 
 301 agcaaccgaa gcggaagcaa gaatgacctt ggccgccgca agcacagacc acagcaacat 
 361 ctcagcgctt tatgccgcgg cgtcaaacat agtgacaaga tgcgtactca acgcagtcca            
 421 cgctcttaca agtcttgcgc caatagcgtt aactgcagcg accaacggag ccaaaaccag 
                                                             
 481 tgggcacatc tcagaagtaa tcgacattct gcagcaggcg tcacaaggta agacagaagg 
     (F3)         (F2)          
 541 aaagtgcata gtgaaaagcg gcggcggtac aacaacagta gcaataaggc aactttacaa 
       (F1c)                        
 601 caaaataggg gacctagaaa aacaaacgac caacaactgc ggcaccagcg tgaccgaagt 
            (B1c)                                               (F2) 
 661 actcgaacac attctaaaac aagaagcgct caaggaagcg ctactttcaa tcgtgaaaaa 
                                    (B3) 
 721 accaaaaggg gcgccagaca aaacagcagc agatgaattg gtcaccgtgc ttatcaacgg 
 781 cgtggtgcca aacagcacag cacagaccca aaaattaaag gagaaaattc taaacacctt 
 841 ggtccccaag cttgtggaag gctcaaaaag ccaagtaaaa ctaaggattc tgaagtaccc 
 901 gggaaaaata cagaaaagca aactcgtatc aatccaagag ttaaaaaccc gagtggagcc 
 961 tgaatctagc actgaaagct gcaagcagca ggtcgccacc aaccaggcac aggaggcatt 
1021 ttgtaacgca attggcgacg acaaagacaa gggtaacaat gagacacgat gcagttacga 
1081 tgacagcaaa ggctcagaca aaaagtgcac atataatgcg gaaaaagcgg aagcaaatgg 
1141 ggcacctgca acgcaacctc aagggggagt gaacgaagca acaacaggaa attgtaaagg 
1201 gaaactggaa cccggatgca ccaaggcaca agaatacgaa tgggaaggaa aagaatccaa 
1261 agattcaagt tttcttgtgg atatgaaatt ggctctgaat atggttgctg cttttgtggc 
1321 ctttctgttt taattttcac ctcttttgaa agaactttgc tgtttcatat actttaacac 
1381 attttcatga atttgtgaa 
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Table 5. SRALAMP7.1 primers 
















B3 CGCTTCTTGTTTTAGAATGTGT 22 
 
Figure 5. Binding sites of novel LAMP primers, coded SRALAMP7.1, 
designed using SRA (AF097331) and the site of the internal deletion 
(between nucleotides 579 and 580) in SRA when compared with 
otherwise similar VSG (highlighted in red) 
AF097331     
   1 cgctattatt agaacagttt ctgtactata ttgaagacac acctctaaga atcacaatag 
  61 caaggcgaac cgaaagcgaa gcacagttaa cgtaacagca atgccccgaa attcgggccg 
 121 gacaacaagt accttggcgc tcgcgctggc cctaaagctg ctggcagtgc ctgtatcgcc 
 181 cagtggcacc gcctttgacg aagagcccgt caagaaggtt tgcaaagtag aaaaaaactt 
 241 agcagacgtc gcaggaatcg ctttggccaa aataaacaac ctgataaaac aagtatcggc 
 301 agcaaccgaa gcggaagcaa gaatgacctt ggccgccgca agcacagacc acagcaacat 
 361 ctcagcgctt tatgccgcgg cgtcaaacat agtgacaaga tgcgtactca acgcagtcca            
                                        
 421 cgctcttaca agtcttgcgc caatagcgtt aactgcagcg accaacggag ccaaaaccag 
                                                              
 481 tgggcacatc tcagaagtaa tcgacattct gcagcaggcg tcacaaggta agacagaagg 
        (F3)    (F2)     
 541 aaagtgcata gtgaaaagcg gcggcggtac aacaacagta gcaataaggc aactttacaa 
     (F1c)                 (B1c) 
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 601 caaaataggg gacctagaaa aacaaacgac caacaactgc ggcaccagcg tgaccgaagt 
                                                             (B2) 
 661 actcga acac attctaaaac aagaagcgct caaggaagcg ctactttcaa tcgtgaaaaa 
                (B3) 
 721 accaaaaggg gcgccagaca aaacagcagc agatgaattg gtcaccgtgc ttatcaacgg 
 781 cgtggtgcca aacagcacag cacagaccca aaaattaaag gagaaaattc taaacacctt 
 841 ggtccccaag cttgtggaag gctcaaaaag ccaagtaaaa ctaaggattc tgaagtaccc 
 901 gggaaaaata cagaaaagca aactcgtatc aatccaagag ttaaaaaccc gagtggagcc 
 961 tgaatctagc actgaaagct gcaagcagca ggtcgccacc aaccaggcac aggaggcatt 
1021 ttgtaacgca attggcgacg acaaagacaa gggtaacaat gagacacgat gcagttacga 
1081 tgacagcaaa ggctcagaca aaaagtgcac atataatgcg gaaaaagcgg aagcaaatgg 
1141 ggcacctgca acgcaacctc aagggggagt gaacgaagca acaacaggaa attgtaaagg 
1201 gaaactggaa cccggatgca ccaaggcaca agaatacgaa tgggaaggaa aagaatccaa 
1261 agattcaagt tttcttgtgg atatgaaatt ggctctgaat atggttgctg cttttgtggc 
1321 ctttctgttt taattttcac ctcttttgaa agaactttgc tgtttcatat actttaacac 
1381 attttcatga atttgtgaa 
 
Table 6. SRALAMP7.2 Primers 












B3 TGCTGCTGTTTTGTCTGG 18 
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Figure 6. Binding sites of novel LAMP primers, coded SRALAMP7.2, 
designed using SRA (AF097331) and the site of the internal deletion 
(between nucleotides 579 and 580) in SRA when compared with 
otherwise similar VSG (highlighted in red) 
AF097331     
   1 cgctattatt agaacagttt ctgtactata ttgaagacac acctctaaga atcacaatag 
  61 caaggcgaac cgaaagcgaa gcacagttaa cgtaacagca atgccccgaa attcgggccg 
 121 gacaacaagt accttggcgc tcgcgctggc cctaaagctg ctggcagtgc ctgtatcgcc 
 181 cagtggcacc gcctttgacg aagagcccgt caagaaggtt tgcaaagtag aaaaaaactt 
 241 agcagacgtc gcaggaatcg ctttggccaa aataaacaac ctgataaaac aagtatcggc 
 301 agcaaccgaa gcggaagcaa gaatgacctt ggccgccgca agcacagacc acagcaacat 
 361 ctcagcgctt tatgccgcgg cgtcaaacat agtgacaaga tgcgtactca acgcagtcca            
                                         
 421 cgctcttaca agtcttgcgc caatagcgtt aactgcagcg accaacggag ccaaaaccag 
                                                              
 481 tgggcacatc tcagaagtaa tcgacattct gcagcaggcg tcacaaggta agacagaagg 
                
 541 aaagtgcata gtgaaaagcg gcggcggtac aacaacagta gcaataaggc aactttacaa 
  (F3)  (F2)       
 601 caaaataggg gacctagaaa aacaaacgac caacaactgc ggcaccagcg tgaccgaagt 
             (F1c)                                          (B1c) 
 661 actcgaacac attctaaaac aagaagcgct caaggaagcg ctactttcaa tcgtgaaaaa 
                                                         (B2) 
 721 accaaaaggg gcgccagaca aaacagcagc agatgaattg gtcaccgtgc ttatcaacgg 
                        (B3) 
 781 cgtggtgcca aacagcacag cacagaccca aaaattaaag gagaaaattc taaacacctt 
 841 ggtccccaag cttgtggaag gctcaaaaag ccaagtaaaa ctaaggattc tgaagtaccc 
 901 gggaaaaata cagaaaagca aactcgtatc aatccaagag ttaaaaaccc gagtggagcc 
 961 tgaatctagc actgaaagct gcaagcagca ggtcgccacc aaccaggcac aggaggcatt 
1021 ttgtaacgca attggcgacg acaaagacaa gggtaacaat gagacacgat gcagttacga 
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1081 tgacagcaaa ggctcagaca aaaagtgcac atataatgcg gaaaaagcgg aagcaaatgg 
1141 ggcacctgca acgcaacctc aagggggagt gaacgaagca acaacaggaa attgtaaagg 
1201 gaaactggaa cccggatgca ccaaggcaca agaatacgaa tgggaaggaa aagaatccaa 
1261 agattcaagt tttcttgtgg atatgaaatt ggctctgaat atggttgctg cttttgtggc 
1321 ctttctgttt taattttcac ctcttttgaa agaactttgc tgtttcatat actttaacac 
1381 attttcatga atttgtgaa 
 
Table 7. SRALAMP7.3 primers 
















B3 GTGACCAATTCATCTGCTG 19 
 
Figure 7. Binding sites of novel LAMP primers, coded SRALAMP7.3 , 
designed using SRA (AF097331) and the site of the internal deletion 
(between nucleotides 579 and 580) in SRA when compared with 
otherwise similar VSG (highlighted in red) 
 
AF097331     
   1 cgctattatt agaacagttt ctgtactata ttgaagacac acctctaaga atcacaatag 
  61 caaggcgaac cgaaagcgaa gcacagttaa cgtaacagca atgccccgaa attcgggccg 
 121 gacaacaagt accttggcgc tcgcgctggc cctaaagctg ctggcagtgc ctgtatcgcc 
 181 cagtggcacc gcctttgacg aagagcccgt caagaaggtt tgcaaagtag aaaaaaactt 
 241 agcagacgtc gcaggaatcg ctttggccaa aataaacaac ctgataaaac aagtatcggc 
 301 agcaaccgaa gcggaagcaa gaatgacctt ggccgccgca agcacagacc acagcaacat 
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 361 ctcagcgctt tatgccgcgg cgtcaaacat agtgacaaga tgcgtactca acgcagtcca            
                                        
 421 cgctcttaca agtcttgcgc caatagcgtt aactgcagcg accaacggag ccaaaaccag 
                                                              
 481 tgggcacatc tcagaagtaa tcgacattct gcagcaggcg tcacaaggta agacagaagg 
               
 541 aaagtgcata gtgaaaagcg gcggcggtac aacaacagta gcaataaggc aactttacaa 
  (F3)           (F2) 
 601 caaaataggg gacctagaaa aacaaacgac caacaactgc ggcaccagcg tgaccgaagt 
                 (F1c)                                       (B1c)     
 661 actcgaacac attctaaaac aagaagcgct caaggaagcg ctactttcaa tcgtgaaaaa 
                                                           (B2) 
 721 accaaaaggg gcgccagaca aaacagcagc agatgaattg gtcaccgtgc ttatcaacgg 
                                      (B3) 
 781 cgtggtgcca aacagcacag cacagaccca aaaattaaag gagaaaattc taaacacctt 
 841 ggtccccaag cttgtggaag gctcaaaaag ccaagtaaaa ctaaggattc tgaagtaccc 
 901 gggaaaaata cagaaaagca aactcgtatc aatccaagag ttaaaaaccc gagtggagcc 
 961 tgaatctagc actgaaagct gcaagcagca ggtcgccacc aaccaggcac aggaggcatt 
1021 ttgtaacgca attggcgacg acaaagacaa gggtaacaat gagacacgat gcagttacga 
1081 tgacagcaaa ggctcagaca aaaagtgcac atataatgcg gaaaaagcgg aagcaaatgg 
1141 ggcacctgca acgcaacctc aagggggagt gaacgaagca acaacaggaa attgtaaagg 
1201 gaaactggaa cccggatgca ccaaggcaca agaatacgaa tgggaaggaa aagaatccaa 
1261 agattcaagt tttcttgtgg atatgaaatt ggctctgaat atggttgctg cttttgtggc 
1321 ctttctgttt taattttcac ctcttttgaa agaactttgc tgtttcatat actttaacac 
1381 attttcatga atttgtgaa 
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Table 8. SRALAMP7.10 primers 

















Figure 8. Binding sites of novel LAMP primers, coded SRALAMP7.10, 
designed using SRA (AF097331) and the site of the internal deletion 
(between nucleotides 579 and 580) in SRA when compared with 
otherwise similar VSG (highlighted in red) 
 
AF097331     
   1 cgctattatt agaacagttt ctgtactata ttgaagacac acctctaaga atcacaatag 
  61 caaggcgaac cgaaagcgaa gcacagttaa cgtaacagca atgccccgaa attcgggccg 
 121 gacaacaagt accttggcgc tcgcgctggc cctaaagctg ctggcagtgc ctgtatcgcc 
 181 cagtggcacc gcctttgacg aagagcccgt caagaaggtt tgcaaagtag aaaaaaactt 
 241 agcagacgtc gcaggaatcg ctttggccaa aataaacaac ctgataaaac aagtatcggc 
 301 agcaaccgaa gcggaagcaa gaatgacctt ggccgccgca agcacagacc acagcaacat 
 361 ctcagcgctt tatgccgcgg cgtcaaacat agtgacaaga tgcgtactca acgcagtcca            
                                        
 421 cgctcttaca agtcttgcgc caatagcgtt aactgcagcg accaacggag ccaaaaccag 
                                                              
 481 tgggcacatc tcagaagtaa tcgacattct gcagcaggcg tcacaaggta agacagaagg 
        (F3)    (F2)     
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 541 aaagtgcata gtgaaaagcg gcggcggtac aacaacagta gcaataaggc aactttacaa 
     (F1c)                 (B1c) 
 601 caaaataggg gacctagaaa aacaaacgac caacaactgc ggcaccagcg tgaccgaagt 
                                                                  (B2) 
 661 actcgaacac attctaaaac aagaagcgct caaggaagcg ctactttcaa tcgtgaaaaa 
                                 (B3) 
 721 accaaaaggg gcgccagaca aaacagcagc agatgaattg gtcaccgtgc ttatcaacgg 
 781 cgtggtgcca aacagcacag cacagaccca aaaattaaag gagaaaattc taaacacctt 
 841 ggtccccaag cttgtggaag gctcaaaaag ccaagtaaaa ctaaggattc tgaagtaccc 
 901 gggaaaaata cagaaaagca aactcgtatc aatccaagag ttaaaaaccc gagtggagcc 
 961 tgaatctagc actgaaagct gcaagcagca ggtcgccacc aaccaggcac aggaggcatt 
1021 ttgtaacgca attggcgacg acaaagacaa gggtaacaat gagacacgat gcagttacga 
1081 tgacagcaaa ggctcagaca aaaagtgcac atataatgcg gaaaaagcgg aagcaaatgg 
1141 ggcacctgca acgcaacctc aagggggagt gaacgaagca acaacaggaa attgtaaagg 
1201 gaaactggaa cccggatgca ccaaggcaca agaatacgaa tgggaaggaa aagaatccaa 
1261 agattcaagt tttcttgtgg atatgaaatt ggctctgaat atggttgctg cttttgtggc 
1321 ctttctgttt taattttcac ctcttttgaa agaactttgc tgtttcatat actttaacac 
1381 attttcatga atttgtgaa 
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Table 9. SRALAMP7.13 primers 















B3 TTCCTTGAGCGCTTCTTG 18 
 
Figure 9. Binding sites of novel LAMP primers, coded SRALAMP7.13, 
designed using SRA (AF097331) and the site of the internal deletion 
(between nucleotides 579 and 580) in SRA when compared with 
otherwise similar VSG (highlighted in red) 
AF097331     
   1 cgctattatt agaacagttt ctgtactata ttgaagacac acctctaaga atcacaatag 
  61 caaggcgaac cgaaagcgaa gcacagttaa cgtaacagca atgccccgaa attcgggccg 
 121 gacaacaagt accttggcgc tcgcgctggc cctaaagctg ctggcagtgc ctgtatcgcc 
 181 cagtggcacc gcctttgacg aagagcccgt caagaaggtt tgcaaagtag aaaaaaactt 
 241 agcagacgtc gcaggaatcg ctttggccaa aataaacaac ctgataaaac aagtatcggc 
 301 agcaaccgaa gcggaagcaa gaatgacctt ggccgccgca agcacagacc acagcaacat 
 361 ctcagcgctt tatgccgcgg cgtcaaacat agtgacaaga tgcgtactca acgcagtcca            
                                        
 421 cgctcttaca agtcttgcgc caatagcgtt aactgcagcg accaacggag ccaaaaccag 
                                                              
 481 tgggcacatc tcagaagtaa tcgacattct gcagcaggcg tcacaaggta agacagaagg 
        (F3)    (F2)     
 541 aaagtgcata gtgaaaagcg gcggcggtac aacaacagta gcaataaggc aactttacaa 
     (F1c)                  
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 601 caaaataggg gacctagaaa aacaaacgac caacaactgc ggcaccagcg tgaccgaagt 
                  (B1c)                                           (B2) 
 661 actcgaacac attctaaaac aagaagcgct caaggaagcg ctactttcaa tcgtgaaaaa 
                              (B3) 
 721 accaaaaggg gcgccagaca aaacagcagc agatgaattg gtcaccgtgc ttatcaacgg 
 781 cgtggtgcca aacagcacag cacagaccca aaaattaaag gagaaaattc taaacacctt 
 841 ggtccccaag cttgtggaag gctcaaaaag ccaagtaaaa ctaaggattc tgaagtaccc 
 901 gggaaaaata cagaaaagca aactcgtatc aatccaagag ttaaaaaccc gagtggagcc 
 961 tgaatctagc actgaaagct gcaagcagca ggtcgccacc aaccaggcac aggaggcatt 
1021 ttgtaacgca attggcgacg acaaagacaa gggtaacaat gagacacgat gcagttacga 
1081 tgacagcaaa ggctcagaca aaaagtgcac atataatgcg gaaaaagcgg aagcaaatgg 
1141 ggcacctgca acgcaacctc aagggggagt gaacgaagca acaacaggaa attgtaaagg 
1201 gaaactggaa cccggatgca ccaaggcaca agaatacgaa tgggaaggaa aagaatccaa 
1261 agattcaagt tttcttgtgg atatgaaatt ggctctgaat atggttgctg cttttgtggc 
1321 ctttctgttt taattttcac ctcttttgaa agaactttgc tgtttcatat actttaacac 
1381 attttcatga atttgtgaa 
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Appendix 8. Results from the Trypanozoon and T. b. 
rhodesiense  PCR and LAMP assays 











1. Tira 24 6.48 + 00:37:24 + - + - 
2. Sikuda 28 47.25 + 00:37:36 + - + - 
3. UGC 0.01 + 00:35:12 + + + + 
4. UGI 1.01 + 00:36:36 + + + + 
5. Dal069 IM52 73.49 + 00:36:48 + + + - 
6. Papol 33 21.96 + 00:35:54 + - + - 
7. Bumanda 146 60.14 + 00:36:00 + - + - 
8. Papol 264 69.57 + 00:36:24 + - + - 
9. UGA 88 22.53 + 00:45:36 + + + + 
10. E. Oketch 15.21 + 00:50:06 + + + + 
11. Papol 285 12.12 + 00:48:18 + + + + 
12. Biyamina 26.87 + 00:47:54 + + + + 
13. Mela 3 24.09 + 00:48:54 + - + - 
14. Papol 103 5.77 + 00:51:00 + + + + 
15. Mawero 66 18.37 + 00:49:18 + + + + 
16. Mela 71 IM87 23.3 + 00:48:06 + + + + 
17. TH149 20.31 + 00:42:42 + - + - 
18. Bida 3 Clone 
A 53.14 
- 
00:46:12 + - + - 
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19. TSW83 27.45 + 00:40:06 + - + - 
20. Katerema 311 7.39 + 00:46:00 + - + - 
21. Musikia Clone 
A 5.72 
- 
00:52:24 - - + - 
22. Suzena 8.13 + 00:52:48 - - + - 
23. Tsuaa 14.77 + 00:49:00 - - + - 
24. Mawero 32 4.62 + 00:43:36 + - + - 
25. Papol 42 1.7 + 00:34:36 + - + - 
26. UGK 9.57 + 00:33:12 + + + + 
27. Papol 60 0.32 + 00:31:54 + - + - 
28. UR4 49.11 + 00:32:36 + - + - 
29. F97 2.75 + 00:32:12 + - + - 
30. Mawero 80 5.49 + 00:33:24 + - + - 
31. Papol 278 7.64 + 00:42:00 + + + + 
32. URI 18.15 + 00:40:54 + + + + 
33. UGH 1.87 + 00:29:18 + + + + 
34. Mela Pig 7.19 + 00:30:36 + - + - 
35. Tira 22 4.44 + 00:29:00 + - + - 
36. Mela 66 6.01 + 00:29:24 + + + + 
37. Uganda B 8.66 + 00:28:00 + + + + 
38. Mela 24 4.34 + 00:28:42 + - + - 
39. Iyolowa 125 13.15 + 00:28:54 + - + - 
40. Tira 168 4.98 + 00:27:42 + - + + 
41. Papol 12 1.45 + 00:31:12 + - + - 
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42. Mela 27 5 + 00:31:30 + + + + 
43. Poyem 11 10.6 + 00:31:36 + - + - 
44. Tira 4 5.13 + 00:31:06 + - + - 
45. Mela pig 2 17.89 + 00:30:18 + - + - 
46. UGE 6.05 + 00:28:48 + + + + 
47. Katerema 72 1.92 + 00:31:54 + + + - 
48. Mawero 42 7.92 + 00:30:36 + + + + 
49. Tira 34 1.71 + 00:38:18 + - + - 
50. H.Taka 20.26 + 00:29:42 + + + + 
51. Uganda A 9.04 + 00:30:30 + + + + 
52. A Kiburige 26.28 + 00:31:54 + + + + 
53. Uganda E 6.04 + 00:30:42 + + + + 
54. Katerema 116 14.12 + 00:30:24 + + + - 
55. Tira 43 5.81 + 00:30:42 + - + - 
56. Tira 92 13.14 + 00:00:00 - - - - 
57. Tira 75 4.93 + 00:36:30 + - + - 
58. Musikia Clone 
B 9.11 
+ 
00:30:00 - - + - 
59. Iyolowa 116 3.94 + 00:25:48 + - + - 
60. Iyolowa 153 5.36 + 00:27:48 + - + - 
61. TH 112 IM56 21.32 + 00:29:00 + - + - 
62. Muraz 15 
IM47 24.87 
+ 
00:00:00 + - + - 
63. Mela 12 6.78 + 00:35:48 + - + - 
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64. Mawero 31 24.32 + 00:33:54 + + + + 
65. F73 7.7 + 00:49:42 + + + + 
66. Tira 27 30.69 + 00:53:54 + - + - 
67. Uganda L 3.19 + 00:46:54 + + + + 
68. F48 8.76 + 00:47:12 + + + + 
69. Tira 68 11.96 + 00:47:30 + - + - 
70. Tira 30 1.52 + 00:48:00 + - + - 
71. Tira 29 1.55 - 00:00:00 + - + - 
72. Papol 371 144.78 + 00:00:00 + - + - 
73. Mawero 85 6.83 + 00:49:00 + - + - 
74. Iyolowa 147 1.33 + 00:45:54 + - + - 
75. Muraz 3 IM46 29.59 + 00:46:00 + - + - 
76. Katerema 41 5.51 + 00:47:24 + - + - 
77. UGG 88 24.29 + 00:47:54 + + + + 
78. Mela 2 3.73 + 00:49:06 + + + + 
79. Uganda M 2.17 + 00:52:06 + + + + 
80. Rose Akinare 2.39 + 00:48:18 + + + + 
81. Uganda B 0.79 + 00:44:54 + + + + 
82. Papol 144 2.88 + 00:46:12 + - + - 
83. Uganda C 9.76 + 00:47:00 + + + + 
84. Sikuda 42.90 8.99 + 00:44:42 + - + - 
85. Sikuda 4 6.3 - 00:00:00 - - - - 
86. D. Obwang 8.2 + 00:41:12 + + + + 
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Appendix 9. Results from the SRALAMP_a assay applied to 






















00:37:36 - - - - - - - 00:42:48 
3. UGC + 00:35:12 + + + + + + + 00:34:06 


































00:47:54 + + + + - + + 00:36:30 
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00:52:48 - - - - - - - 00:00:00 









00:34:36 - - - - - - - 00:00:00 
26. UGK + 00:33:12 + + + + - + - 00:41:36 
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00:31:54 - - - - - - - 00:00:00 
28. UR4 + 00:32:36 - - - - - - - 00:00:00 









00:42:00 + + + + - + - 00:48:54 
32. URI + 00:40:54 + + + + - + - 00:48:18 


































00:31:12 - - - + - - + 00:00:00 
42. Mela + 00:31:30 + + + + - + + 00:51:18 
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00:30:18 - - - + - - + 00:00:00 









































00:30:42 - - - + - - + 00:45:48 
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00:33:54 + + + + + + + 00:38:06 









00:46:54 + + + + + + + 00:31:48 
68. F48 + 00:47:12 + + + + + + + 00:33:24 
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00:44:54 + + + + + + + 00:40:30 
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DNA - - - - - - 00:54:18 
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Appendix 10. Primer binding sites for the published LAMP SRA1 and novel SRALAMP_a 
primers in relation to the internal deletion site which distinguishes SRA  
(The internal deletion site is highlighted in bold red type) 
 
 
SeqA Name                          Len(nt)  SeqB Name                          Len(nt)  Score 
============================================================================================= 
1    gi|19913120|emb|AJ345058.1|   1190     2    gi|19913118|emb|AJ345057.1|   1190     98    
1    gi|19913120|emb|AJ345058.1|   1190     3    gi|24940358|emb|Z37159.2|     1398     97    
1    gi|19913120|emb|AJ345058.1|   1190     4    gi|3851625|gb|AF097331.1|     1399     97    
2    gi|19913118|emb|AJ345057.1|   1190     3    gi|24940358|emb|Z37159.2|     1398     99    
2    gi|19913118|emb|AJ345057.1|   1190     4    gi|3851625|gb|AF097331.1|     1399     99    
3    gi|24940358|emb|Z37159.2|     1398     4    gi|3851625|gb|AF097331.1|     1399     99    
============================================================================================= 
 
CLUSTAL 2.0.12 multiple sequence alignment 
 
 
gi|19913118|emb|AJ345057.1|      -------------------------------------------------- 
gi|24940358|emb|Z37159.2|        CGCTATTATTAGAACAGTTTCTGTACTATATTGA---CACATCTCTAAGA 47 
gi|3851625|gb|AF097331.1|        CGCTATTATTAGAACAGTTTCTGTACTATATTGAAGACACACCTCTAAGA 50 
gi|19913120|emb|AJ345058.1|      -------------------------------------------------- 
                                                                                    
 
gi|19913118|emb|AJ345057.1|      -------------------------------------------------- 
gi|24940358|emb|Z37159.2|        ATCACAATAGCAAGGCGAACCGAAAGCGAAGCACAGTTAACGTAACAGCA 97 
gi|3851625|gb|AF097331.1|        ATCACAATAGCAAGGCGAACCGAAAGCGAAGCACAGTTAACGTAACAGCA 100 
gi|19913120|emb|AJ345058.1|      -------------------------------------------------- 
                                                                                    
 
gi|19913118|emb|AJ345057.1|      --------------------GACAACAAGTACCTTGGCGCTCGCGCTGGC 30 
gi|24940358|emb|Z37159.2|        ATGCCCCGAAATTCGGGCCGGACAACAAGTACCTTGGCGCTCGCCGTGGC 147 
gi|3851625|gb|AF097331.1|        ATGCCCCGAAATTCGGGCCGGACAACAAGTACCTTGGCGCTCGCGCTGGC 150 
gi|19913120|emb|AJ345058.1|      --------------------GACAACAAGTACCTTGGCGCTCGCGCTGGC 30 
                                                     ************************  **** 
 
gi|19913118|emb|AJ345057.1|      CCTAAAGCTGCTGGCAGTGCCTGTATCGCCCAGTGGCACCGCCTTTGACG 80 
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gi|24940358|emb|Z37159.2|        CCTAAAGCTGCTGGCAGTGCCTGTATCGCCCAGTGGCACCGCCTTTGACG 197 
gi|3851625|gb|AF097331.1|        CCTAAAGCTGCTGGCAGTGCCTGTATCGCCCAGTGGCACCGCCTTTGACG 200 
gi|19913120|emb|AJ345058.1|      CCTAAAGCTGCTGGCAGTGCCTGTATCGCCCAGTGGCCCCGCCTTTGACG 80 
                                 ************************************* ************ 
 
gi|19913118|emb|AJ345057.1|      AAGAGCCCGTCAAGAAGGTTTGCAAAGTAGAAAAAAACTTAGCAGACGTC 130 
gi|24940358|emb|Z37159.2|        AAGAGCCCGTCAAGAAGGTTTGCAAAGTAGAAAAAAACTTAGCAGACGTC 247 
gi|3851625|gb|AF097331.1|        AAGAGCCCGTCAAGAAGGTTTGCAAAGTAGAAAAAAACTTAGCAGACGTC 250 
gi|19913120|emb|AJ345058.1|      AAGAGCCCGTCAAGAAGGTTTGCAAAGTAGAAAAAAACTTAGCAGACGTC 130 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      GCAGGAATCGCTTTGGCCAAAATAAACAACCTGATAAAACAAGTATCGGC 180 
gi|24940358|emb|Z37159.2|        GCAGGAATCGCTTTGGCCAAAATAAACAACCTGATAAAACAAGTATCGGC 297 
gi|3851625|gb|AF097331.1|        GCAGGAATCGCTTTGGCCAAAATAAACAACCTGATAAAACAAGTATCGGC 300 
gi|19913120|emb|AJ345058.1|      GCAGGAATCGCTTTGGCCAAAATAAACAACCTGATAAAACAAGTATCGGC 180 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      AGCAACCGAAGCGGAAGCAAGAATGACCTTGGCCGCCGCAAGCACAGACC 230 
gi|24940358|emb|Z37159.2|        AGCAACCGAAGCGGAAGCAAGAATGACCTTGGCCGCCGCAAGCACAGACC 347 
gi|3851625|gb|AF097331.1|        AGCAACCGAAGCGGAAGCAAGAATGACCTTGGCCGCCGCAAGCACAGACC 350 
gi|19913120|emb|AJ345058.1|      AGCAACCGAAGCGGAAGCAAGACTGACCTTGGCCGCTGCAAGCACAGACC 230 
                                 ********************** ************* ************* 
                                           < LAMP SRA1 F3   >        < LAMP SRA1 F2 
 
gi|19913118|emb|AJ345057.1|      ACAGCAACATCTCAGCGCTTTATGCCGCGGCGTCAAACATAGTGACAAGA 280 
gi|24940358|emb|Z37159.2|        ACAGCAACATCTCAGCGCTTTATGCCGCGGCGTCAAACATAGTGACAAGA 397 
gi|3851625|gb|AF097331.1|        ACAGCAACATCTCAGCGCTTTATGCCGCGGCGTCAAACATAGTGACAAGA 400 
gi|19913120|emb|AJ345058.1|      ACAGCAACATCTCAGCGCTTTATGCCGCGGCGTCAAACATAGTGACAAGA 280 
                                 ************************************************** 
                                     >     <  LAMP SRA1 LF   >                   < 
 
gi|19913118|emb|AJ345057.1|      TGCGTACTCAACGCAGTCCACGCTCTTACAAGTCTTGCGCCAATAGCGTT 330 
gi|24940358|emb|Z37159.2|        TGCGTACTCAACGCAGTCCACGCTCTTACAAGTCTTGCGCCAATAGCGTT 447 
gi|3851625|gb|AF097331.1|        TGCGTACTCAACGCAGTCCACGCTCTTACAAGTCTTGCGCCAATAGCGTT 450 
gi|19913120|emb|AJ345058.1|      TGCGTACTCAACGCAGTCCACGCTCTTACAAGTCTTGCGCCAATAGCGTT 330 
                                 ************************************************** 
                                   LAMP SRA1 F1c   > <   LAMP SRA1 B1c   > 
 
gi|19913118|emb|AJ345057.1|      AACTGCAGCGACCAACGGAGCCAAAACCAGTGGGCACATCTCAGAAGTAA 380 
gi|24940358|emb|Z37159.2|        AACTGCAGCGACCAACGGAGCCAAAACCAGTGGGCACATCTCAGAAGTAA 497 
gi|3851625|gb|AF097331.1|        AACTGCAGCGACCAACGGAGCCAAAACCAGTGGGCACATCTCAGAAGTAA 500 
gi|19913120|emb|AJ345058.1|      AACTGCAGCGACCAACGGAGCCAAAACCAGTGGGCACATCTCAGAAGTAA 380 
                                 ************************************************** 
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                                     <  LAMP SRA1 LB  >     <   LAMP SRA1 B2   > 
 
gi|19913118|emb|AJ345057.1|      TCGACATTCTGCAGCAGGCGTCACAAGGTAAGACAGAAGGAAAGTGCATA 430 
gi|24940358|emb|Z37159.2|        TCGACATTCTGCAGCAGGCGTCACAAGGTAAGACAGAAGGAAAGTGCATA 547 
gi|3851625|gb|AF097331.1|        TCGACATTCTGCAGCAGGCGTCACAAGGTAAGACAGAAGGAAAGTGCATA 550 
gi|19913120|emb|AJ345058.1|      TCGACATTCTGCAGCAGGCGTCACAAGGTAAGACAGAAGGAAAGTGCATA 430 
                                 ************************************************** 
          <  LAMP SRA1 B3   > 
 
gi|19913118|emb|AJ345057.1|      GTGAAAAGCGGCGGCGGTACAACAACAGTAGCAATAAGGCAACTTTACAA 480 
gi|24940358|emb|Z37159.2|        GTGAAAAGCGGCGGCGGTACAACAACAGTAGCAATAAGGCAACTTTACAA 597 
gi|3851625|gb|AF097331.1|        GTGAAAAGCGGCGGCGGTACAACAACAGTAGCAATAAGGCAACTTTACAA 600 
gi|19913120|emb|AJ345058.1|      GTGAAAAGCGGCGGCGGTACAACAACAGTAGCAATAAGGCAACTTTACAA 480 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      CAAAATAGGGGACCTAGAAAAACAAACGACCAACAACTGCGGCACCAGCG 530 
gi|24940358|emb|Z37159.2|        CAAAATAGGGGACCTAGAAAAACAAACGACCAACAACTGCGGCACCAGCG 647 
gi|3851625|gb|AF097331.1|        CAAAATAGGGGACCTAGAAAAACAAACGACCAACAACTGCGGCACCAGCG 650 
gi|19913120|emb|AJ345058.1|      CAAAATAGGGGACCTAGAAAAACAAACGACCAACAACTGCGGCACCAGCG 530 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      TGACCGAAGTACTCGAACACATTCTAAAACAAGAAGCGCTCAAGGAAGCG 580 
gi|24940358|emb|Z37159.2|        TGACCGAAGTACTCGAACACATTCTAAAACAAGAAGCGCTCAAGGAAGCC 697 
gi|3851625|gb|AF097331.1|        TGACCGAAGTACTCGAACACATTCTAAAACAAGAAGCGCTCAAGGAAGCG 700 
gi|19913120|emb|AJ345058.1|      TGACCGAAGTACTCGAACACATTCTAAAACAAGAAGCGCTCAAGGAAGCG 580 
                                 *************************************************  
 
gi|19913118|emb|AJ345057.1|      CTACTTTCAATCGTGAAAAAACCAAAAGGGGCGCCAGACAAAACAGCAGC 630 
gi|24940358|emb|Z37159.2|        GTACTTTCAATCGTGAAAAAACCAAAAGGGGCGCCAGACAAAACAGCAGC 747 
gi|3851625|gb|AF097331.1|        CTACTTTCAATCGTGAAAAAACCAAAAGGGGCGCCAGACAAAACAGCAGC 750 
gi|19913120|emb|AJ345058.1|      CTACTTTCAATCGTGAAAAAACCAAAAGGGGCGCCAGACAAAACAGCAGC 630 
                                  ************************************************* 
 
gi|19913118|emb|AJ345057.1|      AGATGAATTGGTCACCGCGCTAATCAACGGCGTGGTGCCAAACAGCACAG 680 
gi|24940358|emb|Z37159.2|        AGATGAATTGGTCACCGCGCTAATCAACGGCGTGGTGCCAAACAGCACAG 797 
gi|3851625|gb|AF097331.1|        AGATGAATTGGTCACCGTGCTTATCAACGGCGTGGTGCCAAACAGCACAG 800 
gi|19913120|emb|AJ345058.1|      AGATGAAATGGTCACCGCGCTAATCAACGGCGTGGTGCCAAACAGCACAG 680 
                                 ******* ********* *** **************************** 
 
gi|19913118|emb|AJ345057.1|      CACAGACCCAAAAATTAAAGGAGAAAATTCTAAACACCTTGGTCCCCAAG 730 
gi|24940358|emb|Z37159.2|        CACAGACCCAAAAATTAAAGGAGAAAATTCTAAACACCTTGGTCCCCAAG 847 
gi|3851625|gb|AF097331.1|        CACAGACCCAAAAATTAAAGGAGAAAATTCTAAACACCTTGGTCCCCAAG 850 
gi|19913120|emb|AJ345058.1|      CACAGACCCAAAAATTAAAGGAGAAAATTCTAAACACCTTGGTCCCCAAG 730 
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                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      CTTGTGGAAGGCTCAAAAAGCCAAGTAAAACTAAGGATTCTGAAGTACCC 780 
gi|24940358|emb|Z37159.2|        CTTGTGGAAGGCTCAAAAAGCCAAGTAAAACTAAGGATTCTGAAGTACCC 897 
gi|3851625|gb|AF097331.1|        CTTGTGGAAGGCTCAAAAAGCCAAGTAAAACTAAGGATTCTGAAGTACCC 900 
gi|19913120|emb|AJ345058.1|      CTTGTGGAAGGCTCAAAAAGCCAAGTAAAACTAAGGATTCTGAAGTACCC 780 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      GGGAAAAATACAGAAAAGCAAACTCGTATCAATCCAAGAGTTAAAAACCC 830 
gi|24940358|emb|Z37159.2|        GGGAAAAATACAGAAAAGCAAACTCGTATCAATCCAAGAGTTAAAAACCC 947 
gi|3851625|gb|AF097331.1|        GGGAAAAATACAGAAAAGCAAACTCGTATCAATCCAAGAGTTAAAAACCC 950 
gi|19913120|emb|AJ345058.1|      GGGAAAAATACAGAAAAGCAAACTCGTATCAATCCAAGAGTTAAAAACCC 830 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      GAGTGGAGCCTGAATCTAGCACTGAAAGCTGCAAGCAGCAGGTCGCCACC 880 
gi|24940358|emb|Z37159.2|        GAGTGGAGCCTGAATCTAGCACTGAAAGCTGCAAGCAGCAGGTCGCCACC 997 
gi|3851625|gb|AF097331.1|        GAGTGGAGCCTGAATCTAGCACTGAAAGCTGCAAGCAGCAGGTCGCCACC 1000 
gi|19913120|emb|AJ345058.1|      GAGTGGAGCCTGAATCTAGCACTGAAAGCTGCAAGCAGCAGGTCGCCACC 880 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      AACCAGGCACAGGAGGCATTTTGTAACGCAATTGGCGACGACAAAGACAA 930 
gi|24940358|emb|Z37159.2|        AACCAGGCACAGGAGGCATTTTGTAACGCAATTGGCGACGACAAAGACAA 1047 
gi|3851625|gb|AF097331.1|        AACCAGGCACAGGAGGCATTTTGTAACGCAATTGGCGACGACAAAGACAA 1050 
gi|19913120|emb|AJ345058.1|      AACCAGGCACAGGAGGCATTTTGTAACGCAATTGGCGACGACAAAGACAA 930 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      GTGTAACAATGAGACACGATGCAGTTACGATGACAGCAAAGGCTCAGACA 980 
gi|24940358|emb|Z37159.2|        GTGTAACAATGAGACACGATGCAGTTACGATGACAGCAAAGGCTCAGACA 1097 
gi|3851625|gb|AF097331.1|        GGGTAACAATGAGACACGATGCAGTTACGATGACAGCAAAGGCTCAGACA 1100 
gi|19913120|emb|AJ345058.1|      GTGTAACAATGAGAAACGATGCAGTTACGATGACAGCAAAGGCTCAGGAA 980 
                                 * ************ ********************************  * 
 
gi|19913118|emb|AJ345057.1|      AAAAGTGCACATATAATGCGGAAAAAGCAGAAGCAAATGGGGCACCTGCA 1030 
gi|24940358|emb|Z37159.2|        AAAAGTGCACATATAATGCGGAAAAAGCAGAAGCAAATGGGGCACCTGCA 1147 
gi|3851625|gb|AF097331.1|        AAAAGTGCACATATAATGCGGAAAAAGCGGAAGCAAATGGGGCACCTGCA 1150 
gi|19913120|emb|AJ345058.1|      AAAAGTGCACATATAATGCCACAAAAGCCGCAGAAAATGGAGTTCCTGCA 1030 
                                 *******************   ****** * ** ****** *  ****** 
 
gi|19913118|emb|AJ345057.1|      ACGCAACCTCAAGGGGGAGTGAACGAAGCAACAACAGGAAATTGTAAAGG 1080 
gi|24940358|emb|Z37159.2|        ACGCAACCTCAAGGGGGAGTGAACGAAGCAACAACAGGAAATTGTAAAGG 1197 
gi|3851625|gb|AF097331.1|        ACGCAACCTCAAGGGGGAGTGAACGAAGCAACAACAGGAAATTGTAAAGG 1200 
gi|19913120|emb|AJ345058.1|      ACGCAACATCAAACGGGAGGGACTGAAGCAACAACAGGAAATTGTAAAGG 1080 
                                 ******* ****  ***** **  ************************** 




gi|19913118|emb|AJ345057.1|      GAAACTGGAACCCGGATGCACCAAGGCACAAGAATACGAATGGGAAGGAA 1130 
gi|24940358|emb|Z37159.2|        GAAACTGGAACCCGGATGCACCAAGGCACAAGAATACGAATGGGAAGGAA 1247 
gi|3851625|gb|AF097331.1|        GAAACTGGAACCCGGATGCACCAAGGCACAAGAATACGAATGGGAAGGAA 1250 
gi|19913120|emb|AJ345058.1|      GAAACTGGAACCCGGATGCACCAAGGCACAAGAATACGAATGGGAAGGAA 1130 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      AAGAATCCAAAGATTCAAGTTTTCTTGTGGATATGAAATTGGCTCTGAAT 1180 
gi|24940358|emb|Z37159.2|        AAGAATCCAAAGATTCAAGTTTTCTTGTGGATATGAAATTGGCTCTGAAT 1297 
gi|3851625|gb|AF097331.1|        AAGAATCCAAAGATTCAAGTTTTCTTGTGGATATGAAATTGGCTCTGAAT 1300 
gi|19913120|emb|AJ345058.1|      AAGAATCCAAAGATTCAAGTTTTCTTGTGGATATGAAATTGGCTCTGAAT 1180 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      ATGGTTGCTG---------------------------------------- 1190 
gi|24940358|emb|Z37159.2|        ATGGTTGCTGCTTTTGTGGCCTTTCTGTTTTAATTTTCACCTCTTTTGAA 1347 
gi|3851625|gb|AF097331.1|        ATGGTTGCTGCTTTTGTGGCCTTTCTGTTTTAATTTTCACCTCTTTTGAA 1350 
gi|19913120|emb|AJ345058.1|      ATGGTTGCTG---------------------------------------- 1190 
                                 **********                                         
 
gi|19913118|emb|AJ345057.1|      -------------------------------------------------- 
gi|24940358|emb|Z37159.2|        AGAACTTTGCTGTTTCATATACTTTAACACATTTTCATGAATTTGTGAAA 1397 
gi|3851625|gb|AF097331.1|        AGAACTTTGCTGTTTCATATACTTTAACACATTTTCATGAATTTGTGAA- 1399 
gi|19913120|emb|AJ345058.1|      -------------------------------------------------- 
                                                                                    
 
gi|19913118|emb|AJ345057.1|      - 
gi|24940358|emb|Z37159.2|        A 1398 
gi|3851625|gb|AF097331.1|        - 
gi|19913120|emb|AJ345058.1|      - 





SeqA Name                          Len(nt)  SeqB Name                          Len(nt)  Score 
============================================================================================= 
1    gi|19913120|emb|AJ345058.1|   1190     2    gi|19913118|emb|AJ345057.1|   1190     98    
1    gi|19913120|emb|AJ345058.1|   1190     3    gi|24940358|emb|Z37159.2|     1398     97    
1    gi|19913120|emb|AJ345058.1|   1190     4    gi|3851625|gb|AF097331.1|     1399     97    
2    gi|19913118|emb|AJ345057.1|   1190     3    gi|24940358|emb|Z37159.2|     1398     99    
2    gi|19913118|emb|AJ345057.1|   1190     4    gi|3851625|gb|AF097331.1|     1399     99    
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3    gi|24940358|emb|Z37159.2|     1398     4    gi|3851625|gb|AF097331.1|     1399     99    
============================================================================================= 
 
CLUSTAL 2.0.12 multiple sequence alignment 
 
 
gi|19913118|emb|AJ345057.1|      -------------------------------------------------- 
gi|24940358|emb|Z37159.2|        CGCTATTATTAGAACAGTTTCTGTACTATATTGA---CACATCTCTAAGA 47 
gi|3851625|gb|AF097331.1|        CGCTATTATTAGAACAGTTTCTGTACTATATTGAAGACACACCTCTAAGA 50 
gi|19913120|emb|AJ345058.1|      -------------------------------------------------- 
                                                                                    
 
gi|19913118|emb|AJ345057.1|      -------------------------------------------------- 
gi|24940358|emb|Z37159.2|        ATCACAATAGCAAGGCGAACCGAAAGCGAAGCACAGTTAACGTAACAGCA 97 
gi|3851625|gb|AF097331.1|        ATCACAATAGCAAGGCGAACCGAAAGCGAAGCACAGTTAACGTAACAGCA 100 
gi|19913120|emb|AJ345058.1|      -------------------------------------------------- 
                                                                                    
 
gi|19913118|emb|AJ345057.1|      --------------------GACAACAAGTACCTTGGCGCTCGCGCTGGC 30 
gi|24940358|emb|Z37159.2|        ATGCCCCGAAATTCGGGCCGGACAACAAGTACCTTGGCGCTCGCCGTGGC 147 
gi|3851625|gb|AF097331.1|        ATGCCCCGAAATTCGGGCCGGACAACAAGTACCTTGGCGCTCGCGCTGGC 150 
gi|19913120|emb|AJ345058.1|      --------------------GACAACAAGTACCTTGGCGCTCGCGCTGGC 30 
                                                     ************************  **** 
 
gi|19913118|emb|AJ345057.1|      CCTAAAGCTGCTGGCAGTGCCTGTATCGCCCAGTGGCACCGCCTTTGACG 80 
gi|24940358|emb|Z37159.2|        CCTAAAGCTGCTGGCAGTGCCTGTATCGCCCAGTGGCACCGCCTTTGACG 197 
gi|3851625|gb|AF097331.1|        CCTAAAGCTGCTGGCAGTGCCTGTATCGCCCAGTGGCACCGCCTTTGACG 200 
gi|19913120|emb|AJ345058.1|      CCTAAAGCTGCTGGCAGTGCCTGTATCGCCCAGTGGCCCCGCCTTTGACG 80 
                                 ************************************* ************ 
 
gi|19913118|emb|AJ345057.1|      AAGAGCCCGTCAAGAAGGTTTGCAAAGTAGAAAAAAACTTAGCAGACGTC 130 
gi|24940358|emb|Z37159.2|        AAGAGCCCGTCAAGAAGGTTTGCAAAGTAGAAAAAAACTTAGCAGACGTC 247 
gi|3851625|gb|AF097331.1|        AAGAGCCCGTCAAGAAGGTTTGCAAAGTAGAAAAAAACTTAGCAGACGTC 250 
gi|19913120|emb|AJ345058.1|      AAGAGCCCGTCAAGAAGGTTTGCAAAGTAGAAAAAAACTTAGCAGACGTC 130 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      GCAGGAATCGCTTTGGCCAAAATAAACAACCTGATAAAACAAGTATCGGC 180 
gi|24940358|emb|Z37159.2|        GCAGGAATCGCTTTGGCCAAAATAAACAACCTGATAAAACAAGTATCGGC 297 
gi|3851625|gb|AF097331.1|        GCAGGAATCGCTTTGGCCAAAATAAACAACCTGATAAAACAAGTATCGGC 300 
gi|19913120|emb|AJ345058.1|      GCAGGAATCGCTTTGGCCAAAATAAACAACCTGATAAAACAAGTATCGGC 180 
                                 ************************************************** 




gi|19913118|emb|AJ345057.1|      AGCAACCGAAGCGGAAGCAAGAATGACCTTGGCCGCCGCAAGCACAGACC 230 
gi|24940358|emb|Z37159.2|        AGCAACCGAAGCGGAAGCAAGAATGACCTTGGCCGCCGCAAGCACAGACC 347 
gi|3851625|gb|AF097331.1|        AGCAACCGAAGCGGAAGCAAGAATGACCTTGGCCGCCGCAAGCACAGACC 350 
gi|19913120|emb|AJ345058.1|      AGCAACCGAAGCGGAAGCAAGACTGACCTTGGCCGCTGCAAGCACAGACC 230 
                                 ********************** ************* ************* 
 
gi|19913118|emb|AJ345057.1|      ACAGCAACATCTCAGCGCTTTATGCCGCGGCGTCAAACATAGTGACAAGA 280 
gi|24940358|emb|Z37159.2|        ACAGCAACATCTCAGCGCTTTATGCCGCGGCGTCAAACATAGTGACAAGA 397 
gi|3851625|gb|AF097331.1|        ACAGCAACATCTCAGCGCTTTATGCCGCGGCGTCAAACATAGTGACAAGA 400 
gi|19913120|emb|AJ345058.1|      ACAGCAACATCTCAGCGCTTTATGCCGCGGCGTCAAACATAGTGACAAGA 280 
                                 ************************************************** 
                                         <  SRALAMP_a F3  >    < SRALAMP_a   
 
gi|19913118|emb|AJ345057.1|      TGCGTACTCAACGCAGTCCACGCTCTTACAAGTCTTGCGCCAATAGCGTT 330 
gi|24940358|emb|Z37159.2|        TGCGTACTCAACGCAGTCCACGCTCTTACAAGTCTTGCGCCAATAGCGTT 447 
gi|3851625|gb|AF097331.1|        TGCGTACTCAACGCAGTCCACGCTCTTACAAGTCTTGCGCCAATAGCGTT 450 
gi|19913120|emb|AJ345058.1|      TGCGTACTCAACGCAGTCCACGCTCTTACAAGTCTTGCGCCAATAGCGTT 330 
                                 ************************************************** 
                                   F2  >< SRALAMP_a LF  >     <   SRALAMP_a F1c  > 
 
gi|19913118|emb|AJ345057.1|      AACTGCAGCGACCAACGGAGCCAAAACCAGTGGGCACATCTCAGAAGTAA 380 
gi|24940358|emb|Z37159.2|        AACTGCAGCGACCAACGGAGCCAAAACCAGTGGGCACATCTCAGAAGTAA 497 
gi|3851625|gb|AF097331.1|        AACTGCAGCGACCAACGGAGCCAAAACCAGTGGGCACATCTCAGAAGTAA 500 
gi|19913120|emb|AJ345058.1|      AACTGCAGCGACCAACGGAGCCAAAACCAGTGGGCACATCTCAGAAGTAA 380 
                                 ************************************************** 
                                                          <   SRALAMP_a B1c  ><  
 
gi|19913118|emb|AJ345057.1|      TCGACATTCTGCAGCAGGCGTCACAAGGTAAGACAGAAGGAAAGTGCATA 430 
gi|24940358|emb|Z37159.2|        TCGACATTCTGCAGCAGGCGTCACAAGGTAAGACAGAAGGAAAGTGCATA 547 
gi|3851625|gb|AF097331.1|        TCGACATTCTGCAGCAGGCGTCACAAGGTAAGACAGAAGGAAAGTGCATA 550 
gi|19913120|emb|AJ345058.1|      TCGACATTCTGCAGCAGGCGTCACAAGGTAAGACAGAAGGAAAGTGCATA 430 
                                 ************************************************** 
                                 SRALAMP_a LB    >             <   SRALAMP_a  B2  > 
 
 
gi|19913118|emb|AJ345057.1|      GTGAAAAGCGGCGGCGGTACAACAACAGTAGCAATAAGGCAACTTTACAA 480 
gi|24940358|emb|Z37159.2|        GTGAAAAGCGGCGGCGGTACAACAACAGTAGCAATAAGGCAACTTTACAA 597 
gi|3851625|gb|AF097331.1|        GTGAAAAGCGGCGGCGGTACAACAACAGTAGCAATAAGGCAACTTTACAA 600 
gi|19913120|emb|AJ345058.1|      GTGAAAAGCGGCGGCGGTACAACAACAGTAGCAATAAGGCAACTTTACAA 480 
                                 ************************************************** 
                                                     <   SRALAMP_a B3   > 
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gi|19913118|emb|AJ345057.1|      CAAAATAGGGGACCTAGAAAAACAAACGACCAACAACTGCGGCACCAGCG 530 
gi|24940358|emb|Z37159.2|        CAAAATAGGGGACCTAGAAAAACAAACGACCAACAACTGCGGCACCAGCG 647 
gi|3851625|gb|AF097331.1|        CAAAATAGGGGACCTAGAAAAACAAACGACCAACAACTGCGGCACCAGCG 650 
gi|19913120|emb|AJ345058.1|      CAAAATAGGGGACCTAGAAAAACAAACGACCAACAACTGCGGCACCAGCG 530 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      TGACCGAAGTACTCGAACACATTCTAAAACAAGAAGCGCTCAAGGAAGCG 580 
gi|24940358|emb|Z37159.2|        TGACCGAAGTACTCGAACACATTCTAAAACAAGAAGCGCTCAAGGAAGCC 697 
gi|3851625|gb|AF097331.1|        TGACCGAAGTACTCGAACACATTCTAAAACAAGAAGCGCTCAAGGAAGCG 700 
gi|19913120|emb|AJ345058.1|      TGACCGAAGTACTCGAACACATTCTAAAACAAGAAGCGCTCAAGGAAGCG 580 
                                 *************************************************  
 
gi|19913118|emb|AJ345057.1|      CTACTTTCAATCGTGAAAAAACCAAAAGGGGCGCCAGACAAAACAGCAGC 630 
gi|24940358|emb|Z37159.2|        GTACTTTCAATCGTGAAAAAACCAAAAGGGGCGCCAGACAAAACAGCAGC 747 
gi|3851625|gb|AF097331.1|        CTACTTTCAATCGTGAAAAAACCAAAAGGGGCGCCAGACAAAACAGCAGC 750 
gi|19913120|emb|AJ345058.1|      CTACTTTCAATCGTGAAAAAACCAAAAGGGGCGCCAGACAAAACAGCAGC 630 
                                  ************************************************* 
 
gi|19913118|emb|AJ345057.1|      AGATGAATTGGTCACCGCGCTAATCAACGGCGTGGTGCCAAACAGCACAG 680 
gi|24940358|emb|Z37159.2|        AGATGAATTGGTCACCGCGCTAATCAACGGCGTGGTGCCAAACAGCACAG 797 
gi|3851625|gb|AF097331.1|        AGATGAATTGGTCACCGTGCTTATCAACGGCGTGGTGCCAAACAGCACAG 800 
gi|19913120|emb|AJ345058.1|      AGATGAAATGGTCACCGCGCTAATCAACGGCGTGGTGCCAAACAGCACAG 680 
                                 ******* ********* *** **************************** 
 
gi|19913118|emb|AJ345057.1|      CACAGACCCAAAAATTAAAGGAGAAAATTCTAAACACCTTGGTCCCCAAG 730 
gi|24940358|emb|Z37159.2|        CACAGACCCAAAAATTAAAGGAGAAAATTCTAAACACCTTGGTCCCCAAG 847 
gi|3851625|gb|AF097331.1|        CACAGACCCAAAAATTAAAGGAGAAAATTCTAAACACCTTGGTCCCCAAG 850 
gi|19913120|emb|AJ345058.1|      CACAGACCCAAAAATTAAAGGAGAAAATTCTAAACACCTTGGTCCCCAAG 730 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      CTTGTGGAAGGCTCAAAAAGCCAAGTAAAACTAAGGATTCTGAAGTACCC 780 
gi|24940358|emb|Z37159.2|        CTTGTGGAAGGCTCAAAAAGCCAAGTAAAACTAAGGATTCTGAAGTACCC 897 
gi|3851625|gb|AF097331.1|        CTTGTGGAAGGCTCAAAAAGCCAAGTAAAACTAAGGATTCTGAAGTACCC 900 
gi|19913120|emb|AJ345058.1|      CTTGTGGAAGGCTCAAAAAGCCAAGTAAAACTAAGGATTCTGAAGTACCC 780 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      GGGAAAAATACAGAAAAGCAAACTCGTATCAATCCAAGAGTTAAAAACCC 830 
gi|24940358|emb|Z37159.2|        GGGAAAAATACAGAAAAGCAAACTCGTATCAATCCAAGAGTTAAAAACCC 947 
gi|3851625|gb|AF097331.1|        GGGAAAAATACAGAAAAGCAAACTCGTATCAATCCAAGAGTTAAAAACCC 950 
gi|19913120|emb|AJ345058.1|      GGGAAAAATACAGAAAAGCAAACTCGTATCAATCCAAGAGTTAAAAACCC 830 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      GAGTGGAGCCTGAATCTAGCACTGAAAGCTGCAAGCAGCAGGTCGCCACC 880 
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gi|24940358|emb|Z37159.2|        GAGTGGAGCCTGAATCTAGCACTGAAAGCTGCAAGCAGCAGGTCGCCACC 997 
gi|3851625|gb|AF097331.1|        GAGTGGAGCCTGAATCTAGCACTGAAAGCTGCAAGCAGCAGGTCGCCACC 1000 
gi|19913120|emb|AJ345058.1|      GAGTGGAGCCTGAATCTAGCACTGAAAGCTGCAAGCAGCAGGTCGCCACC 880 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      AACCAGGCACAGGAGGCATTTTGTAACGCAATTGGCGACGACAAAGACAA 930 
gi|24940358|emb|Z37159.2|        AACCAGGCACAGGAGGCATTTTGTAACGCAATTGGCGACGACAAAGACAA 1047 
gi|3851625|gb|AF097331.1|        AACCAGGCACAGGAGGCATTTTGTAACGCAATTGGCGACGACAAAGACAA 1050 
gi|19913120|emb|AJ345058.1|      AACCAGGCACAGGAGGCATTTTGTAACGCAATTGGCGACGACAAAGACAA 930 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      GTGTAACAATGAGACACGATGCAGTTACGATGACAGCAAAGGCTCAGACA 980 
gi|24940358|emb|Z37159.2|        GTGTAACAATGAGACACGATGCAGTTACGATGACAGCAAAGGCTCAGACA 1097 
gi|3851625|gb|AF097331.1|        GGGTAACAATGAGACACGATGCAGTTACGATGACAGCAAAGGCTCAGACA 1100 
gi|19913120|emb|AJ345058.1|      GTGTAACAATGAGAAACGATGCAGTTACGATGACAGCAAAGGCTCAGGAA 980 
                                 * ************ ********************************  * 
 
gi|19913118|emb|AJ345057.1|      AAAAGTGCACATATAATGCGGAAAAAGCAGAAGCAAATGGGGCACCTGCA 1030 
gi|24940358|emb|Z37159.2|        AAAAGTGCACATATAATGCGGAAAAAGCAGAAGCAAATGGGGCACCTGCA 1147 
gi|3851625|gb|AF097331.1|        AAAAGTGCACATATAATGCGGAAAAAGCGGAAGCAAATGGGGCACCTGCA 1150 
gi|19913120|emb|AJ345058.1|      AAAAGTGCACATATAATGCCACAAAAGCCGCAGAAAATGGAGTTCCTGCA 1030 
                                 *******************   ****** * ** ****** *  ****** 
 
gi|19913118|emb|AJ345057.1|      ACGCAACCTCAAGGGGGAGTGAACGAAGCAACAACAGGAAATTGTAAAGG 1080 
gi|24940358|emb|Z37159.2|        ACGCAACCTCAAGGGGGAGTGAACGAAGCAACAACAGGAAATTGTAAAGG 1197 
gi|3851625|gb|AF097331.1|        ACGCAACCTCAAGGGGGAGTGAACGAAGCAACAACAGGAAATTGTAAAGG 1200 
gi|19913120|emb|AJ345058.1|      ACGCAACATCAAACGGGAGGGACTGAAGCAACAACAGGAAATTGTAAAGG 1080 
                                 ******* ****  ***** **  ************************** 
 
gi|19913118|emb|AJ345057.1|      GAAACTGGAACCCGGATGCACCAAGGCACAAGAATACGAATGGGAAGGAA 1130 
gi|24940358|emb|Z37159.2|        GAAACTGGAACCCGGATGCACCAAGGCACAAGAATACGAATGGGAAGGAA 1247 
gi|3851625|gb|AF097331.1|        GAAACTGGAACCCGGATGCACCAAGGCACAAGAATACGAATGGGAAGGAA 1250 
gi|19913120|emb|AJ345058.1|      GAAACTGGAACCCGGATGCACCAAGGCACAAGAATACGAATGGGAAGGAA 1130 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      AAGAATCCAAAGATTCAAGTTTTCTTGTGGATATGAAATTGGCTCTGAAT 1180 
gi|24940358|emb|Z37159.2|        AAGAATCCAAAGATTCAAGTTTTCTTGTGGATATGAAATTGGCTCTGAAT 1297 
gi|3851625|gb|AF097331.1|        AAGAATCCAAAGATTCAAGTTTTCTTGTGGATATGAAATTGGCTCTGAAT 1300 
gi|19913120|emb|AJ345058.1|      AAGAATCCAAAGATTCAAGTTTTCTTGTGGATATGAAATTGGCTCTGAAT 1180 
                                 ************************************************** 
 
gi|19913118|emb|AJ345057.1|      ATGGTTGCTG---------------------------------------- 1190 
gi|24940358|emb|Z37159.2|        ATGGTTGCTGCTTTTGTGGCCTTTCTGTTTTAATTTTCACCTCTTTTGAA 1347 
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gi|3851625|gb|AF097331.1|        ATGGTTGCTGCTTTTGTGGCCTTTCTGTTTTAATTTTCACCTCTTTTGAA 1350 
gi|19913120|emb|AJ345058.1|      ATGGTTGCTG---------------------------------------- 1190 
                                 **********                                         
 
gi|19913118|emb|AJ345057.1|      -------------------------------------------------- 
gi|24940358|emb|Z37159.2|        AGAACTTTGCTGTTTCATATACTTTAACACATTTTCATGAATTTGTGAAA 1397 
gi|3851625|gb|AF097331.1|        AGAACTTTGCTGTTTCATATACTTTAACACATTTTCATGAATTTGTGAA- 1399 
gi|19913120|emb|AJ345058.1|      -------------------------------------------------- 
                                                                                    
 
gi|19913118|emb|AJ345057.1|      - 
gi|24940358|emb|Z37159.2|        A 1398 
gi|3851625|gb|AF097331.1|        - 
gi|19913120|emb|AJ345058.1|      - 
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Appendix 11. Previous isoenzyme analyses of T. b. gambiense 
stocks used in this study 
 (Group 2 T. b. gambiense highlighted in bold) 
From Godfrey et al. 1987 [248] 
Sample Virulence 
to rodents 
ALAT ASAT ICD  PEP1 PEP2 PGM ME NH SOD 
12. 
Biyamina 
Low 1 2 2 13 9 2 2 1 3 
21. Musikia 
Cl A 
Low 1 2 2 13 9 2 2 1 3 
22. Suzena Low 1 2 2 13 9 2 2 1 3 
58. Musikia 
Cl B 
Low 1 2 2 13 9 2 2 1 3 
62. Muraz 
15 
Low 1 2 2 1 6 2 2 3 Not 
done 
75. Muraz 3 High 2 1 2 2 1 6 1 1 Not 
done 
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From Mehlitz et al. 1982 [246] 
Sample ALAT  ASAT ICD  PEP1 PEP2 PGM ME Zymodeme 
5. Dal069 I II II I VI II II A 
17. 
TH149 
I III II I VI II II D 
19. TSW 
83 
II I II I I II XV C 
61. 
TH112 
X I II II I II I I 
 
From Godfrey and Kilgour, 1976 [252] 
Sample ALAT ASAT 
18. Bida 3 I II 
23. Tsuaa I I 
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Appendix 12 Results from the Trypanozoon and T. b. 
gambiense PCR and LAMP assays. 
PCR LAMP TBG1 Sample [DNA] 
(ng μl-1) TBR TgsGP 
LAMP 
PfrA (Tt) Tt Gel 
1. Tira 24 6.48 + - 00:37:24 01:22:00 + 
2. Sikuda 28 47.25 + - 00:37:36 01:23:48 + 
3. UGC 0.01 + - 00:35:12 01:12:06 + 
4. UGI 1.01 + - 00:36:36 01:07:12 + 
5. Dal069 IM52 73.49 + + 00:36:48 01:08:30 + 
6. Papol 33 21.96 + - 00:35:54 01:07:42 + 
7. Bumanda 146 60.14 + - 00:36:00 01:11:12 + 
8. Papol 264 69.57 + - 00:36:24 01:09:06 + 
9. UGA 88 22.53 + - 00:45:36 01:01:42 + 
10. E. Oketch 15.21 + - 00:50:06 01:13:42 + 
11. Papol 285 12.12 + - 00:48:18 01:19:24 + 
12. Biyamina 26.87 + - 00:47:54 01:13:36 - 
13. Mela 3 24.09 + - 00:48:54 01:23:30 + 
14. Papol 103 5.77 + - 00:51:00 01:15:42 + 
15. Mawero 66 18.37 + - 00:49:18 01:17:24 + 
16. Mela 71 IM87 23.3 + - 00:48:06 01:07:48 + 
17. TH149 20.31 + + 00:42:42 01:10:18 - 
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18. Bida 3 Clone A 53.14 - + 00:46:12 01:17:42 - 
19. TSW83 27.45 + - 00:40:06 00:54:24 - 
20. Katerema 311 7.39 + + 00:46:00 00:00:00 + 
21. Musikia Clone A 5.72 - + 00:52:24 00:00:00 - 
22. Suzena 8.13 + + 00:52:48 00:00:00 - 
23. Tsuaa 14.77 + + 00:49:00 01:13:48 + 
24. Mawero 32 4.62 + - 00:43:36 01:10:18 + 
25. Papol 42 1.7 + - 00:34:36 01:25:30 + 
26. UGK 9.57 + - 00:33:12 01:25:24 + 
27. Papol 60 0.32 + - 00:31:54 01:10:54 + 
28. UR4 49.11 + - 00:32:36 01:18:30 + 
29. F97 2.75 + - 00:32:12 01:05:12 + 
30. Mawero 80 5.49 + - 00:33:24 01:11:42 - 
31. Papol 278 7.64 + - 00:42:00 01:12:48 - 
32. URI 18.15 + - 00:40:54 01:05:54 + 
33. UGH 1.87 + + 00:29:18 01:17:06 + 
34. Mela Pig 7.19 + - 00:30:36 00:00:00 - 
35. Tira 22 4.44 + - 00:29:00 01:12:00 - 
36. Mela 66 6.01 + - 00:29:24 01:20:42 - 
37. Uganda B 8.66 + - 00:28:00 01:17:00 + 
38. Mela 24 4.34 + - 00:28:42 01:12:54 - 
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39. Iyolowa 125 13.15 + - 00:28:54 01:17:54 + 
40. Tira 168 4.98 + - 00:27:42 01:14:30 - 
41. Papol 12 1.45 + - 00:31:12 01:18:12 - 
42. Mela 27 5 + - 00:31:30 01:15:54 + 
43. Poyem 11 10.6 + - 00:31:36 01:19:54 + 
44. Tira 4 5.13 + - 00:31:06 01:12:30 - 
45. Mela pig 2 17.89 + - 00:30:18 01:07:30 + 
46. UGE 6.05 + - 00:28:48 01:08:42 + 
47. Katerema 72 1.92 + - 00:31:54 01:22:42 + 
48. Mawero 42 7.92 + - 00:30:36 01:13:06 - 
49. Tira 34 1.71 + - 00:38:18 00:00:00 - 
50. H.Taka 20.26 + - 00:29:42 01:09:54 - 
51. Uganda A 9.04 + - 00:30:30 01:19:54 - 
52. A Kiburige 26.28 + - 00:31:54 01:13:12 - 
53. Uganda E 6.04 + - 00:30:42 01:08:06 - 
54. Katerema 116 14.12 + - 00:30:24 01:25:06 + 
55. Tira 43 5.81 + - 00:30:42 01:22:54 - 
56. Tira 92 13.14 + - 00:00:00 00:00:00 - 
57. Tira 75 4.93 + - 00:36:30 01:24:12 + 
58. Musikia Clone B 9.11 + + 00:30:00 01:28:12 - 
59. Iyolowa 116 3.94 + - 00:25:48 00:00:00 - 
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60. Iyolowa 153 5.36 + - 00:27:48 01:27:12 - 
61. TH 112 IM56 21.32 + - 00:29:00 01:17:48 + 
62. Muraz 15 IM47 24.87 + - 00:00:00 01:16:12 - 
63. Mela 12 6.78 + - 00:35:48 01:22:42 - 
64. Mawero 31 24.32 + - 00:33:54 01:19:00 + 
65. F73 7.7 + - 00:49:42 00:00:00 + 
66. Tira 27 30.69 + - 00:53:54 00:00:00 - 
67. Uganda L 3.19 + - 00:46:54 01:19:54 + 
68. F48 8.76 + - 00:47:12 01:18:42 + 
69. Tira 68 11.96 + - 00:47:30 01:25:06 - 
70. Tira 30 1.52 + - 00:48:00 00:00:00 - 
71. Tira 29 1.55 - - 00:00:00 00:00:00 - 
72. Papol 371 144.78 + - 00:00:00 00:00:00 - 
73. Mawero 85 6.83 + - 00:49:00 00:00:00 + 
74. Iyolowa 147 1.33 + - 00:45:54 00:00:00 - 
75. Muraz 3 IM46 29.59 + - 00:46:00 01:27:48 + 
76. Katerema 41 5.51 + - 00:47:24 00:00:00 + 
77. UGG 88 24.29 + - 00:47:54 00:00:00 + 
78. Mela 2 3.73 + - 00:49:06 01:09:30 - 
79. Uganda M 2.17 + - 00:52:06 01:28:12 - 
80. Rose Akinare 2.39 + - 00:48:18 01:11:48 - 
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81. Uganda B 0.79 + - 00:44:54 01:11:12 + 
82. Papol 144 2.88 + - 00:46:12 01:15:24 + 
83. Uganda C 9.76 + - 00:47:00 01:14:54 - 
84. Sikuda 42.90 8.99 + - 00:44:42 01:23:00 + 
85. Sikuda 4 6.3 - - 00:00:00 00:00:00 - 
86. D. Obwang 8.2 + - 00:41:12 01:12:00 + 
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Appendix 13. Primer binding sites for LAMP TBG1 primers. 









Figure 1. LAMP TBG1 primer binding sites for four T. b. brucei and four T. 
b. gambiense ITS1-5.8S rRNA-ITS2 sequences from Agbo et al. [249] 
Key: The C3A insertion in T. b. gambiense is highlighted in capital letters. The primer 
binding sites are indicated in colour according to Table 1 above. Differences between 
primer and sequence are underlined. 
 
T. b. brucei H3, AF306770 
   1 tggtgcaata caggtgatcg gaccgtcgct cgtctcgggc gaccgaagtt caccgatatt 
  61 gcttcaatag aggaagcaaa agtcgtaaca aggtagctgt aggtgaacct gcagctggat 
 121 cattttctga tatccattat acaaaaaaga gcgtatttat gtgcatgtat aattgcacag 
 181 tatgcaacca aaaatataca tatatgtttt acatgtatgt gtttctacat gccgtttgac 
 241 atgggagatg agggatgtta tatatagttc tgttattttc taatatgtat gtgtgttaga 
 301 gtgtctgtgt taatatactt tttaatgcat gctctacata atatacagta gtaataacaa 
 361 agagaatacg tatggaatgc gtatctctct atctatatat atatatgtat atatgctatg 
Primer Binding site 
F3 AAGCTCTCTCGAGCCATC 
F2 ATGCCACAT TTCTCAGTGT 
F1c CACCTATTTTGTGTTGTTCAACGC 
B1c CCACCTCT TCTCCTCGTGTG 
B2 TACGATATCTTTCATCTCTTTCTTC
B3 TCGCACATCTTGTGTATGTCA 
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 421 tgtatatcaa cctcgcatat tttctccctg ttgaccacgg ctcccacaac gtgtcgcgat 
 481 ggatgacttg gcttcctatt tcgttgaaga acgcagcaaa gtgcgataag tggtatcaat 
 541 tgcagaatca tttcattgat ctttgaacgC AAAcggcgca tgggagaagc tctctcgagc 
 601 catccccgtg catgccacat ttctcagtgt cgaatataaa aacaaaacgc acacctattt 
 661 tttgtgttgt aaaacgcacg cacaaaatcc cgccctctct tcttctcgtg tggtgcatat 
721 atgtgtgtga gagtgcacac atatacgata t_tttcaactg tttctactca cacaa_tggtg 
 781 tgtgacacgc atatacgtgt gtgtagagag atatggaaga gagaggaagg ggcatatata 
 841 tatatacaca caaaatatat gtgtggattt gtgtgttgag cacatataag gaaaaaggtt 
 901 gtgtgtatat acagagagtc tgtggcggtt gggacatgtg tataaatata tatgtatatg 
 961 tgtgtgttcc gctgtggaga ttttatatct tacggagagt gttcatatat atgtttgtag 
1021 gcatgtattt tggcgccccg tatagagatt aaaaaagaag agaaaaagta tgcaaaagag 
1081 gcggcggata ggtgtgtatg tgtgtatcac agcaagcaac tatattttgc tgcttgtgag 
1141 tatatgcata tatgtacatt atgtgcttgt gcttctttcg tgtacgcttc acttttttat 
1201 attgcatttt tcagacctga gtgtggcagg accacccgct aaacttaagc atattactca 
 1261 gcggaggaaa agaaaacaac cg 
 
T. b. brucei STIB215, AF306771 
      1 tggtgcaata caggtgatcg gaccgtcgct cgtctcgggc gaccgaaagt tcaccgatat 
  61 tgcttcaata gaggaagcaa aagtcgtaac aaggtagctg taggtgaacc tgcagctgga 
 121 tcattttctg atatccatta tacaaaaaag agcatattta tgtgcatgta taattgcaca 
 181 gtatgcaacc aaaaatatac atatatgttt tacatgtatg tgtttctata tgccgtttga 
 241 catgggagat gagggatgtt atatatagtt ctgttatttt ctaatatgta tgtgtgttag 
 301 agtgtctgtg ttaatatact ttttaatgca tgctctacat aatatacagt agtaataaca 
 361 aagagaatac gtatgtaatg cgtatctctc tatatatata tatatgtata tatgctatgt 
 421 gtatatcaac ctccgcatat tttctccctg ttgaccacgg ctcccacaac gtgtcgcgat 
 481 ggatgacttg gcttcctatt tcgttgaaga acgcagcaaa gtgcgataag tggtatcaat 
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 541 tgcagaatca tttcattgat ctttgaacgC AAAcggcgca tgggagaagc tctctcgagc 
 601 catccccgtg catgccacat ttctcagtgt cgaatataaa aacaaaacac acacctattt 
 661 tttgtgttgt tcaacgcacg cacaaaatcc cgccacctct tctcctcgtg tggtgcatat 
 721 tcatgtttgt gagtgtgcac atatacgata tcattcaact gtttctactc gcacaa_tggt 
 781 gtatgtcacg catatacgtg tgtgtagtga gtgatatgga agagaaatgg gaaaggcata 
 841 tatatatgta tatacataat atatatgtgt gtggatttgt gtgttgagca cataggaaaa 
 901 aggtgtgtgt atatacagag agtctgtggc ggttgggaca tgtgtataaa tatatatgta 
 961 tatgtgtgtg ttcccctgtg gagattttat atcttacgga gagtgttcat atatatgttt 
1021 gtacgcatgt attttggcgc cccgtataga gattaaaaaa gaagagaaaa agtatgcaaa 
1081 agaggcgacg gatagtgtgt atgtgtgtat cacaggaaac aactatattt tgctgcttgt 
1141 gagtatactg cactatatgt acattatgtg cttgtgcttc tttcagtgta cggcttcact 
1201 tttttatatt gcatttttca gacctgagtg tggcaggacc acccgctaaa cttaagcata 
1261 ttactcagcg gaggaaaaga aaacaaccg 
 
T. b. brucei B8/18, AF306772 
      1 tggtgcaata caggtgatcg gaccgtcgct cgtctcgggc gaccgaaagt tcaccgatat 
  61 tgcttcaata gaggaagcaa aagtcgtaac aaggtagctg taggtgaacc tgcagctgga 
 121 tcattttctg atatccatta tacaaaaaag agcatattta tgtgcatgta taaattgcac 
 181 agtatgcaac caaaaatata catatatgtt ttacatgtat gtgtttctat atgccgtttg 
 241 acatgggaga tgagggatgc tatacatagt tctgttattt tctatcatgt atgtgtgtta 
 301 gagtgtctgt gttaatatac tttttaatgc atgctctaca taatatacag tagtaataac 
 361 acagagaata cgtatggaat gcgtatctct ctatatatat atgtgtatat atgatatgtg 
 421 tatatcaacc tcgcatattt tctccctgtt gaccacggct cccacaacgt gtcgcgatgg 
 481 atgacttggc ttcctatttc gttgaagaac gcagcaaagt gcgataagtg gtatcaattg 
 541 cagaatcatt tcattgatct ttgaacgCAA Acggcgcatg ggagaagctc tctcgagcca 
 601 tccccgtgca tgccacattt ctcagtgtcg aatataaaaa caaaacgcac acctattttg 
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 661 tgttgttcaa cgcacgcaaa aaatcccgcc acctcttctc ctcgtgtggt gcatattcat 
 721 gtttgtgagt gtgcacatat acgatatctt tcaactgttt ctactcgcac aa_tggtgtat 
 781 gtcacgcata tacgtgtgtg tagtgagtga tatggaagag aaatgggaaa ggcatatgta 
 841 tatatgtata tacataatat atatgtgtgt ggatttgtgt gttgagcaca tataaggaaa 
 901 aaggttgtgt gtatacacag agagtctgtg gcggttggca catgtgtata aatatatatg 
 961 tatatgtgtg tgttccgctg tggagatttt atatcttacg gagacgtgtt catatatata 
1021 tgtttgtacg catgtatttt ggcgccccgt atagagatta aaaaagaaga gaaaaagtat 
1081 gcaaaacagg cggcggatag tgtgtatgtg tgtattcaca gcaagcaact atattttgct 
1141 gcttgtgagt atatgcatat atgtacatta tgtgcttgtg cttctttcgt gtactgcttc 
1201 acttttttat attgtatttt tcagacctga gtgtggcagg accacccgct aaacttaagc 
1261 atattactca gcggaggaaa agaaaacaac cg 
 
T. b. brucei KP2, Clone 7, AF306773 
   1 tggtgcaata caggtgatcg gaccgtcgct cgtctcgggc gaccgaaagt tcaccgatat 
  61 tgcttcaata gaggaagcaa aagtcgtaac aaggtagctg taggtgaacc tgcagctgga 
 121 tcattttctg atatccatta tacaaaaaag agcatattta tgtgcatgta taaattgcac 
 181 agtatgcaac caaaaatata catatatgtt ttacatgtat gtgtttctat atgccgtttg 
 241 acatgggaga tgagggatgc tatacatagt tctgttattt tctatcatgt atgtgtgtta 
 301 gagtgtctgt gttaatatac tttttaatgc atgctctaca taatatacag tagtaataac 
 361 acagagaata cgtatggaat gcgtatctct ctatatatat atgtgtatat atgatatgtg 
 421 tatatcaacc tcgcatattt tctccctgtt gaccacggct cccacaacgt gtcgcgatgg 
 481 atgacttggc ttcctatttc gttgaagaac gcagcaaagt gcgataagtg gtatcaattg 
 541 cagaatcatt tcattgatct ttgaacgCAA Acggcgcatg ggagaagctc tctcgagcca 
 601 tccccgtgca tgccacattt ctcagtgtcg aatataaaaa caaaacgcac atctattttg 
 661 tgttgttcaa cgcacgcaca aaatcccgcc acctcttctc ctcgtgtggt gcatattcat 
 721 gtttgtgagt gtgcacatat acgatatctt tcaactcttt ctcctcgcac aa_ttgtgtat 
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 781 gtcacgcata tacgtgtgtg tagtgagtga tatggaagag aaatgggaaa ggcatatata 
 841 tatatgtata tacataatat atatgtgtgt ggattttgtg ttgttgagca catataagaa 
 901 aaaggttgtg tgtatataca gagagtctgt agcggttggg acatgtgtat aaatatatat 
 961 gtatatgtgt gtgttccgct gtggagattt tatatcttac ggagagtgtt catatatata 
1021 tgtttgtacg catgtatttt ggcgccccgt atagagatta aaaaagaaaa aaaaaagtat 
1081 gcaaaagagg cggcggatag tgtgtatgtg tgtattcaca gcaagcaact atattttgct 
1141 gcttgtgagt atatgcatat atgtacatta tgtgcttgtg cttctttcgt gtacgcttca 
1201 cttttttata ttgtattttt cagacctgag tgtggcagga ccacccgcta aacttaagca 
1261 tattactcag cgaaggaaaa gaaaagttcc g 
 
T. b. gambiense Dal972 (Group I), AF306774 
   1 tggtgcaata caggtgatcg gaccgtcgct cgtctcgggc gaccgaaagt tcaccgatat 
  61 tgcttcaata gaggaagcaa aagtcgtaac aaggtagctg taggtgaacc tgcagctgga 
 121 tcattttctg atatccatta tacaaaaaag agcatattta tgtgcatgta taaattgcac 
 181 agtatgcaac caaaaatata catatatgtt ttacatgtat gtgtttctat atgccgtttg 
 241 acatgggaga tgagggatgc tatacatagt tctgttattt tctatcatgt atgtgtgtta 
 301 gagtgtctgt gttaatatac tttttaatgc atgctctaca taatatacag tagtaataac 
 361 acagagaata cgtatggaat gcgtatctct ctatatatat ttatgtatat atgctatgtg 
 421 tatatcaacc tcgcatattt tctccctgtt gaccacggct cccacaacgt gtcgcgatgg 
 481 atgacttggc ttcctatttc gttgaagaac gcagcaaagt gcgataagtg gtatcaattg 
 541 cagaatcatt tcattgCCCA atctttgaac gcaaacggcg catgggagaa gctctctcga 
 601 gccatccccg tgcatgccac atttctcagt gtcgaatata aaaacaaaac acacacctat 
 661 tttgtgttgt tcaacgcacg caaaaaatcc cgccacctct tttccttggg gggggcatat 
 721 tcatgtttga gtgtgcacaa acacgatatc tttcaactct ttatactcgc acaatggtgt 
 781 atgtcacgca tatacgtgtg tgtagtgagt gatatggaag agaaatggga gaggcatatg 
 841 tatatatgta tatacataat atatatgtgt gtggatttgt gtgttgagca catataagga 
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 901 aaaaggttgt gtgtatatac agagagtctg tggcggttgg gacatgtgta taaatatata 
 961 tgtatatgtg tgtgttccgc tgtggagatt ttatatctta cggagagtgt tcatagatat 
1021 atgtttgaac gcatgtattt tggcgccccg tatagagatt aaaaaagaag agaaaaagta 
1081 tgcaaaagag gcggcggata gtgtgtatgt gtgtattcac agcaagcaac tatattttgc 
1141 tgcttgtgag tatatgcata tatgtacatt atgtgcttgt gcttctttcg tgtacgcttc 
1201 acttttttat attgtatttt tcagacctga gtgtggcagg accacccgct aaacttaagc 
1261 atattactca gcggaggaaa agaaaacaac cg 
 
T. b. gambiense Suzena (Group I), AF306775 
   1 tggtgcaata caggtgatcg gaccgtcgct cgtctcgggc gaccgaaagt tcaccgatat 
  61 tgcttcaata gaggaagcaa aagtcgtaac aaggtagctg taggtgaacc tgcagctgga 
 121 tcattttctg atatccatta tacaaaaaag agcatattta tgtgcatgta taaattgcac 
 181 agtatgcaac caaaaatata catatatgtt ttacatgtat gtgtttctat atgccgtttg 
 241 acatgggaga tgagggatgc tatacatagt tctgttattt tctatcatgt atgtgtgtta 
 301 gagtgtctgt gttaatatac tttttaatgc atgctctaca taatatacag tagtaataac 
 361 acagagaata cgtatggaat gcgtatctct ctatatatat ttatgtatat atgctatgtg 
 421 tatatcaacc tcgcatattt tctccctgtt gaccacggct cccacaacgt gtcgcgatgg 
 481 atgacttggc ttcctatttc gttgaagaac gcagcaaagt gcgataagtg gtatcaattg 
 541 cagaatcatt tcattgCCCA atctttgaac gcaaacggcg catgggagaa gctctctcga 
 601 gccatccccg tgcatgccac atttctcagt gtcgaatata aaaacaaaac acacacctat 
 661 tttgtgttgt tcaacgcacg caaaaaatcc cgccacctct tctcctcgtg tggggcatat 
721 tcatgtttga gtgtgcacaa acacgatatc tttgcaactc tttctactcg 
caca__atg_gta 
 781 tgtcacgcat atacgtgtgt gtagtgagtg atatggaaga aatatgggat aaggcataag 
 841 tatatatgta taaacatgat atatatgtgt gtggatctgt gtgttgagca catataagga 
 901 aaaagggtgt gtgtatatac agagagtctg tggcggttgg gacatgtgta taaatatata 
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 961 tgtatatgtg tgtgttccgc tgtggagatt ttatatctta cggagagtgt tcatatatat 
1021 atgtttgtac gcatgtattt tggcgccccg tatagagatt aaaaaagaag agaaaaagta 
1081 tgcaaaagag gcggcggata gtgtgtatgt gtgtattcac aggcaagcaa ctatattttg 
1141 ctgcttgtga gtatatgcat atatgtacat tatgtgcttg tgcttctttc agtgtactgc 
1201 ttcacttttt tatattgtat ttttcagacc tgagtgtggc aggaccaccc gctaaactta 
1261 agcatattac tcagcggagg aaaagaaaac aaccg 
 
T. b. gambiense NW2 (Group I), AF306776 
   1 tggtgcatac aggtgatcgg accgtcgctc gtctcgggcg accgaaagtt caccgatatt 
  61 gcttcaatag aggaagcaaa agtcgtaaca aggtagctgt aggtgaacct gcagctggat 
 121 cattttctga tatccattat acaaaaaaga gcatatttat gtgcatgtat aaattgcaca 
 181 gtatgcaacc aaaaatatac atatatgttt tacatgtatg tgtttctata tgccgtttga 
 241 catgggagat gagggatgct atacatagtt ctgttatttt ctatcatgta tgtgtgttag 
 301 agtgtctgtg ttaatatact ttttaatgca tgctctacat aatatacagt agtaataaca 
 361 cagagaatac gtatggaatg cgtatctctc tatatatatt tatgtatata tgatatgtgt 
 421 atatcaacct cgcatatttt ctccctgttg accacggctc ccacaacgtg tcgcgatgga 
 481 tgacttggct tcctatttcg ttgaagaacg cagcaaagtg cgataagtgg tatcaattgc 
 541 agaatcattt cattgCCCAa tctttgaacg caaacggcgc atgggagaag ctctctcgag 
 601 ccatccccgt gcatgccaca tttctcagtg tcgaatataa aaacaaaaca cacacctatt 
 661 ttgtgttgtt caacgcacgc aaaaaatccc gccacctctt cttctcgtgt ggggcatatt 
 721 catgtttgtg agtgtgcaca tatacgatat ctttcagctc tttctactcg cacaa tggtg 
 781 tatgtcacgc atatacgtgt gtgtagtgag tgatatgcaa cagaaatggg aaaggcatat 
 841 gtatatatgt atatacataa tatatatgtg tgtggatttg tgtgttgagc acatataagg 
 901 aaaaaggttg tgtgtatata cagagagtct gtggcggttg ggacatgtgt ataaatatat 
 961 atgtatatgt gtgtgttccg ctgtggagat tttatatctt acggagagtg ttcatatata 
1021 tatgtttgta cgcatgtatt ttggcgcccc gtatagagat taaaaaagaa gagaaaaagt 
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1081 atgcaaaaga ggcggcggat agtgtgtatg tgtgtattca cagcaagcaa ctatattttg 
1141 ctgcttgtga gtatatgcat atatgtacat tatgtgcttg tgcttctttc gtgtacgctt 
1201 cactttttta tattgtattt ttcagacctg agtgtggcag gaccacccgc taaacttaag 
1261 catattactc agcggaggaa aagaaaacaa ccg 
 
T. b. gambiense TH2 (Grp II), AF306777 
      1 tggtgcaata caggtgatcg gaccgtcgct cgtctcgggc gaccgaaagt tcaccgatat 
  61 tgcttcaata gaggaagcaa aagtcgtaac aaggtagctg taggtgaacc tgcagctgga 
 121 tcattttctg atatccatta tacaaaaaag agcatattta tgtgcatgta taaattgcac 
 181 agtatgcaac caaaaatata catatatgtt ttacatgtat gtgtttctat atgccgtttg 
 241 acatgggaga tgagggatgc tatacatagt tctgttattt tctatcatgt atgtgtgtta 
 301 gagtgtctgt gttaatatac tttttaatgc atgctctaca taatatacag tagtaataac 
 361 acagagaata cgtatggaat gcgtatctct ctatatatat ttatgtatat atgatatgtg 
 421 tatatcaacc tcgcatattt tctccctgtt gaccacggct cccacaacgt gtcgcgatgg 
 481 atgacttggc ttcctatttc gttgaagaac gcagcaaagt gcgataagtg gtatcaattg 
 541 cagaatcatt tcattgCCCA atctttgaac gcaaacggcg catgggagaa gctctctcga 
 601 gccatccccg tgcatgccac atttctcagt gtcgaatata aaaacaaaac gcacacctat 
 661 tttgtgttgt tcaacgcacg caaaaaatcc cgccacctct tctcctcgtg tggggcatat 
 721 tcatgtttgt gagtgtgcac atatacgata tctttcatct ctttcttctc gcacatattg 
 781 tgtatgtcac gcatatacgt gtgtgtagtg agtgatatga aagagaaatg ggaaaggcat 
 841 atgtatatat gtatacacat aatatatatg tgtgtggatt tgtgtgttga gcacatataa 
 901 ggaaaaaggt tgtgtgtata cacagagagt ctgtggcggt tgggacatgt gtataaatat 
 961 atatgtatat gtgtgtgttc cgctgtggag atttatattc ttacggagag tgttcatata 
1021 tatatgtttg aacgcatgta ttttggcgcc ccgtatagag attaaaaaag aagaggaaaa 
1081 gtatgcaaaa gaggcggcgg atagtgtgta tgtgtgtatt cacagcaagc aactatattt 
1141 tgctgcttgt gagtatatgc atatatgtac attatgtgct tgtgcttctt tcgtgtacgc 
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1201 ttcacttttt tatattgtat ttttcagacc tgagtgtggc aggaccaccc gctaaactta 
1261 agcatattac tcagcggagg aaaagaaaac aacctg 
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Appendix 14. LAMP primer sets generated by Primer Explorer V4 for the TgsGP gene. 
Target DNA AACATGTCGG CAGCGGGACC GGATTGGAGA AACCAGTTCG TCAGCAGCAA AGGTGTTAAG CAGGAATGGG
(Complement) ttgtacagcc gtcgccctgg cctaacctct ttggtcaagc agtcgtcgtt tccacaattc Gtccttaccc
CONSENSUS(*) ********** ********** ********** ********** ********** ********** **********
Primer  dG(dimer) 251 261 271 281 291 301 311 
[22] -1.12               
[59] -2.32               
[11] -1.67 [11]    CGGGACC GGATTGGAGA A    GTTCG TCAGCAGCAA AGGT   
[18] -2.12     [18]         CG TCAGCAGCAA AGGTGT          G
[28] -1.52               
Target DNA AGCCAACAGC GAAGAACAAA GCCGTAGCGG AGGCATGGGC GCGTACGTAC GCGGGATGGA TCAACACAGC
(Complement) tcggttgtcg cttcttgttt cggcatcgcc tccgtacccg cgcatgcatg cgccctacct Agttgtgtcg
CONSENSUS(*) ********** ********** ********** ********** ********** ********** **********
Primer  dG(dimer) 321 331 341 351 361 371 381 
[22] -1.12           [22]       CAGC
[59] -2.32               
[11] -1.67        tcg cttcttgttt cggcatcgc           AC GCGGGATGGA TCAACACAG 
[18] -2.12 AGCCAACAGC GAAGAACA      gcatgcatg cgccctacct ag      GC
[28] -1.52               
Target DNA ACTCGTCCTT TATGCAGGCG GCAGCGACGA CAGGAAACGA GCGATCAGCA AATTTGACAG CATGGGAGAT
(Complement) tgagcaggaa atacgtccgc cgtcgctgct gtcctttgct cgctagtcgt ttaaactgtc Gtaccctcta
CONSENSUS(*) ********** ********** ********** ********** ********** ********** **********
Primer  dG(dimer) 391 401 411 421 431 441 451 
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[22] -1.12 ACTCGTCCTT TATGCA  CAGCGACGA CAGGAAACG       
[59] -2.32               
[11] -1.67         cctttgct cgctagtcgt        Ctcta
[18] -2.12 ACTCGTCCTT TATGCAGGCG          aactgtc Gtaccctcta
[28] -1.52   [28]          A CAGGAAACGA GCGATCAG        CAG CATGGGAGAT
Target DNA GCAACTCGCA AGCTAGCACA GCGGAAGCTG GAAGCCATTT TGGCAAAAGT GCAGCCGCTG AGAAGCAAGC
(Complement) cgttgagcgt tcgatcgtgt cgccttcgac cttcggtaaa accgttttca cgtcggcgac tcttcgttcg
CONSENSUS(*) ********** ********** ********** ********** ********** ********** **********
Primer  dG(dimer) 461 471 481 491 501 511 521 
[22] -1.12       gcgt tcgatcgtgt cgcctt      CAGCCGCTG AGAAGCAAGC
[59] -2.32               
[11] -1.67 cgttgagcgt tcga [11]         
[18] -2.12 cg     ccttcgac cttcggtaaa ac [18]   
[28] -1.52 GCAACTC           taaa accgttttca cgtcggcgTG AGAAGCAAGC
Target DNA TCAGTGCACT TAAAGCGGTA GTAGAAGCGG GAACGGGCAA GGCTGTCACG GACTTGCTCA AGGCGGCGCT
(Complement) agtcacgtga atttcgccat catcttcgcc cttgcccgtt ccgacagtgc ctgaacgagt tccgccgcga
CONSENSUS(*) ********** ********** ********** ********** ********** ********** **********
Primer  dG(dimer) 531 541 551 561 571 581 591 
[22] -1.12 TC          acagtgc ctgaacgagt tc       a
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[59] -2.32               
[11] -1.67               
[18] -2.12               
[28] -1.52 TCAGTGCACT           cagtgc ctgaacgagt tcc      a
Target DNA CTACGGCGGT ATCGACGGCG GCAGTGACTT CGAGGACGCG ACAAAGGACA AGGACGGCGA ACGTGTGCGA
(Complement) gatgccgcca tagctgccgc cgtcactgaa gctcctgcgc tgtttcctgt tcctgccgct tgcacacgct
CONSENSUS(*) ********** ********** ********** ********** ********** ********** **********
Primer  dG(dimer) 601 611 621 631 641 651 661 
[22] -1.12 gatgccgcca tagctgc [22]         
[59] -2.32               
[11] -1.67               
[18] -2.12               
[28] -1.52 gatgccgcca tagctgc [28]         
Target DNA ACGTGTGCGA GGCATCTGCA AGGCCGCCGG AAAAGTGAAG GGTAACCAGA CACTGGCAGA TGTGCTGCTT
(Complement) tgcacacgct ccgtagacgt tccggcggcc ttttcacttc ccattggtct gtgaccgtct acacgacgaa
CONSENSUS(*) ********** ********** ********** ********** ********** ********** **********
Primer  dG(dimer) 661 671 681 691 701 711 721 
[22] -1.12               
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[59] -2.32               
[11] -1.67               
[18] -2.12               
[28] -1.52               
Target DNA TGCGTATGCG ATACCGCAGT AAGCTACGGC GACGACGGCA ACAAAAAAAT TTGTGCCAAA CTGAGCGGTA
(Complement) acgcatacgc tatggcgtca ttcgatgccg ctgctgccgt tgttttttta aacacggttt gactcgccat
CONSENSUS(*) ********** ********** ********** ********** ********** ********** **********
Primer  dG(dimer) 731 741 751 761 771 781 791 
[22] -1.12               
[59] -2.32               
[11] -1.67               
[18] -2.12               
[28] -1.52               
Target DNA AGGCCGGAGC GAAGCAGTGG GACCTTAGCG ACAGGGGCGA TGTCGCTGCT GTGTTCGGAG AGCTCAGACA
(Complement) tccggcctcg cttcgtcacc ctggaatcgc tgtccccgct acagcgacga cacaagcctc tcgagtctgt
CONSENSUS(*) ********** ********** ********** ********** ********** ********** **********
Primer  dG(dimer) 801 811 821 831 841 851 861 
[22] -1.12               
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[59] -2.32 [59] GAAGCAGTGG GACCTTAGC        CGA TGTCGCTGCT GTGTTC   
[11] -1.67               
[18] -2.12               
[28] -1.52               
Target DNA GGGCTGTAAT AGCAAGCAAG AGCACAAAAC CACAGCAGGC GGGATCAGGG CGGCCCTGGC GGCGATAAGG
(Complement) cccgacatta tcgttcgttc tcgtgttttg gtgtcgtccg ccctagtccc gccgggaccg ccgctattcc
CONSENSUS(*) ********** ********** ********** ********** ********** ********** **********
Primer  dG(dimer) 871 881 891 901 911 921 931 
[22] -1.12               
[59] -2.32          ttttg gtgtcgtccg ccctag     
[11] -1.67               
[18] -2.12               
[28] -1.52               
Target DNA AGCAAATTCC AAATTGACGG GGACAACGGC TATCTAGGAA GGTACGACAC CGACGGCAAC TGCACAGGAA
(Complement) tcgtttaagg tttaactgcc cctgttgccg atagatcctt ccatgctgtg gctgccgttg acgtgtcctt
CONSENSUS(*) ********** ********** ********** ********** ********** ********** **********
Primer  dG(dimer) 941 951 961 971 981 991 1001 
[22] -1.12               
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[59] -2.32        TCC AAATTGACGG GGACAACGG           gttg acgtgtcctt
[11] -1.67               
[18] -2.12               
[28] -1.52               
Target DNA CGGCGCCAGG CGGTGTCTGC GTTAAATATG CCGGCTACGG    
(Complement) gccgcggtcc gccacagacg caatttatac ggccgatgcc    
CONSENSUS(*) ********** ********** ********** **********    
Primer  dG(dimer) 1011 1021 1031 1041    
[22] -1.12            
[59] -2.32 gccg   tcc gccacagacg caatt [59]    
[11] -1.67            
[18] -2.12            
[28] -1.52            
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Appendix 15. Binding sites of the TgsGP nested PCR primers 
and the LAMP TgsGP primers on the TgsGP gene 
Table 1. Key to Figure 1 
Reaction Primer Binding site on the TgsGP gene 
PCR TgsGPf1 719 - 738 
 TgsGPr1 1220 - 1241 
 TgsGPf2 845 - 863 
 TgsGPr2 1134 - 1152 
LAMP FIP-F1c 896 - 916 
 FIP-F2 838 - 856 
 BIP-B1c 948 - 969 
 BIP-B2 997 - 1014 
 LF 855 - 875 
 LB 970 - 992 
 F3 811 - 829 
 B3 1018 -1035 
 
Figure 1a. Binding sites of the TgsGP nested PCR primers on the TgsGP 
gene (Accession number AJ277951) 
 
   1 atctcgacgg acttttgtaa ttttcaaaag aagcagagaa agctaactaa tacgagaaat 
  61 gtggcaatta ctagcaatag cggcggcgct agcactttca tcacggccat cagacggaga 
 121 ggacagtgca ggcgaaaatg gcggcacgta cgcagccctc tgtacactgc taacagaagc 
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 181 acttggtgaa gttgaccaag cgcagcccac taaaggatgg gaacaggcat atgcttctat 
 241 tcttgaagcc aacatgtcgg cagcgggacc ggattggaga aaccagttcg tcagcagcaa 
 301 aggtgttaag caggaatggg agccaacagc gaagaacaaa gccgtagcgg aggcatgggc 
 361 gcgtacgtac gcgggatgga tcaacacagc actcgtcctt tatgcaggcg gcagcgacga 
 421 caggaaacga gcgatcagca aatttgacag catgggagat gcaactcgca agctagcaca 
 481 gcggaagctg gaagccattt tggcaaaagt gcagccgctg agaagcaagc tcagtgcact 
 541 taaagcggta gtagaagcgg gaacgggcaa ggctgtcacg gacttgctca aggcggcgct 
 601 ctacggcggt atcgacggcg gcagtgactt cgaggacgcg acaaaggaca aggacggcga 
 661 acgtgtgcga ggcatctgca aggccgccgg aaaagtgaag ggtaaccaga cactggcaga 
 721 tgtgctgctt tgcgtatgcg ataccgcagt aagctacggc gacgacggca acaaaaaaat 
 781 ttgtgccaaa ctgagcggta aggccggagc gaagcagtgg gaccttagcg acaggggcga 
 841 tgtcgctgct gtgttcggag agctcagaca gggctgtaat agcaagcaag agcacaaaac 
 901 cacagcaggc gggatcaggg cggccctggc ggcgataagg agcaaattcc aaattgacgg 
 961 ggacaacggc tatctaggaa ggtacgacac cgacggcaac tgcacaggaa cggcgccagg 
1021 cggtgtctgc gttaaatatg ccggctacgg caccaacact gggaacggtt ggcacgatat 
1081 tcaatgggtc aggcatgcaa cggccgcagc tgcagcaatt gaggcaggag cccgagcggc 
1141 aagcacgatg gcagcgctgg agcccctgct agaagcagcg gcggttgaag cttgggaagt 
1201 ggcaaacacc acagcaagca attcttatgt gatgaaggcc cctcttttgc ttgcattttt 
1261 gcttttttaa aattttcccc tatttaaaga actttgctat ttgatatatt ttaacac 
 
Figure 1b. Binding sites of the LAMP TgsGP primers on the TgsGP gene 
(Accession number AJ277951) 
 
   1 atctcgacgg acttttgtaa ttttcaaaag aagcagagaa agctaactaa tacgagaaat 
  61 gtggcaatta ctagcaatag cggcggcgct agcactttca tcacggccat cagacggaga 
 121 ggacagtgca ggcgaaaatg gcggcacgta cgcagccctc tgtacactgc taacagaagc 
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 181 acttggtgaa gttgaccaag cgcagcccac taaaggatgg gaacaggcat atgcttctat 
 241 tcttgaagcc aacatgtcgg cagcgggacc ggattggaga aaccagttcg tcagcagcaa 
 301 aggtgttaag caggaatggg agccaacagc gaagaacaaa gccgtagcgg aggcatgggc 
 361 gcgtacgtac gcgggatgga tcaacacagc actcgtcctt tatgcaggcg gcagcgacga 
 421 caggaaacga gcgatcagca aatttgacag catgggagat gcaactcgca agctagcaca 
 481 gcggaagctg gaagccattt tggcaaaagt gcagccgctg agaagcaagc tcagtgcact 
 541 taaagcggta gtagaagcgg gaacgggcaa ggctgtcacg gacttgctca aggcggcgct 
 601 ctacggcggt atcgacggcg gcagtgactt cgaggacgcg acaaaggaca aggacggcga 
 661 acgtgtgcga ggcatctgca aggccgccgg aaaagtgaag ggtaaccaga cactggcaga 
 721 tgtgctgctt tgcgtatgcg ataccgcagt aagctacggc gacgacggca acaaaaaaat 
 781 ttgtgccaaa ctgagcggta aggccggagc gaagcagtgg gaccttagcg acaggggcga 
 841 tgtcgctgct gtgttcggag agctcagaca gggctgtaat agcaagcaag agcacaaaac 
 901 cacagcaggc gggatcaggg cggccctggc ggcgataagg agcaaattcc aaattgacgg 
 961 ggacaacggc tatctaggaa ggtacgacac cgacggcaac tgcacaggaa cggcgccagg 
1021 cggtgtctgc gttaaatatg ccggctacgg caccaacact gggaacggtt ggcacgatat 
1081 tcaatgggtc aggcatgcaa cggccgcagc tgcagcaatt gaggcaggag cccgagcggc 
1141 aagcacgatg gcagcgctgg agcccctgct agaagcagcg gcggttgaag cttgggaagt 
1201 ggcaaacacc acagcaagca attcttatgt gatgaaggcc cctcttttgc ttgcattttt 
1261 gcttttttaa aattttcccc tatttaaaga actttgctat ttgatatatt ttaacac 
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Appendix 16. Results from the TgsGP LAMP assay applied to 
the total sample set 












1. Tira 24 6.48 + - 00:37:24 00:00:00 
2. Sikuda 28 47.25 + - 00:37:36 00:00:00 
3. UGC 0.01 + - 00:35:12 00:00:00 
4. UGI 1.01 + - 00:36:36 00:00:00 
5. Dal069 IM52 73.49 + + 00:36:48 00:37:30 
6. Papol 33 21.96 + - 00:35:54 00:00:00 
7. Bumanda 146 60.14 + - 00:36:00 00:00:00 
8. Papol 264 69.57 + - 00:36:24 00:00:00 
9. UGA 88 22.53 + - 00:45:36 00:00:00 
10. E. Oketch 15.21 + - 00:50:06 00:00:00 
11. Papol 285 12.12 + - 00:48:18 00:00:00 
12. Biyamina 26.87 + - 00:47:54 01:05:36 
13. Mela 3 24.09 + - 00:48:54 00:00:00 
14. Papol 103 5.77 + - 00:51:00 00:00:00 
15. Mawero 66 18.37 + - 00:49:18 00:00:00 
16. Mela 71 IM87 23.3 + - 00:48:06 00:00:00 
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17. TH149 20.31 + + 00:42:42 00:40:00 
18. Bida 3 Clone A 53.14 - + 00:46:12 00:50:54 
19. TSW83 27.45 + - 00:40:06 00:00:00 
20. Katerema 311 7.39 + + 00:46:00 00:00:00 
21. Musikia Clone A 5.72 - + 00:52:24 00:00:00 
22. Suzena 8.13 + + 00:52:48 00:00:00 
23. Tsuaa 14.77 + + 00:49:00 00:54:54 
24. Mawero 32 4.62 + - 00:43:36 00:00:00 
25. Papol 42 1.7 + - 00:34:36 00:00:00 
26. UGK 9.57 + - 00:33:12 00:00:00 
27. Papol 60 0.32 + - 00:31:54 00:00:00 
28. UR4 49.11 + - 00:32:36 00:00:00 
29. F97 2.75 + - 00:32:12 00:00:00 
30. Mawero 80 5.49 + - 00:33:24 00:00:00 
31. Papol 278 7.64 + - 00:42:00 00:00:00 
32. URI 18.15 + - 00:40:54 00:00:00 
33. UGH 1.87 + + 00:29:18 00:00:00 
34. Mela Pig 7.19 + - 00:30:36 00:00:00 
35. Tira 22 4.44 + - 00:29:00 00:00:00 
36. Mela 66 6.01 + - 00:29:24 00:00:00 
37. Uganda B 8.66 + - 00:28:00 00:00:00 
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38. Mela 24 4.34 + - 00:28:42 00:00:00 
39. Iyolowa 125 13.15 + - 00:28:54 00:00:00 
40. Tira 168 4.98 + - 00:27:42 00:00:00 
41. Papol 12 1.45 + - 00:31:12 00:00:00 
42. Mela 27 5 + - 00:31:30 00:00:00 
43. Poyem 11 10.6 + - 00:31:36 00:00:00 
44. Tira 4 5.13 + - 00:31:06 00:00:00 
45. Mela pig 2 17.89 + - 00:30:18 00:00:00 
46. UGE 6.05 + - 00:28:48 00:00:00 
47. Katerema 72 1.92 + - 00:31:54 00:00:00 
48. Mawero 42 7.92 + - 00:30:36 00:00:00 
49. Tira 34 1.71 + - 00:38:18 01:05:24 
50. H.Taka 20.26 + - 00:29:42 00:00:00 
51. Uganda A 9.04 + - 00:30:30 00:00:00 
52. A Kiburige 26.28 + - 00:31:54 00:00:00 
53. Uganda E 6.04 + - 00:30:42 00:00:00 
54. Katerema 116 14.12 + - 00:30:24 00:00:00 
55. Tira 43 5.81 + - 00:30:42 00:00:00 
56. Tira 92 13.14 + - 00:00:00 00:00:00 
57. Tira 75 4.93 + - 00:36:30 00:00:00 
58. Musikia Clone B 9.11 + + 00:30:00 00:58:24 
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human sleeping 
sickness: towards a point-of-care diagnostic test 
Appendices 379 
59. Iyolowa 116 3.94 + - 00:25:48 00:00:00 
60. Iyolowa 153 5.36 + - 00:27:48 00:00:00 
61. TH 112 IM56 21.32 + - 00:29:00 00:00:00 
62. Muraz 15 IM47 24.87 + - 00:00:00 00:00:00 
63. Mela 12 6.78 + - 00:35:48 00:00:00 
64. Mawero 31 24.32 + - 00:33:54 00:00:00 
65. F73 7.7 + - 00:49:42 00:00:00 
66. Tira 27 30.69 + - 00:53:54 00:00:00 
67. Uganda L 3.19 + - 00:46:54 00:00:00 
68. F48 8.76 + - 00:47:12 00:00:00 
69. Tira 68 11.96 + - 00:47:30 00:00:00 
70. Tira 30 1.52 + - 00:48:00 00:00:00 
71. Tira 29 1.55 - - 00:00:00 00:00:00 
72. Papol 371 144.78 + - 00:00:00 00:00:00 
73. Mawero 85 6.83 + - 00:49:00 00:00:00 
74. Iyolowa 147 1.33 + - 00:45:54 00:00:00 
75. Muraz 3 IM46 29.59 + - 00:46:00 00:00:00 
76. Katerema 41 5.51 + - 00:47:24 00:00:00 
77. UGG 88 24.29 + - 00:47:54 00:00:00 
78. Mela 2 3.73 + - 00:49:06 01:27:36 
79. Uganda M 2.17 + - 00:52:06 00:00:00 
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80. Rose Akinare 2.39 + - 00:48:18 00:00:00 
81. Uganda B 0.79 + - 00:44:54 00:00:00 
82. Papol 144 2.88 + - 00:46:12 00:00:00 
83. Uganda C 9.76 + - 00:47:00 00:00:00 
84. Sikuda 42.90 8.99 + - 00:44:42 00:00:00 
85. Sikuda 4 6.3 - - 00:00:00 00:00:00 
86. D. Obwang 8.2 + - 00:41:12 01:24:18 
 
Table 2. TgsGP LAMP, in triplicate for all 86 Trypanosome DNA samples, 
assessed by turbidity and gel electrophoresis 
 Run 1 Run 2 Run 3 
Sample Turbidity Gel Turbidity Gel Turbidity Gel 
1. Tira 24 - - - - - - 
2. Sikuda 28 - - - - - - 
3. UGC - - - - - - 
4. UGI - - - - - - 
5. Dal069 IM52 + + + + + + 
6. Papol 33 - - - - - - 
7. Bumanda 146 - - - - - - 
8. Papol 264 - - - - - - 
9. UGA 88 - - - - - - 
10. E. Oketch - - - - - - 
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11. Papol 285 - - - - - - 
12. Biyamina - - - - - - 
13. Mela 3 - - - - - - 
14. Papol 103 - - - - - - 
15. Mawero 66 - - - - - - 
16. Mela 71 IM87 - - - - - - 
17. TH149 + + - - + + 
18. Bida 3 Clone 
A + + + + + + 
19. TSW83 - - - - - - 
20. Katerema 311 - + - + + + 
21. Musikia 
Clone A + + - + + + 
22. Suzena - + - - + + 
23. Tsuaa + + + + + + 
24. Mawero 32 - - - - - - 
25. Papol 42 - - - - - - 
26. UGK - - - - - - 
27. Papol 60 - - - - - - 
28. UR4 - - - - - - 
29. F97 - - - - - - 
30. Mawero 80 - - - - - - 
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human sleeping 
sickness: towards a point-of-care diagnostic test 
Appendices 382 
31. Papol 278 - - - - - - 
32. URI - - - - - - 
33. UGH - - - - - - 
34. Mela Pig - - - - - - 
35. Tira 22 - - - - - - 
36. Mela 66 - - - - - + 
37. Uganda B - - - - - - 
38. Mela 24 - - - - - - 
39. Iyolowa 125 - - - - - - 
40. Tira 168 - - - - - - 
41. Papol 12 - - - - - - 
42. Mela 27 - - - - - - 
43. Poyem 11 - - - - - - 
44. Tira 4 - - - - - - 
45. Mela pig 2 - - - - - - 
46. UGE - - - - - - 
47. Katerema 72 - - - - - - 
48. Mawero 42 - - - - - - 
49. Tira 34 - - + + - - 
50. H.Taka - - - - - - 
51. Uganda A - - - - + + 
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human sleeping 
sickness: towards a point-of-care diagnostic test 
Appendices 383 
52. A Kiburige - - - - - - 
53. Uganda E - - - - + + 
54. Katerema 116 - - - - - - 
55. Tira 43 - - + + - - 
56. Tira 92 - - - - - - 
57. Tira 75 - - - - - - 
58. Musikia 
Clone B - + + + + + 
59. Iyolowa 116 - - - - - - 
60. Iyolowa 153 - - - - - - 
61. TH 112 IM56 - - - - - - 
62. Muraz 15 
IM47 - - - - + + 
63. Mela 12 - - - - + + 
64. Mawero 31 - - - + - - 
65. F73 - - - + - + 
66. Tira 27 - - - - - - 
67. Uganda L - - - - - - 
68. F48 - - + + - + 
69. Tira 68 - - - - - - 
70. Tira 30 - - - - - - 
71. Tira 29 - - - - - - 
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72. Papol 371 - - - - + + 
73. Mawero 85 - - - - - - 
74. Iyolowa 147 - - - - - - 
75. Muraz 3 
IM46 - - - - - - 
76. Katerema 41 - - - - - - 
77. UGG 88 - - - - - - 
78. Mela 2 - - - - + + 
79. Uganda M - - - - - - 
80. Rose Akinare - - - - - - 
81. Uganda B - - - - - - 
82. Papol 144 - - - - - - 
83. Uganda C - - - - - - 
84. Sikuda 42.90 - - - - - - 
85. Sikuda 4 - - - - - - 
86. D. Obwang - - - - - - 
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Appendix 17. All PCR and LAMP assay results. 
Table 1. PCR assay results for the 86 DNA samples 
SRA PCR SRA PCR Sample TBR 
PCR 
TgsGP 





PCR VSG SRA GPI-
PLC 
1. Tira 24 + - + - + 44. Tira 4 + - + - + 
2. Sikuda 28 + - + - + 45. Mela pig 2 + - + - + 
3. UGC + - + + + 46. UGE + - + + + 
4. UGI + - + + + 47. Katerema 72 + - + + + 
5. Dal069 IM52 + + + + + 48. Mawero 42 + - + + + 
6. Papol 33 + - + - + 49. Tira 34 + - + - + 
7. Bumanda 146 + - + - + 50. H.Taka + - + + + 
8. Papol 264 + - + - + 51. Uganda A + - + + + 
9. UGA 88 + - + + + 52. A Kiburige + - + + + 
10. E. Oketch + - + + + 53. Uganda E + - + + + 
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11. Papol 285 + - + + + 54. Katerema 116 + - + + + 
12. Biyamina + - + + + 55. Tira 43 + - + - + 
13. Mela 3 + - + - + 56. Tira 92 + - - - - 
14. Papol 103 + - + + + 57. Tira 75 + - + - + 
15. Mawero 66 + - + + + 58. Musikia Clone B + + - - + 
16. Mela 71 IM87 + - + + + 59. Iyolowa 116 + - + - + 
17. TH149 + + + - + 60. Iyolowa 153 + - + - + 
18. Bida 3 Clone A - + + - + 61. TH 112 IM56 + - + - + 
19. TSW83 + - + - + 62. Muraz 15 IM47 + - + - + 
20. Katerema 311 + + + - + 63. Mela 12 + - + - + 
21. Musikia Clone A - + - - + 64. Mawero 31 + - + + + 
22. Suzena + + - - + 65. F73 + - + + + 
23. Tsuaa + + - - + 66. Tira 27 + - + - + 
25. Papol 42 + - + - + 68. F48 + - + + + 
26. UGK + - + + + 69. Tira 68 + - + - + 
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27. Papol 60 + - + - + 70. Tira 30 + - + - + 
28. UR4 + - + - + 71. Tira 29 - - + - + 
29. F97 + - + - + 72. Papol 371 + - + - + 
30. Mawero 80 + - + - + 73. Mawero 85 + - + - + 
31. Papol 278 + - + + + 74. Iyolowa 147 + - + - + 
32. URI + - + + + 75. Muraz 3 IM46 + - + - + 
33. UGH + + + + + 76. Katerema 41 + - + - + 
34. Mela Pig + - + - + 77. UGG 88 + - + + + 
35. Tira 22 + - + - + 78. Mela 2 + - + + + 
36. Mela 66 + - + + + 79. Uganda M + - + + + 
37. Uganda B + - + + + 80. Rose Akinare + - + + + 
38. Mela 24 + - + - + 81. Uganda B + - + + + 
39. Iyolowa 125 + - + - + 82. Papol 144 + - + - + 
40. Tira 168 + - + - + 83. Uganda C + - + + + 
41. Papol 12 + - + - + 84. Sikuda 42.90 + - + - + 
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42. Mela 27 + - + + + 85. Sikuda 4 - - - - - 
43. Poyem 11 + - + - + 86. D. Obwang + - + + + 
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Table 2. LAMP assay results for the 86 DNA samples 
Sample LAMP RIME LAMP PfrA LAMP TgsGP LAMP SRA1 SRALAMP_a 
 i ii iii iv v i ii iii iv v i ii iii iv v i ii iii iv v i ii iii iv v
1. Tira 24 + + + + + + + + + + - - - - - - - - + - - + - - - 
2. Sikuda 28 + + + + + + + + + + - - - - - - + - - - - - - - - 
3. UGC + + + + + + + + + + - - - - - + + + + + + + + + +
4. UGI + + + + + + + + + + - - - - - + + + + + + + + + +
5. Dal069 IM52 + + + + + + + + + + + + + + + - - - - - - - - - +
6. Papol 33 + + + + + + + + + + - - - - - - - - - - - - - - +
7. Bumanda 146 + + + + + + + + + + - - - - - - - - - - - - - - - 
8. Papol 264 + + + + + + + + + + - - - - - - - - - - - - - - - 
9. UGA 88 + + + + + + + + + + - - - - - + + + + + + + + + +
10. E. Oketch + + +   + + +   - - -   + + +   + + +   
11. Papol 285 + + +   + + +   - - -   + + +   + + +   
12. Biyamina + + +   + + +   - - -   + + +   + + +   
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13. Mela 3 + + +   + + +   - - -   - - -   - - -   
14. Papol 103 + + + + + + + + + + - - - - - + + + + + + + + + +
15. Mawero 66 + + +   + + +   - - -   + + +   + + +   
16. Mela 71 IM87 + + +   + + +   - - -   + + +   + + +   
17. TH149 + + + + + + + + + + + - + + + - - - - - - - - - - 
18. Bida 3 Clone A + + + + + + + + + + + + + + + - - - - - - + + + - 
19. TSW83 + + +   + + +   - - -   - - -   - - -   
20. Katerema 311 + + + + + + + + + + + + + - - - - - - - - - - - - 
21. Musikia Clone A + + + + + - + + - + + + + - + - - + - - - - - - - 
22. Suzena + + +   + + +   + - +   - - -   - - -   
23. Tsuaa + + +   + + +   + + +   - - -   - - -   
24. Mawero 32 + + +   + + +   - - -   - - -   - - +   
25. Papol 42 + + +   + + +   - - -   - - -   - - -   
26. UGK + + +   + + +   - - -   + + +   + + +   
27. Papol 60 + + +   + + +   - - -   - - -   - - -   
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human sleeping sickness: towards a point-of-care 
diagnostic test 
Appendices 391 
28. UR4 + + +   + + +   - - -   - - -   - - -   
29. F97 + + +   + + +   - - -   - - -   - - -   
30. Mawero 80 + + +   + + +   - - -   - - -   + - -   
31. Papol 278 + + +   + + +   - - -   + + +   + + +   
32. URI + + +   + + +   - - -   + + +   + + +   
33. UGH + + +   + + +   - - -   + + +   + + +   
34. Mela Pig + + +   + + +   - - -   - - -   - - -   
35. Tira 22 + + +   + + +   - - -   - - -   - - -   
36. Mela 66 + + +   + + +   - - +   + + +   + + +   
37. Uganda B + + +   + + +   - - -   + + +   + + +   
38. Mela 24 + + +   + + +   - - -   - - -   - - -   
39. Iyolowa 125 + + +   + + +   - - -   - - -   - - +   
40. Tira 168 + + +   - + +   - - -   + - -   - - +   
41. Papol 12 + + +   - + +   - - -   - + +   - - +   
42. Mela 27 + + +   - + +   - - -   + + +   + + +   
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human sleeping sickness: towards a point-of-care 
diagnostic test 
Appendices 392 
43. Poyem 11 + + +   - + +   - - -   - - -   - - +   
44. Tira 4 + + +   - + +   - - -   - - -   - - -   
45. Mela pig 2 + + +   - + +   - - -   - - +   - - +   
46. UGE + + +   - + +   - - -   + + +   + + +   
47. Katerema 72 + + +   - + +   - - -   - - -   - - -   
48. Mawero 42 + + +   - + +   - - -   + + +   + + +   
49. Tira 34 - + -   + + -   - + -   - - -   - - +   
50. H.Taka + + +   + + +   - - -   + + +   + + +   
51. Uganda A + + +   + + +   - - +   + + +   + + +   
52. A Kiburige + + +   - + +   - - -   + + +   + + +   
53. Uganda E + + +   + + +   - - +   + + +   + + +   
54. Katerema 116 + + +   + + +   - - -   - + +   + + +   
55. Tira 43 + + +   - + +   - + -   - + -   - - +   
56. Tira 92 - + -   + - -   - - -   - - -   - - -   
57. Tira 75 + + +   - + +   - - -   - - -   + - -   
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58. Musikia Clone B + + +   - + +   + + +   - - -   - - -   
59. Iyolowa 116 + + +   - + +   - - -   - - -   - + -   
60. Iyolowa 153 + + +   + + +   - - -   - - -   - - -   
61. TH 112 IM56 + + +   + + +   - - -   - + -   - - -   
62. Muraz 15 IM47 + + +   - + +   - - +   - - -   - - -   
63. Mela 12 + + +   - + +   - - +   - - -   - + -   
64. Mawero 31 + + +   + + +   - + -   + + +   + + +   
65. F73 + + +   + + +   - + +   + + +   + + +   
66. Tira 27 + + +   + + +   - - -   - - -   - - -   
67. Uganda L + + +   + + +   - - -   + + +   + + +   
68. F48 + + +   + + +   - + +   + + +   + + +   
69. Tira 68 + + +   + + +   - - -   - - -   - - +   
70. Tira 30 + + +   + + +   - - -   - - -   - - -   
71. Tira 29 + + +   - - -   - - -   - - -   - + -   
72. Papol 371 + + +   + + +   - - +   - - -   - - -   
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73. Mawero 85 + + +   + + +   - - -   - - -   - - -   
74. Iyolowa 147 + + +   + + +   - - -   - - -   - - -   
75. Muraz 3 IM46 + + +   + + +   - - -   - - -   - - -   
76. Katerema 41 + + +   + + +   - - -   - - -   - - -   
77. UGG 88 + + +   + + +   - - -   + + +   + + +   
78. Mela 2 + + +   + + +   - - +   + + +   + + +   
79. Uganda M + + +   + + +   - - -   + + +   + + +   
80. Rose Akinare + + + + + + + + + + - - - - - + + + + + + + + + +
81. Uganda B + + +   + + +   - - -   + + +   + + +   
82. Papol 144 + + +   + + +   - - -   - - -   - - -   
83. Uganda C + + +   + + +   - - -   + + +   + + +   
84. Sikuda 42.90 + + +   + + +   - - -   - - -   - - +   
85. Sikuda 4 + + +   - - -   - - -   - - -   - - -   
86. D. Obwang + + +   + + +   - - -   + + +   + + +   
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Appendix 18 Agreement between LAMP assays and the 
reference PCRs using control DNA samples 
Table 1. Two by two table for LAMP RIME and TBR PCR 
  LAMP RIME i LAMP RIME ii LAMP RIME iii 
  + - Total + - Total + - Total 
+ 80 2 82 82 0 82 80 2 82 
- 4 0 4 4 0 4 4 0 4 
TBR 
PCR 
Total 84 2 86 86 0 86 84 2 86 
 
Table 2. Two by two table for LAMP PfrA and TBR PCR 
  LAMP PfrA i LAMP PfrA ii LAMP PfrA iii 
  + - Total + - Total + - Total 
+ 66 16 82 81 1 82 80 2 82 
- 1 3 4 2 2 4 2 2 4 
TBR 
PCR 
Total 67 19 86 83 3 86 82 4 86 
 
Table 3. Two by two table for LAMP TgsGP and TgsGP PCR 
  LAMP TgsGP i LAMP TgsGP ii LAMP TgsGP iii 
  + - Total + - Total + - Total 
+ 8 1 9 6 3 9 8 1 9 
- 0 77 77 5 72 77 9 68 77 
TgsGP 
PCR 
Total 8 78 86 11 75 86 17 69 86 
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Table 4. Two by two table summarising the agreement between the 
three repeats of LAMP SRA1 and SRA PCR 
  LAMP SRA1 i LAMP SRA1 ii LAMP SRA1 iii 
  + - Total + - Total + - Total 
+ 33 3 36 34 2 36 34 2 36 
- 1 49 50 4 46 50 3 47 50 
SRA 
PCR 
Total 34 52 86 38 48 86 37 49 86 
 
Table 5. Two by two table summarising the agreement between the 
three repeats of SRALAMP_a and SRA PCR 
  SRALAMP_a i SRALAMP_a ii SRALAMP_a iii 
  + - Total + - Total + - Total 
+ 34 2 36 34 2 36 34 2 36 
- 2 48 50 5 45 50 11 39 50 
SRA 
PCR 
Total 36 50 86 39 47 86 45 41 86 
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Table 6. LAMP assay agreement with reference PCR results 




κobserved 95% CI 
RIME i 0.656 0.930 0.023 -0.032 (-0.828, 
0.764) 
RIME ii κobserved 0.953 0.046 0 (-0.957, 
0.957) 
TBR  
RIME iii 0.656 0.930 0.023 -0.032 (-0.828, 
0.764) 
PfrA i 0.294 0.732 0.174 0.199 (-0.142, 
0.540) 
PfrA ii 0.851 0.919 0.012 0.554 (0.057, 1.050) 
TBR  
PfrA iii 1 0.907 0 0.476 (-0.026, 
0.977) 
TgsGP i κobserved 0.802 0.012 0.935 (0.808, 1.062) 
TgsGP ii 0.887 0.767 0.023 0.548 (0.250, 0.846) 
TgsGP 
TgsGP iii 0.644 0.698 0.093 0.554 (0.295, 0.814) 
SRA1 i 0.952 0.186 0.023 0.904 (0.812, 0.996) 
SRA1 ii 0.953 0.140 0.023 0.858 (0.748, 0.968) 
SRA 
SRA1 iii 0.976 0.151 0.012 0.881 (0.780, 0.982) 
SRALAMP_a i 1 0.163 0 0.904 (0.813, 0.996) 
SRALAMP_a ii 0.929 0.128 0.035 0.835 (0.717, 0.952) 
SRA 
SRALAMP_a iii 0.792 0.058 0.105 0.700 (0.550-0.850) 
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Appendix 19. LAMP test-retest agreement using control DNA 
samples. 
Table 1. Two by two table for comparisons of LAMP RIME repeats  
  RIME ii RIME iii 
  + - Total + - Total 
+ 84 0 84 84 0 84 
- 2 0 2 0 2 2 
RIME i 
Total 86 0 86 84 2 86 
+ 84 0 84    
- 2 0 2    
RIME 
iii 
Total 86 0 86    
 
Table 2. Two by two table for comparisons of LAMP PfrA repeats  
  PfrA ii PfrA iii 
  + - Total + - Total 
+ 66 1 67 65 2 67 
- 17 2 19 17 2 19 
PfrA i 
Total 83 3 86 82 4 86 
+ 82 0 82    
- 1 3 4    
PfrA iii 
Total 83 3 86    
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Table 3. Two by two table for comparisons of LAMP TgsGP repeats  
  TgsGP ii TgsGP iii 
  + - Total + - Total 
+ 6 2 8 8 0 8 
- 5 73 78 9 69 78 
TgsGP i 
Total 11 75 86 17 69 86 
+ 8 9 17    
- 3 66 69    
TgsGP 
iii 
Total 11 77 86    
 
Table 4. Two by two table for comparisons of LAMP SRA1 repeats  
  SRA1 ii SRA1 iii 
  + - Total + - Total 
+ 33 1 34 33 1 34 
- 5 47 52 4 48 52 
SRA1 i 
Total 38 48 86 37 49 86 
+ 35 2 37    
- 3 46 49    
SRA1 iii 
Total 38 48 86    
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Table 5. Two by two table for comparisons of SRALAMP_a repeats  
  SRALAMP_a ii SRALAMP_a iii 
  + - Total + - Total 
+ 34 2 36 34 2 36 
- 5 45 50 11 39 50 
SRALAMP_a 
i 
Total 39 47 86 45 41 86 
+ 35 10 45    
- 4 37 41    
SRALAMP_a 
iii 
Total 39 47 86    
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Table 6. LAMP assay test-retest agreement  







i - ii κobserved 0.977 0.023 0 (-1.370, 1.370) 
i - iii κobserved 0.953 0 1 (1,1) 
RIME 
ii - iii κobserved 0.977 0.023 0 (-1.370, 1.370) 
i - ii 0.226 0.744 0.186 0.129 (-0.228, 0.487) 
i - iii 0.294 0.733 0.185 0.105 (-0.250, 0.460) 
PfrA 
ii - iii κobserved 0.975 0.012 0.851 (0.561, 1.141) 
i - ii 0.823 0.779 0.035 0.587 (0.294, 0.880) 
i - iii κobserved 0.709 0.105 0.588 (0.333, 0.843) 
TgsGP 
ii - iii 0.746 0.674 0.070 0.493 (0.226, 0.759) 
i - ii 0.905 0.163 0.047 0.857 (0.747, 0.962) 
i - iii 0.928 0.174 0.035 0.880 (0.778, 0.982) 
SRA1 
ii - iii 0.953 0.128 0.012 0.882 (0.781, 0.982) 
i - ii 0.929 0.128 0.035 0.835 (0.717, 0.952) 
i - iii 0.792 0.058 0.104 0.700 (0.550, 0.850) 
SRALAMP_a 
ii - iii 0.861 0.023 0.070 0.676 (0.520, 0.831) 
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Appendix 20. LAMP and PCR test-retest agreement using 
DNA eluted from cattle blood samples on Whatman FTA 
cards 
Table 1. Two by two table for comparisons of LAMP RIME repeats  
  RIME ii RIME iii 
  + - Total + - Total 
+ 9 8 17 7 10 17 
- 5 26 31 12 19 31 
RIME i 
Total 14 34 48 19 29 48 
+ 8 11 19    
- 6 23 29    
RIME 
iii 
Total 14 34 48    
 
Table 2. Two by two table for comparisons of TBR PCR repeats  
  TBR PCR ii TBR PCR iii 
  + - Total + - Total 
+ 21 2 23 23 0 23 
- 1 31 25 1 24 25 
TBR 
PCR i 
Total 22 34 48 24 24 48 
+ 21 5 24    
- 2 29 24    
TBR 
PCR iii 
Total 22 34 48    
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Table 3. LAMP and PCR test-retest agreement using DNA prepared from 










i - ii 0.958 0.063 0.021 0.875 (0.737, 1.012) 
i - iii κobserved 0.021 0.021 0.958 (0.878, 1.039) 
TBR PCR 
ii - iii 0.840 0.042 0.042 0.833 (0.677, 0.990) 
i - ii 0.858 0.354 0.063 0.383 (0.097, 0.670) 
i - iii 0.911 0.25 0.042 0.024 (-0.276, 0.324) 
RIME 
ii - iii 0.772 0.313 0.104 0.224 (-0.072, 0.521) 
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Appendix 21. LAMP and PCR test-retest agreement using 
DNA eluted from human blood samples on Whatman FTA 
cards 
Table 1. Two by two table for comparisons of LAMP RIME repeats  
  RIME ii RIME iii 
  + - Total + - Total 
+ 41 3 44 43 1 44 
- 7 1 8 6 2 8 
RIME i 
Total 48 4 52 49 3 52 
+ 46 3 49    
- 2 1 3    
RIME 
iii 
Total 48 4 52    
 
Table 2. Two by two table for comparisons of TBR PCR repeats  
  TBR PCR ii TBR PCR iii 
  + - Total + - Total 
+ 52 0 52 52 0 52 
- 0 0 0 0 0 0 
TBR 
PCR i 
Total 52 0 52 52 0 52 
+ 52 0 52    
- 0 0 0    
TBR 
PCR iii 
Total 52 0 52    
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Table 3. Three by three table for comparisons of SRA PCR repeats  
  SRA PCR  ii SRA PCR  iii 
  + - Insufficient 
DNA 
Total + - Insufficient 
DNA 
Total 
+ 30 5 0 35 30 4 0 34 
- 4 2 2 8 3 3 2 8 
Insufficient 
DNA 




Total 37 9 6 52 34 9 8 51 
+ 29 5 0 34     
- 6 2 1 9     
Insufficient 
DNA 




Total 37 8 6 51     
 
Table 4. Two by two table for comparisons of LAMP SRA1 repeats  
  SRA1 ii SRA1 iii 
  + - Total + - Total 
+ 41 1 42 39 3 42 
- 0 10 10 3 7 10 
SRA1 i 
Total 41 11 52 39 13 52 
+ 36 3 39    
- 5 8 13    
SRA1 iii 
Total 41 11 52    
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Table 5. Two by two table for comparisons of SRALAMP_a repeats  
  SRALAMP_a ii SRALAMP_a iii 
  + - Total + - Total 
+ 8 12 20 7 13 20 
- 2 30 32 11 21 32 
SRALAMP_a 
i 
Total 10 42 52 18 34 52 
+ 4 14 18    
- 6 28 34    
SRALAMP_a 
iii 
Total 10 42 52    
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Table 6. LAMP and PCR test-retest agreement using DNA prepared from 







κobserved 95% confidence 
interval 
i - ii  1 0   
i - iii  1 0   
TBR PCR 
ii - iii  1 0   
i - ii 0.629 0.769 0.077 0.071 (-0.446, 0.589) 
i - iii 0.504 0.788 0.096 0.305 (-0.173, 0.784) 
RIME 
ii - iii 0.847 0.865 0.019 0.235 (-0.402, 0.873) 
i - ii    0.352 (0.087, 0.616) 
i - iii    0.530 (0.297, 0.762) 
SRA PCR 
ii - iii    0.374 (0.109, 0.640) 
i - ii 0.940 0.596 0.019 0.463 (0.144, 0.782) 
i - iii 0.833 0.558 0.058 0.500 (0.203, 0.797) 
SRA1 
ii - iii 0.892 0.538 0.038 0.568 (0.292, 0.843) 
i - ii 0.552 0.423 0.192 0.372 (0.091, 0.653) 
i - iii 0.917 0.269 0.038 0.006 (-0.285, 0.298) 
SRALAMP_a 
ii - iii 0.620 0.462 0.154 0.051 (-0.275, 0.377) 
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Appendix 22. LAMP and PCR test-retest agreement using 
pooled data from cattle and human sample sets 
Table 1. Two by two table for comparisons of LAMP RIME repeats  
  RIME ii RIME iii 
  + - Total + - Total 
+ 50 11 61 50 11 61 
- 12 27 39 18 21 39 
RIME i 
Total 62 38 100 68 32 100 
+ 54 14 68    
- 8 24 32    
RIME 
iii 
Total 62 38 100    
 
Table 2. Two by two table for comparisons of TBR PCR repeats  
  TBR PCR ii TBR PCR iii 
  + - Total + - Total 
+ 73 2 75 75 0 75 
- 1 24 25 1 24 25 
TBR 
PCR i 
Total 74 26 100 76 24 100 
+ 73 3 76    
- 1 23 24    
TBR 
PCR iii 
Total 74 26 100    
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Table 3. Three by three table for comparisons of SRA PCR repeats  
  SRA PCR  ii SRA PCR  iii 
  + - Insufficient 
DNA 
Total + - Insufficient 
DNA 
Total
+ 31 5 0 36 30 5 0 35 
- 5 3 7 15 3 5 7 15 
Insufficient 
DNA 




Total 39 10 51 100 34 16 49 99 
+ 29 5 0 34     
- 7 2 7 16     
Insufficient 
DNA 




Total 39 9 51 99     
 
Table 4. Two by two table for comparisons of LAMP SRA1 repeats  
  SRA1 ii SRA1 iii 
  + - Total + - Total 
+ 39 11 50 39 11 50 
- 5 45 50 10 40 50 
SRA1 i 
Total 44 56 100 49 51 100 
+ 37 12 49    
- 7 44 51    
SRA1 iii 
Total 44 56 100    
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Table 5. Two by two table for comparisons of SRALAMP_a repeats  
  SRALAMP_a ii SRALAMP_a iii 
  + - Total + - Total 
+ 9 13 22 8 14 22 
- 3 75 78 12 66 78 
SRALAMP_a 
i 
Total 12 88 100 20 80 100 
+ 5 15 20    
- 7 73 80    
SRALAMP_a 
iii 
Total 12 88 100    
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Table 6. LAMP and PCR test – retest agreement pooling all data from 







κobserved 95% confidence 
interval 
i - ii 0.974 0.490 0.010 0.921 (0.833, 1.009) 
i - iii κobserved 0.510 0.010 0.973 (0.920, 1.026) 
TBR PCR 
ii - iii 0.947 0.500 0.020 0.893 (0.791, 0.996) 
i - ii 0.979 0.230 0.010 0.514 (0.340, 0.689) 
i - iii 0.848 0.290 0.070 0.370 (0.177, 0.563) 
RIME 
ii - iii 0.869 0.300 0.060 0.518 (0.341, 0.696) 
i - ii    0.630 (0.494, 0.767) 
i - iii    0.635 (0.501, 0.770) 
SRA PCR 
ii - iii    0.605 (0.463, 0.746) 
i - ii 0.880 0.060 0.060 0.680 (0.536, 0.824) 
i - iii 0.980 0.010 0.010 0.580 (0.420, 0.740) 
SRA1 
ii - iii 0.900 0.070 0.050 0.619 (0.465, 0.773) 
i - ii 0.652 0.660 0.100 0.443 (0.193, 0.693) 
i - iii 0.940 0.580 0.020 0.217 (-0.042, 0.476) 
SRALAMP_a 
ii - iii 0.191 0.680 0.080 0.191 (-0.107, 0.490) 
 
Loop-mediated isothermal amplification (LAMP) for the diagnosis of human 
sleeping sickness: towards a point-of-care diagnostic test 
Appendices 412 
Appendix 23. LAMP assays with calcein and MnCl2 
Table 1. LAMP PfrA with Tween 
 Replicate 1 Replicate 2 Replicate 3 
Dilution Colour Fluor. Gel Colour Fluor. Gel Colour Fluor. Gel
1 x 10-1 Green? + + Green/orange +? + Orange +? + 
1 x 10-2 Green? + + Green - + Orange +? + 
1 x 10-3 Green? + + Green - - Orange +? - 
1 x 10-4 Orange - -     Green - - Orange +? - 
1 x 10-5 Orange - - Orange - - Orange +? - 
1 x 10-6 Orange - - Orange - - Orange +? - 
1 x 10-7 Orange - - Orange - - Orange +? - 
 
Table 2. LAMP SRA1 with Tween 
 Replicate 1 Replicate 2 Replicate 3 
Dilution Colour Fluor. Gel Colour Fluor. Gel Colour Fluor. Gel
1 x 10-1 Green ++ + Orange ++ - Not done 
1 x 10-2 Green ++ + Orange + - Not done 
1 x 10-3 Green/Orange ++ + Orange + - Not done 
1 x 10-4 Orange - - Orange + - Not done 
1 x 10-5 Orange - + Orange + - Not done 
1 x 10-6 Orange - - Orange - - Not done 
1 x 10-7 Orange - - Orange + - Not done 
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Table 3. SRALAMP_a with Triton 
 Replicate 1 Replicate 2 Replicate 3 
Dilution Colour Fluor. Gel Colour Fluor. Gel Colour Fluor. Gel 
1 x 10-1 Green + + Orange - - Orange + + 
1 x 10-2 Orange - - Orange - - Orange + + 
1 x 10-3 Orange - - Orange - - Orange - + 
1 x 10-4 Orange - - Orange - - Orange - + 
1 x 10-5 Orange - - Orange - - Orange - - 
1 x 10-6 Orange - - Orange - - Orange - - 
1 x 10-7 Orange - - Orange - - Orange - - 
 
Table 4. SRALAMP_a with Tween 
 Replicate 1 Replicate 2 Replicate 3 
Dilution Colour Fluor. Gel Colour Fluor. Gel Colour Fluor. Gel 
1 x 10-1 Green + + Green ++ + Green + + 
1 x 10-2 Green + + Green ++ + Green + - 
1 x 10-3 Orange - - Green/Orange ++ + Green + Weak 
+ 
1 x 10-4 Orange - -     Orange - - Green + - 
1 x 10-5 Orange - - Orange - + Green + - 
1 x 10-6 Orange - - Orange - - Green + + 
1 x 10-7 Orange - - Orange - - Green + - 
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Appendix 24. Turbidity verus gel electrophoresis for LAMP 
PfrA, SRALAMP_a and LAMP TgsGP for the total set of 




Table 1. Two by two tables comparing turbidity with UV illumination 
after gel electrophoresis for reading the results of LAMP PfrA reactions 
for three separate screens of the sample set 
  (i) (ii) (iii) 
  Turbidity Turbidity Turbidity 
  + - Total + - Total + - Total 
Gel + 59 8 67 81 2 83 77 5 82 
 - 0 19 19 1 2 3 0 4 4 
 Total 59 27 86 82 4 86 77 9 86 
 
Table 2. Two by two table comparing turbidity with UV illumination after 
gel electrophoresis for reading the results of LAMP PfrA reactions for 
three screens of the sample set combined 
  Turbidity   
  + - Total 
Gel + 217 15 232 
 - 1 25 26 
 Total 218 40 258 
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Table 3. Two by two tables comparing turbidity with UV illumination 
after gel electrophoresis for reading the results of SRALAMP_a 
reactions for three separate screens of the sample set 
  (i) (ii) (iii) 
  Turbidity Turbidity Turbidity 
  + - Total + - Total + - Total 
Gel + 16 20 36 37 2 39 42 3 45 
 - 0 47 47 0 44 44 0 38 38 
 Total 16 67 83 37 46 83 42 41 83 
 
Table 4. Two by two table comparing turbidity with UV illumination after 
gel electrophoresis for reading the results of SRALAMP_a reactions for 
three screens of the sample set combined 
  Turbidity   
  + - Total 
Gel + 95 25 120 
 - 0 129 129 
 Total 95 154 249 
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LAMP TgsGP   
 
Table 5. Two by two tables comparing turbidity with UV illumination 
after gel electrophoresis for reading the results of LAMP TgsGP 
reactions for three separate screens of the sample set 
  (i) (ii) (iii) 
  Turbidity Turbidity Turbidity 
  + - Total + - Total + - Total 
Gel + 5 3 8 7 4 11 12 3 15 
 - 0 75 75 0 72 72 0 68 68 
 Total 5 78 83 7 76 83 12 71 83 
 
Table 6. Two by two table comparing turbidity with UV illumination after 
gel electrophoresis for reading the results of LAMP TgsGP reactions for 
three screens of the sample set combined 
  Turbidity   
  + - Total 
Gel + 24 10 34 
 - 0 215 215 
 Total 24 225 249 
 
